Regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
cytokine	O
gene	O
expression	O
in	O
myeloid	B-cell_type
cells	I-cell_type
by	O
NF-kappa	B-protein
B/Rel	I-protein
transcription	B-protein
factors	I-protein
.	O

CD4+	B-cell_line
macrophages	I-cell_line
in	O
tissues	O
such	O
as	O
lung	O
,	O
skin	O
,	O
and	O
lymph	O
nodes	O
,	O
promyelocytic	B-cell_type
cells	I-cell_type
in	O
bone	O
marrow	O
,	O
and	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
serve	O
as	O
important	O
targets	O
and	O
reservoirs	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O

HIV-1-infected	O
myeloid	B-cell_type
cells	I-cell_type
are	O
often	O
diminished	O
in	O
their	O
ability	O
to	O
participate	O
in	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
intracellular	O
killing	O
.	O

HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
can	O
lead	O
to	O
the	O
expression	O
of	O
surface	B-protein
receptors	I-protein
associated	O
with	O
cellular	O
activation	O
and/or	O
differentiation	O
that	O
increase	O
the	O
responsiveness	O
of	O
these	O
cells	O
to	O
cytokines	B-protein
secreted	O
by	O
neighboring	O
cells	O
as	O
well	O
as	O
to	O
bacteria	O
or	O
other	O
pathogens	O
.	O

Enhancement	O
of	O
HIV-1	O
replication	O
is	O
related	O
in	O
part	O
to	O
increased	O
DNA-binding	O
activity	O
of	O
cellular	B-protein
transcription	I-protein
factors	I-protein
such	O
as	O
NF-kappa	B-protein
B	I-protein
.	O

NF-kappa	B-protein
B	I-protein
binds	O
to	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
region	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
and	O
contributes	O
to	O
the	O
inducibility	O
of	O
HIV-1	O
gene	O
expression	O
in	O
response	O
to	O
multiple	O
activating	O
agents	O
.	O

Phosphorylation	O
and	O
degradation	O
of	O
the	O
cytoplasmic	B-protein
inhibitor	I-protein
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
are	O
crucial	O
regulatory	O
events	O
in	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
.	O

Both	O
N-	O
and	O
C-terminal	O
residues	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	O
are	O
required	O
for	O
inducer-mediated	O
degradation	O
.	O

Chronic	O
HIV-1	O
infection	O
of	O
myeloid	B-cell_type
cells	I-cell_type
leads	O
to	O
constitutive	O
NF-kappa	B-protein
B	I-protein
DNA-binding	O
activity	O
and	O
provides	O
an	O
intranuclear	O
environment	O
capable	O
of	O
perpetuating	O
HIV-1	O
replication	O
.	O

Increased	O
intracellular	O
stores	O
of	O
latent	B-protein
NF-kappa	I-protein
B	I-protein
may	O
also	O
result	O
in	O
rapid	O
inducibility	O
of	O
NF-kappa	B-protein
B	I-protein
-dependent	O
cytokine	B-protein
gene	O
expression	O
.	O

In	O
response	O
to	O
secondary	O
pathogenic	O
infections	O
or	O
antigenic	O
challenge	O
,	O
cytokine	B-protein
gene	O
expression	O
is	O
rapidly	O
induced	O
,	O
enhanced	O
,	O
and	O
sustained	O
over	O
prolonged	O
periods	O
in	O
HIV-1-infected	B-cell_line
myeloid	I-cell_line
cells	I-cell_line
compared	O
with	O
uninfected	B-cell_type
cells	I-cell_type
.	O

Elevated	O
levels	O
of	O
several	O
inflammatory	B-protein
cytokines	I-protein
have	O
been	O
detected	O
in	O
the	O
sera	O
of	O
HIV-1-infected	O
individuals	O
.	O

Secretion	O
of	O
myeloid	B-protein
cell-derived	I-protein
cytokines	I-protein
may	O
both	O
increase	O
virus	O
production	O
and	O
contribute	O
to	O
AIDS-associated	O
disorders	O
.	O

MicroBtoLocIcaL	NULL
ReviEws	NULL
,	NULL
Sept.	NULL
1995	NULL
,	NULL
p.	NULL
481-505	NULL
0146-0749/95/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1995	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

59	NULL
,	NULL
No	NULL
.	NULL

3	NULL
Regulation	NULL
of	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
and	NULL
Cytokine	NULL
Gene	NULL
Expression	NULL
in	NULL
Myeloid	NULL
Cells	NULL
by	NULL
Transcription	NULL
Factors	NULL
ANNE	NULL
ROULSTON	NULL
,	NULL
*	NULL
``	NULL
¢	NULL
RONGTUAN	NULL
LIN	NULL
,	NULL
PIERRE	NULL
BEAUPARLANT	NULL
,	NULL
``	NULL
'*	NULL
MARK	NULL
A.	NULL
WAINBERG	NULL
,	NULL
**	NULL
anp	NULL
JOHN	NULL
HISCOTT~	NULL
>	NULL
*	NULL
Terry	NULL
Fox	NULL
Molecular	NULL
Oncology	NULL
Group	NULL
,	NULL
Abe	NULL
Stern	NULL
Cancer	NULL
Research	NULL
Laboratory	NULL
,	NULL
Lady	NULL
Davis	NULL
Institute	NULL
for	NULL
Medical	NULL
Research	NULL
,	NULL
Sir	NULL
Mortimer	NULL
B.	NULL
Davis	NULL
Jewish	NULL
General	NULL
Hospital	NULL
,	NULL
``	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
McGill	NULL
University	NULL
,	NULL
``	NULL
and	NULL
McGill	NULL
AIDS	NULL
Center	NULL
,	NULL
``	NULL
Montreal	NULL
,	NULL
Quebec	NULL
,	NULL
Canada	NULL
H3T	NULL
1E2	NULL
INTRODUCTION	NULL
481	NULL
COURSE	NULL
OF	NULL
HIV-1	NULL
INFECTION	NULL
482	NULL
HIV-1	NULL
INFECTION	NULL
OF	NULL
MYELOID	NULL
CELLS	NULL
482	NULL
MACROPHAGE	NULL
TROPISM	NULL
AND	NULL
HOST	NULL
PERMISSIVITY	NULL
482	NULL
REGULATION	NULL
OF	NULL
HIV-1	NULL
TRANSCRIPTION	NULL
483	NULL
Tat-TAR	NULL
RNA	NULL
Interactions	NULL
483	NULL
TAR	NULL
DNA	NULL
Element	NULL
484	NULL
Core	NULL
Promoter	NULL
484	NULL
Modulatory	NULL
Elements	NULL
484	NULL
HIV-1	NULL
Enhancer	NULL
485	NULL
NF-KB/REL	NULL
FAMILY	NULL
OF	NULL
TRANSCRIPTION	NULL
FACTORS	NULL
485	NULL
NF-B/Rel	NULL
DNA-Binding	NULL
Subunits	NULL
485	NULL
IB	NULL
Regulatory	NULL
Proteins	NULL
486	NULL
Regulation	NULL
of	NULL
NF-KB	NULL
DNA-Binding	NULL
Activity	NULL
486	NULL
IxBa	NULL
Phosphorylation	NULL
and	NULL
Degradation	NULL
488	NULL
PHYSIOLOGICAL	NULL
CHANGES	NULL
IN	NULL
HIV-1-INFECTED	NULL
MYELOID	NULL
CELLS	NULL
490	NULL
Functional	NULL
Changes	NULL
490	NULL
Cytokine	NULL
Gene	NULL
Expression	NULL
490	NULL
Myeloid	NULL
Cell	NULL
Differentiation	NULL
491	NULL
NF-B	NULL
DNA-Binding	NULL
Activity	NULL
491	NULL
COFACTORS	NULL
IN	NULL
HIV-1	NULL
DISEASE	NULL
PROGRESSION	NULL
492	NULL
Viral	NULL
Cofactors	NULL
492	NULL
Bacterial	NULL
Products	NULL
492	NULL
Physical	NULL
Stress	NULL
492	NULL
CYTOKINE	NULL
MODULATION	NULL
OF	NULL
HIV-1	NULL
REPLICATION	NULL
493	NULL
Activating	NULL
Cytokines	NULL
493	NULL
Bifunctional	NULL
Cytokines	NULL
494	NULL
Inhibitory	NULL
Cytokines	NULL
494	NULL
CYTOKINES	NULL
AND	NULL
HIV-1-ASSOCIATED	NULL
DISORDERS	NULL
495	NULL
Neurological	NULL
Disorders	NULL
495	NULL
Hematopoietic	NULL
Disorders	NULL
495	NULL
AIDS-Associated	NULL
Malignancies	NULL
495	NULL
POTENTIAL	NULL
ANTI-HIV-1	NULL
THERAPIES	NULL
496	NULL
CONCLUDING	NULL
REMARKS	NULL
496	NULL
ACKNOWLEDGMENTS	NULL
497	NULL
REFERENCES	NULL
497	NULL
INTRODUCTION	NULL
as	NULL
bacterial	NULL
or	NULL
viral	NULL
infections	NULL
and	NULL
other	NULL
opportunistic	NULL
infec-	NULL
The	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV-1	NULL
)	NULL
was	NULL
first	NULL
identified	NULL
in	NULL
1983	NULL
(	NULL
21	NULL
,	NULL
106	NULL
,	NULL
197	NULL
)	NULL
and	NULL
is	NULL
now	NULL
recognized	NULL
as	NULL
the	NULL
virus	NULL
responsible	NULL
for	NULL
the	NULL
progressive	NULL
immune	NULL
system	NULL
degeneration	NULL
that	NULL
leads	NULL
to	NULL
the	NULL
development	NULL
of	NULL
AIDS	NULL
.	NULL

As	NULL
knowledge	NULL
of	NULL
HIV-1	NULL
and	NULL
its	NULL
interactions	NULL
with	NULL
the	NULL
host	NULL
immune	NULL
system	NULL
in-creases	NULL
,	NULL
it	NULL
is	NULL
apparent	NULL
that	NULL
a	NULL
number	NULL
of	NULL
secondary	NULL
factors	NULL
such	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Lady	NULL
Davis	NULL
Institute	NULL
for	NULL
Medical	NULL
Research	NULL
,	NULL
Sir	NULL
Mortimer	NULL
B.	NULL
Davis	NULL
Jewish	NULL
General	NULL
Hospital	NULL
,	NULL
3755	NULL
Cote	NULL
Ste	NULL
.	NULL

Catherine	NULL
,	NULL
Montreal	NULL
,	NULL
Quebec	NULL
H3T	NULL
1E2	NULL
,	NULL
Canada	NULL
.	NULL

¢	NULL
Present	NULL
address	NULL
:	NULL
Chiron	NULL
Corp.	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
94608	NULL
.	NULL

481	NULL
tions	NULL
influence	NULL
the	NULL
progression	NULL
of	NULL
asymptomatic	NULL
individuals	NULL
to	NULL
AIDS	NULL
.	NULL

Although	NULL
T	NULL
cells	NULL
are	NULL
targeted	NULL
for	NULL
infection	NULL
,	NULL
CD4	NULL
*	NULL
cells	NULL
of	NULL
the	NULL
myeloid	NULL
lineage	NULL
are	NULL
also	NULL
very	NULL
important	NULL
in	NULL
HIV-1	NULL
disease	NULL
.	NULL

Promonocytes	NULL
and	NULL
macrophages	NULL
serve	NULL
as	NULL
reservoirs	NULL
of	NULL
HIV-1	NULL
virions	NULL
within	NULL
various	NULL
tissues	NULL
such	NULL
as	NULL
the	NULL
lung	NULL
,	NULL
skin	NULL
,	NULL
lymph	NULL
nodes	NULL
,	NULL
and	NULL
bone	NULL
marrow	NULL
.	NULL

Physiological	NULL
changes	NULL
in	NULL
HIV-1-infected	NULL
myeloid	NULL
cells	NULL
including	NULL
alterations	NULL
in	NULL
cytokine	NULL
secretion	NULL
,	NULL
antigen	NULL
presentation	NULL
,	NULL
and	NULL
phagocytosis-in	NULL
conjunction	NULL
with	NULL
secondary	NULL
infections-may	NULL
enhance	NULL
HIV-1	NULL
replication	NULL
,	NULL
contribute	NULL
to	NULL
AIDS-associated	NULL
disorders	NULL
,	NULL
and	NULL
accelerate	NULL
the	NULL
progression	NULL
of	NULL
HIV-1	NULL
disease	NULL
.	NULL

Efforts	NULL
to	NULL
control	NULL
the	NULL
HIV-1	NULL
pandemic	NULL
focus	NULL
on	NULL
all	NULL
aspects	NULL
of	NULL
482	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

the	NULL
disease	NULL
,	NULL
including	NULL
public	NULL
awareness	NULL
,	NULL
education	NULL
,	NULL
development	NULL
of	NULL
therapies	NULL
aimed	NULL
at	NULL
interrupting	NULL
the	NULL
viral	NULL
replication	NULL
cycle	NULL
,	NULL
enhancement	NULL
of	NULL
the	NULL
host	NULL
immune	NULL
system	NULL
,	NULL
and	NULL
vaccine	NULL
development	NULL
.	NULL

More	NULL
is	NULL
known	NULL
about	NULL
this	NULL
virus	NULL
,	NULL
perhaps	NULL
,	NULL
than	NULL
any	NULL
other	NULL
pathogen	NULL
,	NULL
yet	NULL
the	NULL
most	NULL
realistic	NULL
goal	NULL
in	NULL
terms	NULL
of	NULL
therapeutic	NULL
intervention	NULL
may	NULL
be	NULL
a	NULL
regimen	NULL
of	NULL
combination	NULL
therapy	NULL
designed	NULL
to	NULL
delay	NULL
viral	NULL
spread	NULL
and/or	NULL
disease	NULL
progression	NULL
.	NULL

Understanding	NULL
the	NULL
factors	NULL
which	NULL
influence	NULL
HIV-1	NULL
gene	NULL
expression	NULL
and	NULL
replication	NULL
will	NULL
form	NULL
the	NULL
basis	NULL
for	NULL
the	NULL
development	NULL
of	NULL
effective	NULL
antiviral	NULL
therapies	NULL
.	NULL

COURSE	NULL
OF	NULL
HIV-1	NULL
INFECTION	NULL
HIV-1	NULL
infection	NULL
is	NULL
transmitted	NULL
sexually	NULL
,	NULL
through	NULL
intravenous	NULL
contact	NULL
with	NULL
contaminated	NULL
blood	NULL
products	NULL
,	NULL
or	NULL
across	NULL
broken	NULL
mucosal	NULL
or	NULL
epidermal	NULL
epithelia	NULL
.	NULL

HIV-1	NULL
can	NULL
also	NULL
be	NULL
transmitted	NULL
vertically	NULL
from	NULL
infected	NULL
mothers	NULL
in	NULL
utero	NULL
or	NULL
through	NULL
lactation	NULL
after	NULL
birth	NULL
(	NULL
225	NULL
)	NULL
.	NULL

The	NULL
typical	NULL
course	NULL
of	NULL
HIV-1	NULL
disease	NULL
begins	NULL
with	NULL
a	NULL
primary	NULL
infection	NULL
that	NULL
is	NULL
followed	NULL
in	NULL
50	NULL
to	NULL
70	NULL
%	NULL
of	NULL
individuals	NULL
by	NULL
an	NULL
acute	NULL
viral	NULL
syndrome	NULL
characterized	NULL
by	NULL
a	NULL
mononucleosis-like	NULL
illness	NULL
,	NULL
generalized	NULL
lymphadenopathy	NULL
,	NULL
intense	NULL
plasma	NULL
viremia	NULL
,	NULL
and	NULL
a	NULL
significant	NULL
decrease	NULL
in	NULL
circulating	NULL
CD4*	NULL
T	NULL
cells	NULL
approximately	NULL
3	NULL
to	NULL
6	NULL
weeks	NULL
after	NULL
the	NULL
initial	NULL
infection	NULL
(	NULL
380	NULL
)	NULL
.	NULL

This	NULL
is	NULL
followed	NULL
by	NULL
extensive	NULL
viral	NULL
dissemination	NULL
to	NULL
surrounding	NULL
tissues	NULL
such	NULL
as	NULL
the	NULL
lungs	NULL
,	NULL
bone	NULL
marrow	NULL
,	NULL
and	NULL
liver	NULL
but	NULL
particularly	NULL
to	NULL
the	NULL
lymph	NULL
nodes	NULL
(	NULL
281	NULL
)	NULL
.	NULL

At	NULL
these	NULL
sites	NULL
,	NULL
an	NULL
immune	NULL
response	NULL
to	NULL
HIV-1	NULL
that	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
suppression	NULL
of	NULL
plasma	NULL
viremia	NULL
is	NULL
mounted	NULL
.	NULL

As	NULL
a	NULL
result	NULL
,	NULL
the	NULL
acute	NULL
syndrome	NULL
resolves	NULL
,	NULL
the	NULL
number	NULL
of	NULL
circulating	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
recovers	NULL
,	NULL
and	NULL
infection	NULL
may	NULL
enter	NULL
a	NULL
period	NULL
of	NULL
clinical	NULL
latency	NULL
that	NULL
can	NULL
last	NULL
for	NULL
10	NULL
years	NULL
or	NULL
longer	NULL
(	NULL
280	NULL
)	NULL
.	NULL

During	NULL
this	NULL
time	NULL
,	NULL
HIV-1	NULL
persists	NULL
in	NULL
the	NULL
lymph	NULL
nodes	NULL
,	NULL
where	NULL
it	NULL
continues	NULL
to	NULL
replicate	NULL
and	NULL
infect	NULL
circulating	NULL
T	NULL
cells	NULL
(	NULL
279	NULL
)	NULL
.	NULL

Recent	NULL
developments	NULL
indicate	NULL
that	NULL
during	NULL
this	NULL
asymptomatic	NULL
or	NULL
stationary	NULL
phase	NULL
,	NULL
plasma	NULL
viremia	NULL
is	NULL
maintained	NULL
in	NULL
a	NULL
low	NULL
steady	NULL
state	NULL
by	NULL
a	NULL
con-tinuous	NULL
,	NULL
vigorous	NULL
response	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
to	NULL
the	NULL
rapid	NULL
replication	NULL
of	NULL
HIV-1	NULL
(	NULL
56	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
patients	NULL
with	NULL
potent	NULL
inhibitors	NULL
of	NULL
HIV	NULL
replication	NULL
revealed	NULL
that	NULL
throughout	NULL
the	NULL
period	NULL
of	NULL
clinical	NULL
latency	NULL
,	NULL
virus	NULL
is	NULL
rapidly	NULL
cleared	NULL
from	NULL
the	NULL
bloodstream	NULL
.	NULL

Furthermore	NULL
,	NULL
during	NULL
this	NULL
phase	NULL
,	NULL
CD4*	NULL
lymphocytes	NULL
are	NULL
destroyed	NULL
and	NULL
replenished	NULL
at	NULL
a	NULL
rate	NULL
of	NULL
~2	NULL
%	NULL
10°	NULL
cells	NULL
per	NULL
day	NULL
and	NULL
new	NULL
virions	NULL
are	NULL
produced	NULL
and	NULL
cleared	NULL
from	NULL
the	NULL
circulation	NULL
at	NULL
a	NULL
rate	NULL
of	NULL
~1	NULL
X	NULL
10°	NULL
virions	NULL
per	NULL
day	NULL
.	NULL

Such	NULL
a	NULL
dynamic	NULL
replication	NULL
rate	NULL
yields	NULL
an	NULL
extremely	NULL
high	NULL
mutation	NULL
rate	NULL
(	NULL
142	NULL
,	NULL
402	NULL
)	NULL
.	NULL

The	NULL
result	NULL
,	NULL
over	NULL
a	NULL
time	NULL
course	NULL
that	NULL
encompasses	NULL
years	NULL
,	NULL
is	NULL
the	NULL
net	NULL
decline	NULL
in	NULL
the	NULL
number	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
and	NULL
the	NULL
gradual	NULL
deterioration	NULL
of	NULL
multiple	NULL
aspects	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

In	NULL
later	NULL
stages	NULL
of	NULL
HIV-1	NULL
disease	NULL
,	NULL
virus	NULL
is	NULL
usually	NULL
detectable	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
(	NULL
281	NULL
)	NULL
because	NULL
of	NULL
a	NULL
breakdown	NULL
in	NULL
the	NULL
ultrastructure	NULL
of	NULL
lymph	NULL
nodes	NULL
that	NULL
permits	NULL
virus	NULL
to	NULL
escape	NULL
into	NULL
the	NULL
circulation	NULL
(	NULL
87	NULL
)	NULL
.	NULL

Once	NULL
the	NULL
circulating	NULL
CD4*	NULL
T-cell	NULL
level	NULL
drops	NULL
below	NULL
200	NULL
cells	NULL
per	NULL
mm*	NULL
,	NULL
patients	NULL
may	NULL
become	NULL
increasingly	NULL
susceptible	NULL
to	NULL
life-threatening	NULL
opportunistic	NULL
infections	NULL
and	NULL
malignancies	NULL
(	NULL
87	NULL
)	NULL
.	NULL

HIV-1	NULL
INFECTION	NULL
OF	NULL
MYELOID	NULL
CELLS	NULL
CD4	NULL
*	NULL
cells	NULL
of	NULL
the	NULL
myeloid	NULL
lineage	NULL
,	NULL
including	NULL
monocytes	NULL
and	NULL
macrophages	NULL
,	NULL
are	NULL
important	NULL
targets	NULL
for	NULL
HIV-1	NULL
infection	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
143	NULL
,	NULL
229-231	NULL
,	NULL
304	NULL
)	NULL
.	NULL

The	NULL
peripheral	NULL
blood	NULL
monocyte	NULL
represents	NULL
an	NULL
intermediate	NULL
stage	NULL
of	NULL
maturation	NULL
;	NULL
terminally	NULL
differentiated	NULL
macrophages	NULL
are	NULL
found	NULL
only	NULL
after	NULL
migration	NULL
from	NULL
the	NULL
bloodstream	NULL
into	NULL
organs	NULL
and	NULL
tissues	NULL
(	NULL
236	NULL
)	NULL
.	NULL

Myeloid	NULL
cells	NULL
are	NULL
susceptible	NULL
to	NULL
HIV-1	NULL
infection	NULL
at	NULL
multiple	NULL
stages	NULL
of	NULL
differentiation	NULL
(	NULL
247	NULL
)	NULL
.	NULL

HIV-1-infected	NULL
CD34	NULL
*	NULL
myeloid	NULL
precursor	NULL
cells	NULL
are	NULL
present	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
of	NULL
a	NULL
significant	NULL
MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

number	NULL
of	NULL
AIDS	NULL
patients	NULL
(	NULL
304	NULL
)	NULL
and	NULL
can	NULL
be	NULL
infected	NULL
in	NULL
vitro	NULL
(	NULL
98	NULL
)	NULL
.	NULL

Estimates	NULL
of	NULL
the	NULL
proportion	NULL
of	NULL
circulating	NULL
blood	NULL
monocytes	NULL
infected	NULL
by	NULL
HIV-1	NULL
range	NULL
from	NULL
less	NULL
than	NULL
14	NULL
%	NULL
(	NULL
368	NULL
)	NULL
to	NULL
greater	NULL
than	NULL
50	NULL
%	NULL
(	NULL
144	NULL
,	NULL
146	NULL
)	NULL
as	NULL
measured	NULL
by	NULL
PCR	NULL
.	NULL

HIV-1	NULL
infection	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
in	NULL
vivo	NULL
occurs	NULL
predominantly	NULL
in	NULL
terminally	NULL
differentiated	NULL
macrophages	NULL
in	NULL
tissues	NULL
such	NULL
as	NULL
the	NULL
lungs	NULL
,	NULL
skin	NULL
,	NULL
brain	NULL
,	NULL
and	NULL
lymph	NULL
nodes	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
143	NULL
)	NULL
.	NULL

In	NULL
situ	NULL
hybridization	NULL
for	NULL
HIV-1	NULL
RNA	NULL
in	NULL
brain	NULL
tissue	NULL
of	NULL
infected	NULL
individuals	NULL
shows	NULL
a	NULL
frequency	NULL
of	NULL
productively	NULL
infected	NULL
macrophages	NULL
of	NULL
1	NULL
to	NULL
10	NULL
%	NULL
(	NULL
173	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
HIV-1	NULL
proteins	NULL
or	NULL
nucleic	NULL
acids	NULL
are	NULL
detected	NULL
in	NULL
10	NULL
to	NULL
50	NULL
%	NULL
of	NULL
the	NULL
alveolar	NULL
macrophages	NULL
isolated	NULL
from	NULL
bronchiolar	NULL
lavage	NULL
fluids	NULL
(	NULL
300	NULL
,	NULL
339	NULL
)	NULL
.	NULL

HIV-l-infected	NULL
epidermal	NULL
Langerhans	NULL
cells	NULL
,	NULL
the	NULL
dendritic	NULL
antigen-presenting	NULL
cells	NULL
of	NULL
the	NULL
skin	NULL
,	NULL
are	NULL
detected	NULL
in	NULL
up	NULL
to	NULL
20	NULL
%	NULL
of	NULL
seropositive	NULL
patients	NULL
(	NULL
229	NULL
,	NULL
386	NULL
)	NULL
.	NULL

CD4	NULL
*	NULL
myeloid	NULL
cells	NULL
infected	NULL
with	NULL
HIV-1	NULL
are	NULL
present	NULL
in	NULL
various	NULL
other	NULL
tissues	NULL
including	NULL
the	NULL
placenta	NULL
(	NULL
Hofbauer	NULL
cells	NULL
)	NULL
(	NULL
9	NULL
,	NULL
199	NULL
)	NULL
,	NULL
liver	NULL
(	NULL
Kupffer	NULL
cells	NULL
)	NULL
(	NULL
50	NULL
)	NULL
,	NULL
and	NULL
lymph	NULL
nodes	NULL
(	NULL
follicular	NULL
dendritic	NULL
cells	NULL
)	NULL
(	NULL
278	NULL
,	NULL
279	NULL
)	NULL
.	NULL

Myeloid	NULL
cells	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
HIV-1	NULL
disease	NULL
,	NULL
since	NULL
they	NULL
are	NULL
probably	NULL
the	NULL
first	NULL
cells	NULL
infected	NULL
during	NULL
sexual	NULL
transmission	NULL
.	NULL

Following	NULL
infection	NULL
by	NULL
the	NULL
epidermal	NULL
route	NULL
,	NULL
HIV-1	NULL
can	NULL
bind	NULL
to	NULL
cells	NULL
such	NULL
as	NULL
epidermal	NULL
Langerhans	NULL
cells	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
tissue	NULL
eosinophils	NULL
.	NULL

These	NULL
cells	NULL
are	NULL
able	NULL
to	NULL
move	NULL
from	NULL
the	NULL
epidermis	NULL
into	NULL
proximal	NULL
lymphoid	NULL
organs	NULL
,	NULL
through	NULL
either	NULL
the	NULL
peripheral	NULL
vascular	NULL
system	NULL
or	NULL
the	NULL
lymphatic	NULL
system	NULL
(	NULL
225	NULL
)	NULL
.	NULL

Lymphatic	NULL
drainage	NULL
of	NULL
HIV-1-infected	NULL
cells	NULL
may	NULL
play	NULL
a	NULL
particularly	NULL
important	NULL
role	NULL
in	NULL
the	NULL
infectious	NULL
process	NULL
.	NULL

Following	NULL
entry	NULL
through	NULL
afferent	NULL
lymphatics	NULL
,	NULL
macrophages	NULL
become	NULL
part	NULL
of	NULL
the	NULL
dendritic	NULL
antigen-presenting	NULL
population	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
lymph	NULL
nodes	NULL
.	NULL

Presentation	NULL
of	NULL
viral	NULL
antigens	NULL
leads	NULL
to	NULL
an	NULL
immune	NULL
response	NULL
against	NULL
HIV-1	NULL
;	NULL
virus	NULL
is	NULL
simultaneously	NULL
spread	NULL
to	NULL
uninfected	NULL
cells	NULL
by	NULL
cell-cell	NULL
transmission	NULL
.	NULL

The	NULL
immediate	NULL
result	NULL
is	NULL
a	NULL
massive	NULL
follicular	NULL
hyperplasia	NULL
seen	NULL
early	NULL
in	NULL
the	NULL
course	NULL
of	NULL
HIV-1	NULL
infection	NULL
(	NULL
149	NULL
)	NULL
.	NULL

Most	NULL
remarkably	NULL
,	NULL
HIV-1-infected	NULL
macrophages	NULL
in	NULL
vitro	NULL
are	NULL
not	NULL
subject	NULL
to	NULL
the	NULL
same	NULL
cytopathic	NULL
effects	NULL
as	NULL
are	NULL
T	NULL
cells	NULL
;	NULL
in	NULL
fact	NULL
,	NULL
populations	NULL
of	NULL
chronically	NULL
infected	NULL
myeloid	NULL
cell	NULL
lines	NULL
can	NULL
be	NULL
maintained	NULL
in	NULL
culture	NULL
for	NULL
prolonged	NULL
periods	NULL
(	NULL
229	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
HIV-1-infected	NULL
myeloid	NULL
cells	NULL
,	NULL
sequestered	NULL
from	NULL
recognition	NULL
by	NULL
the	NULL
host	NULL
immune	NULL
system	NULL
,	NULL
represent	NULL
a	NULL
true	NULL
reservoir	NULL
for	NULL
dissemination	NULL
of	NULL
HIV-1	NULL
to	NULL
other	NULL
macrophages	NULL
,	NULL
T	NULL
cells	NULL
,	NULL
or	NULL
target	NULL
tissues	NULL
.	NULL

MACROPHAGE	NULL
TROPISM	NULL
AND	NULL
HOST	NULL
PERMISSIVITY	NULL
Although	NULL
most	NULL
clinical	NULL
isolates	NULL
of	NULL
HIV-1	NULL
are	NULL
able	NULL
to	NULL
infect	NULL
primary	NULL
T	NULL
lymphocytes	NULL
or	NULL
macrophages	NULL
(	NULL
94	NULL
,	NULL
178	NULL
)	NULL
,	NULL
various	NULL
isolates	NULL
that	NULL
have	NULL
differing	NULL
tropisms	NULL
for	NULL
macrophages	NULL
and	NULL
myeloid	NULL
cell	NULL
lines	NULL
have	NULL
been	NULL
identified	NULL
(	NULL
110	NULL
,	NULL
116	NULL
)	NULL
.	NULL

These	NULL
isolates	NULL
may	NULL
exhibit	NULL
altered	NULL
kinetics	NULL
of	NULL
replication	NULL
within	NULL
these	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
many	NULL
do	NULL
not	NULL
result	NULL
in	NULL
a	NULL
productive	NULL
viral	NULL
infection	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
HIV-1	NULL
isolates	NULL
to	NULL
infect	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
cell	NULL
lines	NULL
appears	NULL
to	NULL
correlate	NULL
with	NULL
disease	NULL
progression	NULL
in	NULL
the	NULL
AIDS	NULL
patients	NULL
from	NULL
whom	NULL
these	NULL
viruses	NULL
were	NULL
isolated	NULL
.	NULL

HIV-1	NULL
isolates	NULL
from	NULL
asymptomatic	NULL
individuals	NULL
grow	NULL
slowly	NULL
in	NULL
phytohemagglutinin-stimulated	NULL
mononuclear	NULL
cells	NULL
,	NULL
lack	NULL
the	NULL
capacity	NULL
to	NULL
form	NULL
syncytia	NULL
(	NULL
non-syncytium	NULL
inducing	NULL
[	NULL
NSI	NULL
]	NULL
)	NULL
,	NULL
and	NULL
can	NULL
not	NULL
be	NULL
passaged	NULL
into	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
HIV-1	NULL
isolates	NULL
from	NULL
AIDS	NULL
patients	NULL
are	NULL
fast	NULL
replicating	NULL
,	NULL
syncytium	NULL
inducing	NULL
(	NULL
ST	NULL
)	NULL
,	NULL
and	NULL
T-cell	NULL
tropic	NULL
.	NULL

In	NULL
95	NULL
%	NULL
of	NULL
asymptomatic	NULL
individuals	NULL
,	NULL
only	NULL
NSI	NULL
variants	NULL
of	NULL
HIV-1	NULL
are	NULL
detected	NULL
(	NULL
347	NULL
)	NULL
.	NULL

NSI	NULL
variants	NULL
in	NULL
general	NULL
have	NULL
the	NULL
capacity	NULL
to	NULL
replicate	NULL
in	NULL
primary	NULL
monocyte-derived	NULL
macrophages	NULL
.	NULL

SI	NULL
variants	NULL
,	NULL
characterized	NULL
by	NULL
a	NULL
high	NULL
rate	NULL
of	NULL
replication	NULL
,	NULL
emerge	NULL
during	NULL
the	NULL
course	NULL
of	NULL
infection	NULL
and	NULL
are	NULL
detected	NULL
in	NULL
half	NULL
of	NULL
the	NULL
individuals	NULL
with	NULL
advanced	NULL
disease	NULL
.	NULL

It	NULL
has	NULL
been	NULL
proposed	NULL
that	NULL
SI	NULL
variants	NULL
are	NULL
cleared	NULL
effectively	NULL
during	NULL
the	NULL
initial	NULL
stages	NULL
of	NULL
HIV-1	NULL
infection	NULL
by	NULL
a	NULL
noncompromised	NULL
immune	NULL
system	NULL
.	NULL

The	NULL
Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
emergence	NULL
of	NULL
SI	NULL
variants	NULL
during	NULL
the	NULL
later	NULL
stages	NULL
of	NULL
disease	NULL
progression	NULL
following	NULL
immune	NULL
deterioration	NULL
supports	NULL
the	NULL
idea	NULL
that	NULL
SI	NULL
variants	NULL
are	NULL
more	NULL
susceptible	NULL
to	NULL
immune	NULL
surveillance	NULL
whereas	NULL
NSI	NULL
variants	NULL
may	NULL
be	NULL
less	NULL
vulnerable	NULL
to	NULL
immune	NULL
system	NULL
destruction	NULL
because	NULL
of	NULL
their	NULL
persistence	NULL
in	NULL
macrophages	NULL
(	NULL
347	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
NSI	NULL
variants	NULL
can	NULL
be	NULL
detected	NULL
throughout	NULL
the	NULL
course	NULL
of	NULL
HIV-1	NULL
infection	NULL
,	NULL
even	NULL
at	NULL
stages	NULL
when	NULL
SI	NULL
variants	NULL
predominate	NULL
,	NULL
thus	NULL
demonstrating	NULL
the	NULL
role	NULL
of	NULL
macrophage-tropic	NULL
variants	NULL
in	NULL
viral	NULL
persistence	NULL
.	NULL

Virus	NULL
isolates	NULL
derived	NULL
from	NULL
monocytes	NULL
and	NULL
then	NULL
serially	NULL
passaged	NULL
in	NULL
T	NULL
lymphocytes	NULL
have	NULL
a	NULL
reduced	NULL
capacity	NULL
to	NULL
reinfect	NULL
monocytes	NULL
or	NULL
macrophages	NULL
.	NULL

However	NULL
,	NULL
viruses	NULL
isolated	NULL
from	NULL
monocytes	NULL
show	NULL
dual	NULL
tropism	NULL
for	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
.	NULL

Tropism	NULL
for	NULL
various	NULL
cell	NULL
types	NULL
is	NULL
a	NULL
function	NULL
of	NULL
both	NULL
viral	NULL
and	NULL
cellular	NULL
determinants	NULL
.	NULL

The	NULL
envelope	NULL
V3	NULL
loop	NULL
region	NULL
is	NULL
a	NULL
major	NULL
determinant	NULL
of	NULL
macrophage	NULL
tropism	NULL
.	NULL

One	NULL
group	NULL
has	NULL
identified	NULL
a	NULL
20-amino-acid	NULL
sequence	NULL
in	NULL
the	NULL
envelope	NULL
V3	NULL
loop	NULL
of	NULL
gp120	NULL
from	NULL
the	NULL
macrophage-tropic	NULL
Bal	NULL
isolate	NULL
that	NULL
is	NULL
sufficient	NULL
to	NULL
confer	NULL
macrophage	NULL
tropism	NULL
on	NULL
the	NULL
HTLV-IIIB	NULL
strain	NULL
(	NULL
145	NULL
)	NULL
.	NULL

There	NULL
are	NULL
profound	NULL
phenotypic	NULL
differences	NULL
in	NULL
the	NULL
virions	NULL
produced	NULL
from	NULL
monocytes	NULL
and	NULL
lymphocytes	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
,	NULL
35	NULL
%	NULL
of	NULL
the	NULL
total	NULL
viral	NULL
proteins	NULL
produced	NULL
are	NULL
env	NULL
gene	NULL
products	NULL
,	NULL
while	NULL
in	NULL
monocytes	NULL
,	NULL
the	NULL
predominant	NULL
viral	NULL
proteins	NULL
are	NULL
capsid	NULL
proteins	NULL
and	NULL
env	NULL
gene	NULL
products	NULL
constitute	NULL
less	NULL
than	NULL
10	NULL
%	NULL
(	NULL
229	NULL
)	NULL
.	NULL

Electron	NULL
microscopy	NULL
of	NULL
virus	NULL
produced	NULL
from	NULL
infected	NULL
T	NULL
cells	NULL
reveals	NULL
the	NULL
characteristic	NULL
spikes	NULL
protruding	NULL
from	NULL
the	NULL
membrane	NULL
that	NULL
correspond	NULL
to	NULL
gp120	NULL
;	NULL
these	NULL
spikes	NULL
are	NULL
absent	NULL
in	NULL
virus	NULL
from	NULL
infected	NULL
monocytes	NULL
(	NULL
143	NULL
)	NULL
.	NULL

Initial	NULL
experiments	NULL
indicated	NULL
that	NULL
cellular	NULL
activation	NULL
influenced	NULL
the	NULL
permissiveness	NULL
of	NULL
cells	NULL
to	NULL
HIV-1	NULL
infection	NULL
,	NULL
since	NULL
quiescent	NULL
T	NULL
cells	NULL
were	NULL
not	NULL
permissive	NULL
to	NULL
HIV-1	NULL
infection	NULL
(	NULL
371	NULL
,	NULL
415-417	NULL
)	NULL
.	NULL

Resting	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
also	NULL
require	NULL
activation	NULL
and/or	NULL
intracellular	NULL
changes	NULL
to	NULL
be	NULL
permissive	NULL
to	NULL
HIV-1	NULL
infection	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
47	NULL
,	NULL
196	NULL
,	NULL
and	NULL
395	NULL
)	NULL
.	NULL

Myeloid	NULL
cells	NULL
become	NULL
``	NULL
activated	NULL
``	NULL
as	NULL
they	NULL
differentiate	NULL
from	NULL
a	NULL
circulating	NULL
monocyte	NULL
to	NULL
a	NULL
tissue	NULL
macrophage	NULL
as	NULL
a	NULL
result	NULL
of	NULL
exposure	NULL
to	NULL
antigenic	NULL
agents	NULL
,	NULL
cytokines	NULL
,	NULL
or	NULL
extracellular	NULL
matrix	NULL
proteins	NULL
whose	NULL
expression	NULL
is	NULL
increased	NULL
during	NULL
an	NULL
immune	NULL
response	NULL
(	NULL
253	NULL
)	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
isolated	NULL
from	NULL
normal	NULL
donors	NULL
are	NULL
10	NULL
to	NULL
100	NULL
times	NULL
more	NULL
susceptible	NULL
to	NULL
HIV-1	NULL
infection	NULL
in	NULL
vitro	NULL
following	NULL
antigenic	NULL
stimulation	NULL
with	NULL
either	NULL
keyhole	NULL
limpet	NULL
hemocyanin	NULL
or	NULL
tetanus	NULL
toxoid	NULL
than	NULL
are	NULL
cells	NULL
not	NULL
exposed	NULL
to	NULL
antigens	NULL
(	NULL
220	NULL
)	NULL
.	NULL

Exposure	NULL
of	NULL
PBMCs	NULL
to	NULL
noninfectious	NULL
but	NULL
mitogenic	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
virions	NULL
before	NULL
,	NULL
immediately	NULL
following	NULL
,	NULL
or	NULL
several	NULL
days	NULL
after	NULL
HIV-1	NULL
infection	NULL
in	NULL
vitro	NULL
results	NULL
in	NULL
increased	NULL
HIV-1	NULL
production	NULL
(	NULL
417	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
freshly	NULL
isolated	NULL
primary	NULL
monocytes	NULL
do	NULL
not	NULL
support	NULL
productive	NULL
HIV-1	NULL
infection	NULL
(	NULL
349	NULL
,	NULL
391	NULL
,	NULL
404	NULL
)	NULL
;	NULL
however	NULL
,	NULL
after	NULL
growth	NULL
factor-enhanced	NULL
differentiation	NULL
,	NULL
monocyte-derived	NULL
macrophages	NULL
(	NULL
MDMs	NULL
)	NULL
are	NULL
susceptible	NULL
to	NULL
infection	NULL
by	NULL
HIV-1	NULL
(	NULL
58	NULL
,	NULL
272	NULL
,	NULL
285	NULL
,	NULL
319	NULL
)	NULL
.	NULL

Following	NULL
terminal	NULL
myeloid	NULL
differentiation	NULL
,	NULL
HIV-1	NULL
replication	NULL
is	NULL
less	NULL
efficient	NULL
(	NULL
196	NULL
,	NULL
391	NULL
)	NULL
.	NULL

HIV-1	NULL
production	NULL
by	NULL
macrophage	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
macrophages	NULL
can	NULL
be	NULL
increased	NULL
by	NULL
treatment	NULL
with	NULL
growth	NULL
and/or	NULL
differentiation	NULL
factors	NULL
that	NULL
increase	NULL
the	NULL
proliferative	NULL
state	NULL
of	NULL
the	NULL
cell	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
[	NULL
GM-CSF	NULL
]	NULL
and	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
[	NULL
M-CSF	NULL
]	NULL
)	NULL
(	NULL
58	NULL
,	NULL
97	NULL
,	NULL
116	NULL
,	NULL
169	NULL
,	NULL
179	NULL
)	NULL
.	NULL

HIV-1	NULL
production	NULL
from	NULL
primary	NULL
macrophages	NULL
can	NULL
also	NULL
be	NULL
increased	NULL
by	NULL
factors	NULL
such	NULL
as	NULL
gamma	NULL
interferon	NULL
that	NULL
activate	NULL
macrophage	NULL
function	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
proliferation	NULL
(	NULL
179	NULL
)	NULL
.	NULL

A	NULL
fraction	NULL
of	NULL
terminally	NULL
differentiated	NULL
macrophages	NULL
do	NULL
proliferate	NULL
in	NULL
vitro	NULL
(	NULL
54	NULL
)	NULL
,	NULL
and	NULL
recent	NULL
evidence	NULL
suggests	NULL
that	NULL
an	NULL
activation	NULL
state	NULL
corresponding	NULL
to	NULL
the	NULL
G	NULL
,	NULL
/S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
but	NULL
not	NULL
mitosis	NULL
,	NULL
is	NULL
necessary	NULL
for	NULL
productive	NULL
infection	NULL
(	NULL
348	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
MDMs	NULL
express	NULL
fewer	NULL
CD4	NULL
receptors	NULL
than	NULL
do	NULL
freshly	NULL
isolated	NULL
blood	NULL
monocytes	NULL
(	NULL
272	NULL
,	NULL
390	NULL
,	NULL
391	NULL
)	NULL
REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
483	NULL
but	NULL
are	NULL
more	NULL
susceptible	NULL
to	NULL
infection	NULL
.	NULL

This	NULL
apparent	NULL
paradox	NULL
substantiates	NULL
evidence	NULL
that	NULL
monocytic	NULL
differentiation	NULL
induces	NULL
intracellular	NULL
physiological	NULL
changes	NULL
which	NULL
in	NULL
turn	NULL
enhance	NULL
HIV-1	NULL
replication	NULL
but	NULL
do	NULL
not	NULL
alter	NULL
viral	NULL
entry	NULL
(	NULL
268	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
decreased	NULL
intracellular	NULL
nucleotide	NULL
pools	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
rate-limiting	NULL
step	NULL
for	NULL
reverse	NULL
transcriptase	NULL
activity	NULL
in	NULL
macrophages	NULL
(	NULL
269	NULL
)	NULL
.	NULL

Increased	NULL
permissiveness	NULL
in	NULL
mature	NULL
myeloid	NULL
cells	NULL
may	NULL
correlate	NULL
with	NULL
changes	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
cellular	NULL
transcription	NULL
factors	NULL
.	NULL

In	NULL
monocytes	NULL
,	NULL
the	NULL
level	NULL
of	NULL
constitutive	NULL
NF-	NULL
«	NULL
B-binding	NULL
activity	NULL
increases	NULL
with	NULL
the	NULL
stage	NULL
of	NULL
differentiation	NULL
(	NULL
127	NULL
)	NULL
and	NULL
is	NULL
capable	NULL
of	NULL
activating	NULL
HIV-1	NULL
gene	NULL
expression	NULL
(	NULL
256	NULL
)	NULL
.	NULL

Transient	NULL
transfections	NULL
show	NULL
that	NULL
monocytic	NULL
differentiation	NULL
results	NULL
in	NULL
a	NULL
20-fold	NULL
upregulation	NULL
of	NULL
basal	NULL
transcription	NULL
from	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
and	NULL
enhancement	NULL
of	NULL
Tat-mediated	NULL
transcription	NULL
(	NULL
249	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
demonstrate	NULL
that	NULL
intracellular	NULL
levels	NULL
of	NULL
both	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
and	NULL
IxBa	NULL
proteins	NULL
increase	NULL
with	NULL
in	NULL
vitro	NULL
differentiation	NULL
of	NULL
primary	NULL
monocytes	NULL
to	NULL
MDMs	NULL
(	NULL
58a	NULL
)	NULL
.	NULL

Virally	NULL
encoded	NULL
factors	NULL
may	NULL
also	NULL
aid	NULL
in	NULL
the	NULL
establishment	NULL
of	NULL
productive	NULL
infection	NULL
.	NULL

Both	NULL
the	NULL
HIV-1	NULL
Gag	NULL
(	NULL
matrix	NULL
)	NULL
and	NULL
Vpr	NULL
proteins	NULL
form	NULL
a	NULL
nucleophilic	NULL
preintegration	NULL
complex	NULL
with	NULL
viral	NULL
nucleic	NULL
acid	NULL
(	NULL
44	NULL
,	NULL
137	NULL
)	NULL
.	NULL

The	NULL
function	NULL
of	NULL
these	NULL
virion-associated	NULL
proteins	NULL
is	NULL
to	NULL
transport	NULL
the	NULL
preintegration	NULL
complex	NULL
to	NULL
the	NULL
nucleus	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
mitosis	NULL
(	NULL
44	NULL
,	NULL
137	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Vpr	NULL
may	NULL
induce	NULL
differentiation	NULL
(	NULL
195	NULL
)	NULL
in	NULL
the	NULL
infected	NULL
host	NULL
cell	NULL
and	NULL
thus	NULL
indirectly	NULL
modulate	NULL
virus	NULL
replication	NULL
.	NULL

Host	NULL
and	NULL
viral	NULL
determinants	NULL
of	NULL
tropism	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
involvement	NULL
of	NULL
Th1/Th2	NULL
cytokines	NULL
in	NULL
pathogenesis	NULL
,	NULL
are	NULL
described	NULL
in	NULL
detail	NULL
in	NULL
several	NULL
recent	NULL
articles	NULL
(	NULL
61	NULL
,	NULL
239	NULL
)	NULL
.	NULL

REGULATION	NULL
OF	NULL
HIV-1	NULL
TRANSCRIPTION	NULL
Transcription	NULL
of	NULL
the	NULL
HIV-1	NULL
genome	NULL
depends	NULL
on	NULL
the	NULL
intracellular	NULL
environment	NULL
into	NULL
which	NULL
the	NULL
virus	NULL
integrates	NULL
and	NULL
is	NULL
regulated	NULL
by	NULL
a	NULL
complex	NULL
interplay	NULL
between	NULL
viral	NULL
regulatory	NULL
proteins	NULL
and	NULL
cellular	NULL
transcription	NULL
factors	NULL
that	NULL
interact	NULL
with	NULL
the	NULL
viral	NULL
LTR	NULL
region	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
12	NULL
and	NULL
111	NULL
)	NULL
.	NULL

Sequences	NULL
involved	NULL
in	NULL
viral	NULL
gene	NULL
expression	NULL
are	NULL
contained	NULL
within	NULL
U3	NULL
and	NULL
R	NULL
regions	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
and	NULL
may	NULL
be	NULL
subdivided	NULL
into	NULL
the	NULL
core	NULL
promoter	NULL
elements	NULL
,	NULL
the	NULL
enhancer	NULL
,	NULL
the	NULL
modulatory	NULL
and	NULL
negative	NULL
regulatory	NULL
elements	NULL
,	NULL
and	NULL
the	NULL
Tat	NULL
responsive	NULL
element	NULL
(	NULL
TAR	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
DNA-binding	NULL
activity	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
is	NULL
modulated	NULL
in	NULL
response	NULL
to	NULL
cellular	NULL
activation	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
the	NULL
actions	NULL
of	NULL
cytokines	NULL
and	NULL
mito-gens	NULL
.	NULL

Tat-TAR	NULL
RNA	NULL
Interactions	NULL
The	NULL
tat	NULL
gene	NULL
encodes	NULL
a	NULL
15-kDa	NULL
trans-activator	NULL
protein	NULL
that	NULL
enhances	NULL
LTR-derived	NULL
gene	NULL
expression	NULL
and	NULL
is	NULL
required	NULL
for	NULL
high-level	NULL
expression	NULL
of	NULL
all	NULL
viral	NULL
genes	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
62	NULL
,	NULL
88	NULL
,	NULL
389	NULL
,	NULL
and	NULL
407	NULL
)	NULL
.	NULL

Tat	NULL
has	NULL
three	NULL
functional	NULL
domains	NULL
:	NULL
an	NULL
amino-terminal	NULL
amphipathic	NULL
«	NULL
-helix	NULL
,	NULL
a	NULL
domain	NULL
found	NULL
in	NULL
many	NULL
transcriptional	NULL
activators	NULL
;	NULL
a	NULL
cysteine-rich	NULL
domain	NULL
which	NULL
may	NULL
be	NULL
important	NULL
for	NULL
dimerization	NULL
;	NULL
and	NULL
a	NULL
basic	NULL
domain	NULL
,	NULL
critical	NULL
for	NULL
nuclear	NULL
localization	NULL
and	NULL
TAR	NULL
RNA	NULL
binding	NULL
(	NULL
108	NULL
,	NULL
186	NULL
,	NULL
337	NULL
)	NULL
.	NULL

TAR	NULL
RNA	NULL
is	NULL
formed	NULL
by	NULL
the	NULL
nascent	NULL
RNA	NULL
transcript	NULL
derived	NULL
from	NULL
nucleotides	NULL
+1	NULL
and	NULL
+59	NULL
;	NULL
the	NULL
core	NULL
secondary	NULL
stem-loop	NULL
structure	NULL
(	NULL
nucleotides	NULL
+18	NULL
to	NULL
+44	NULL
)	NULL
is	NULL
critical	NULL
for	NULL
Tat-TAR	NULL
interactions	NULL
and	NULL
for	NULL
Tat-mediated	NULL
transactivation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

The	NULL
bulge	NULL
region	NULL
in	NULL
TAR	NULL
(	NULL
+22	NULL
to	NULL
+24	NULL
)	NULL
serves	NULL
as	NULL
the	NULL
primary	NULL
binding	NULL
site	NULL
for	NULL
Tat	NULL
,	NULL
and	NULL
the	NULL
loop	NULL
sequences	NULL
(	NULL
+30	NULL
to	NULL
+35	NULL
)	NULL
also	NULL
contribute	NULL
to	NULL
this	NULL
interaction	NULL
(	NULL
334	NULL
,	NULL
335	NULL
,	NULL
353	NULL
)	NULL
.	NULL

TAR	NULL
RNA	NULL
essentially	NULL
serves	NULL
as	NULL
an	NULL
anchor	NULL
for	NULL
Tat	NULL
and	NULL
certain	NULL
cellular	NULL
factors	NULL
(	NULL
TRP-185	NULL
and	NULL
p68	NULL
)	NULL
(	NULL
218	NULL
,	NULL
360	NULL
)	NULL
to	NULL
facilitate	NULL
interactions	NULL
with	NULL
promoter	NULL
elements	NULL
such	NULL
as	NULL
TATA	NULL
,	NULL
Sp1	NULL
,	NULL
and	NULL
the	NULL
484	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

Mitogens	NULL
Viral	NULL
Proteins	NULL
Cytokines	NULL
(	NULL
PMA	NULL
,	NULL
LPS	NULL
)	NULL
(	NULL
HTLV-1	NULL
Tax	NULL
,	NULL
(	NULL
TNF	NULL
,	NULL
IL-1	NULL
)	NULL
HSV-IE	NULL
)	NULL
AGGGACTTTCCGCTGGGGACTTTCC	NULL
DISTAL	NULL
ENHANCER	NULL
,	NULL
~~	NULL
CORE	NULL
PROMOTER	NULL
TAR	NULL
ELEMENT	NULL
NF-	NULL
«	NULL
8	NULL
|	NULL
||	NULL
__	NULL
spj	NULL
AP-2	NULL
LEF	NULL
~	NULL
NF-AT	NULL
USF	NULL
,	NULL
-455	NULL
COUP/AP-1	NULL
MYB	NULL
l	NULL
*~	NULL
+80	NULL
UBPJ1/LBP-1	NULL
(	NULL
3	NULL
)	NULL
UBP-2	NULL
CTE/NF1	NULL
a	NULL
+98	NULL
+182	NULL
U	NULL
§	NULL
M	NULL
E	NULL
_s	NULL
U5	NULL
GAG	NULL
-	NULL
POL-	NULL
ENY	NULL
...	NULL
..	NULL
DiSTAL	NULL
REGULATORY	NULL
ELEMENTS	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Schematic	NULL
diagram	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

The	NULL
U3	NULL
and	NULL
R	NULL
regions	NULL
are	NULL
subdivided	NULL
into	NULL
the	NULL
TAR	NULL
DNA	NULL
element	NULL
,	NULL
core	NULL
promoter	NULL
,	NULL
and	NULL
enhancer	NULL
,	NULL
modulatory	NULL
,	NULL
and	NULL
negative	NULL
regulatory	NULL
elements	NULL
to	NULL
which	NULL
cellular	NULL
transcription	NULL
factors	NULL
bind	NULL
.	NULL

The	NULL
virally	NULL
encoded	NULL
Tat	NULL
protein	NULL
binds	NULL
to	NULL
TAR	NULL
RNA	NULL
in	NULL
addition	NULL
to	NULL
several	NULL
cellular	NULL
factors	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
TRP185	NULL
and	NULL
p68	NULL
)	NULL
and	NULL
markedly	NULL
enhances	NULL
HIV-1	NULL
LTR-driven	NULL
transcription	NULL
.	NULL

The	NULL
general	NULL
transcription	NULL
initiation	NULL
complex	NULL
is	NULL
represented	NULL
by	NULL
TFIID	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
TATA	NULL
box	NULL
.	NULL

The	NULL
degree	NULL
of	NULL
transcriptional	NULL
activation	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
number	NULL
and	NULL
combination	NULL
of	NULL
factors	NULL
bound	NULL
to	NULL
the	NULL
LTR	NULL
at	NULL
a	NULL
given	NULL
time	NULL
;	NULL
generally	NULL
,	NULL
the	NULL
factors	NULL
Myb	NULL
,	NULL
Sp1	NULL
,	NULL
NF-xB	NULL
,	NULL
LEF-1	NULL
(	NULL
TCF-1a	NULL
)	NULL
,	NULL
NF-AT	NULL
,	NULL
and	NULL
AP-1	NULL
are	NULL
thought	NULL
to	NULL
have	NULL
a	NULL
positive	NULL
effect	NULL
on	NULL
transcription	NULL
(	NULL
see	NULL
the	NULL
text	NULL
)	NULL
,	NULL
while	NULL
UBP-1/LBP-1	NULL
,	NULL
USF	NULL
,	NULL
and	NULL
COUP	NULL
have	NULL
a	NULL
negative	NULL
effect	NULL
.	NULL

The	NULL
significance	NULL
of	NULL
other	NULL
factors	NULL
is	NULL
not	NULL
clearly	NULL
understood	NULL
.	NULL

Strong	NULL
inducers	NULL
of	NULL
HIV-1	NULL
LTR-directed	NULL
gene	NULL
expression	NULL
include	NULL
antigenic	NULL
stimuli	NULL
,	NULL
mitogens	NULL
,	NULL
viral	NULL
proteins	NULL
,	NULL
and	NULL
cytokines	NULL
,	NULL
which	NULL
stimulate	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
.	NULL

HIV-1	NULL
enhancer	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
NF-kB-	NULL
and	NULL
Sp1-binding	NULL
sites	NULL
from	NULL
the	NULL
HIV-1	NULL
promoter	NULL
abrogates	NULL
Tat-mediated	NULL
trans-activation	NULL
,	NULL
suggesting	NULL
that	NULL
once	NULL
brought	NULL
into	NULL
the	NULL
vicinity	NULL
of	NULL
the	NULL
promoter	NULL
,	NULL
Tat	NULL
interacts	NULL
with	NULL
transcription	NULL
factors	NULL
bound	NULL
at	NULL
the	NULL
NF-	NULL
«	NULL
B/Spl	NULL
region	NULL
to	NULL
stimulate	NULL
transcription	NULL
initiation	NULL
and	NULL
stabilize	NULL
elongation	NULL
complexes	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Tat	NULL
may	NULL
be	NULL
able	NULL
to	NULL
transactivate	NULL
independently	NULL
of	NULL
TAR	NULL
RNA	NULL
,	NULL
since	NULL
TAR-defective	NULL
viruses	NULL
are	NULL
replication	NULL
competent	NULL
but	NULL
still	NULL
require	NULL
Tat	NULL
.	NULL

In	NULL
each	NULL
case	NULL
,	NULL
TAR	NULL
maps	NULL
to	NULL
the	NULL
NF-KB	NULL
sites	NULL
within	NULL
the	NULL
HIV	NULL
enhancer	NULL
(	NULL
18	NULL
,	NULL
221	NULL
,	NULL
376	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
transcription	NULL
initiation	NULL
,	NULL
Tat	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
elongation	NULL
and	NULL
transcription	NULL
processivity	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
155	NULL
)	NULL
.	NULL

Following	NULL
transcription	NULL
initiation	NULL
,	NULL
paused	NULL
polymerase	NULL
complexes	NULL
accumulate	NULL
and	NULL
are	NULL
prematurely	NULL
terminated	NULL
at	NULL
random	NULL
locations	NULL
(	NULL
191	NULL
,	NULL
219	NULL
)	NULL
.	NULL

The	NULL
IST	NULL
(	NULL
initiator	NULL
of	NULL
short	NULL
transcripts	NULL
)	NULL
sequence	NULL
(	NULL
312	NULL
,	NULL
358	NULL
)	NULL
is	NULL
a	NULL
DNA	NULL
sequence	NULL
(	NULL
-5	NULL
to	NULL
+80	NULL
)	NULL
that	NULL
overlaps	NULL
with	NULL
TAR	NULL
and	NULL
mediates	NULL
the	NULL
synthesis	NULL
of	NULL
short	NULL
transcripts	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Tat	NULL
(	NULL
2	NULL
,	NULL
165	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
mechanism	NULL
remains	NULL
unclear	NULL
,	NULL
Tat	NULL
in	NULL
combination	NULL
with	NULL
a	NULL
cellular	NULL
coactivator	NULL
can	NULL
bind	NULL
TAR	NULL
(	NULL
217	NULL
,	NULL
359	NULL
)	NULL
,	NULL
modify	NULL
the	NULL
transcription	NULL
complex	NULL
,	NULL
release	NULL
it	NULL
from	NULL
the	NULL
promoter	NULL
,	NULL
and	NULL
allow	NULL
full-length	NULL
viral	NULL
transcription	NULL
to	NULL
take	NULL
place	NULL
(	NULL
126	NULL
)	NULL
.	NULL

TAR	NULL
DNA	NULL
Element	NULL
The	NULL
TAR	NULL
DNA	NULL
element	NULL
extends	NULL
from	NULL
+1	NULL
to	NULL
+59	NULL
within	NULL
the	NULL
R	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
and	NULL
includes	NULL
binding	NULL
sites	NULL
for	NULL
a	NULL
number	NULL
of	NULL
cellular	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

There	NULL
is	NULL
a	NULL
high-affinity	NULL
binding	NULL
site	NULL
for	NULL
upstream	NULL
binding	NULL
protein/leader-binding	NULL
protein	NULL
(	NULL
UBP-1/LBP-1	NULL
)	NULL
located	NULL
from	NULL
nucleotides	NULL
-16	NULL
to	NULL
+27	NULL
within	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
159	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
transcription	NULL
assays	NULL
indicate	NULL
that	NULL
purified	NULL
UBP-1/LBP-1	NULL
also	NULL
binds	NULL
to	NULL
a	NULL
low-affinity	NULL
site	NULL
(	NULL
nucleotides	NULL
-38	NULL
to	NULL
-16	NULL
,	NULL
not	NULL
included	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
inhibits	NULL
HIV-1	NULL
gene	NULL
expression	NULL
possibly	NULL
by	NULL
interfering	NULL
with	NULL
TFIID	NULL
binding	NULL
to	NULL
the	NULL
TATA	NULL
element	NULL
(	NULL
159	NULL
)	NULL
.	NULL

Depending	NULL
on	NULL
the	NULL
level	NULL
of	NULL
UBP-1/LBP-1	NULL
relative	NULL
to	NULL
potentially	NULL
competing	NULL
DNA-binding	NULL
proteins	NULL
,	NULL
both	NULL
positive	NULL
and	NULL
negative	NULL
effects	NULL
of	NULL
this	NULL
protein	NULL
on	NULL
HIV-1	NULL
gene	NULL
expression	NULL
are	NULL
possible	NULL
.	NULL

Other	NULL
cellular	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
upstream	NULL
binding	NULL
protein	NULL
2	NULL
(	NULL
UBP-2	NULL
)	NULL
or	NULL
CTF/	NULL
NF1	NULL
,	NULL
also	NULL
bind	NULL
to	NULL
TAR	NULL
DNA	NULL
(	NULL
109	NULL
,	NULL
154	NULL
)	NULL
,	NULL
but	NULL
the	NULL
effect	NULL
of	NULL
these	NULL
factors	NULL
on	NULL
HIV-1	NULL
gene	NULL
expression	NULL
is	NULL
not	NULL
known	NULL
.	NULL

Core	NULL
Promoter	NULL
The	NULL
core	NULL
promoter	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
resembles	NULL
that	NULL
of	NULL
many	NULL
eukaryotic	NULL
genes	NULL
transcribed	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
promoter	NULL
contains	NULL
a	NULL
consensus	NULL
TATA	NULL
sequence	NULL
(	NULL
-27	NULL
to	NULL
-23	NULL
)	NULL
and	NULL
initiator	NULL
elements	NULL
(	NULL
-2	NULL
to	NULL
+8	NULL
and	NULL
+32	NULL
to	NULL
+41	NULL
)	NULL
to	NULL
which	NULL
general	NULL
transcription	NULL
factors	NULL
bind	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
29	NULL
and	NULL
311	NULL
)	NULL
.	NULL

A	NULL
complex	NULL
array	NULL
of	NULL
factors	NULL
interacting	NULL
either	NULL
directly	NULL
or	NULL
indirectly	NULL
with	NULL
the	NULL
TATA	NULL
region	NULL
in	NULL
combination	NULL
with	NULL
upstream	NULL
DNA-binding	NULL
factors	NULL
is	NULL
critical	NULL
for	NULL
regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
.	NULL

Immediately	NULL
upstream	NULL
of	NULL
the	NULL
TATA	NULL
element	NULL
are	NULL
three	NULL
GC-rich	NULL
sequences	NULL
(	NULL
-78	NULL
to	NULL
-46	NULL
)	NULL
,	NULL
to	NULL
which	NULL
the	NULL
ubiquitous	NULL
Spl	NULL
transcription	NULL
factor	NULL
binds	NULL
(	NULL
153	NULL
)	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
studies	NULL
with	NULL
templates	NULL
mutated	NULL
at	NULL
Spl	NULL
demonstrate	NULL
a	NULL
loss	NULL
in	NULL
the	NULL
number	NULL
of	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
Spl	NULL
flanking	NULL
sequences	NULL
,	NULL
indicating	NULL
that	NULL
Spl	NULL
may	NULL
facilitate	NULL
gene	NULL
expression	NULL
by	NULL
stabilizing	NULL
the	NULL
binding	NULL
of	NULL
both	NULL
general	NULL
and	NULL
upstream	NULL
transcription	NULL
factors	NULL
(	NULL
153	NULL
)	NULL
.	NULL

Modulatory	NULL
Elements	NULL
The	NULL
region	NULL
located	NULL
between	NULL
nucleotides	NULL
-410	NULL
and	NULL
-157	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
has	NULL
a	NULL
negative	NULL
effect	NULL
on	NULL
the	NULL
rate	NULL
of	NULL
RNA	NULL
initiation	NULL
in	NULL
Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
vivo	NULL
(	NULL
211	NULL
)	NULL
and	NULL
in	NULL
vitro	NULL
(	NULL
271	NULL
)	NULL
and	NULL
was	NULL
originally	NULL
defined	NULL
as	NULL
the	NULL
negative	NULL
regulatory	NULL
element	NULL
.	NULL

Within	NULL
this	NULL
distal	NULL
enhancer	NULL
element	NULL
are	NULL
binding	NULL
sites	NULL
for	NULL
a	NULL
number	NULL
of	NULL
positively	NULL
(	NULL
Myb	NULL
)	NULL
(	NULL
315	NULL
)	NULL
and	NULL
negatively	NULL
(	NULL
USF	NULL
,	NULL
COUP	NULL
)	NULL
(	NULL
59	NULL
,	NULL
212	NULL
)	NULL
acting	NULL
cellular	NULL
transcription	NULL
factors	NULL
;	NULL
however	NULL
,	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
this	NULL
region	NULL
downregulates	NULL
HIV-1	NULL
transcription	NULL
is	NULL
unknown	NULL
.	NULL

Two	NULL
potential	NULL
AP-1-binding	NULL
sites	NULL
are	NULL
located	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
between	NULL
-357	NULL
and	NULL
-316	NULL
bp	NULL
from	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
101	NULL
)	NULL
.	NULL

AP-1	NULL
is	NULL
present	NULL
in	NULL
all	NULL
cells	NULL
and	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
immediate-carly	NULL
genes	NULL
in	NULL
response	NULL
to	NULL
mitogenic	NULL
stimuli	NULL
including	NULL
se-rum	NULL
,	NULL
growth	NULL
factors	NULL
,	NULL
and	NULL
phorbol	NULL
esters	NULL
.	NULL

The	NULL
region	NULL
within	NULL
the	NULL
HIV-1	NULL
LTR	NULL
that	NULL
binds	NULL
NF-AT	NULL
(	NULL
between	NULL
nucleotides	NULL
-254	NULL
and	NULL
-216	NULL
)	NULL
is	NULL
partially	NULL
responsible	NULL
for	NULL
upregulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
T-cell	NULL
activation	NULL
by	NULL
agents	NULL
such	NULL
as	NULL
ionomycin	NULL
,	NULL
phorbol	NULL
esters	NULL
,	NULL
and	NULL
phytohemagglutinin	NULL
(	NULL
363	NULL
)	NULL
.	NULL

NF-AT	NULL
is	NULL
a	NULL
cytoplasmic	NULL
T-cell-specific	NULL
factor	NULL
which	NULL
combines	NULL
with	NULL
members	NULL
of	NULL
the	NULL
AP-1	NULL
and	NULL
possibly	NULL
NF-	NULL
«	NULL
B/Rel	NULL
proteins	NULL
to	NULL
activate	NULL
transcription	NULL
(	NULL
265	NULL
)	NULL
.	NULL

LEF-1	NULL
(	NULL
TCF-1	NULL
«	NULL
)	NULL
is	NULL
a	NULL
T-cell-specific	NULL
factor	NULL
which	NULL
binds	NULL
between	NULL
nucleotides	NULL
-139	NULL
and	NULL
-124	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
384	NULL
,	NULL
401	NULL
)	NULL
.	NULL

Within	NULL
the	NULL
context	NULL
of	NULL
the	NULL
TcRa	NULL
promoter	NULL
,	NULL
LEF-1	NULL
bends	NULL
DNA	NULL
,	NULL
facilitating	NULL
the	NULL
formation	NULL
of	NULL
nucleoprotein	NULL
complexes	NULL
between	NULL
upstream	NULL
factors	NULL
and	NULL
the	NULL
basal	NULL
transcription	NULL
machinery	NULL
(	NULL
121	NULL
)	NULL
.	NULL

In	NULL
transient	NULL
transfections	NULL
,	NULL
LEF-1	NULL
activates	NULL
transcription	NULL
from	NULL
the	NULL
HIV-1	NULL
LTR	NULL
alone	NULL
and	NULL
in	NULL
synergy	NULL
with	NULL
Tat	NULL
by	NULL
a	NULL
similar	NULL
DNA-bending	NULL
mechanism	NULL
(	NULL
1202	NULL
)	NULL
.	NULL

HIV-1	NULL
Enhancer	NULL
The	NULL
most	NULL
widely	NULL
studied	NULL
element	NULL
in	NULL
the	NULL
modulatory	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
is	NULL
the	NULL
enhancer	NULL
region	NULL
,	NULL
which	NULL
consists	NULL
of	NULL
two	NULL
10-bp	NULL
conserved	NULL
sequences	NULL
(	NULL
-109	NULL
to	NULL
-79	NULL
)	NULL
known	NULL
as	NULL
NF-kB	NULL
motifs	NULL
.	NULL

Nabel	NULL
and	NULL
Baltimore	NULL
(	NULL
256	NULL
)	NULL
first	NULL
established	NULL
the	NULL
role	NULL
of	NULL
NF-kB	NULL
in	NULL
controlling	NULL
transcription	NULL
from	NULL
the	NULL
HIV-1	NULL
LTR	NULL
by	NULL
demonstrating	NULL
a	NULL
direct	NULL
correlation	NULL
between	NULL
increases	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
and	NULL
HIV-1	NULL
LTR-directed	NULL
transcriptional	NULL
activity	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

Mutation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
motifs	NULL
in	NULL
HIV-1	NULL
LTR	NULL
chloramphenicol	NULL
acetyltransferase	NULL
reporter	NULL
constructs	NULL
results	NULL
in	NULL
a	NULL
marked	NULL
decrease	NULL
in	NULL
gene	NULL
expression	NULL
following	NULL
transfection	NULL
into	NULL
lymphoid	NULL
cells	NULL
,	NULL
in	NULL
both	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
the	NULL
tat	NULL
gene	NULL
(	NULL
256	NULL
)	NULL
.	NULL

Transient-transfection	NULL
studies	NULL
,	NULL
with	NULL
combinations	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
and	NULL
HIV-1	NULL
enhancer	NULL
sequences	NULL
linked	NULL
to	NULL
reporter	NULL
genes	NULL
,	NULL
demonstrate	NULL
that	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
leads	NULL
to	NULL
increased	NULL
HIV-1	NULL
LTR-directed	NULL
gene	NULL
expression	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
128	NULL
)	NULL
.	NULL

The	NULL
NF-KB	NULL
sites	NULL
act	NULL
in	NULL
synergy	NULL
with	NULL
NF-AT	NULL
sites	NULL
in	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
-stimulated	NULL
T	NULL
cells	NULL
(	NULL
75	NULL
,	NULL
182	NULL
,	NULL
260	NULL
,	NULL
371	NULL
)	NULL
to	NULL
increase	NULL
the	NULL
rate	NULL
of	NULL
viral	NULL
replication	NULL
in	NULL
cells	NULL
that	NULL
respond	NULL
to	NULL
mitogenic	NULL
stimulation	NULL
.	NULL

Among	NULL
the	NULL
elements	NULL
identified	NULL
as	NULL
positively	NULL
acting	NULL
factors	NULL
in	NULL
basal	NULL
HIV-1	NULL
transcription	NULL
,	NULL
TATA	NULL
,	NULL
Sp1	NULL
,	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
elements	NULL
are	NULL
the	NULL
most	NULL
influential	NULL
in	NULL
primary	NULL
monocytes	NULL
while	NULL
NF-kB	NULL
and	NULL
NF-AT	NULL
have	NULL
strong	NULL
effects	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
249	NULL
)	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
AP-2	NULL
is	NULL
present	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
motif	NULL
5-CCGCTGGGGA-3	NULL
'	NULL
between	NULL
the	NULL
two	NULL
NF-kB	NULL
motifs	NULL
within	NULL
the	NULL
HIV	NULL
enhancer	NULL
(	NULL
406	NULL
)	NULL
.	NULL

AP-2	NULL
may	NULL
have	NULL
a	NULL
positive	NULL
effect	NULL
on	NULL
HIV	NULL
transcription	NULL
in	NULL
unstimulated	NULL
T	NULL
cells	NULL
since	NULL
mutations	NULL
within	NULL
the	NULL
AP-2	NULL
site	NULL
reduce	NULL
HIV	NULL
LTR	NULL
directed	NULL
transcription	NULL
fivefold	NULL
(	NULL
288	NULL
)	NULL
.	NULL

AP-2	NULL
binds	NULL
in	NULL
a	NULL
mutually	NULL
exclusive	NULL
manner	NULL
with	NULL
proteins	NULL
and	NULL
does	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
PMA	NULL
or	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
(	NULL
TNF-a	NULL
)	NULL
responsiveness	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
element	NULL
(	NULL
288	NULL
)	NULL
.	NULL

NF-B/Rel	NULL
FAMILY	NULL
OF	NULL
TRANSCRIPTION	NULL
FACTORS	NULL
NF-KB	NULL
is	NULL
a	NULL
ubiquitous	NULL
transcription	NULL
factor	NULL
that	NULL
participates	NULL
in	NULL
various	NULL
biological	NULL
processes	NULL
including	NULL
immunological	NULL
re	NULL
REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
485	NULL
sponsiveness	NULL
,	NULL
lymphoid	NULL
cell	NULL
differentiation	NULL
,	NULL
growth	NULL
control	NULL
,	NULL
and	NULL
dorsal-ventral	NULL
axis	NULL
determination	NULL
in	NULL
Drosophila	NULL
melano-gaster	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
17	NULL
,	NULL
128	NULL
,	NULL
129	NULL
,	NULL
205	NULL
,	NULL
and	NULL
253	NULL
)	NULL
.	NULL

NF-kB	NULL
exists	NULL
in	NULL
the	NULL
cytoplasm	NULL
in	NULL
latent	NULL
form	NULL
as	NULL
a	NULL
complex	NULL
consisting	NULL
of	NULL
a	NULL
dimer	NULL
of	NULL
DNA-binding	NULL
subunits	NULL
bound	NULL
to	NULL
an	NULL
inhibitor	NULL
,	NULL
IxB	NULL
.	NULL

NF-	NULL
«	NULL
B-regulated	NULL
genes	NULL
encode	NULL
proteins	NULL
involved	NULL
in	NULL
the	NULL
rapid	NULL
response	NULL
to	NULL
pathogens	NULL
or	NULL
stress	NULL
,	NULL
including	NULL
the	NULL
acute-phase	NULL
proteins	NULL
,	NULL
cytokines	NULL
,	NULL
and	NULL
cellular	NULL
adhesion	NULL
molecules	NULL
(	NULL
17	NULL
)	NULL
.	NULL

NF-KB	NULL
also	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

In	NULL
activated	NULL
monocytes	NULL
and	NULL
macrophages	NULL
,	NULL
genes	NULL
such	NULL
as	NULL
those	NULL
encoding	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
G-CSF	NULL
)	NULL
,	NULL
M-CSF	NULL
,	NULL
and	NULL
GM-CSF	NULL
,	NULL
the	NULL
inflammatory	NULL
cytokines	NULL
beta	NULL
interferon	NULL
[	NULL
IFN-B	NULL
]	NULL
,	NULL
TNF-	NULL
«	NULL
,	NULL
interleukin-1	NULL
(	NULL
IL-1	NULL
)	NULL
and	NULL
IL-6	NULL
,	NULL
receptors	NULL
for	NULL
tissue	NULL
factor	NULL
and	NULL
IL-2	NULL
«	NULL
-chain	NULL
,	NULL
the	NULL
chemotactic	NULL
protein	NULL
MCP-1/JE	NULL
,	NULL
and	NULL
nitric	NULL
oxide	NULL
synthase	NULL
are	NULL
highly	NULL
induced	NULL
as	NULL
a	NULL
result	NULL
of	NULL
regulatory	NULL
control	NULL
by	NULL
NF-kB	NULL
(	NULL
253	NULL
)	NULL
.	NULL

The	NULL
production	NULL
of	NULL
these	NULL
immunomodulatory	NULL
cytokines	NULL
is	NULL
an	NULL
essential	NULL
part	NULL
of	NULL
the	NULL
host	NULL
immune	NULL
response	NULL
to	NULL
bacterial	NULL
and	NULL
viral	NULL
pathogens	NULL
.	NULL

NF-B/Rel	NULL
DNA-Binding	NULL
Subunits	NULL
Each	NULL
of	NULL
the	NULL
five	NULL
DNA-binding	NULL
members	NULL
of	NULL
the	NULL
Rel	NULL
family	NULL
(	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
RelA	NULL
,	NULL
c-Rel	NULL
,	NULL
and	NULL
RelB	NULL
)	NULL
shares	NULL
a	NULL
region	NULL
of	NULL
homology	NULL
termed	NULL
the	NULL
NF-	NULL
«	NULL
xB/Rel/dorsal	NULL
(	NULL
NRD	NULL
)	NULL
region	NULL
,	NULL
which	NULL
spans	NULL
approximately	NULL
300	NULL
amino	NULL
acids	NULL
at	NULL
the	NULL
amino	NULL
terminus	NULL
of	NULL
each	NULL
protein	NULL
(	NULL
36	NULL
,	NULL
205	NULL
)	NULL
.	NULL

The	NULL
domain	NULL
structures	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B/IkB	NULL
family	NULL
members	NULL
are	NULL
illustrated	NULL
schematically	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

The	NULL
NRD	NULL
region	NULL
is	NULL
responsible	NULL
for	NULL
DNA	NULL
binding	NULL
(	NULL
184	NULL
,	NULL
223	NULL
)	NULL
,	NULL
dimerization	NULL
(	NULL
210	NULL
)	NULL
,	NULL
nuclear	NULL
localization	NULL
,	NULL
and	NULL
interaction	NULL
with	NULL
the	NULL
inhibitory	NULL
subunit	NULL
(	NULL
s	NULL
)	NULL
,	NULL
IkB	NULL
(	NULL
26	NULL
,	NULL
409	NULL
)	NULL
.	NULL

The	NULL
crystal	NULL
structure	NULL
of	NULL
p50	NULL
homodimers	NULL
bound	NULL
to	NULL
DNA	NULL
reveals	NULL
that	NULL
each	NULL
DNA-binding	NULL
subunit	NULL
surrounds	NULL
DNA	NULL
by	NULL
folding	NULL
into	NULL
a	NULL
pattern	NULL
that	NULL
resembles	NULL
immunoglobulin-like	NULL
modules	NULL
(	NULL
120	NULL
,	NULL
250	NULL
)	NULL
.	NULL

The	NULL
NRD	NULL
DNA-binding	NULL
region	NULL
is	NULL
divided	NULL
into	NULL
two	NULL
domains	NULL
separated	NULL
by	NULL
a	NULL
flexible	NULL
hinge	NULL
:	NULL
the	NULL
amino-terminal	NULL
portion	NULL
contains	NULL
a	NULL
recognition	NULL
loop	NULL
which	NULL
interacts	NULL
within	NULL
the	NULL
major	NULL
groove	NULL
of	NULL
DNA	NULL
,	NULL
and	NULL
the	NULL
carboxyl-terminal	NULL
region	NULL
functions	NULL
as	NULL
a	NULL
dimerization	NULL
interface	NULL
(	NULL
120	NULL
,	NULL
250	NULL
)	NULL
.	NULL

Two	NULL
of	NULL
the	NULL
DNA-binding	NULL
subunits	NULL
are	NULL
synthesized	NULL
as	NULL
inactive	NULL
cytoplasmic	NULL
precursor	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
product	NULL
of	NULL
the	NULL
nfkb1	NULL
gene	NULL
is	NULL
a	NULL
105-kDa	NULL
protein	NULL
which	NULL
gives	NULL
rise	NULL
to	NULL
a	NULL
50-kDa	NULL
DNA-binding	NULL
subunit	NULL
,	NULL
p50	NULL
(	NULL
36	NULL
,	NULL
166	NULL
,	NULL
237	NULL
)	NULL
.	NULL

The	NULL
nfkb2-encoded	NULL
p100	NULL
precursor	NULL
is	NULL
very	NULL
similar	NULL
to	NULL
p105	NULL
;	NULL
its	NULL
mature	NULL
DNA-binding	NULL
form	NULL
is	NULL
p52	NULL
(	NULL
262	NULL
)	NULL
.	NULL

Each	NULL
precursor	NULL
protein	NULL
has	NULL
two	NULL
functional	NULL
domains	NULL
:	NULL
the	NULL
carboxy-terminal	NULL
inhibitory	NULL
domain	NULL
,	NULL
containing	NULL
seven	NULL
ankyrin	NULL
repeats	NULL
,	NULL
and	NULL
the	NULL
amino-terminal	NULL
NRD	NULL
(	NULL
134	NULL
,	NULL
206	NULL
,	NULL
318	NULL
)	NULL
.	NULL

A	NULL
glycine-rich	NULL
region	NULL
divides	NULL
the	NULL
two	NULL
functional	NULL
domains	NULL
and	NULL
allows	NULL
sufficient	NULL
structural	NULL
flexibility	NULL
for	NULL
amino	NULL
and	NULL
carboxy	NULL
termini	NULL
to	NULL
physically	NULL
interact	NULL
(	NULL
139	NULL
)	NULL
.	NULL

This	NULL
physical	NULL
interaction	NULL
masks	NULL
the	NULL
nuclear	NULL
localization	NULL
sequence	NULL
within	NULL
the	NULL
NRD	NULL
region	NULL
,	NULL
preventing	NULL
nuclear	NULL
translocation	NULL
and	NULL
DNA	NULL
binding	NULL
.	NULL

The	NULL
processed	NULL
DNA-binding	NULL
subunits	NULL
which	NULL
are	NULL
composed	NULL
almost	NULL
entirely	NULL
of	NULL
the	NULL
NRD	NULL
region	NULL
,	NULL
arise	NULL
following	NULL
ubiquitin-dependent	NULL
proteolytic	NULL
degradation	NULL
of	NULL
the	NULL
carboxy	NULL
termini	NULL
up	NULL
to	NULL
a	NULL
site	NULL
adjacent	NULL
to	NULL
the	NULL
glycine-rich	NULL
hinge	NULL
(	NULL
84	NULL
,	NULL
277	NULL
)	NULL
.	NULL

The	NULL
other	NULL
NF-	NULL
«	NULL
B/	NULL
Rel	NULL
DNA-binding	NULL
proteins	NULL
are	NULL
not	NULL
proteolytically	NULL
processed	NULL
from	NULL
precursors	NULL
but	NULL
remain	NULL
cytoplasmic	NULL
through	NULL
interactions	NULL
with	NULL
inhibitory	NULL
molecules	NULL
.	NULL

c-Rel	NULL
is	NULL
an	NULL
85-kDa	NULL
protein	NULL
,	NULL
which	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
NRD	NULL
region	NULL
,	NULL
contains	NULL
a	NULL
unique	NULL
300-amino-acid	NULL
carboxy-terminal	NULL
domain	NULL
and	NULL
is	NULL
highly	NULL
related	NULL
to	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
(	NULL
46	NULL
,	NULL
148	NULL
)	NULL
.	NULL

The	NULL
carboxy	NULL
termini	NULL
of	NULL
c-Rel	NULL
and	NULL
RelA	NULL
contain	NULL
two	NULL
distinct	NULL
activation	NULL
domains	NULL
similar	NULL
to	NULL
those	NULL
in	NULL
the	NULL
viral	NULL
transactivator	NULL
VP16	NULL
(	NULL
20	NULL
,	NULL
129	NULL
,	NULL
289	NULL
,	NULL
343	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
RelB	NULL
subunit	NULL
contains	NULL
an	NULL
elongated	NULL
amino-terminal	NULL
segment	NULL
but	NULL
lacks	NULL
trans-activating	NULL
potential	NULL
(	NULL
338	NULL
)	NULL
.	NULL

The	NULL
physiological	NULL
role	NULL
of	NULL
the	NULL
two	NULL
DNA-binding	NULL
subunits	NULL
in	NULL
486	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

DNA	NULL
BINDING	NULL
NON-DNA	NULL
BINDING	NULL
INHIBITORS	NULL
Trans	NULL
Ankyrin	NULL
Rel	NULL
Homology	NULL
activation	NULL
Reznats	NULL
PEST	NULL
§	NULL
&	NULL
Trans	NULL
IkBa	NULL
.	NULL

Rel	NULL
Homology	NULL
activatlon	NULL
Trans	NULL
Ankyrin	NULL
Ret	NULL
Homology	NULL
activation	NULL
Repeats	NULL
RRRERRRE	NULL
]	NULL
\	NULL
Oss	NULL
:	NULL
\	NULL
[	NULL
C	NULL
@	NULL
Bcl-3	NULL
Ankyrin	NULL
Rel	NULL
Homology	NULL
Repeats	NULL
proteolytic	NULL
.	NULL

``	NULL
t	NULL
Coj	NULL
\	NULL
Ankyrin	NULL
Repeats	NULL
Rel	NULL
Homology	NULL
proteolytic	NULL
cleavage	NULL
Rel	NULL
Homology	NULL
RelB	NULL
Repeat	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Schematic	NULL
representation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B/Rel	NULL
and	NULL
IxB	NULL
family	NULL
of	NULL
proteins	NULL
.	NULL

The	NULL
different	NULL
mammalian	NULL
NF-	NULL
«	NULL
B/Rel	NULL
and	NULL
IxB	NULL
proteins	NULL
are	NULL
organized	NULL
as	NULL
DNA-binding	NULL
proteins	NULL
,	NULL
nonbinding	NULL
proteins	NULL
,	NULL
and	NULL
inhibitors	NULL
.	NULL

The	NULL
name	NULL
of	NULL
each	NULL
protein	NULL
is	NULL
indicated	NULL
below	NULL
each	NULL
structure	NULL
.	NULL

Arrows	NULL
indicate	NULL
the	NULL
proteolytic	NULL
cleavage	NULL
of	NULL
the	NULL
non-DNA-binding	NULL
p105	NULL
and	NULL
p100	NULL
proteins	NULL
into	NULL
the	NULL
DNA-binding	NULL
p50	NULL
and	NULL
p52	NULL
proteins	NULL
,	NULL
respectively	NULL
.	NULL

A	NULL
second	NULL
arrow	NULL
in	NULL
the	NULL
p105	NULL
structure	NULL
indicates	NULL
the	NULL
alternative	NULL
splicing	NULL
of	NULL
the	NULL
p105	NULL
mRNA	NULL
to	NULL
produce	NULL
the	NULL
inhibitory	NULL
molecule	NULL
IxBy	NULL
.	NULL

Symbols	NULL
and	NULL
abbreviations	NULL
:	NULL
ZZZ	NULL
,	NULL
DNA-binding	NULL
portion	NULL
of	NULL
the	NULL
Rel	NULL
homology	NULL
(	NULL
RH	NULL
)	NULL
domain	NULL
;	NULL
22	NULL
,	NULL
dimerization	NULL
portion	NULL
of	NULL
the	NULL
RH	NULL
domain	NULL
;	NULL
®	NULL
,	NULL
PKA	NULL
phosphorylation	NULL
site	NULL
present	NULL
in	NULL
the	NULL
RH	NULL
domain	NULL
;	NULL
NLS	NULL
,	NULL
nuclear	NULL
localization	NULL
signal	NULL
;	NULL
G	NULL
,	NULL
glycine-rich	NULL
hinge	NULL
region	NULL
present	NULL
in	NULL
p105	NULL
and	NULL
p100	NULL
;	NULL
P	NULL
and	NULL
S/P	NULL
,	NULL
proline-rich	NULL
and	NULL
serine-	NULL
and	NULL
proline-rich	NULL
regions	NULL
,	NULL
respectively	NULL
;	NULL
[	NULL
__	NULL
]	NULL
,	NULL
transactivation	NULL
domains	NULL
present	NULL
in	NULL
p65	NULL
,	NULL
p6S5A	NULL
,	NULL
c-Rel	NULL
,	NULL
and	NULL
RelB	NULL
;	NULL
ankyrin	NULL
repeats	NULL
present	NULL
in	NULL
p105	NULL
,	NULL
p100	NULL
,	NULL
and	NULL
the	NULL
inhibitor	NULL
proteins	NULL
;	NULL
RW	NULL
,	NULL
protein	NULL
degradation	NULL
signal	NULL
PEST	NULL
present	NULL
in	NULL
IxBa	NULL
and	NULL
IBB	NULL
.	NULL

vivo	NULL
has	NULL
been	NULL
characterized	NULL
in	NULL
mice	NULL
homozygously	NULL
deficient	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
and	NULL
RelB	NULL
subunits	NULL
(	NULL
356	NULL
,	NULL
403	NULL
)	NULL
.	NULL

Targeted	NULL
disruption	NULL
of	NULL
the	NULL
relb	NULL
locus	NULL
yields	NULL
mice	NULL
with	NULL
multiple	NULL
immunological	NULL
abnormalities	NULL
including	NULL
dysfunction	NULL
of	NULL
the	NULL
hematopoietic	NULL
system	NULL
and	NULL
inflammatory	NULL
response	NULL
;	NULL
however	NULL
,	NULL
there	NULL
are	NULL
no	NULL
apparent	NULL
defects	NULL
in	NULL
lymphoid	NULL
cell	NULL
development	NULL
(	NULL
403	NULL
)	NULL
.	NULL

Mice	NULL
deficient	NULL
in	NULL
the	NULL
p50	NULL
subunit	NULL
show	NULL
no	NULL
developmental	NULL
abnormalities	NULL
but	NULL
have	NULL
impaired	NULL
B-cell-mediated	NULL
(	NULL
specific	NULL
)	NULL
and	NULL
nonspecific	NULL
immune	NULL
responses	NULL
(	NULL
356	NULL
)	NULL
.	NULL

IB	NULL
Regulatory	NULL
Proteins	NULL
The	NULL
IxB	NULL
family	NULL
of	NULL
proteins	NULL
is	NULL
defined	NULL
by	NULL
its	NULL
ability	NULL
to	NULL
interact	NULL
with	NULL
NF-kB/Rel	NULL
subunits	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
between	NULL
five	NULL
and	NULL
seven	NULL
repeats	NULL
of	NULL
a	NULL
33-amino-acid	NULL
sequence	NULL
termed	NULL
the	NULL
ankyrin	NULL
motif	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
24	NULL
)	NULL
.	NULL

The	NULL
ankyrin	NULL
motif	NULL
may	NULL
mediate	NULL
the	NULL
sequestration	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
cytoplasm	NULL
,	NULL
possibly	NULL
in	NULL
association	NULL
with	NULL
cytoskeletal	NULL
proteins	NULL
(	NULL
35	NULL
)	NULL
.	NULL

IxBa	NULL
(	NULL
132	NULL
)	NULL
is	NULL
the	NULL
most	NULL
extensively	NULL
studied	NULL
protein	NULL
in	NULL
this	NULL
family	NULL
,	NULL
but	NULL
other	NULL
members	NULL
include	NULL
IBB	NULL
(	NULL
379	NULL
)	NULL
,	NULL
IxBy	NULL
(	NULL
147	NULL
,	NULL
206	NULL
)	NULL
,	NULL
and	NULL
the	NULL
product	NULL
of	NULL
the	NULL
proto-oncogene	NULL
bel-3	NULL
(	NULL
134	NULL
,	NULL
270	NULL
)	NULL
.	NULL

The	NULL
full-length	NULL
precursors	NULL
p105	NULL
and	NULL
p100	NULL
also	NULL
have	NULL
demonstrated	NULL
inhibitory	NULL
capabilities	NULL
,	NULL
not	NULL
only	NULL
over	NULL
their	NULL
own	NULL
amino	NULL
termini	NULL
but	NULL
also	NULL
through	NULL
interaction	NULL
with	NULL
c-Rel	NULL
and	NULL
RelA	NULL
(	NULL
318	NULL
)	NULL
.	NULL

There	NULL
is	NULL
specificity	NULL
in	NULL
the	NULL
interaction	NULL
between	NULL
the	NULL
inhibitory	NULL
subunits	NULL
and	NULL
the	NULL
DNA-binding	NULL
members	NULL
;	NULL
IxBa	NULL
and	NULL
IxBB	NULL
exclusively	NULL
inhibit	NULL
dimers	NULL
containing	NULL
RelA	NULL
and	NULL
c-Rel	NULL
(	NULL
66	NULL
,	NULL
132	NULL
,	NULL
164	NULL
)	NULL
,	NULL
whereas	NULL
IxBy	NULL
and	NULL
Bel-3	NULL
preferentially	NULL
interact	NULL
with	NULL
p50-and/or	NULL
p52-containing	NULL
dimers	NULL
(	NULL
103	NULL
,	NULL
163	NULL
,	NULL
206	NULL
,	NULL
266	NULL
,	NULL
409	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
DNA-Binding	NULL
Activity	NULL
In	NULL
most	NULL
cell	NULL
types	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
present	NULL
in	NULL
an	NULL
inactive	NULL
cytosolic	NULL
form	NULL
that	NULL
can	NULL
be	NULL
induced	NULL
following	NULL
exposure	NULL
to	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
activating	NULL
agents	NULL
including	NULL
cytokines	NULL
,	NULL
T-cell	NULL
mitogens	NULL
,	NULL
bacterial	NULL
products	NULL
,	NULL
and	NULL
viruses	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
NF-kB	NULL
requires	NULL
the	NULL
disruption	NULL
of	NULL
IxB-DNA-binding	NULL
subunit	NULL
interactions	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
indicate	NULL
that	NULL
phosphorylation	NULL
of	NULL
IxB	NULL
is	NULL
an	NULL
important	NULL
posttranslational	NULL
modification	NULL
involved	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
direct	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
487	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Biochemistry	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

transcription	NULL
factor	NULL
exists	NULL
in	NULL
two	NULL
latent	NULL
cytoplasmic	NULL
forms	NULL
:	NULL
(	NULL
i	NULL
)	NULL
complexed	NULL
to	NULL
an	NULL
inhibitor	NULL
IB	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
in	NULL
association	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
precursors	NULL
p100	NULL
or	NULL
p105	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
is	NULL
induced	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
agents	NULL
and	NULL
pathogens	NULL
,	NULL
some	NULL
of	NULL
which	NULL
interact	NULL
with	NULL
specific	NULL
receptors	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
.	NULL

Second-messenger	NULL
signaling	NULL
molecules	NULL
generated	NULL
by	NULL
these	NULL
agents	NULL
lead	NULL
to	NULL
the	NULL
phosphorylation	NULL
followed	NULL
by	NULL
polyubiquitination	NULL
(	NULL
Ub	NULL
)	NULL
and	NULL
subsequent	NULL
degradation	NULL
of	NULL
IxBa	NULL
in	NULL
the	NULL
268	NULL
multisubunit	NULL
proteasome	NULL
complex	NULL
(	NULL
277	NULL
)	NULL
.	NULL

IxB	NULL
degradation	NULL
liberates	NULL
dimeric	NULL
combinations	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
subunits	NULL
,	NULL
which	NULL
rapidly	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

Active	NULL
NF-	NULL
«	NULL
B	NULL
dimers	NULL
are	NULL
also	NULL
generated	NULL
following	NULL
proteolytic	NULL
degradation	NULL
of	NULL
the	NULL
carboxy	NULL
termini	NULL
of	NULL
the	NULL
p105	NULL
or	NULL
p100	NULL
precursor	NULL
proteins	NULL
.	NULL

Target	NULL
genes	NULL
are	NULL
selectively	NULL
regulated	NULL
by	NULL
the	NULL
distinct	NULL
transcriptional	NULL
activation	NULL
potential	NULL
of	NULL
different	NULL
subunit	NULL
combinations	NULL
,	NULL
variations	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
consensus	NULL
sequence	NULL
,	NULL
promoter	NULL
context	NULL
,	NULL
and	NULL
synergism	NULL
with	NULL
other	NULL
transcription	NULL
factors	NULL
(	NULL
17	NULL
,	NULL
205	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B-regulated	NULL
transcription	NULL
is	NULL
restricted	NULL
as	NULL
newly	NULL
synthesized	NULL
IxB	NULL
interacts	NULL
with	NULL
cytoplasmic	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
,	NULL
restoring	NULL
the	NULL
latent	NULL
cytoplasmic	NULL
complex	NULL
;	NULL
nuclear	NULL
IxBa	NULL
may	NULL
directly	NULL
dissociate	NULL
NF-	NULL
«	NULL
B-DNA	NULL
complexes	NULL
.	NULL

The	NULL
transcriptional	NULL
upregulation	NULL
of	NULL
nfkb1	NULL
,	NULL
nfkb2	NULL
,	NULL
c-rel	NULL
,	NULL
bel-3	NULL
,	NULL
and	NULL
Ikba	NULL
(	NULL
MAD-3	NULL
)	NULL
genes	NULL
in	NULL
response	NULL
to	NULL
NF-	NULL
«	NULL
B-activating	NULL
stimuli	NULL
restores	NULL
intracellular	NULL
pools	NULL
of	NULL
latent	NULL
NF-kB	NULL
.	NULL

occurs	NULL
with	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
,	NULL
PKA	NULL
,	NULL
heme-regulated	NULL
eukaryotic	NULL
initiation	NULL
factor	NULL
2	NULL
kinase	NULL
,	NULL
cyclic	NULL
AMP-responsive	NULL
kinase	NULL
,	NULL
and	NULL
the	NULL
double-stranded	NULL
RNA	NULL
(	NULL
dsRNA	NULL
)	NULL
-dependent	NULL
kinase	NULL
(	NULL
PKR	NULL
)	NULL
(	NULL
34	NULL
,	NULL
139	NULL
,	NULL
183	NULL
,	NULL
205	NULL
,	NULL
216	NULL
)	NULL
.	NULL

In	NULL
cells	NULL
,	NULL
both	NULL
Raf	NULL
and	NULL
Src	NULL
kinases	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B-binding	NULL
activity	NULL
(	NULL
92	NULL
,	NULL
174	NULL
,	NULL
200	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
kinase	NULL
inhibitors	NULL
can	NULL
block	NULL
PMA-induced	NULL
NF-kB	NULL
activation	NULL
(	NULL
381	NULL
)	NULL
.	NULL

IxB	NULL
degradation	NULL
also	NULL
coincides	NULL
directly	NULL
with	NULL
the	NULL
appearance	NULL
of	NULL
nuclear	NULL
NF-kB	NULL
and	NULL
is	NULL
necessary	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
(	NULL
138	NULL
)	NULL
.	NULL

Events	NULL
responsible	NULL
for	NULL
IxB	NULL
degradation	NULL
are	NULL
highly	NULL
inducible	NULL
,	NULL
and	NULL
stimulation	NULL
of	NULL
cells	NULL
may	NULL
lead	NULL
to	NULL
a	NULL
modification	NULL
of	NULL
IkB	NULL
(	NULL
such	NULL
as	NULL
phosphorylation	NULL
)	NULL
that	NULL
targets	NULL
the	NULL
inhibitor	NULL
for	NULL
rapid	NULL
degradation	NULL
.	NULL

Recent	NULL
work	NULL
by	NULL
Palombella	NULL
et	NULL
al	NULL
.	NULL

demonstrates	NULL
that	NULL
TNF-	NULL
«	NULL
-induced	NULL
IxBa	NULL
degradation	NULL
is	NULL
blocked	NULL
by	NULL
inhibitors	NULL
of	NULL
ubiquitin-dependent	NULL
proteasomes	NULL
(	NULL
277	NULL
)	NULL
.	NULL

Proteolytic	NULL
processing	NULL
of	NULL
the	NULL
precursors	NULL
p105	NULL
and	NULL
p100	NULL
into	NULL
their	NULL
active	NULL
p50	NULL
and	NULL
p52	NULL
forms	NULL
is	NULL
an	NULL
additional	NULL
level	NULL
at	NULL
which	NULL
NF-	NULL
«	NULL
kB	NULL
DNA-binding	NULL
activity	NULL
may	NULL
be	NULL
controlled	NULL
.	NULL

For	NULL
example	NULL
,	NULL
p105	NULL
and	NULL
p100	NULL
exist	NULL
complexed	NULL
to	NULL
other	NULL
Rel	NULL
family	NULL
members	NULL
such	NULL
as	NULL
RelA	NULL
,	NULL
c-Rel	NULL
,	NULL
and	NULL
proteolytically	NULL
released	NULL
p50	NULL
(	NULL
233	NULL
,	NULL
259	NULL
,	NULL
318	NULL
,	NULL
373	NULL
)	NULL
.	NULL

Proteolytic	NULL
cleavage	NULL
of	NULL
the	NULL
carboxyl	NULL
terminal	NULL
of	NULL
p105	NULL
activates	NULL
DNA-binding	NULL
p50-p50	NULL
,	NULL
p50-c-Rel	NULL
,	NULL
and	NULL
p50-RelIA	NULL
dimers	NULL
(	NULL
233	NULL
,	NULL
259	NULL
,	NULL
318	NULL
)	NULL
.	NULL

This	NULL
mechanism	NULL
,	NULL
however	NULL
,	NULL
is	NULL
not	NULL
likely	NULL
to	NULL
result	NULL
in	NULL
a	NULL
rapid	NULL
appearance	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL

Recent	NULL
experiments	NULL
in	NULL
vivo	NULL
have	NULL
shown	NULL
that	NULL
p105	NULL
is	NULL
phosphorylated	NULL
and	NULL
its	NULL
carboxy	NULL
terminus	NULL
is	NULL
degraded	NULL
by	NULL
the	NULL
ubiquitin-dependent	NULL
proteasome	NULL
pathway	NULL
(	NULL
277	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
two	NULL
types	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
can	NULL
exist	NULL
in	NULL
the	NULL
cytoplasm	NULL
:	NULL
those	NULL
retained	NULL
by	NULL
IxBa	NULL
and	NULL
those	NULL
retained	NULL
by	NULL
NF-kB	NULL
precursors	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Each	NULL
target	NULL
may	NULL
respond	NULL
independently	NULL
to	NULL
different	NULL
types	NULL
of	NULL
environmental	NULL
stimuli	NULL
or	NULL
differential	NULL
signals	NULL
.	NULL

Once	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
is	NULL
activated	NULL
,	NULL
numerous	NULL
target	NULL
genes	NULL
are	NULL
selectively	NULL
regulated	NULL
by	NULL
the	NULL
transcriptional	NULL
activation	NULL
potential	NULL
of	NULL
different	NULL
homo-	NULL
and	NULL
heterodimer	NULL
com-binations	NULL
.	NULL

As	NULL
well	NULL
,	NULL
variations	NULL
in	NULL
the	NULL
NF-kB	NULL
consensus	NULL
sequence	NULL
488	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

S32	NULL
S36	NULL
LLDDRHDSGLDSMKDEEYEQM	NULL
MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

6	NULL
*	NULL
m	NULL
*	NULL
YSPYQLTWGRPSTRIQQQLGQLTLONLQMLPESEDEESYDTESEFTEFTEDELPYDDCVFGGQRLTL	NULL
$	NULL
283	NULL
T291	NULL
R22	NULL
0	NULL
A2___	NULL
T299	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Schematic	NULL
representation	NULL
of	NULL
human	NULL
I	NULL
«	NULL
xBa	NULL
.	NULL

Human	NULL
IxBa	NULL
contains	NULL
five	NULL
internal	NULL
ankyrin	NULL
repeats	NULL
(	NULL
SWI6/ANK	NULL
)	NULL
that	NULL
bind	NULL
to	NULL
NF-xB	NULL
molecules	NULL
and	NULL
mask	NULL
the	NULL
nuclear	NULL
localization	NULL
sequence	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
N-terminal	NULL
region	NULL
of	NULL
IxBa	NULL
«	NULL
is	NULL
expanded	NULL
above	NULL
the	NULL
schematic	NULL
to	NULL
show	NULL
the	NULL
one-letter	NULL
amino	NULL
acid	NULL
sequence	NULL
between	NULL
amino	NULL
acids	NULL
25	NULL
and	NULL
45	NULL
.	NULL

Within	NULL
this	NULL
region	NULL
of	NULL
IxBa	NULL
«	NULL
are	NULL
two	NULL
phosphorylation	NULL
sites	NULL
(	NULL
Ser-32	NULL
and	NULL
Ser-36	NULL
,	NULL
indicated	NULL
by	NULL
triangles	NULL
)	NULL
,	NULL
shown	NULL
previously	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
inducer-mediated	NULL
degradation	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Both	NULL
sites	NULL
represent	NULL
potential	NULL
phosphorylation	NULL
sites	NULL
by	NULL
CKII	NULL
(	NULL
CKII	NULL
consensus	NULL
S/T-X-X-E/D	NULL
)	NULL
.	NULL

A	NULL
region	NULL
rich	NULL
in	NULL
proline	NULL
,	NULL
serine	NULL
,	NULL
threonine	NULL
,	NULL
and	NULL
glutamic	NULL
acid	NULL
(	NULL
the	NULL
PEST	NULL
domain	NULL
)	NULL
spans	NULL
amino	NULL
acids	NULL
264	NULL
to	NULL
317	NULL
;	NULL
the	NULL
C-terminal	NULL
region	NULL
of	NULL
IxBa	NULL
«	NULL
between	NULL
amino	NULL
acids	NULL
251	NULL
and	NULL
317	NULL
is	NULL
expanded	NULL
below	NULL
the	NULL
schematic	NULL
to	NULL
show	NULL
the	NULL
one-letter	NULL
amino	NULL
acid	NULL
sequence	NULL
.	NULL

The	NULL
PEST	NULL
domain	NULL
contains	NULL
several	NULL
CKII	NULL
phosphorylation	NULL
sites	NULL
clustered	NULL
within	NULL
the	NULL
highly	NULL
acidic	NULL
domain	NULL
(	NULL
thick	NULL
line	NULL
)	NULL
at	NULL
$	NULL
-283	NULL
,	NULL
T-291	NULL
,	NULL
and	NULL
T-299	NULL
(	NULL
underlined	NULL
)	NULL
(	NULL
23	NULL
,	NULL
202	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
residues	NULL
T-291	NULL
and	NULL
T-299	NULL
also	NULL
generates	NULL
new	NULL
potential	NULL
CKII	NULL
phosphorylation	NULL
sites	NULL
at	NULL
residues	NULL
$	NULL
-288	NULL
,	NULL
T-296	NULL
,	NULL
and	NULL
$	NULL
-293	NULL
(	NULL
denoted	NULL
by	NULL
lines	NULL
and	NULL
asterisks	NULL
above	NULL
the	NULL
sequence	NULL
)	NULL
.	NULL

A	NULL
potential	NULL
PKC	NULL
site	NULL
located	NULL
between	NULL
the	NULL
ankyrin	NULL
repeats	NULL
and	NULL
the	NULL
PEST	NULL
domain	NULL
is	NULL
also	NULL
shown	NULL
.	NULL

(	NULL
5'-GGGANNYYCC-3	NULL
'	NULL
)	NULL
to	NULL
which	NULL
the	NULL
subunits	NULL
bind	NULL
(	NULL
185	NULL
,	NULL
205	NULL
,	NULL
388	NULL
)	NULL
and	NULL
cooperativity	NULL
between	NULL
different	NULL
transcription	NULL
factor	NULL
families	NULL
and	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

l	NULL
contribute	NULL
to	NULL
the	NULL
specificity	NULL
of	NULL
gene	NULL
activation	NULL
(	NULL
17	NULL
,	NULL
205	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B-mediated	NULL
transcription	NULL
is	NULL
down-regulated	NULL
by	NULL
de	NULL
novo	NULL
synthesis	NULL
of	NULL
IxBa	NULL
which	NULL
interacts	NULL
with	NULL
nuclear	NULL
or	NULL
cytoplasmic	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
in	NULL
transit	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Increased	NULL
levels	NULL
of	NULL
IxBa	NULL
may	NULL
also	NULL
dissociate	NULL
protein-DNA	NULL
complexes	NULL
and	NULL
restore	NULL
the	NULL
cytoplasmic	NULL
pool	NULL
of	NULL
latent	NULL
NF-	NULL
«	NULL
B/IKB	NULL
complexes	NULL
(	NULL
14	NULL
,	NULL
414	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
transcriptional	NULL
upregulation	NULL
of	NULL
nfkb1	NULL
,	NULL
nfkb2	NULL
,	NULL
c-rel	NULL
,	NULL
bel-3	NULL
,	NULL
and	NULL
Ikba	NULL
(	NULL
MAD-3	NULL
)	NULL
genes	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
provides	NULL
an	NULL
autoregulatory	NULL
mechanism	NULL
to	NULL
restore	NULL
intracellular	NULL
pools	NULL
of	NULL
latent	NULL
NF-kB	NULL
(	NULL
36	NULL
,	NULL
45	NULL
,	NULL
232	NULL
,	NULL
237	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Disruption	NULL
of	NULL
IxBa	NULL
autoregulation	NULL
with	NULL
IkBa	NULL
antisense	NULL
RNA	NULL
results	NULL
in	NULL
malignant	NULL
transformation	NULL
and	NULL
altered	NULL
NF-	NULL
«	NULL
B-regulated	NULL
gene	NULL
activity	NULL
,	NULL
indicating	NULL
that	NULL
IxBa	NULL
may	NULL
represent	NULL
a	NULL
potential	NULL
growth	NULL
suppressor	NULL
activity	NULL
(	NULL
22	NULL
)	NULL
.	NULL

IxBa	NULL
Phosphorylation	NULL
and	NULL
Degradation	NULL
IxBa	NULL
has	NULL
a	NULL
half-life	NULL
of	NULL
1	NULL
to	NULL
2	NULL
h	NULL
when	NULL
complexed	NULL
with	NULL
NF-kB	NULL
but	NULL
is	NULL
rapidly	NULL
degraded	NULL
following	NULL
inducer-mediated	NULL
stimulation	NULL
of	NULL
cells	NULL
(	NULL
317	NULL
,	NULL
352	NULL
,	NULL
372	NULL
)	NULL
.	NULL

The	NULL
short	NULL
half-life	NULL
of	NULL
IxBa	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
C-terminal	NULL
domain	NULL
rich	NULL
in	NULL
proline	NULL
,	NULL
glutamic	NULL
acid	NULL
,	NULL
serine	NULL
,	NULL
and	NULL
threonine	NULL
,	NULL
called	NULL
the	NULL
PEST	NULL
domain	NULL
(	NULL
132	NULL
,	NULL
324	NULL
)	NULL
.	NULL

Activating	NULL
agents	NULL
,	NULL
such	NULL
as	NULL
dsRNA	NULL
,	NULL
phorbol	NULL
esters	NULL
,	NULL
TNF-	NULL
«	NULL
@	NULL
,	NULL
IL-1	NULL
,	NULL
and	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
,	NULL
accelerate	NULL
the	NULL
degradation	NULL
of	NULL
cytosolic	NULL
IxBa	NULL
,	NULL
thereby	NULL
promoting	NULL
the	NULL
release	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
kB/Rel	NULL
dimers	NULL
(	NULL
24-26	NULL
,	NULL
129	NULL
,	NULL
205	NULL
)	NULL
.	NULL

Nuclear	NULL
NF-kB/Rel	NULL
dimers	NULL
transactivate	NULL
target	NULL
gene	NULL
expression	NULL
,	NULL
including	NULL
transcriptional	NULL
upregulation	NULL
of	NULL
the	NULL
MAD-3	NULL
(	NULL
IxBa	NULL
)	NULL
gene	NULL
,	NULL
thereby	NULL
establishing	NULL
an	NULL
autoregulatory	NULL
loop	NULL
in	NULL
which	NULL
newly	NULL
synthesized	NULL
IxBa	NULL
restores	NULL
the	NULL
cytoplasmic	NULL
pool	NULL
of	NULL
latent	NULL
NF-kB	NULL
(	NULL
43	NULL
,	NULL
77	NULL
,	NULL
193	NULL
,	NULL
372	NULL
)	NULL
.	NULL

Phosphorylation	NULL
and	NULL
subsequent	NULL
degradation	NULL
of	NULL
IxBa	NULL
appear	NULL
to	NULL
be	NULL
critical	NULL
processes	NULL
involved	NULL
in	NULL
NF-kB	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Following	NULL
inducer-mediated	NULL
stimulation	NULL
,	NULL
IxBa	NULL
becomes	NULL
hy-perphosphorylated	NULL
,	NULL
detectable	NULL
in	NULL
immunoblots	NULL
as	NULL
a	NULL
slowly	NULL
migrating	NULL
form	NULL
that	NULL
is	NULL
sensitive	NULL
to	NULL
phosphatase	NULL
treatment	NULL
(	NULL
25	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Hyperphosphorylation	NULL
does	NULL
not	NULL
impair	NULL
the	NULL
ability	NULL
of	NULL
IxBa	NULL
to	NULL
associate	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
but	NULL
is	NULL
believed	NULL
to	NULL
represent	NULL
a	NULL
signal	NULL
for	NULL
subsequent	NULL
degradation	NULL
(	NULL
6	NULL
,	NULL
71	NULL
,	NULL
93	NULL
,	NULL
204	NULL
,	NULL
383	NULL
)	NULL
via	NULL
the	NULL
ubiquitin-proteasome	NULL
degradation	NULL
pathway	NULL
(	NULL
277	NULL
)	NULL
.	NULL

An	NULL
important	NULL
question	NULL
with	NULL
regard	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
NF-xB	NULL
transcriptional	NULL
activity	NULL
concerns	NULL
the	NULL
signaling	NULL
pathways	NULL
that	NULL
stimulate	NULL
IxBa	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
.	NULL

It	NULL
re	NULL
mains	NULL
unclear	NULL
whether	NULL
different	NULL
stimuli	NULL
trigger	NULL
multiple	NULL
independent	NULL
signaling	NULL
pathways	NULL
or	NULL
whether	NULL
signaling	NULL
events	NULL
converge	NULL
upon	NULL
a	NULL
common	NULL
host	NULL
kinase	NULL
activity	NULL
that	NULL
stimulates	NULL
phosphorylation	NULL
and	NULL
subsequent	NULL
degradation	NULL
of	NULL
IxBa	NULL
«	NULL
.	NULL

A	NULL
number	NULL
of	NULL
potential	NULL
kinases	NULL
which	NULL
are	NULL
capable	NULL
of	NULL
phosphorylating	NULL
IxBa	NULL
in	NULL
vitro	NULL
have	NULL
been	NULL
identified	NULL
.	NULL

dsRNA-dependent	NULL
protein	NULL
kinase	NULL
(	NULL
PKR	NULL
)	NULL
phosphorylates	NULL
IxBa	NULL
«	NULL
in	NULL
vitro	NULL
(	NULL
183	NULL
)	NULL
,	NULL
and	NULL
antisense	NULL
RNA	NULL
complementary	NULL
to	NULL
PKR	NULL
blocks	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
induced	NULL
by	NULL
dsRNA	NULL
(	NULL
216	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
PKR	NULL
appears	NULL
to	NULL
be	NULL
restricted	NULL
to	NULL
dsRNA	NULL
stimulation	NULL
,	NULL
since	NULL
antisense	NULL
PKR	NULL
RNA	NULL
does	NULL
not	NULL
block	NULL
TNF-	NULL
«	NULL
-induced	NULL
NF-kB	NULL
activity	NULL
.	NULL

TNF-	NULL
«	NULL
stimulation	NULL
appears	NULL
to	NULL
involve	NULL
at	NULL
least	NULL
three	NULL
kinases	NULL
:	NULL
Raf-1	NULL
,	NULL
the	NULL
{	NULL
isoform	NULL
of	NULL
PKC	NULL
,	NULL
and	NULL
casein	NULL
kinase	NULL
II	NULL
(	NULL
CKII	NULL
)	NULL
.	NULL

Both	NULL
PKC-£	NULL
and	NULL
CKII	NULL
are	NULL
activated	NULL
by	NULL
TNF-	NULL
«	NULL
,	NULL
whereas	NULL
Raf-1	NULL
activity	NULL
is	NULL
not	NULL
stimulated	NULL
by	NULL
TNF-	NULL
«	NULL
(	NULL
70	NULL
,	NULL
297	NULL
,	NULL
405	NULL
)	NULL
.	NULL

However	NULL
,	NULL
Raf-1	NULL
dominant	NULL
positive	NULL
mutants	NULL
induce	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Conversely	NULL
,	NULL
dominant	NULL
negative	NULL
mutants	NULL
of	NULL
Raf-1	NULL
or	NULL
PKC-£	NULL
block	NULL
TNF-	NULL
«	NULL
-induced	NULL
NF-kB	NULL
activation	NULL
(	NULL
69	NULL
,	NULL
92	NULL
,	NULL
200	NULL
)	NULL
.	NULL

Although	NULL
Raf-1	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
interact	NULL
with	NULL
IxBa	NULL
in	NULL
experiments	NULL
with	NULL
the	NULL
yeast	NULL
two-hybrid	NULL
system	NULL
(	NULL
200	NULL
)	NULL
,	NULL
it	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
Raf-1	NULL
or	NULL
PKC-	NULL
is	NULL
directly	NULL
involved	NULL
in	NULL
phosphorylating	NULL
IxBa	NULL
or	NULL
,	NULL
rather	NULL
,	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
signal	NULL
transduction	NULL
cascade	NULL
leading	NULL
to	NULL
IxBa	NULL
phosphorylation	NULL
.	NULL

To	NULL
further	NULL
characterize	NULL
the	NULL
signaling	NULL
events	NULL
that	NULL
contribute	NULL
to	NULL
IxBa	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
,	NULL
we	NULL
isolated	NULL
a	NULL
kinase	NULL
activity	NULL
from	NULL
Jurkat	NULL
T	NULL
cells	NULL
that	NULL
specifically	NULL
interacts	NULL
with	NULL
IxBa	NULL
in	NULL
an	NULL
affinity	NULL
chromatography	NULL
step	NULL
and	NULL
phosphorylates	NULL
IxBa	NULL
with	NULL
high	NULL
specificity	NULL
in	NULL
vitro	NULL
.	NULL

Biochemical	NULL
and	NULL
immunological	NULL
cross-reactivity	NULL
identified	NULL
the	NULL
kinase	NULL
activity	NULL
as	NULL
CKII	NULL
(	NULL
202	NULL
)	NULL
.	NULL

Point	NULL
mutation	NULL
analysis	NULL
revealed	NULL
that	NULL
a	NULL
double	NULL
mutation	NULL
of	NULL
residues	NULL
Thr-291	NULL
and	NULL
Ser-283	NULL
eliminated	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
by	NULL
the	NULL
CKII	NULL
in	NULL
vitro	NULL
and	NULL
reduced	NULL
phosphorylation	NULL
about	NULL
10-fold	NULL
in	NULL
vivo	NULL
,	NULL
although	NULL
IxBa	NULL
degradation	NULL
was	NULL
unaffected	NULL
.	NULL

Brown	NULL
et	NULL
al	NULL
.	NULL

demonstrated	NULL
that	NULL
Ser-32	NULL
and	NULL
Ser-36	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
C-terminal	NULL
end	NULL
,	NULL
were	NULL
both	NULL
required	NULL
for	NULL
inducer-mediated	NULL
degradation	NULL
(	NULL
41	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
both	NULL
Ser-32	NULL
and	NULL
Ser-36	NULL
residues	NULL
also	NULL
represent	NULL
natural	NULL
CKII	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
CKII	NULL
or	NULL
an	NULL
enzyme	NULL
with	NULL
the	NULL
same	NULL
phosphorylation	NULL
sites	NULL
represents	NULL
the	NULL
IxBa	NULL
kinase	NULL
.	NULL

CKII	NULL
is	NULL
a	NULL
highly	NULL
conserved	NULL
and	NULL
ubiquitous	NULL
serine/threonine-specific	NULL
kinase	NULL
composed	NULL
of	NULL
two	NULL
larger	NULL
catalytic	NULL
subunits	NULL
(	NULL
a	NULL
and/or	NULL
«	NULL
'	NULL
;	NULL
relative	NULL
molecular	NULL
mass	NULL
,	NULL
35	NULL
to	NULL
44	NULL
kDa	NULL
)	NULL
and	NULL
two	NULL
smaller	NULL
B	NULL
regulatory	NULL
subunits	NULL
(	NULL
relative	NULL
molecular	NULL
mass	NULL
,	NULL
25	NULL
to	NULL
28	NULL
kDa	NULL
)	NULL
(	NULL
227	NULL
,	NULL
297	NULL
)	NULL
.	NULL

Immunocytochemical	NULL
studies	NULL
localize	NULL
CKII	NULL
to	NULL
Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
CKIl	NULL
--	NULL
f	NULL
A	NULL
B	NULL
REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
489	NULL
C	NULL
D	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Model	NULL
of	NULL
inducer-mediated	NULL
degradation	NULL
of	NULL
IxBa	NULL
«	NULL
.	NULL

In	NULL
unstimulated	NULL
cells	NULL
,	NULL
IxBa	NULL
may	NULL
acquire	NULL
a	NULL
conformation	NULL
permitting	NULL
interaction	NULL
between	NULL
the	NULL
N	NULL
and	NULL
C	NULL
termini	NULL
(	NULL
A	NULL
)	NULL
.	NULL

This	NULL
conformation	NULL
may	NULL
also	NULL
permit	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
complex	NULL
with	NULL
a	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
-p50	NULL
heterodimer	NULL
in	NULL
which	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
C-terminal	NULL
domain	NULL
of	NULL
IxBa	NULL
is	NULL
masked	NULL
by	NULL
RelA	NULL
;	NULL
contact	NULL
between	NULL
the	NULL
ankyrin	NULL
repeat	NULL
domains	NULL
and	NULL
the	NULL
nuclear	NULL
localization	NULL
sequence	NULL
maintains	NULL
the	NULL
NF-	NULL
«	NULL
B/IxB	NULL
heterotrimer	NULL
in	NULL
the	NULL
cytoplasm	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Following	NULL
TNF-a	NULL
or	NULL
LPS	NULL
stimulation	NULL
,	NULL
IxBa	NULL
is	NULL
recognized	NULL
and	NULL
phosphorylated	NULL
by	NULL
CKII	NULL
(	NULL
B	NULL
)	NULL
on	NULL
N-terminal	NULL
residues	NULL
S-32	NULL
and	NULL
S-36	NULL
(	NULL
42	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
on	NULL
C-terminal	NULL
residues	NULL
$	NULL
-283	NULL
,	NULL
T-291	NULL
,	NULL
and	NULL
T-299	NULL
(	NULL
23	NULL
,	NULL
202	NULL
,	NULL
323	NULL
)	NULL
.	NULL

The	NULL
increased	NULL
net	NULL
negative	NULL
charge	NULL
of	NULL
the	NULL
domains	NULL
may	NULL
modify	NULL
IxBa	NULL
structure	NULL
,	NULL
forcing	NULL
the	NULL
protein	NULL
to	NULL
adopt	NULL
a	NULL
new	NULL
conformation	NULL
(	NULL
B	NULL
)	NULL
,	NULL
which	NULL
can	NULL
be	NULL
recognized	NULL
and	NULL
degraded	NULL
by	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
(	NULL
C	NULL
)	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
p65-p50	NULL
heterodimer	NULL
would	NULL
then	NULL
translocate	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
bind	NULL
DNA	NULL
(	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
heterodimer	NULL
is	NULL
based	NULL
loosely	NULL
on	NULL
the	NULL
structural	NULL
data	NULL
of	NULL
the	NULL
p30	NULL
homodimer	NULL
[	NULL
120	NULL
,	NULL
250	NULL
]	NULL
)	NULL
.	NULL

Depicted	NULL
in	NULL
the	NULL
scheme	NULL
are	NULL
domains	NULL
in	NULL
the	NULL
N	NULL
and	NULL
C	NULL
termini	NULL
of	NULL
IxB	NULL
«	NULL
involved	NULL
in	NULL
inducer-mediated	NULL
degradation	NULL
.	NULL

The	NULL
structures	NULL
of	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
the	NULL
CKII	NULL
tetramer	NULL
are	NULL
illustrated	NULL
schematically	NULL
.	NULL

the	NULL
nucleus	NULL
,	NULL
the	NULL
cytoplasm	NULL
,	NULL
and	NULL
the	NULL
plasma	NULL
membrane	NULL
(	NULL
181	NULL
,	NULL
413	NULL
)	NULL
.	NULL

CKII	NULL
phosphorylates	NULL
a	NULL
variety	NULL
of	NULL
nuclear	NULL
factors	NULL
including	NULL
c-ErbA	NULL
,	NULL
adenovirus	NULL
E1A	NULL
,	NULL
human	NULL
papillomavirus	NULL
E7	NULL
,	NULL
c-Myb	NULL
,	NULL
Fos	NULL
,	NULL
CREB/ATF	NULL
,	NULL
p53	NULL
,	NULL
serum	NULL
response	NULL
factor	NULL
,	NULL
and	NULL
c-Jun	NULL
(	NULL
201	NULL
,	NULL
227	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
HSP90	NULL
(	NULL
361	NULL
)	NULL
,	NULL
FKBP25	NULL
(	NULL
152	NULL
)	NULL
,	NULL
and	NULL
p53	NULL
(	NULL
91	NULL
,	NULL
140	NULL
,	NULL
251	NULL
)	NULL
.	NULL

Studies	NULL
with	NULL
Saccharomyces	NULL
cerevisiae	NULL
demonstrate	NULL
that	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
CKII	NULL
is	NULL
required	NULL
for	NULL
yeast	NULL
cell	NULL
growth	NULL
(	NULL
276	NULL
)	NULL
.	NULL

Conversely	NULL
,	NULL
phosphorylation	NULL
of	NULL
serine	NULL
residues	NULL
in	NULL
c-Myb	NULL
,	NULL
c-ErbA	NULL
,	NULL
and	NULL
c-Fos	NULL
by	NULL
CKII	NULL
may	NULL
repress	NULL
transcription	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
metabolic	NULL
regulation	NULL
,	NULL
cell	NULL
growth	NULL
,	NULL
or	NULL
differentiation	NULL
(	NULL
227	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
CKIll	NULL
«	NULL
transgenic	NULL
mice	NULL
were	NULL
created	NULL
that	NULL
developed	NULL
lymphoproliferative	NULL
disorders	NULL
resembling	NULL
the	NULL
fatal	NULL
lymphoproliferative	NULL
syndrome	NULL
associated	NULL
with	NULL
the	NULL
protozoan	NULL
parasite	NULL
Theileria	NULL
parva	NULL
in	NULL
cattle	NULL
.	NULL

Interestingly	NULL
,	NULL
theileriosis	NULL
in	NULL
cattle	NULL
is	NULL
characterized	NULL
by	NULL
the	NULL
overexpression	NULL
of	NULL
CKII	NULL
.	NULL

In	NULL
the	NULL
murine	NULL
transgenic	NULL
model	NULL
,	NULL
CKII	NULL
«	NULL
-expressing	NULL
mice	NULL
displayed	NULL
a	NULL
stochastic	NULL
potential	NULL
to	NULL
develop	NULL
lymphoma	NULL
;	NULL
coexpression	NULL
of	NULL
a	NULL
e-myc	NULL
transgene	NULL
in	NULL
addition	NULL
to	NULL
CKII	NULL
«	NULL
resulted	NULL
in	NULL
neonatal	NULL
leukemia	NULL
.	NULL

This	NULL
study	NULL
showed	NULL
that	NULL
CKII	NULL
can	NULL
serve	NULL
as	NULL
an	NULL
oncogene	NULL
,	NULL
and	NULL
its	NULL
dysregulated	NULL
expression	NULL
is	NULL
capable	NULL
of	NULL
transforming	NULL
lymphocytes	NULL
in	NULL
cooperation	NULL
with	NULL
e-mye	NULL
(	NULL
354	NULL
)	NULL
.	NULL

A	NULL
highly	NULL
acidic	NULL
region	NULL
of	NULL
IxBa	NULL
composed	NULL
of	NULL
20	NULL
amino	NULL
acids	NULL
(	NULL
Ser-283	NULL
to	NULL
Asp-302	NULL
)	NULL
contains	NULL
six	NULL
potential	NULL
sites	NULL
of	NULL
phosphorylation	NULL
by	NULL
CKII	NULL
(	NULL
23	NULL
,	NULL
82	NULL
,	NULL
202	NULL
)	NULL
.	NULL

The	NULL
consensus	NULL
CKII	NULL
sites	NULL
(	NULL
S/T	NULL
X-X-E/D	NULL
)	NULL
are	NULL
formed	NULL
by	NULL
an	NULL
N-terminal	NULL
serine	NULL
or	NULL
threonine	NULL
separated	NULL
by	NULL
two	NULL
residues	NULL
from	NULL
a	NULL
C-terminal	NULL
acidic	NULL
amino	NULL
acid	NULL
(	NULL
aspartic	NULL
acid	NULL
or	NULL
glutamic	NULL
acid	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
acidic	NULL
amino	NULL
acid	NULL
at	NULL
position	NULL
4	NULL
of	NULL
the	NULL
consensus	NULL
sequence	NULL
may	NULL
be	NULL
contributed	NULL
by	NULL
any	NULL
phosphorylated	NULL
amino	NULL
acid	NULL
(	NULL
227	NULL
,	NULL
297	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
IxBa	NULL
,	NULL
Ser-283	NULL
,	NULL
Thr-291	NULL
,	NULL
and	NULL
Thr-299	NULL
represent	NULL
natural	NULL
sites	NULL
of	NULL
phosphorylation	NULL
by	NULL
CKII	NULL
and	NULL
phosphorylation	NULL
at	NULL
Thr-291	NULL
and	NULL
Thr-299	NULL
creates	NULL
the	NULL
potential	NULL
for	NULL
sequential	NULL
CKII	NULL
phosphorylation	NULL
at	NULL
Ser-288	NULL
and	NULL
Thr-296	NULL
,	NULL
respectively	NULL
.	NULL

Finally	NULL
,	NULL
phosphorylation	NULL
of	NULL
Thr-296	NULL
generates	NULL
a	NULL
potential	NULL
CKII	NULL
phosphorylation	NULL
site	NULL
at	NULL
Ser-293	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
C-terminal	NULL
PEST	NULL
domain	NULL
or	NULL
,	NULL
more	NULL
precisely	NULL
,	NULL
the	NULL
CKII	NULL
cluster	NULL
between	NULL
amino	NULL
acids	NULL
283	NULL
and	NULL
302	NULL
,	NULL
results	NULL
in	NULL
an	NULL
IxBa	NULL
molecule	NULL
that	NULL
is	NULL
resistant	NULL
to	NULL
inducer-mediated	NULL
degradation	NULL
(	NULL
23	NULL
,	NULL
202	NULL
)	NULL
.	NULL

Biochemical	NULL
characterization	NULL
of	NULL
the	NULL
domain	NULL
structure	NULL
of	NULL
IxBa	NULL
demonstrates	NULL
that	NULL
IxBa	NULL
contains	NULL
a	NULL
highly	NULL
structured	NULL
central	NULL
domain	NULL
that	NULL
is	NULL
resistant	NULL
to	NULL
proteolysis	NULL
and	NULL
flexible	NULL
N-	NULL
and	NULL
C-terminal	NULL
extensions	NULL
that	NULL
are	NULL
sensitive	NULL
to	NULL
proteolytic	NULL
digestion	NULL
(	NULL
151	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
the	NULL
C-terminal	NULL
region	NULL
,	NULL
but	NULL
not	NULL
the	NULL
N-terminal	NULL
region	NULL
,	NULL
is	NULL
protected	NULL
from	NULL
proteolysis	NULL
when	NULL
IxBa	NULL
is	NULL
bound	NULL
to	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
region	NULL
of	NULL
the	NULL
protein	NULL
directly	NULL
interfaces	NULL
with	NULL
Re-1A¥	NULL
(	NULL
p65	NULL
)	NULL
and	NULL
was	NULL
thus	NULL
masked	NULL
in	NULL
the	NULL
IxBa-RelA	NULL
complex	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
both	NULL
the	NULL
N-terminal	NULL
and	NULL
C-terminal	NULL
domains	NULL
are	NULL
recognized	NULL
by	NULL
the	NULL
protease	NULL
machinery	NULL
after	NULL
inducer-mediated	NULL
phosphorylation	NULL
(	NULL
23	NULL
,	NULL
41	NULL
,	NULL
42	NULL
,	NULL
323	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
PEST	NULL
domain	NULL
alone	NULL
may	NULL
be	NULL
recognized	NULL
but	NULL
in	NULL
uninduced	NULL
cells	NULL
the	NULL
C-terminal	NULL
region	NULL
is	NULL
masked	NULL
from	NULL
recognition	NULL
by	NULL
the	NULL
proteasome	NULL
because	NULL
of	NULL
the	NULL
conformation	NULL
of	NULL
IxBa	NULL
or	NULL
its	NULL
association	NULL
with	NULL
other	NULL
proteins	NULL
.	NULL

Simultaneous	NULL
phosphorylation	NULL
of	NULL
N-terminal	NULL
and	NULL
C-terminal	NULL
sites	NULL
may	NULL
increase	NULL
the	NULL
acidic	NULL
nature	NULL
of	NULL
the	NULL
regions	NULL
and	NULL
force	NULL
IxBa	NULL
to	NULL
adopt	NULL
a	NULL
new	NULL
conformation	NULL
in	NULL
which	NULL
the	NULL
PEST	NULL
domain	NULL
is	NULL
exposed	NULL
to	NULL
the	NULL
proteasome	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Two	NULL
major	NULL
classes	NULL
of	NULL
proteases	NULL
are	NULL
known	NULL
to	NULL
operate	NULL
outside	NULL
of	NULL
the	NULL
lysosome	NULL
,	NULL
the	NULL
calpains	NULL
(	NULL
Ca**-dependent	NULL
cysteine	NULL
pro-teases	NULL
)	NULL
and	NULL
the	NULL
proteasome	NULL
.	NULL

Central	NULL
to	NULL
the	NULL
proteasome	NULL
machinery	NULL
is	NULL
the	NULL
ATP-dependent	NULL
268	NULL
multisubunit	NULL
proteasome	NULL
,	NULL
which	NULL
can	NULL
operate	NULL
in	NULL
a	NULL
ubiquitin-dependent	NULL
or	NULL
-independent	NULL
fashion	NULL
(	NULL
292	NULL
)	NULL
.	NULL

The	NULL
proteases	NULL
involved	NULL
in	NULL
the	NULL
degradation	NULL
of	NULL
IxBa	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
identified	NULL
;	NULL
however	NULL
,	NULL
two	NULL
observations	NULL
implicate	NULL
the	NULL
proteasomes	NULL
:	NULL
(	NULL
i	NULL
)	NULL
ATP	NULL
is	NULL
required	NULL
for	NULL
IxBa	NULL
degradation	NULL
upon	NULL
LPS	NULL
stimulation	NULL
(	NULL
150	NULL
)	NULL
;	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
calpain	NULL
inhibitor	NULL
I	NULL
(	NULL
204	NULL
)	NULL
,	NULL
only	NULL
proteasome	NULL
inhibitors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
prevent	NULL
IxBa	NULL
degradation	NULL
induced	NULL
by	NULL
TNF-a	NULL
(	NULL
93	NULL
,	NULL
277	NULL
,	NULL
383	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
PSI	NULL
and	NULL
MG115	NULL
proteasome	NULL
inhibitors	NULL
prevent	NULL
IxBa	NULL
degradation	NULL
but	NULL
not	NULL
IxBa	NULL
hy-perphosphorylation	NULL
,	NULL
illustrating	NULL
that	NULL
these	NULL
two	NULL
events	NULL
are	NULL
independent	NULL
(	NULL
277	NULL
,	NULL
383	NULL
)	NULL
.	NULL

A	NULL
unique	NULL
function	NULL
of	NULL
IxBa	NULL
is	NULL
the	NULL
capacity	NULL
to	NULL
dissociate	NULL
NF-	NULL
«	NULL
kB-DNA	NULL
complexes	NULL
,	NULL
an	NULL
activity	NULL
that	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
ankyrin	NULL
repeats	NULL
as	NULL
well	NULL
as	NULL
the	NULL
PEST	NULL
domain	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
predominantly	NULL
cytoplasmic	NULL
localization	NULL
of	NULL
IxBa	NULL
,	NULL
the	NULL
biological	NULL
significance	NULL
of	NULL
NF-	NULL
«	NULL
B-DNA	NULL
complex	NULL
dissociation	NULL
by	NULL
IxBa	NULL
is	NULL
not	NULL
yet	NULL
understood	NULL
,	NULL
although	NULL
IxBa	NULL
has	NULL
previously	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
nucleus	NULL
(	NULL
60	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
vitro	NULL
transcription	NULL
studies	NULL
with	NULL
purified	NULL
NF-kB	NULL
proteins	NULL
demonstrate	NULL
that	NULL
addition	NULL
of	NULL
recombinant	NULL
IxBa	NULL
to	NULL
the	NULL
transcription	NULL
reactions	NULL
inhibits	NULL
transcription	NULL
(	NULL
203	NULL
,	NULL
414	NULL
)	NULL
.	NULL

These	NULL
experiments	NULL
suggest	NULL
that	NULL
a	NULL
novel	NULL
nuclear	NULL
role	NULL
for	NULL
newly	NULL
synthesized	NULL
IxBa	NULL
may	NULL
be	NULL
to	NULL
directly	NULL
inhibit	NULL
NF-	NULL
«	NULL
B-dependent	NULL
gene	NULL
expres-	NULL
490	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

sion	NULL
by	NULL
dissociating	NULL
NF-kB-DNA	NULL
transcription	NULL
complexes	NULL
.	NULL

This	NULL
idea	NULL
is	NULL
further	NULL
supported	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
following	NULL
induction	NULL
,	NULL
de	NULL
novo	NULL
synthesized	NULL
IxBa	NULL
protein	NULL
transiently	NULL
appears	NULL
in	NULL
the	NULL
nucleus	NULL
and	NULL
negatively	NULL
regulates	NULL
NF-kB-dependent	NULL
transcription	NULL
(	NULL
14	NULL
)	NULL
.	NULL

IxBB	NULL
was	NULL
recently	NULL
cloned	NULL
and	NULL
characterized	NULL
(	NULL
379	NULL
)	NULL
.	NULL

Structur-ally	NULL
,	NULL
IxBB	NULL
contains	NULL
six	NULL
ankyrin	NULL
repeat	NULL
regions	NULL
and	NULL
a	NULL
putative	NULL
C-terminal	NULL
PEST	NULL
domain	NULL
;	NULL
interestingly	NULL
,	NULL
several	NULL
potential	NULL
CKII	NULL
sites	NULL
are	NULL
conserved	NULL
in	NULL
IxBRB	NULL
in	NULL
the	NULL
C-terminal	NULL
PEST	NULL
domain	NULL
.	NULL

A	NULL
primary	NULL
biological	NULL
difference	NULL
between	NULL
IxBa	NULL
and	NULL
IxBRB	NULL
is	NULL
their	NULL
response	NULL
to	NULL
different	NULL
inducers	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
.	NULL

IxBB	NULL
is	NULL
rapidly	NULL
degraded	NULL
upon	NULL
LPS	NULL
or	NULL
IL-1	NULL
stimulation	NULL
,	NULL
but	NULL
neither	NULL
TNF-	NULL
«	NULL
nor	NULL
phorbol	NULL
ester	NULL
stimulation	NULL
induces	NULL
IxBB	NULL
degradation	NULL
.	NULL

Conversely	NULL
,	NULL
IxBa	NULL
degradation	NULL
is	NULL
induced	NULL
by	NULL
all	NULL
four	NULL
stimuli	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
unlike	NULL
IxBa	NULL
,	NULL
IxBB	NULL
is	NULL
used	NULL
not	NULL
for	NULL
regulating	NULL
rapid	NULL
responses	NULL
but	NULL
for	NULL
responding	NULL
to	NULL
persistent	NULL
signals	NULL
that	NULL
result	NULL
in	NULL
a	NULL
more	NULL
permanent	NULL
activation	NULL
of	NULL
gene	NULL
expression	NULL
(	NULL
379	NULL
)	NULL
.	NULL

Additional	NULL
studies	NULL
will	NULL
define	NULL
more	NULL
precisely	NULL
the	NULL
complex	NULL
associations	NULL
between	NULL
IxBa	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
relationship	NULL
of	NULL
these	NULL
interactions	NULL
with	NULL
the	NULL
newly	NULL
cloned	NULL
IxBRB	NULL
.	NULL

PHYSIOLOGICAL	NULL
CHANGES	NULL
IN	NULL
HIV-1-INFECTED	NULL
MYELOID	NULL
CELLS	NULL
The	NULL
primary	NULL
cause	NULL
of	NULL
immune	NULL
system	NULL
dysfunction	NULL
in	NULL
HIV-1-infected	NULL
individuals	NULL
is	NULL
depletion	NULL
of	NULL
the	NULL
CD4	NULL
*	NULL
helper	NULL
T-cell	NULL
population	NULL
.	NULL

However	NULL
,	NULL
the	NULL
impaired	NULL
function	NULL
of	NULL
other	NULL
subsets	NULL
of	NULL
immune	NULL
effector	NULL
cells	NULL
,	NULL
such	NULL
as	NULL
myeloid	NULL
cells	NULL
,	NULL
may	NULL
also	NULL
contribute	NULL
to	NULL
immune	NULL
dysfunction	NULL
by	NULL
increasing	NULL
susceptibility	NULL
to	NULL
secondary	NULL
pathogenic	NULL
infections	NULL
.	NULL

The	NULL
primary	NULL
function	NULL
of	NULL
mature	NULL
myeloid	NULL
cells	NULL
or	NULL
macrophages	NULL
is	NULL
to	NULL
clear	NULL
the	NULL
blood	NULL
,	NULL
lymph	NULL
,	NULL
and	NULL
tissues	NULL
of	NULL
microbial	NULL
pathogens	NULL
and	NULL
other	NULL
foreign	NULL
particles	NULL
by	NULL
phagocytosis	NULL
.	NULL

Effective	NULL
killing	NULL
of	NULL
microorganisms	NULL
requires	NULL
several	NULL
important	NULL
steps	NULL
:	NULL
migration	NULL
of	NULL
monocytes	NULL
to	NULL
the	NULL
appropriate	NULL
site	NULL
,	NULL
particle	NULL
recognition	NULL
and	NULL
attachment	NULL
,	NULL
and	NULL
particle	NULL
ingestion	NULL
by	NULL
phagocytosis	NULL
.	NULL

Following	NULL
phagocytosis	NULL
,	NULL
most	NULL
organisms	NULL
are	NULL
killed	NULL
by	NULL
oxidative	NULL
mechanisms	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Functional	NULL
Changes	NULL
Several	NULL
studies	NULL
document	NULL
defective	NULL
chemotaxis	NULL
of	NULL
phagocytic	NULL
cells	NULL
from	NULL
HIV-l-infected	NULL
individuals	NULL
(	NULL
264	NULL
,	NULL
301	NULL
,	NULL
367	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
defective	NULL
chemotaxis	NULL
is	NULL
also	NULL
seen	NULL
in	NULL
monocytes	NULL
from	NULL
seronegative	NULL
donors	NULL
after	NULL
in	NULL
vitro	NULL
exposure	NULL
to	NULL
gp41	NULL
or	NULL
gp120	NULL
(	NULL
399	NULL
)	NULL
.	NULL

Monocytes	NULL
from	NULL
AIDS	NULL
patients	NULL
do	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
impaired	NULL
for	NULL
nonspecific	NULL
(	NULL
C3-receptor-mediated	NULL
)	NULL
or	NULL
immune	NULL
system-specific	NULL
(	NULL
Fe-receptor-mediated	NULL
)	NULL
phagocytosis	NULL
(	NULL
27	NULL
,	NULL
83	NULL
,	NULL
118	NULL
,	NULL
264	NULL
,	NULL
301	NULL
,	NULL
332	NULL
)	NULL
.	NULL

Estevez	NULL
et	NULL
al	NULL
.	NULL

(	NULL
83	NULL
)	NULL
reported	NULL
that	NULL
phagocytosis	NULL
of	NULL
Candida	NULL
pseudotropicalis	NULL
is	NULL
efficient	NULL
whereas	NULL
intracellular	NULL
killing	NULL
(	NULL
lytic	NULL
activity	NULL
)	NULL
is	NULL
reduced	NULL
.	NULL

Similarly	NULL
,	NULL
intracellular	NULL
killing	NULL
by	NULL
superoxide	NULL
generation	NULL
is	NULL
reported	NULL
to	NULL
be	NULL
either	NULL
normal	NULL
(	NULL
255	NULL
,	NULL
264	NULL
)	NULL
or	NULL
deficient	NULL
(	NULL
39	NULL
,	NULL
252	NULL
)	NULL
in	NULL
cells	NULL
isolated	NULL
from	NULL
AIDS	NULL
patients	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
vitro	NULL
models	NULL
of	NULL
HIV-1-infected	NULL
promonocytic	NULL
cells	NULL
display	NULL
an	NULL
amplification	NULL
of	NULL
the	NULL
oxidative	NULL
burst	NULL
response	NULL
(	NULL
167	NULL
)	NULL
.	NULL

Altered	NULL
oxidative	NULL
burst	NULL
may	NULL
be	NULL
related	NULL
to	NULL
differences	NULL
in	NULL
the	NULL
disease	NULL
stage	NULL
of	NULL
patients	NULL
under	NULL
study	NULL
,	NULL
since	NULL
Roux-Lombard	NULL
et	NULL
al	NULL
.	NULL

demonstrated	NULL
a	NULL
decline	NULL
in	NULL
the	NULL
oxidative	NULL
burst	NULL
response	NULL
with	NULL
advancing	NULL
disease	NULL
(	NULL
332	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
monocytes	NULL
and	NULL
macrophages	NULL
isolated	NULL
from	NULL
HIV-1-infected	NULL
individuals	NULL
at	NULL
various	NULL
disease	NULL
stages	NULL
show	NULL
decreased	NULL
ability	NULL
to	NULL
mediate	NULL
tumor	NULL
cell	NULL
lysis	NULL
(	NULL
327	NULL
)	NULL
.	NULL

Monocytes	NULL
serve	NULL
as	NULL
accessory	NULL
cells	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Antigen	NULL
presentation	NULL
in	NULL
the	NULL
context	NULL
of	NULL
a	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
molecule	NULL
(	NULL
HLA-DR	NULL
in	NULL
humans	NULL
)	NULL
on	NULL
the	NULL
macrophage	NULL
cell	NULL
surface	NULL
is	NULL
required	NULL
for	NULL
CD4*	NULL
T-lymphocyte	NULL
MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

activation	NULL
.	NULL

Normal	NULL
(	NULL
130	NULL
,	NULL
228	NULL
)	NULL
or	NULL
decreased	NULL
(	NULL
136	NULL
,	NULL
333	NULL
)	NULL
HLA-DR	NULL
expression	NULL
,	NULL
correlating	NULL
with	NULL
decreased	NULL
ability	NULL
to	NULL
stimulate	NULL
T	NULL
cells	NULL
(	NULL
95	NULL
,	NULL
168	NULL
,	NULL
357	NULL
)	NULL
,	NULL
is	NULL
reported	NULL
to	NULL
occur	NULL
in	NULL
chronically	NULL
infected	NULL
myeloid	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
treatment	NULL
of	NULL
monocytes	NULL
in	NULL
vitro	NULL
with	NULL
either	NULL
free	NULL
HIV-1	NULL
or	NULL
purified	NULL
gp120	NULL
leads	NULL
to	NULL
differentiation	NULL
and	NULL
increased	NULL
HLA-DR	NULL
expression	NULL
(	NULL
7	NULL
,	NULL
399	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
support	NULL
the	NULL
idea	NULL
that	NULL
a	NULL
biphasic	NULL
response	NULL
of	NULL
host	NULL
mononuclear	NULL
cells	NULL
begins	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
HLA-DR	NULL
expression	NULL
followed	NULL
by	NULL
a	NULL
decline	NULL
during	NULL
chronic	NULL
infection	NULL
(	NULL
136	NULL
,	NULL
182	NULL
,	NULL
295	NULL
)	NULL
.	NULL

The	NULL
downregulation	NULL
of	NULL
antigen-presenting	NULL
complexes	NULL
may	NULL
be	NULL
a	NULL
mechanism	NULL
by	NULL
which	NULL
infected	NULL
cells	NULL
escape	NULL
immune	NULL
surveillance	NULL
and	NULL
promote	NULL
viral	NULL
persistence	NULL
.	NULL

Cytokine	NULL
Gene	NULL
Expression	NULL
Secretion	NULL
of	NULL
immunoregulatory	NULL
cytokines	NULL
by	NULL
macrophages	NULL
is	NULL
essential	NULL
for	NULL
lymphocyte	NULL
activation	NULL
,	NULL
antibody	NULL
production	NULL
,	NULL
and	NULL
cytotoxic	NULL
cellular	NULL
responses	NULL
.	NULL

Cytokine	NULL
gene	NULL
expression	NULL
studies	NULL
of	NULL
PBMCs	NULL
from	NULL
HIV-1-infected	NULL
individuals	NULL
generate	NULL
conflicting	NULL
results	NULL
.	NULL

For	NULL
example	NULL
,	NULL
spontaneous	NULL
and	NULL
LPS-induced	NULL
TNF-	NULL
,	NULL
IL-1	NULL
,	NULL
and	NULL
IL-6	NULL
secretion	NULL
is	NULL
not	NULL
significantly	NULL
different	NULL
in	NULL
PBMCs	NULL
isolated	NULL
from	NULL
AIDS	NULL
patients	NULL
and	NULL
those	NULL
isolated	NULL
from	NULL
uninfected	NULL
donors	NULL
(	NULL
291	NULL
,	NULL
396	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
alveolar	NULL
macrophages	NULL
(	NULL
but	NULL
not	NULL
monocytes	NULL
)	NULL
isolated	NULL
from	NULL
patients	NULL
with	NULL
early-	NULL
and	NULL
late-stage	NULL
disease	NULL
express	NULL
increased	NULL
levels	NULL
of	NULL
LPS-stimulated	NULL
TNF-	NULL
«	NULL
,	NULL
IL-1f	NULL
,	NULL
and	NULL
IL-6	NULL
mRNA	NULL
(	NULL
364	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
levels	NULL
of	NULL
basal	NULL
and	NULL
stimulated	NULL
TNF-	NULL
«	NULL
secretion	NULL
by	NULL
PBMCs	NULL
from	NULL
HIV-l-infected	NULL
individuals	NULL
increase	NULL
with	NULL
disease	NULL
progression	NULL
(	NULL
327	NULL
,	NULL
408	NULL
)	NULL
.	NULL

Cytokine	NULL
release	NULL
from	NULL
HIV-1-infected	NULL
myeloid	NULL
cells	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
elevated	NULL
levels	NULL
of	NULL
TNF-	NULL
«	NULL
(	NULL
172	NULL
,	NULL
188	NULL
,	NULL
194	NULL
)	NULL
,	NULL
IL-1	NULL
(	NULL
224	NULL
)	NULL
,	NULL
IL-6	NULL
(	NULL
32	NULL
,	NULL
40	NULL
)	NULL
,	NULL
transforming	NULL
growth	NULL
factor	NULL
B	NULL
(	NULL
TGF-B	NULL
)	NULL
(	NULL
8	NULL
)	NULL
,	NULL
and	NULL
IFN-y	NULL
(	NULL
104	NULL
)	NULL
,	NULL
present	NULL
in	NULL
the	NULL
sera	NULL
of	NULL
AIDS	NULL
patients	NULL
with	NULL
late-stage	NULL
disease	NULL
.	NULL

Elevated	NULL
IFN-	NULL
«	NULL
@	NULL
/B	NULL
activity	NULL
is	NULL
also	NULL
present	NULL
in	NULL
the	NULL
sera	NULL
of	NULL
AIDS	NULL
patients	NULL
with	NULL
late-stage	NULL
disease	NULL
and	NULL
serves	NULL
as	NULL
a	NULL
marker	NULL
for	NULL
poor	NULL
prognosis	NULL
(	NULL
320	NULL
)	NULL
.	NULL

Paradoxically	NULL
,	NULL
in	NULL
PBMCs	NULL
isolated	NULL
from	NULL
HIV-1-infected	NULL
individuals	NULL
,	NULL
IFN-	NULL
«	NULL
production	NULL
becomes	NULL
increasingly	NULL
impaired	NULL
as	NULL
the	NULL
disease	NULL
progresses	NULL
(	NULL
396	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
defect	NULL
in	NULL
IFN-	NULL
«	NULL
production	NULL
occurs	NULL
in	NULL
HIV-1-infected	NULL
PBMCs	NULL
treated	NULL
with	NULL
dsRNA	NULL
,	NULL
Newcastle	NULL
disease	NULL
virus	NULL
,	NULL
or	NULL
herpes	NULL
simplex	NULL
virus	NULL
(	NULL
HSV	NULL
)	NULL
;	NULL
IFN	NULL
mRNA	NULL
expression	NULL
is	NULL
reduced	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
(	NULL
115	NULL
)	NULL
.	NULL

Cells	NULL
isolated	NULL
from	NULL
patients	NULL
at	NULL
different	NULL
stages	NULL
of	NULL
disease	NULL
and	NULL
with	NULL
different	NULL
degrees	NULL
of	NULL
immunodeficiency	NULL
may	NULL
account	NULL
for	NULL
reported	NULL
variations	NULL
in	NULL
cytokine	NULL
secretion	NULL
from	NULL
primary	NULL
cells	NULL
.	NULL

Recent	NULL
work	NULL
demonstrates	NULL
that	NULL
when	NULL
PBMCs	NULL
isolated	NULL
from	NULL
HIV-infected	NULL
individuals	NULL
are	NULL
stimulated	NULL
in	NULL
vitro	NULL
with	NULL
Staphylococcus	NULL
aureus	NULL
,	NULL
they	NULL
produce	NULL
fivefold-less	NULL
IL-12	NULL
than	NULL
do	NULL
PBMCs	NULL
from	NULL
healthy	NULL
donors	NULL
(	NULL
53	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
PBMCs	NULL
infected	NULL
with	NULL
HIV	NULL
in	NULL
vitro	NULL
also	NULL
have	NULL
a	NULL
reduced	NULL
ability	NULL
to	NULL
synthesize	NULL
IL-12	NULL
.	NULL

Since	NULL
IL-12	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
stimulation	NULL
of	NULL
natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
cell	NULL
activity	NULL
and	NULL
the	NULL
differentiation	NULL
of	NULL
Th1	NULL
cells	NULL
,	NULL
defective	NULL
IL-12	NULL
production	NULL
may	NULL
contribute	NULL
to	NULL
immunosuppres-sion	NULL
in	NULL
the	NULL
HIV-infected	NULL
patient	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
385	NULL
)	NULL
.	NULL

Constitutive	NULL
expression	NULL
of	NULL
IL-18B	NULL
,	NULL
TNF-	NULL
«	NULL
and	NULL
M-CSF	NULL
mRNA	NULL
is	NULL
not	NULL
observed	NULL
in	NULL
PLB-985	NULL
,	NULL
THP	NULL
-1	NULL
,	NULL
and	NULL
U937	NULL
cell	NULL
lines	NULL
chronically	NULL
infected	NULL
by	NULL
HIV-1	NULL
.	NULL

Nonetheless	NULL
,	NULL
increased	NULL
cytokine	NULL
mRNA	NULL
levels	NULL
are	NULL
seen	NULL
after	NULL
treatment	NULL
with	NULL
LPS	NULL
or	NULL
Sendai	NULL
virus	NULL
compared	NULL
with	NULL
those	NULL
in	NULL
uninfected	NULL
controls	NULL
(	NULL
63	NULL
,	NULL
64	NULL
,	NULL
244	NULL
,	NULL
411	NULL
)	NULL
.	NULL

No	NULL
difference	NULL
in	NULL
mRNA	NULL
stability	NULL
is	NULL
detected	NULL
between	NULL
HIV-1-infected	NULL
and	NULL
uninfected	NULL
cell	NULL
lines	NULL
,	NULL
suggesting	NULL
that	NULL
cytokine	NULL
genes	NULL
may	NULL
be	NULL
upregulated	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
(	NULL
328	NULL
)	NULL
.	NULL

In	NULL
chronically	NULL
infected	NULL
U1	NULL
cells	NULL
stimulated	NULL
with	NULL
Epstein-Barr	NULL
virus-	NULL
or	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
-derived	NULL
antigens	NULL
,	NULL
enhanced	NULL
monokine	NULL
secretion	NULL
correlates	NULL
directly	NULL
with	NULL
enhanced	NULL
HIV-1	NULL
replication	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Both	NULL
normal	NULL
and	NULL
enhanced	NULL
cytokine	NULL
gene	NULL
expression	NULL
is	NULL
reported	NULL
in	NULL
PBMCs	NULL
infected	NULL
with	NULL
HIV-1	NULL
in	NULL
Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
vitro	NULL
.	NULL

Secondary	NULL
stimulation	NULL
of	NULL
HIV-1-infected	NULL
PBMCs	NULL
by	NULL
en-dotoxin	NULL
(	NULL
245	NULL
)	NULL
,	NULL
LPS	NULL
(	NULL
254	NULL
)	NULL
,	NULL
or	NULL
dsRNA	NULL
(	NULL
115	NULL
)	NULL
leads	NULL
to	NULL
cytokine	NULL
expression	NULL
comparable	NULL
to	NULL
levels	NULL
seen	NULL
from	NULL
uninfected	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
secondary	NULL
stimulation	NULL
with	NULL
LPS	NULL
(	NULL
123	NULL
,	NULL
243	NULL
)	NULL
,	NULL
Preumo-cystis	NULL
carinii	NULL
(	NULL
156	NULL
)	NULL
,	NULL
or	NULL
Mycobacterium	NULL
avium	NULL
(	NULL
263	NULL
)	NULL
leads	NULL
to	NULL
the	NULL
selective	NULL
enhancement	NULL
of	NULL
TNF-	NULL
«	NULL
,	NULL
IL-1	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
IL-8	NULL
mRNA	NULL
expression	NULL
in	NULL
HIV-1-infected	NULL
PBMCs	NULL
compared	NULL
with	NULL
uninfected	NULL
controls	NULL
.	NULL

Transcriptional	NULL
upregulation	NULL
of	NULL
cytokine	NULL
genes	NULL
may	NULL
involve	NULL
signal	NULL
transduction	NULL
pathways	NULL
activated	NULL
by	NULL
gp120-CD4	NULL
interactions	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
.	NULL

TNF-a	NULL
,	NULL
IL-1	NULL
,	NULL
and	NULL
IL-6	NULL
mRNA	NULL
,	NULL
as	NULL
well	NULL
as	NULL
metabolites	NULL
of	NULL
arachidonic	NULL
acid	NULL
,	NULL
are	NULL
produced	NULL
from	NULL
normal	NULL
PBMCs	NULL
exposed	NULL
to	NULL
either	NULL
purified	NULL
gp120	NULL
(	NULL
119	NULL
,	NULL
235	NULL
,	NULL
243	NULL
,	NULL
398	NULL
)	NULL
or	NULL
inactivated	NULL
HIV-1	NULL
(	NULL
258	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
CD4	NULL
antigen	NULL
induces	NULL
the	NULL
lymphoid	NULL
cell-specific	NULL
tyrosine	NULL
kinase	NULL
Lek	NULL
,	NULL
involved	NULL
in	NULL
T-cell	NULL
activation	NULL
(	NULL
393	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
the	NULL
Lek	NULL
signaling	NULL
cascade	NULL
or	NULL
a	NULL
similar	NULL
pathway	NULL
in	NULL
monocytes	NULL
may	NULL
also	NULL
lead	NULL
to	NULL
cytokine	NULL
gene	NULL
activation	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
cytokine	NULL
secretion	NULL
is	NULL
upregulated	NULL
in	NULL
response	NULL
to	NULL
secondary	NULL
antigenic	NULL
challenge	NULL
may	NULL
not	NULL
be	NULL
HIV-1	NULL
specific	NULL
,	NULL
since	NULL
viral	NULL
infection	NULL
in	NULL
other	NULL
myeloid	NULL
cell	NULL
systems	NULL
also	NULL
gives	NULL
rise	NULL
to	NULL
a	NULL
potentiated	NULL
cytokine	NULL
response	NULL
.	NULL

Murine	NULL
CMV	NULL
infection	NULL
of	NULL
a	NULL
macrophage	NULL
cell	NULL
line	NULL
is	NULL
insufficient	NULL
to	NULL
induce	NULL
IL-1	NULL
secretion	NULL
,	NULL
but	NULL
following	NULL
stimulation	NULL
with	NULL
LPS	NULL
,	NULL
IL-1	NULL
secretion	NULL
is	NULL
enhanced	NULL
more	NULL
than	NULL
100-fold	NULL
(	NULL
198	NULL
)	NULL
.	NULL

Potentiated	NULL
TNF-	NULL
mRNA	NULL
expression	NULL
is	NULL
also	NULL
observed	NULL
with	NULL
influenza	NULL
virus-infected	NULL
macrophages	NULL
challenged	NULL
with	NULL
LPS	NULL
(	NULL
124	NULL
,	NULL
257	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
indicate	NULL
that	NULL
changes	NULL
in	NULL
cellular	NULL
physiology	NULL
associated	NULL
with	NULL
virus	NULL
infection	NULL
may	NULL
give	NULL
rise	NULL
to	NULL
altered	NULL
cytokine	NULL
gene	NULL
transcription	NULL
.	NULL

Physiological	NULL
changes	NULL
associated	NULL
with	NULL
cellular	NULL
differentiation	NULL
may	NULL
cause	NULL
myeloid	NULL
cells	NULL
to	NULL
be	NULL
highly	NULL
responsive	NULL
to	NULL
antigenic	NULL
stimulation	NULL
.	NULL

For	NULL
example	NULL
,	NULL
when	NULL
PBMCs	NULL
are	NULL
fractionated	NULL
into	NULL
nonadherent	NULL
(	NULL
immature	NULL
)	NULL
and	NULL
adherent	NULL
(	NULL
mature	NULL
)	NULL
populations	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
Sendai	NULL
virus	NULL
,	NULL
LPS	NULL
,	NULL
or	NULL
PMA	NULL
,	NULL
approximately	NULL
200-fold-higher	NULL
levels	NULL
of	NULL
TNF-	NULL
«	NULL
are	NULL
produced	NULL
from	NULL
the	NULL
mature	NULL
adherent	NULL
cells	NULL
than	NULL
from	NULL
the	NULL
nonadherent	NULL
cells	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Dudding	NULL
et	NULL
al	NULL
.	NULL

(	NULL
78	NULL
)	NULL
report	NULL
that	NULL
human	NULL
CMV	NULL
infection	NULL
of	NULL
the	NULL
ML-3	NULL
promyelomonocytic	NULL
cell	NULL
line	NULL
does	NULL
not	NULL
induce	NULL
cytokine	NULL
or	NULL
inflammatory	NULL
response	NULL
gene	NULL
transcription	NULL
.	NULL

However	NULL
,	NULL
PMA-induced	NULL
differentiation	NULL
of	NULL
ML-3	NULL
cells	NULL
followed	NULL
by	NULL
CMV	NULL
infection	NULL
leads	NULL
to	NULL
enhanced	NULL
transcription	NULL
,	NULL
translation	NULL
,	NULL
and	NULL
stability	NULL
of	NULL
IL-1	NULL
,	NULL
TNF-	NULL
«	NULL
,	NULL
MAD-9	NULL
,	NULL
and	NULL
mRNA	NULL
(	NULL
78	NULL
)	NULL
.	NULL

Myeloid	NULL
Cell	NULL
Differentiation	NULL
HIV-1	NULL
infection	NULL
of	NULL
promonocytic	NULL
U937	NULL
cells	NULL
induces	NULL
phenotypic	NULL
changes	NULL
associated	NULL
with	NULL
cellular	NULL
differentiation	NULL
and	NULL
viral	NULL
expression	NULL
(	NULL
112	NULL
,	NULL
207	NULL
,	NULL
284	NULL
,	NULL
285	NULL
,	NULL
295	NULL
)	NULL
.	NULL

Chronic	NULL
HIV-1	NULL
infection	NULL
of	NULL
PLB-985	NULL
cells	NULL
leads	NULL
to	NULL
morphological	NULL
changes	NULL
consistent	NULL
with	NULL
irreversible	NULL
differentiation	NULL
along	NULL
the	NULL
monocytic	NULL
pathway	NULL
and	NULL
mRNA	NULL
expression	NULL
of	NULL
myeloid	NULL
cell-specific	NULL
surface	NULL
markers	NULL
(	NULL
CD14	NULL
and	NULL
c-fms	NULL
)	NULL
(	NULL
331	NULL
)	NULL
.	NULL

Acutely	NULL
but	NULL
not	NULL
chronically	NULL
HIV-1-infected	NULL
THP-1	NULL
monocytes	NULL
also	NULL
display	NULL
changes	NULL
indicative	NULL
of	NULL
monocytic	NULL
maturation	NULL
(	NULL
244	NULL
)	NULL
.	NULL

In	NULL
other	NULL
studies	NULL
,	NULL
the	NULL
promyelocytic	NULL
cell	NULL
lines	NULL
PLB-985	NULL
and	NULL
HL-60	NULL
do	NULL
not	NULL
spontaneously	NULL
dif-ferentiate	NULL
.	NULL

Despite	NULL
infection	NULL
by	NULL
HIV-1	NULL
over	NULL
20	NULL
days	NULL
,	NULL
each	NULL
cell	NULL
line	NULL
maintains	NULL
its	NULL
capacity	NULL
for	NULL
either	NULL
monocytic	NULL
or	NULL
granulocytic	NULL
differentiation	NULL
in	NULL
response	NULL
to	NULL
differentiation-inducing	NULL
agents	NULL
(	NULL
49	NULL
,	NULL
298	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
primary	NULL
monocytes	NULL
isolated	NULL
from	NULL
HIV-1-infected	NULL
donors	NULL
fail	NULL
to	NULL
undergo	NULL
normal	NULL
in	NULL
vitro	NULL
maturation	NULL
after	NULL
7	NULL
days	NULL
in	NULL
culture	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Changes	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
surface	NULL
receptors	NULL
associated	NULL
with	NULL
myeloid	NULL
differentiation	NULL
or	NULL
activation	NULL
may	NULL
be	NULL
one	NULL
mechanism	NULL
whereby	NULL
differentiation-induced	NULL
signals	NULL
can	NULL
lead	NULL
to	NULL
a	NULL
``	NULL
priming	NULL
effect	NULL
``	NULL
in	NULL
HIV-1-infected	NULL
cells	NULL
.	NULL

Upregulation	NULL
of	NULL
CD14	NULL
REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
491	NULL
is	NULL
reported	NULL
to	NULL
occur	NULL
in	NULL
HIV-l-infected	NULL
promonocytic	NULL
cells	NULL
(	NULL
331	NULL
)	NULL
and	NULL
may	NULL
lead	NULL
to	NULL
increased	NULL
responsiveness	NULL
to	NULL
LPS	NULL
and	NULL
LPS-induced	NULL
HIV-1	NULL
gene	NULL
expression	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
HIV-1-infected	NULL
monocytic	NULL
cell	NULL
lines	NULL
show	NULL
increased	NULL
TNF	NULL
receptor	NULL
(	NULL
48	NULL
)	NULL
,	NULL
IL-2	NULL
receptor	NULL
(	NULL
7	NULL
)	NULL
,	NULL
and	NULL
c-Fms	NULL
(	NULL
CSF-1	NULL
receptor	NULL
)	NULL
(	NULL
331	NULL
)	NULL
expression	NULL
,	NULL
which	NULL
could	NULL
lead	NULL
to	NULL
increased	NULL
cytokine	NULL
and	NULL
growth	NULL
factor	NULL
responsiveness	NULL
.	NULL

DNA-Binding	NULL
Activity	NULL
HIV-1	NULL
infection	NULL
in	NULL
myeloid	NULL
cells	NULL
may	NULL
also	NULL
induce	NULL
alterations	NULL
in	NULL
signal	NULL
transduction	NULL
pathways	NULL
which	NULL
modulate	NULL
cellular	NULL
transcription	NULL
factors	NULL
.	NULL

activity	NULL
,	NULL
expression	NULL
of	NULL
an	NULL
HIV-1	NULL
LTR	NULL
reporter	NULL
gene	NULL
,	NULL
and	NULL
monocytic	NULL
differentiation	NULL
are	NULL
coordinately	NULL
inducible	NULL
in	NULL
immature	NULL
myeloid	NULL
cells	NULL
(	NULL
HL-60	NULL
and	NULL
U937	NULL
)	NULL
(	NULL
127	NULL
)	NULL
.	NULL

In	NULL
the	NULL
more	NULL
mature	NULL
P388	NULL
,	NULL
THP-1	NULL
,	NULL
and	NULL
P45-1.8	NULL
cells	NULL
and	NULL
in	NULL
primary	NULL
macrophages	NULL
,	NULL
NF-	NULL
«	NULL
xB-binding	NULL
activity	NULL
and	NULL
expression	NULL
of	NULL
an	NULL
HIV-1	NULL
LTR	NULL
reporter	NULL
gene	NULL
are	NULL
constitutively	NULL
high	NULL
and	NULL
not	NULL
further	NULL
inducible	NULL
,	NULL
indicating	NULL
that	NULL
NF-	NULL
«	NULL
B-binding	NULL
activity	NULL
is	NULL
induced	NULL
during	NULL
the	NULL
promyelocytic-to-monocytic	NULL
transition	NULL
(	NULL
127	NULL
)	NULL
.	NULL

However	NULL
,	NULL
examination	NULL
of	NULL
the	NULL
nuclear	NULL
NF-kB	NULL
levels	NULL
in	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
promonocytic	NULL
and	NULL
monocytic	NULL
cell	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
primary	NULL
blood	NULL
monocytes	NULL
,	NULL
does	NULL
not	NULL
always	NULL
yield	NULL
a	NULL
correlation	NULL
between	NULL
maturation	NULL
state	NULL
and	NULL
constitutive	NULL
,	NULL
nuclear	NULL
NF-kB	NULL
(	NULL
17	NULL
,	NULL
100	NULL
)	NULL
.	NULL

The	NULL
Ikbe	NULL
(	NULL
MAD-3	NULL
)	NULL
gene	NULL
is	NULL
highly	NULL
induced	NULL
in	NULL
macrophages	NULL
upon	NULL
adherence	NULL
to	NULL
their	NULL
substratum	NULL
(	NULL
132	NULL
)	NULL
.	NULL

NF-kB-binding	NULL
activity	NULL
is	NULL
also	NULL
activated	NULL
following	NULL
binding	NULL
of	NULL
B1	NULL
integrins	NULL
to	NULL
cellular	NULL
adhesion	NULL
molecules	NULL
(	NULL
209	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
easily	NULL
activated	NULL
upon	NULL
adherence	NULL
or	NULL
physical	NULL
manipulation	NULL
;	NULL
this	NULL
could	NULL
lead	NULL
to	NULL
variations	NULL
in	NULL
constitutive	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
between	NULL
various	NULL
cell	NULL
lines	NULL
and	NULL
primary	NULL
cells	NULL
.	NULL

Productive	NULL
viral	NULL
infection	NULL
also	NULL
causes	NULL
sustained	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
in	NULL
HIV-1-infected	NULL
monocytic	NULL
cell	NULL
lines	NULL
(	NULL
16	NULL
,	NULL
286	NULL
,	NULL
314	NULL
,	NULL
329	NULL
,	NULL
331	NULL
,	NULL
375	NULL
)	NULL
.	NULL

A	NULL
direct	NULL
temporal	NULL
correlation	NULL
exists	NULL
between	NULL
HIV-1	NULL
infection	NULL
and	NULL
the	NULL
appearance	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
in	NULL
the	NULL
monomyeloblastic	NULL
cell	NULL
line	NULL
PLB-985	NULL
(	NULL
330	NULL
)	NULL
.	NULL

Sustained	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
may	NULL
be	NULL
dependent	NULL
on	NULL
the	NULL
maintenance	NULL
of	NULL
a	NULL
virus-mediated	NULL
activation	NULL
signal	NULL
.	NULL

Bachelerie	NULL
et	NULL
al	NULL
.	NULL

demonstrate	NULL
constitutive	NULL
NF-	NULL
«	NULL
B-binding	NULL
activity	NULL
in	NULL
the	NULL
chronically	NULL
HIV-1-infected	NULL
promonocytic	NULL
cell	NULL
line	NULL
U937	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Increased	NULL
transcription	NULL
and	NULL
processing	NULL
of	NULL
the	NULL
p105	NULL
precursor	NULL
gives	NULL
rise	NULL
to	NULL
increased	NULL
intracellular	NULL
pools	NULL
of	NULL
NF-kB	NULL
p50	NULL
in	NULL
chronically	NULL
infected	NULL
U937	NULL
cells	NULL
(	NULL
286	NULL
)	NULL
.	NULL

In	NULL
HIV-1-infected	NULL
cells	NULL
,	NULL
p105	NULL
processing	NULL
may	NULL
be	NULL
mediated	NULL
by	NULL
the	NULL
virus-encoded	NULL
protease	NULL
(	NULL
321	NULL
)	NULL
.	NULL

HIV-1	NULL
infection	NULL
of	NULL
the	NULL
monocytic	NULL
THP-1	NULL
cell	NULL
line	NULL
results	NULL
in	NULL
two	NULL
populations	NULL
of	NULL
chronically	NULL
infected	NULL
cells	NULL
:	NULL
those	NULL
with	NULL
productive	NULL
and	NULL
those	NULL
with	NULL
restricted	NULL
virus	NULL
expression	NULL
(	NULL
314	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
productively	NULL
infected	NULL
cells	NULL
contain	NULL
increased	NULL
NF-	NULL
«	NULL
B	NULL
p50-RelA	NULL
heterodimer-binding	NULL
activity	NULL
,	NULL
whereas	NULL
extracts	NULL
from	NULL
cells	NULL
expressing	NULL
low	NULL
levels	NULL
of	NULL
virus	NULL
(	NULL
restricted	NULL
ex-pression	NULL
)	NULL
display	NULL
only	NULL
p50	NULL
homodimer-binding	NULL
activity	NULL
.	NULL

Similarly	NULL
,	NULL
p50-ReIA	NULL
heterodimer-binding	NULL
activity	NULL
is	NULL
constitutively	NULL
present	NULL
in	NULL
chronically	NULL
HIV-1-infected	NULL
(	NULL
and	NULL
more	NULL
differenti-ated	NULL
)	NULL
PLB-IIIB	NULL
cells	NULL
but	NULL
is	NULL
not	NULL
present	NULL
or	NULL
inducible	NULL
in	NULL
the	NULL
immature	NULL
parental	NULL
PLB-985	NULL
myelomonoblastic	NULL
cell	NULL
line	NULL
(	NULL
329-331	NULL
)	NULL
.	NULL

Increased	NULL
p50-RelA-binding	NULL
activity	NULL
is	NULL
observed	NULL
in	NULL
HIV-1-infected	NULL
PBMCs	NULL
and	NULL
macrophages	NULL
but	NULL
not	NULL
in	NULL
the	NULL
promonocytic	NULL
cell	NULL
line	NULL
U937	NULL
,	NULL
suggesting	NULL
that	NULL
a	NULL
certain	NULL
level	NULL
of	NULL
myeloid	NULL
maturation	NULL
is	NULL
required	NULL
prior	NULL
to	NULL
induction	NULL
of	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
(	NULL
375	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
specific	NULL
lysosomal	NULL
proteases	NULL
expressed	NULL
in	NULL
myelomonocytic	NULL
cells	NULL
,	NULL
including	NULL
primary	NULL
monocytes	NULL
,	NULL
HL-60	NULL
,	NULL
and	NULL
certain	NULL
clones	NULL
of	NULL
U937	NULL
and	NULL
THP-1	NULL
cells	NULL
,	NULL
results	NULL
in	NULL
the	NULL
carboxyl-terminal	NULL
cleavage	NULL
of	NULL
the	NULL
RelA	NULL
subunit	NULL
of	NULL
NF-kB	NULL
,	NULL
giving	NULL
rise	NULL
to	NULL
492	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

protein-DNA	NULL
complexes	NULL
without	NULL
transcriptional	NULL
activity	NULL
that	NULL
functionally	NULL
resemble	NULL
p50	NULL
homodimers	NULL
(	NULL
102	NULL
)	NULL
.	NULL

Chronically	NULL
infected	NULL
cells	NULL
exhibiting	NULL
``	NULL
restricted	NULL
``	NULL
viral	NULL
replication	NULL
express	NULL
the	NULL
protease	NULL
,	NULL
whereas	NULL
clones	NULL
which	NULL
are	NULL
``	NULL
productively	NULL
``	NULL
infected	NULL
do	NULL
not	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
proteases	NULL
is	NULL
downregu-lated	NULL
after	NULL
exposure	NULL
to	NULL
agents	NULL
that	NULL
induce	NULL
monocytic	NULL
but	NULL
not	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

Cleavage	NULL
of	NULL
RelA	NULL
is	NULL
thought	NULL
to	NULL
occur	NULL
only	NULL
in	NULL
vitro	NULL
during	NULL
cell	NULL
extract	NULL
preparation	NULL
;	NULL
however	NULL
,	NULL
protease	NULL
expression	NULL
may	NULL
correlate	NULL
with	NULL
the	NULL
expression	NULL
of	NULL
other	NULL
genes	NULL
responsible	NULL
for	NULL
the	NULL
replicative	NULL
phenotype	NULL
of	NULL
HIV	NULL
in	NULL
myeloid	NULL
cells	NULL
(	NULL
102	NULL
)	NULL
.	NULL

COFACTORS	NULL
IN	NULL
HIV-1	NULL
DISEASE	NULL
PROGRESSION	NULL
Many	NULL
pathogenic	NULL
agents	NULL
upregulate	NULL
HIV-1	NULL
transcription	NULL
by	NULL
inducing	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
(	NULL
326	NULL
)	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
secondary	NULL
opportunistic	NULL
infections	NULL
which	NULL
result	NULL
in	NULL
immune	NULL
system	NULL
activation	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
progression	NULL
of	NULL
AIDS	NULL
.	NULL

Furthermore	NULL
,	NULL
pathogens	NULL
encountered	NULL
by	NULL
an	NULL
HIV-1-infected	NULL
individual	NULL
during	NULL
a	NULL
normal	NULL
immune	NULL
response	NULL
can	NULL
increase	NULL
the	NULL
susceptibility	NULL
of	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
to	NULL
infection	NULL
by	NULL
HIV-1	NULL
.	NULL

AIDS	NULL
patients	NULL
are	NULL
subject	NULL
to	NULL
multiple	NULL
pathogenic	NULL
opportunistic	NULL
infections	NULL
,	NULL
such	NULL
as	NULL
those	NULL
caused	NULL
by	NULL
Pneumocystis	NULL
carinii	NULL
,	NULL
Toxoplasma	NULL
gondii	NULL
,	NULL
and	NULL
Mycobacterium	NULL
avium	NULL
(	NULL
336	NULL
)	NULL
.	NULL

As	NULL
a	NULL
sexually	NULL
transmitted	NULL
and	NULL
blood-borne	NULL
agent	NULL
,	NULL
HIV-1	NULL
is	NULL
often	NULL
found	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
other	NULL
pathogens	NULL
,	NULL
including	NULL
Treponema	NULL
pal-lidum	NULL
,	NULL
Neisseria	NULL
gonorrhoeae	NULL
,	NULL
CMV	NULL
,	NULL
HSV	NULL
-1	NULL
and	NULL
HSV	NULL
-2	NULL
,	NULL
human	NULL
herpesvirus	NULL
6	NULL
,	NULL
hepatitis	NULL
B	NULL
virus	NULL
,	NULL
and	NULL
human	NULL
papillomavirus	NULL
.	NULL

The	NULL
human	NULL
herpesviruses	NULL
are	NULL
among	NULL
the	NULL
most	NULL
common	NULL
viral	NULL
pathogens	NULL
associated	NULL
with	NULL
HIV-1	NULL
infection	NULL
.	NULL

Many	NULL
individuals	NULL
infected	NULL
with	NULL
HIV-1	NULL
are	NULL
also	NULL
infected	NULL
with	NULL
amoebae	NULL
and	NULL
other	NULL
parasites	NULL
that	NULL
cause	NULL
malaria	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
260	NULL
)	NULL
.	NULL

The	NULL
response	NULL
of	NULL
the	NULL
infected	NULL
host	NULL
to	NULL
these	NULL
organisms	NULL
could	NULL
indirectly	NULL
favor	NULL
HIV-1	NULL
replication	NULL
and	NULL
heighten	NULL
progression	NULL
to	NULL
AIDS	NULL
.	NULL

Viral	NULL
Cofactors	NULL
There	NULL
are	NULL
several	NULL
mechanisms	NULL
by	NULL
which	NULL
viruses	NULL
can	NULL
increase	NULL
HIV-1	NULL
gene	NULL
expression	NULL
.	NULL

First	NULL
,	NULL
at	NULL
a	NULL
molecular	NULL
level	NULL
,	NULL
DNA	NULL
viruses	NULL
commonly	NULL
found	NULL
in	NULL
AIDS	NULL
patients	NULL
can	NULL
encode	NULL
transactivator	NULL
proteins	NULL
capable	NULL
of	NULL
increasing	NULL
expression	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

These	NULL
include	NULL
the	NULL
herpesviruses	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
CMV	NULL
(	NULL
65	NULL
,	NULL
261	NULL
)	NULL
,	NULL
HSV	NULL
(	NULL
89	NULL
,	NULL
117	NULL
,	NULL
248	NULL
)	NULL
,	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
162	NULL
)	NULL
,	NULL
and	NULL
human	NULL
herpesvirus	NULL
6	NULL
(	NULL
215	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
adenoviruses	NULL
(	NULL
171	NULL
)	NULL
,	NULL
papovavi-ruses	NULL
(	NULL
117	NULL
)	NULL
,	NULL
and	NULL
hepatitis	NULL
B	NULL
virus	NULL
(	NULL
387	NULL
)	NULL
.	NULL

The	NULL
CMV	NULL
and	NULL
HSV	NULL
trans-activator	NULL
proteins	NULL
,	NULL
involved	NULL
in	NULL
increased	NULL
expression	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
,	NULL
are	NULL
encoded	NULL
by	NULL
immediate-early	NULL
gene	NULL
products	NULL
(	NULL
275	NULL
,	NULL
287	NULL
,	NULL
378	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
these	NULL
frans-activators	NULL
on	NULL
LTR-driven	NULL
expression	NULL
are	NULL
shown	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
promoter	NULL
regions	NULL
,	NULL
some	NULL
of	NULL
which	NULL
are	NULL
distinct	NULL
from	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
(	NULL
89	NULL
,	NULL
287	NULL
)	NULL
.	NULL

Slcond	NULL
,	NULL
several	NULL
viruses	NULL
or	NULL
viral	NULL
gene	NULL
products	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
hepatitis	NULL
B	NULL
virus	NULL
X	NULL
and	NULL
HTLV-1	NULL
Tax	NULL
)	NULL
can	NULL
activate	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
17	NULL
)	NULL
,	NULL
which	NULL
directly	NULL
enhances	NULL
HIV-1	NULL
LTR-regulated	NULL
transcription	NULL
.	NULL

One	NULL
common	NULL
point	NULL
at	NULL
which	NULL
the	NULL
infection	NULL
cycle	NULL
of	NULL
these	NULL
viruses	NULL
may	NULL
overlap	NULL
is	NULL
in	NULL
generation	NULL
of	NULL
dsRNA	NULL
during	NULL
viral	NULL
replication	NULL
,	NULL
which	NULL
may	NULL
in	NULL
turn	NULL
activate	NULL
PKR	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
341	NULL
)	NULL
.	NULL

PKR	NULL
is	NULL
induced	NULL
by	NULL
interferon	NULL
and	NULL
is	NULL
activated	NULL
by	NULL
binding	NULL
to	NULL
dsRNA	NULL
molecules	NULL
generated	NULL
during	NULL
viral	NULL
infection	NULL
.	NULL

Recent	NULL
work	NULL
implicates	NULL
PKR	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

PKR	NULL
can	NULL
phosphorylate	NULL
IxBa	NULL
and	NULL
activate	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
in	NULL
cell	NULL
extracts	NULL
(	NULL
183	NULL
)	NULL
.	NULL

In	NULL
PKR-depleted	NULL
HeLa	NULL
cells	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
is	NULL
not	NULL
activated	NULL
by	NULL
dsRNA	NULL
MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

[	NULL
poly	NULL
(	NULL
I	NULL
)	NULL
-poly	NULL
(	NULL
C	NULL
)	NULL
]	NULL
(	NULL
216	NULL
)	NULL
.	NULL

Increased	NULL
PKR	NULL
protein	NULL
and	NULL
activity	NULL
is	NULL
a	NULL
possible	NULL
mechanism	NULL
by	NULL
which	NULL
constitutive	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
may	NULL
be	NULL
perpetuated	NULL
in	NULL
chronically	NULL
infected	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
PKR	NULL
may	NULL
induce	NULL
NF-kB	NULL
by	NULL
two	NULL
potential	NULL
mecha-nisms	NULL
:	NULL
phosphorylation-induced	NULL
degradation	NULL
of	NULL
IxB	NULL
and/or	NULL
inhibition	NULL
of	NULL
de	NULL
novo	NULL
IxB	NULL
protein	NULL
synthesis	NULL
at	NULL
the	NULL
translational	NULL
level	NULL
.	NULL

Studies	NULL
are	NULL
under	NULL
way	NULL
to	NULL
dissect	NULL
the	NULL
role	NULL
of	NULL
PKR	NULL
in	NULL
NF-kB	NULL
activation	NULL
and	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

Third	NULL
,	NULL
viruses	NULL
play	NULL
an	NULL
indirect	NULL
role	NULL
in	NULL
increasing	NULL
virus	NULL
spread	NULL
and	NULL
susceptibility	NULL
of	NULL
cells	NULL
to	NULL
infection	NULL
.	NULL

For	NULL
example	NULL
,	NULL
some	NULL
strains	NULL
of	NULL
human	NULL
herpesvirus	NULL
6	NULL
upregulate	NULL
CD4	NULL
surface	NULL
expression	NULL
on	NULL
CD8*	NULL
T	NULL
cells	NULL
,	NULL
expanding	NULL
the	NULL
repertoire	NULL
of	NULL
cells	NULL
permissive	NULL
to	NULL
HIV-1	NULL
infection	NULL
(	NULL
214	NULL
)	NULL
.	NULL

Herpesviruses	NULL
also	NULL
upregulate	NULL
Fc	NULL
receptors	NULL
on	NULL
myeloid	NULL
cells	NULL
,	NULL
thus	NULL
providing	NULL
an	NULL
alternate	NULL
route	NULL
of	NULL
HIV-1	NULL
entry	NULL
into	NULL
uninfected	NULL
cells	NULL
(	NULL
226	NULL
)	NULL
.	NULL

Viral	NULL
dissemination	NULL
may	NULL
also	NULL
be	NULL
enhanced	NULL
by	NULL
attraction	NULL
of	NULL
HIV-1-infected	NULL
monocytes	NULL
to	NULL
sites	NULL
of	NULL
secondary	NULL
infection	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
CMV	NULL
in	NULL
the	NULL
central	NULL
nervous	NULL
system	NULL
[	NULL
CNS	NULL
]	NULL
)	NULL
(	NULL
260	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
HIV-1	NULL
upregulation	NULL
may	NULL
occur	NULL
indirectly	NULL
in	NULL
virally	NULL
infected	NULL
cells	NULL
through	NULL
the	NULL
production	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
(	NULL
see	NULL
below	NULL
)	NULL
(	NULL
293	NULL
)	NULL
.	NULL

Bacterial	NULL
Products	NULL
LPS	NULL
is	NULL
a	NULL
major	NULL
component	NULL
of	NULL
the	NULL
outer	NULL
membrane	NULL
of	NULL
most	NULL
gram-negative	NULL
bacteria	NULL
and	NULL
is	NULL
used	NULL
to	NULL
simulate	NULL
certain	NULL
effects	NULL
of	NULL
bacterial	NULL
infection	NULL
in	NULL
cell	NULL
culture	NULL
models	NULL
.	NULL

LPS	NULL
binds	NULL
to	NULL
a	NULL
55-kDa	NULL
cell	NULL
surface	NULL
protein	NULL
,	NULL
CD14	NULL
,	NULL
expressed	NULL
mainly	NULL
on	NULL
monocytes	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
B	NULL
cells	NULL
but	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
on	NULL
epithelial	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
CD14	NULL
expression	NULL
is	NULL
upregulated	NULL
in	NULL
chronically	NULL
HIV-l-infected	NULL
PLB-985	NULL
cells	NULL
as	NULL
an	NULL
marker	NULL
of	NULL
monocytic	NULL
differentiation	NULL
(	NULL
331	NULL
)	NULL
.	NULL

Exposure	NULL
to	NULL
LPS	NULL
leads	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
genes	NULL
associated	NULL
with	NULL
cellular	NULL
activation	NULL
and	NULL
differentiation	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
the	NULL
x	NULL
light-chain	NULL
gene	NULL
in	NULL
pre-B	NULL
cells	NULL
and	NULL
cytokine	NULL
genes	NULL
in	NULL
myeloid	NULL
cells	NULL
.	NULL

LPS	NULL
is	NULL
able	NULL
to	NULL
rapidly	NULL
stimulate	NULL
NF-kB-binding	NULL
activity	NULL
in	NULL
both	NULL
of	NULL
these	NULL
cell	NULL
types	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
253	NULL
)	NULL
.	NULL

LPS	NULL
induces	NULL
transcription	NULL
from	NULL
the	NULL
HIV-1	NULL
LTR	NULL
in	NULL
monocytes	NULL
but	NULL
not	NULL
T	NULL
cells	NULL
(	NULL
19	NULL
,	NULL
310	NULL
)	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
differentiation	NULL
state	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

For	NULL
example	NULL
,	NULL
LPS	NULL
stimulates	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
in	NULL
dividing	NULL
,	NULL
freshly	NULL
isolated	NULL
monocytes	NULL
and	NULL
U937	NULL
promonocytic	NULL
cells	NULL
(	NULL
30	NULL
)	NULL
but	NULL
downregulates	NULL
HIV-1	NULL
expression	NULL
in	NULL
PMA-stimulated	NULL
,	NULL
nondividing	NULL
U937	NULL
cells	NULL
and	NULL
macrophages	NULL
.	NULL

The	NULL
reduction	NULL
in	NULL
HIV-1	NULL
LTR-directed	NULL
gene	NULL
expression	NULL
is	NULL
mediated	NULL
through	NULL
an	NULL
element	NULL
distinct	NULL
from	NULL
NF-	NULL
«	NULL
B	NULL
enhancer	NULL
sites	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Physical	NULL
Stress	NULL
Physical	NULL
factors	NULL
causing	NULL
cellular	NULL
stress	NULL
,	NULL
such	NULL
as	NULL
UV	NULL
light	NULL
and	NULL
heat	NULL
,	NULL
enhance	NULL
HIV-1	NULL
replication	NULL
during	NULL
de	NULL
novo	NULL
infection	NULL
and	NULL
in	NULL
chronically	NULL
infected	NULL
cells	NULL
(	NULL
370	NULL
)	NULL
.	NULL

A	NULL
transcriptional	NULL
mechanism	NULL
,	NULL
mediated	NULL
by	NULL
stress-induced	NULL
activation	NULL
of	NULL
NF-kB	NULL
,	NULL
is	NULL
implicated	NULL
in	NULL
the	NULL
process	NULL
,	NULL
since	NULL
UV	NULL
light	NULL
and	NULL
heat	NULL
both	NULL
induce	NULL
expression	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
reporter	NULL
constructs	NULL
in	NULL
an	NULL
NF-kB-dependent	NULL
manner	NULL
(	NULL
392	NULL
)	NULL
.	NULL

Temperatures	NULL
of	NULL
approximately	NULL
41°C	NULL
synergize	NULL
with	NULL
IL-6	NULL
in	NULL
the	NULL
enhancement	NULL
of	NULL
HIV-1	NULL
expression	NULL
in	NULL
chronically	NULL
infected	NULL
promonocytic	NULL
and	NULL
T	NULL
cells	NULL
(	NULL
369	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
deletion	NULL
of	NULL
NF-KB	NULL
sites	NULL
within	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
abrogates	NULL
heat	NULL
shock	NULL
induction	NULL
of	NULL
HIV-1	NULL
LTR-directed	NULL
gene	NULL
expression	NULL
(	NULL
369	NULL
)	NULL
.	NULL

Emotional	NULL
stress	NULL
can	NULL
impair	NULL
several	NULL
immunological	NULL
responses	NULL
in	NULL
humans	NULL
and	NULL
animals	NULL
and	NULL
is	NULL
usually	NULL
accompanied	NULL
by	NULL
altered	NULL
levels	NULL
of	NULL
neurohormones	NULL
or	NULL
CNS-related	NULL
peptides	NULL
in	NULL
the	NULL
blood	NULL
(	NULL
125	NULL
)	NULL
.	NULL

Myeloid	NULL
cells	NULL
express	NULL
surface	NULL
receptors	NULL
for	NULL
several	NULL
of	NULL
these	NULL
CNS-derived	NULL
proteins	NULL
,	NULL
which	NULL
result	NULL
in	NULL
impaired	NULL
macrophage	NULL
cytotoxic	NULL
functions	NULL
(	NULL
133	NULL
)	NULL
.	NULL

However	NULL
,	NULL
establishing	NULL
a	NULL
correlation	NULL
between	NULL
in	NULL
vitro	NULL
studies	NULL
and	NULL
the	NULL
effects	NULL
of	NULL
psychological	NULL
stress	NULL
to	NULL
the	NULL
in	NULL
vivo	NULL
progression	NULL
of	NULL
HIV	NULL
disease	NULL
Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
493	NULL
TABLE	NULL
1	NULL
.	NULL

Cytokine	NULL
modulation	NULL
of	NULL
HIV	NULL
expression	NULL
Cell	NULL
type	NULL
``	NULL
Cytokine	NULL
Effect	NULL
Molecular	NULL
mechanism	NULL
Reference	NULL
(	NULL
s	NULL
)	NULL
Source	NULL
Target	NULL
IL-la/B	NULL
t	NULL
T	NULL
,	NULL
B	NULL
,	NULL
M	NULL
,	NULL
fibroblast	NULL
M	NULL
,	NULL
T	NULL
Transcription	NULL
by	NULL
induction	NULL
of	NULL
NF-kB	NULL
180	NULL
,	NULL
307	NULL
IL-2	NULL
t	NULL
T	NULL
M	NULL
?	NULL

Transcription	NULL
by	NULL
induction	NULL
of	NULL
NF-kB	NULL
38	NULL
,	NULL
55	NULL
,	NULL
158	NULL
,	NULL
235	NULL
IL-3	NULL
t	NULL
T	NULL
M	NULL
2	NULL
?	NULL

179	NULL
,	NULL
349	NULL
IL-6	NULL
t	NULL
T	NULL
,	NULL
B	NULL
,	NULL
M	NULL
M	NULL
Posttranscriptional	NULL
302	NULL
TNF-o/B	NULL
t	NULL
M	NULL
,	NULL
T	NULL
,	NULL
B	NULL
M	NULL
,	NULL
T	NULL
Transcription	NULL
by	NULL
induction	NULL
of	NULL
NF-kB	NULL
79	NULL
,	NULL
96	NULL
,	NULL
187	NULL
,	NULL
274	NULL
,	NULL
350	NULL
GM-CSF	NULL
t	NULL
M	NULL
,	NULL
T	NULL
,	NULL
fibroblast	NULL
M	NULL
Transcription	NULL
97	NULL
,	NULL
116	NULL
,	NULL
179	NULL
IL-4	NULL
t	NULL
l	NULL
T	NULL
,	NULL
endothelial	NULL
cell	NULL
M	NULL
?	NULL

Transcription	NULL
(	NULL
}	NULL
)	NULL
160	NULL
,	NULL
267	NULL
,	NULL
349	NULL
TGF-B	NULL
t	NULL
lb	NULL
Platelet	NULL
M	NULL
,	NULL
T	NULL
2	NULL
?	NULL

192	NULL
,	NULL
294	NULL
,	NULL
308	NULL
IFN-y	NULL
t	NULL
b	NULL
T	NULL
,	NULL
NK	NULL
M	NULL
Viral	NULL
budding	NULL
(	NULL
}	NULL
)	NULL
33	NULL
,	NULL
179	NULL
U	NULL
B	NULL
,	NULL
leukocyte	NULL
M	NULL
,	NULL
T	NULL
RT	NULL
``	NULL
or	NULL
integration	NULL
177	NULL
,	NULL
238	NULL
,	NULL
309	NULL
,	NULL
362	NULL
Transcription/RNA	NULL
stability	NULL
76	NULL
,	NULL
114	NULL
,	NULL
115	NULL
Assembly/release	NULL
141	NULL
,	NULL
366	NULL
,	NULL
410	NULL
,	NULL
412	NULL
IL-10	NULL
U	NULL
T	NULL
M	NULL
Virus	NULL
assembly	NULL
175	NULL
IL-13	NULL
U	NULL
T	NULL
M	NULL
?	NULL

Early	NULL
246	NULL
*	NULL
T	NULL
,	NULL
T	NULL
lymphocyte	NULL
;	NULL
B	NULL
,	NULL
B	NULL
lymphocyte	NULL
;	NULL
M	NULL
,	NULL
monocyte/macrophage	NULL
.	NULL

®	NULL
RT	NULL
,	NULL
reverse	NULL
transcriptase	NULL
.	NULL

is	NULL
exceedingly	NULL
difficult	NULL
.	NULL

One	NULL
study	NULL
showed	NULL
no	NULL
correlation	NULL
between	NULL
CD4	NULL
cell	NULL
counts	NULL
and	NULL
degree	NULL
of	NULL
emotional	NULL
stress	NULL
in	NULL
seropositive	NULL
individuals	NULL
over	NULL
a	NULL
1-year	NULL
period	NULL
(	NULL
290	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
malnutrition	NULL
is	NULL
associated	NULL
with	NULL
immunological	NULL
impairment	NULL
(	NULL
51	NULL
)	NULL
.	NULL

Malnutrition	NULL
occurs	NULL
frequently	NULL
during	NULL
HIV	NULL
infection	NULL
and	NULL
is	NULL
enhanced	NULL
with	NULL
disease	NULL
progression	NULL
.	NULL

Indicators	NULL
of	NULL
malnutrition	NULL
such	NULL
as	NULL
low	NULL
albumin	NULL
and	NULL
transferrin	NULL
levels	NULL
in	NULL
serum	NULL
correlate	NULL
with	NULL
poor	NULL
clinical	NULL
outcome	NULL
in	NULL
AIDS	NULL
patients	NULL
,	NULL
independent	NULL
of	NULL
CD4	NULL
lymphocyte	NULL
counts	NULL
(	NULL
374	NULL
)	NULL
.	NULL

CYTOKINE	NULL
MODULATION	NULL
OF	NULL
HIV-1	NULL
REPLICATION	NULL
Inflammatory	NULL
mediators	NULL
and	NULL
cytokines	NULL
are	NULL
secreted	NULL
by	NULL
activated	NULL
myeloid	NULL
and	NULL
lymphoid	NULL
cells	NULL
during	NULL
normal	NULL
immune	NULL
responsiveness	NULL
to	NULL
pathogenic	NULL
infections	NULL
.	NULL

Many	NULL
cytokines	NULL
released	NULL
by	NULL
activated	NULL
lymphoid	NULL
and	NULL
myeloid	NULL
cells	NULL
stimulate	NULL
viral	NULL
replication	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
contribute	NULL
to	NULL
HIV-1	NULL
pathogenesis	NULL
,	NULL
and	NULL
hasten	NULL
progression	NULL
to	NULL
AIDS	NULL
(	NULL
reviewed	NULL
in	NULL
references	NULL
47	NULL
,	NULL
85	NULL
,	NULL
304	NULL
,	NULL
and	NULL
305	NULL
)	NULL
.	NULL

Cytokines	NULL
stimulate	NULL
the	NULL
production	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
additional	NULL
cytokines	NULL
in	NULL
an	NULL
autocrine	NULL
and/or	NULL
paracrine	NULL
manner	NULL
.	NULL

The	NULL
microenvironment	NULL
of	NULL
the	NULL
lymph	NULL
node	NULL
provides	NULL
an	NULL
environment	NULL
where	NULL
B	NULL
cells	NULL
,	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
myeloid	NULL
cells	NULL
are	NULL
in	NULL
close	NULL
contact	NULL
;	NULL
hence	NULL
,	NULL
complex	NULL
cytokine	NULL
networks	NULL
involving	NULL
paracrine	NULL
and	NULL
autocrine	NULL
effects	NULL
may	NULL
be	NULL
important	NULL
in	NULL
such	NULL
tissues	NULL
with	NULL
regard	NULL
to	NULL
clinical	NULL
latency	NULL
and	NULL
disease	NULL
progression	NULL
.	NULL

Increased	NULL
cytokine	NULL
expression	NULL
occurs	NULL
in	NULL
lymph	NULL
nodes	NULL
proximal	NULL
to	NULL
areas	NULL
of	NULL
virus	NULL
replication	NULL
(	NULL
80	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
activated	NULL
B	NULL
lymphocytes	NULL
,	NULL
isolated	NULL
from	NULL
the	NULL
lymph	NULL
nodes	NULL
of	NULL
AIDS	NULL
patients	NULL
,	NULL
are	NULL
able	NULL
to	NULL
stimulate	NULL
HIV-1	NULL
expression	NULL
in	NULL
autologous	NULL
T	NULL
cells	NULL
by	NULL
secretion	NULL
of	NULL
IL-6	NULL
and	NULL
TNF-	NULL
«	NULL
(	NULL
377	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
coculture	NULL
of	NULL
monocytes	NULL
from	NULL
infected	NULL
donors	NULL
with	NULL
allogeneic	NULL
T	NULL
cells	NULL
and	NULL
mitogens	NULL
results	NULL
in	NULL
monocytic	NULL
differentiation	NULL
and	NULL
HIV-1	NULL
expression	NULL
(	NULL
346	NULL
)	NULL
;	NULL
cell-to-cell	NULL
contact	NULL
and	NULL
cytokine	NULL
gene	NULL
expression	NULL
is	NULL
required	NULL
to	NULL
stimulate	NULL
HIV-1	NULL
replication	NULL
(	NULL
345	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
a	NULL
given	NULL
cytokine	NULL
on	NULL
HIV-1	NULL
replication	NULL
are	NULL
dependent	NULL
on	NULL
the	NULL
mixture	NULL
of	NULL
soluble	NULL
mediators	NULL
present	NULL
within	NULL
the	NULL
immediate	NULL
environment	NULL
of	NULL
infected	NULL
cells	NULL
.	NULL

Although	NULL
the	NULL
stimulatory	NULL
and/or	NULL
inhibitory	NULL
effects	NULL
of	NULL
many	NULL
cytokines	NULL
are	NULL
studied	NULL
in	NULL
vitro	NULL
,	NULL
a	NULL
direct	NULL
correlation	NULL
with	NULL
cytokine	NULL
effects	NULL
in	NULL
vivo	NULL
is	NULL
difficult	NULL
to	NULL
establish	NULL
.	NULL

Activating	NULL
Cytokines	NULL
Several	NULL
cytokines	NULL
exert	NULL
stimulatory	NULL
effects	NULL
on	NULL
HIV-1	NULL
replication	NULL
and	NULL
HIV-1	NULL
LTR-driven	NULL
transcription	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

TNF-	NULL
«	NULL
,	NULL
also	NULL
known	NULL
as	NULL
cachectin	NULL
,	NULL
was	NULL
first	NULL
described	NULL
as	NULL
an	NULL
endotoxin-induced	NULL
factor	NULL
that	NULL
was	NULL
cytotoxic	NULL
for	NULL
certain	NULL
tumor	NULL
cells	NULL
(	NULL
31	NULL
)	NULL
.	NULL

TNF-a	NULL
is	NULL
produced	NULL
primarily	NULL
by	NULL
macrophages	NULL
,	NULL
NK	NULL
cells	NULL
,	NULL
and	NULL
T	NULL
cells	NULL
and	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
the	NULL
acute-phase	NULL
response	NULL
to	NULL
bacterial	NULL
pathogens	NULL
.	NULL

TNF-	NULL
(	NULL
lymphotoxin	NULL
)	NULL
is	NULL
closely	NULL
related	NULL
to	NULL
TNF-	NULL
«	NULL
(	NULL
30	NULL
%	NULL
amino	NULL
acid	NULL
homology	NULL
)	NULL
but	NULL
is	NULL
produced	NULL
exclusively	NULL
by	NULL
lymphocytes	NULL
(	NULL
394	NULL
)	NULL
.	NULL

Both	NULL
molecules	NULL
bind	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
the	NULL
same	NULL
two	NULL
receptors	NULL
,	NULL
TNFR-	NULL
«	NULL
(	NULL
75	NULL
kDa	NULL
)	NULL
and	NULL
TNFR-B	NULL
(	NULL
55	NULL
kDa	NULL
)	NULL
,	NULL
expressed	NULL
on	NULL
virtually	NULL
all	NULL
cell	NULL
types	NULL
(	NULL
68	NULL
,	NULL
208	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
a	NULL
common	NULL
receptor	NULL
,	NULL
TNF-	NULL
«	NULL
and	NULL
TNF-B	NULL
exhibit	NULL
similar	NULL
biological	NULL
activities	NULL
including	NULL
induction	NULL
of	NULL
B-cell	NULL
and	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
,	NULL
procoagulant	NULL
activity	NULL
,	NULL
bone	NULL
resorption	NULL
,	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
cytokines	NULL
IL-1	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
GM-CSF	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Overproduction	NULL
of	NULL
TNF-	NULL
«	NULL
and	NULL
TNF-f	NULL
in	NULL
vivo	NULL
is	NULL
implicated	NULL
in	NULL
cachexia	NULL
(	NULL
progressive	NULL
wasting	NULL
)	NULL
,	NULL
septic	NULL
shock	NULL
,	NULL
and	NULL
autoimmune	NULL
disorders	NULL
(	NULL
273	NULL
,	NULL
382	NULL
)	NULL
.	NULL

The	NULL
inductive	NULL
effect	NULL
of	NULL
TNF-	NULL
«	NULL
/B	NULL
on	NULL
HIV-1	NULL
expression	NULL
is	NULL
well	NULL
documented	NULL
for	NULL
T	NULL
lymphocytes	NULL
and	NULL
mononuclear	NULL
phagocytes	NULL
.	NULL

When	NULL
supernatants	NULL
from	NULL
phytohemagglutinin-stimulated	NULL
PBMCs	NULL
or	NULL
LPS-stimulated	NULL
macrophages	NULL
are	NULL
added	NULL
to	NULL
chronically	NULL
infected	NULL
T-cell	NULL
lines	NULL
,	NULL
upregulation	NULL
of	NULL
HIV-1	NULL
replication	NULL
is	NULL
observed	NULL
(	NULL
55	NULL
,	NULL
97	NULL
)	NULL
.	NULL

Most	NULL
of	NULL
the	NULL
inductive	NULL
activity	NULL
from	NULL
these	NULL
supernatants	NULL
originates	NULL
from	NULL
TNF-	NULL
«	NULL
(	NULL
55	NULL
,	NULL
96	NULL
)	NULL
.	NULL

TNF-	NULL
«	NULL
/B	NULL
can	NULL
also	NULL
enhance	NULL
viral	NULL
replication	NULL
when	NULL
added	NULL
exogenously	NULL
in	NULL
vitro	NULL
or	NULL
when	NULL
produced	NULL
endogenously	NULL
during	NULL
virus	NULL
spread	NULL
in	NULL
culture	NULL
(	NULL
55	NULL
,	NULL
96	NULL
,	NULL
180	NULL
,	NULL
187	NULL
,	NULL
306	NULL
;	NULL
reviewed	NULL
in	NULL
reference	NULL
242	NULL
)	NULL
.	NULL

TNF-	NULL
«	NULL
triggers	NULL
HIV-1	NULL
activation	NULL
by	NULL
inducing	NULL
NF-kB	NULL
(	NULL
79	NULL
,	NULL
274	NULL
)	NULL
.	NULL

The	NULL
signal	NULL
transduction	NULL
pathway	NULL
leading	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
involves	NULL
signaling	NULL
through	NULL
the	NULL
55-kDa	NULL
TNF-	NULL
«	NULL
receptor	NULL
via	NULL
sphingomyelinase	NULL
and	NULL
ceramide	NULL
(	NULL
350	NULL
)	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
TNF-a	NULL
can	NULL
rescue	NULL
virus	NULL
replication	NULL
in	NULL
cell	NULL
lines	NULL
infected	NULL
with	NULL
a	NULL
mutant	NULL
clone	NULL
deleted	NULL
in	NULL
the	NULL
Spl	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
282	NULL
)	NULL
.	NULL

TNF-	NULL
«	NULL
@	NULL
/B	NULL
is	NULL
therefore	NULL
an	NULL
important	NULL
mediator	NULL
of	NULL
HIV-1	NULL
replication	NULL
,	NULL
and	NULL
elevated	NULL
levels	NULL
in	NULL
blood	NULL
serum	NULL
seen	NULL
in	NULL
advanced	NULL
disease	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
severe	NULL
weight	NULL
loss	NULL
common	NULL
in	NULL
AIDS	NULL
patients	NULL
(	NULL
355	NULL
)	NULL
.	NULL

494	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

IL-1	NULL
is	NULL
a	NULL
pleiotropic	NULL
cytokine	NULL
consisting	NULL
of	NULL
two	NULL
distinct	NULL
but	NULL
related	NULL
proteins	NULL
,	NULL
IL-la	NULL
and	NULL
IL-1f	NULL
.	NULL

IL-1	NULL
is	NULL
produced	NULL
mainly	NULL
by	NULL
activated	NULL
macrophages	NULL
but	NULL
also	NULL
by	NULL
fibroblasts	NULL
,	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
,	NULL
and	NULL
brain	NULL
astrocytes	NULL
and	NULL
microglia	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Its	NULL
biological	NULL
activities	NULL
are	NULL
diverse	NULL
and	NULL
include	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
and	NULL
induction	NULL
of	NULL
prostaglandin	NULL
E	NULL
,	NULL
synthesis	NULL
.	NULL

IL-1	NULL
contributes	NULL
to	NULL
symptoms	NULL
such	NULL
as	NULL
fever	NULL
,	NULL
sleep	NULL
,	NULL
and	NULL
anorexia	NULL
,	NULL
seen	NULL
in	NULL
individuals	NULL
exposed	NULL
to	NULL
pathogenic	NULL
stimuli	NULL
(	NULL
72	NULL
)	NULL
.	NULL

IL-1	NULL
also	NULL
stimulates	NULL
HIV-1	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
by	NULL
inducing	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
180	NULL
)	NULL
and	NULL
in	NULL
chronically	NULL
infected	NULL
promonocytes	NULL
(	NULL
307	NULL
)	NULL
.	NULL

IL-2	NULL
was	NULL
originally	NULL
described	NULL
as	NULL
a	NULL
lymphokine	NULL
produced	NULL
by	NULL
antigen-	NULL
or	NULL
mitogen-stimulated	NULL
T	NULL
cells	NULL
.	NULL

Its	NULL
primary	NULL
function	NULL
is	NULL
to	NULL
cause	NULL
the	NULL
proliferation	NULL
and	NULL
activation	NULL
of	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
,	NULL
although	NULL
it	NULL
also	NULL
stimulates	NULL
macrophages	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
NK	NULL
cells	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
its	NULL
role	NULL
in	NULL
T-cell	NULL
activation	NULL
,	NULL
IL-2	NULL
does	NULL
not	NULL
influence	NULL
HIV-1	NULL
replication	NULL
in	NULL
T-cell	NULL
lines	NULL
(	NULL
55	NULL
,	NULL
135	NULL
)	NULL
.	NULL

However	NULL
,	NULL
enhanced	NULL
replication	NULL
of	NULL
HIV-1	NULL
occurs	NULL
in	NULL
PBMCs	NULL
in	NULL
patients	NULL
undergoing	NULL
IL-2	NULL
cancer	NULL
therapy	NULL
(	NULL
158	NULL
)	NULL
.	NULL

Transcriptional	NULL
mechanisms	NULL
may	NULL
be	NULL
involved	NULL
since	NULL
IL-2	NULL
stimulates	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
in	NULL
primary	NULL
monocytes	NULL
but	NULL
not	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
.	NULL

IL-2	NULL
may	NULL
also	NULL
stimulate	NULL
HIV-1	NULL
replication	NULL
indirectly	NULL
in	NULL
vivo	NULL
via	NULL
the	NULL
production	NULL
of	NULL
TNF-a	NULL
and	NULL
IL-6	NULL
(	NULL
242	NULL
)	NULL
.	NULL

IL-3	NULL
and	NULL
the	NULL
CSFs	NULL
GM-CSF	NULL
and	NULL
M-CSF	NULL
upregulate	NULL
HIV-1	NULL
expression	NULL
in	NULL
primary	NULL
macrophages	NULL
and	NULL
several	NULL
myeloid	NULL
cell	NULL
lines	NULL
(	NULL
97	NULL
,	NULL
114	NULL
,	NULL
116	NULL
,	NULL
179	NULL
,	NULL
349	NULL
)	NULL
.	NULL

These	NULL
growth	NULL
factors	NULL
are	NULL
primarily	NULL
responsible	NULL
for	NULL
hematopoiesis	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
.	NULL

They	NULL
are	NULL
produced	NULL
by	NULL
T	NULL
cells	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
endothelial	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
cytokine	NULL
or	NULL
inflammatory	NULL
stimuli	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
myelomonocytic	NULL
progenitor	NULL
cells	NULL
(	NULL
which	NULL
are	NULL
permissive	NULL
to	NULL
HIV-1	NULL
infection	NULL
)	NULL
are	NULL
highly	NULL
sensitive	NULL
to	NULL
these	NULL
growth	NULL
factors	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
CSFs	NULL
may	NULL
affect	NULL
HIV-1	NULL
replication	NULL
in	NULL
cells	NULL
at	NULL
multiple	NULL
stages	NULL
of	NULL
myeloid	NULL
cell	NULL
differentiation	NULL
(	NULL
304	NULL
)	NULL
.	NULL

The	NULL
increased	NULL
expression	NULL
of	NULL
HIV-1	NULL
following	NULL
stimulation	NULL
of	NULL
macrophages	NULL
with	NULL
GM-CSF	NULL
does	NULL
not	NULL
act	NULL
through	NULL
the	NULL
NF-kB-binding	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
;	NULL
the	NULL
region	NULL
responsible	NULL
for	NULL
GM-CSF	NULL
activation	NULL
in	NULL
these	NULL
cells	NULL
is	NULL
located	NULL
slightly	NULL
upstream	NULL
of	NULL
and	NULL
partially	NULL
overlaps	NULL
the	NULL
NF-kB	NULL
binding	NULL
regions	NULL
(	NULL
415	NULL
)	NULL
.	NULL

IL-6	NULL
was	NULL
first	NULL
characterized	NULL
as	NULL
a	NULL
B-cell	NULL
stimulatory	NULL
factor	NULL
that	NULL
was	NULL
strongly	NULL
induced	NULL
in	NULL
virus-infected	NULL
fibroblasts	NULL
(	NULL
5	NULL
)	NULL
.	NULL

It	NULL
is	NULL
secreted	NULL
by	NULL
macrophages	NULL
,	NULL
T	NULL
cells	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
endothelial	NULL
cells	NULL
,	NULL
brain	NULL
astrocytes	NULL
,	NULL
and	NULL
bone	NULL
marrow	NULL
stromal	NULL
cells	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
cytokines	NULL
IL-1	NULL
and	NULL
TNF	NULL
,	NULL
IL-6	NULL
is	NULL
multifunctional	NULL
and	NULL
is	NULL
produced	NULL
as	NULL
an	NULL
acute-phase	NULL
response	NULL
factor	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Its	NULL
biological	NULL
activities	NULL
include	NULL
induction	NULL
of	NULL
T-cell	NULL
,	NULL
B-cell	NULL
,	NULL
macrophage	NULL
,	NULL
and	NULL
neural	NULL
cell	NULL
differentiation	NULL
and	NULL
hematopoietic	NULL
stem	NULL
cell	NULL
growth	NULL
(	NULL
5	NULL
)	NULL
.	NULL

IL-6	NULL
induces	NULL
HIV-1	NULL
expression	NULL
and	NULL
replication	NULL
in	NULL
both	NULL
acutely	NULL
infected	NULL
MDMs	NULL
and	NULL
a	NULL
chronically	NULL
infected	NULL
monocytic	NULL
cell	NULL
line	NULL
(	NULL
302	NULL
)	NULL
.	NULL

IL-6	NULL
does	NULL
not	NULL
seem	NULL
to	NULL
affect	NULL
viral	NULL
replication	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
302	NULL
)	NULL
,	NULL
even	NULL
though	NULL
it	NULL
is	NULL
known	NULL
to	NULL
induce	NULL
T-cell	NULL
activation	NULL
.	NULL

Of	NULL
interest	NULL
is	NULL
the	NULL
fact	NULL
that	NULL
IL-6	NULL
induces	NULL
HIV-1	NULL
expression	NULL
at	NULL
a	NULL
posttranscriptional	NULL
level	NULL
,	NULL
most	NULL
probably	NULL
by	NULL
enhancing	NULL
translation	NULL
of	NULL
viral	NULL
proteins	NULL
(	NULL
302	NULL
)	NULL
.	NULL

However	NULL
,	NULL
IL-6	NULL
can	NULL
also	NULL
synergize	NULL
with	NULL
TNF-a	NULL
and	NULL
IL-1	NULL
to	NULL
enhance	NULL
viral	NULL
transcription	NULL
(	NULL
302	NULL
,	NULL
307	NULL
)	NULL
.	NULL

Bifunctional	NULL
Cytokines	NULL
A	NULL
level	NULL
of	NULL
complexity	NULL
exists	NULL
in	NULL
terms	NULL
of	NULL
the	NULL
regulatory	NULL
effects	NULL
of	NULL
cytokines	NULL
on	NULL
HIV-1	NULL
replication	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
,	NULL
either	NULL
stimulatory	NULL
or	NULL
inhibitory	NULL
activities	NULL
seem	NULL
to	NULL
be	NULL
a	NULL
function	NULL
of	NULL
cell	NULL
type	NULL
and	NULL
differentiation	NULL
state	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

TGF-f	NULL
is	NULL
produced	NULL
primarily	NULL
by	NULL
platelets	NULL
and	NULL
bone	NULL
marrow	NULL
stromal	NULL
cells	NULL
(	NULL
222	NULL
)	NULL
.	NULL

TGF-B	NULL
has	NULL
an	NULL
extremely	NULL
wide	NULL
range	NULL
of	NULL
biological	NULL
activities	NULL
which	NULL
vary	NULL
depending	NULL
on	NULL
cell	NULL
type	NULL
,	NULL
state	NULL
of	NULL
differentiation	NULL
,	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
other	NULL
cytokines	NULL
.	NULL

With	NULL
few	NULL
exceptions	NULL
,	NULL
all	NULL
cells	NULL
have	NULL
surface	NULL
receptors	NULL
for	NULL
and	NULL
respond	NULL
to	NULL
TGF-B	NULL
.	NULL

Although	NULL
TGF-B	NULL
MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

has	NULL
stimulatory	NULL
effects	NULL
on	NULL
growth	NULL
in	NULL
some	NULL
situations	NULL
,	NULL
the	NULL
most	NULL
common	NULL
effects	NULL
are	NULL
inhibition	NULL
of	NULL
proliferation	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
hematopoietic	NULL
progenitors	NULL
.	NULL

TGF-f	NULL
is	NULL
also	NULL
suppressive	NULL
for	NULL
the	NULL
killing	NULL
activity	NULL
of	NULL
NK	NULL
cells	NULL
and	NULL
macrophages	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
222	NULL
)	NULL
.	NULL

With	NULL
respect	NULL
to	NULL
HIV-1	NULL
replication	NULL
,	NULL
TGF-B	NULL
has	NULL
both	NULL
stimulatory	NULL
and	NULL
inhibitory	NULL
effects	NULL
.	NULL

In	NULL
primary	NULL
T-cell	NULL
or	NULL
MDM	NULL
cultures	NULL
and	NULL
in	NULL
promonocytic	NULL
U937	NULL
cells	NULL
,	NULL
TGF-B	NULL
treatment	NULL
prior	NULL
to	NULL
infection	NULL
has	NULL
a	NULL
predominantly	NULL
positive	NULL
effect	NULL
on	NULL
viral	NULL
replication	NULL
(	NULL
192	NULL
,	NULL
294	NULL
,	NULL
308	NULL
)	NULL
.	NULL

However	NULL
,	NULL
if	NULL
either	NULL
primary	NULL
cells	NULL
or	NULL
cell	NULL
lines	NULL
are	NULL
infected	NULL
prior	NULL
to	NULL
cytokine	NULL
addition	NULL
,	NULL
TGF-B	NULL
attenuates	NULL
PMA-	NULL
,	NULL
TNF-	NULL
«	NULL
-	NULL
,	NULL
or	NULL
IL-6-stimulated	NULL
HIV-1	NULL
infection	NULL
(	NULL
308	NULL
)	NULL
.	NULL

IFN-y	NULL
is	NULL
produced	NULL
by	NULL
T	NULL
lymphocytes	NULL
and	NULL
NK	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
antigenic	NULL
or	NULL
mitogenic	NULL
stimuli	NULL
.	NULL

IFN-y	NULL
induces	NULL
expression	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
expression	NULL
on	NULL
epithelial	NULL
and	NULL
mononuclear	NULL
cells	NULL
,	NULL
allowing	NULL
them	NULL
to	NULL
become	NULL
active	NULL
antigen-presenting	NULL
cells	NULL
.	NULL

IFN-y	NULL
also	NULL
acts	NULL
as	NULL
a	NULL
very	NULL
potent	NULL
stimulus	NULL
of	NULL
macrophage	NULL
cytocidal	NULL
activity	NULL
against	NULL
tumors	NULL
(	NULL
13	NULL
)	NULL
.	NULL

One	NULL
study	NULL
reported	NULL
that	NULL
IFN-y	NULL
enhances	NULL
the	NULL
formation	NULL
of	NULL
syncytia	NULL
in	NULL
lymphocytes	NULL
and	NULL
PBMCs	NULL
(	NULL
397	NULL
)	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
effects	NULL
of	NULL
TGF-B	NULL
,	NULL
pretreatment	NULL
of	NULL
cells	NULL
with	NULL
IFN-y	NULL
prior	NULL
to	NULL
infection	NULL
results	NULL
in	NULL
upregulation	NULL
of	NULL
HIV-1	NULL
production	NULL
whereas	NULL
postinfection	NULL
treatment	NULL
with	NULL
IFN-y	NULL
decreases	NULL
virus	NULL
expression	NULL
(	NULL
179	NULL
)	NULL
.	NULL

Decreased	NULL
virus	NULL
expression	NULL
in	NULL
macrophages	NULL
may	NULL
result	NULL
from	NULL
the	NULL
accumulation	NULL
of	NULL
virus	NULL
particles	NULL
in	NULL
intracytoplasmic	NULL
vacuoles	NULL
(	NULL
33	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
state	NULL
of	NULL
differentiation	NULL
or	NULL
activation	NULL
can	NULL
also	NULL
influence	NULL
the	NULL
effects	NULL
of	NULL
IFN-y	NULL
on	NULL
HIV-1	NULL
replication	NULL
.	NULL

IL-4	NULL
is	NULL
a	NULL
pleiotropic	NULL
cytokine	NULL
that	NULL
is	NULL
released	NULL
primarily	NULL
by	NULL
activated	NULL
lymphocytes	NULL
.	NULL

IL-4	NULL
enhances	NULL
the	NULL
generation	NULL
of	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
,	NULL
induces	NULL
macrophage	NULL
cytocidal	NULL
activity	NULL
,	NULL
and	NULL
enhances	NULL
cell	NULL
adhesion	NULL
molecule	NULL
expression	NULL
on	NULL
endothelial	NULL
cells	NULL
.	NULL

In	NULL
B	NULL
cells	NULL
,	NULL
IL-4	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
growth	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
immunoglobulin	NULL
isotype	NULL
switching	NULL
(	NULL
13	NULL
,	NULL
283	NULL
)	NULL
.	NULL

IL-4	NULL
either	NULL
induces	NULL
or	NULL
suppresses	NULL
HIV-1	NULL
replication	NULL
in	NULL
primary	NULL
MDMs	NULL
as	NULL
a	NULL
function	NULL
of	NULL
maturational	NULL
stage	NULL
.	NULL

In	NULL
freshly	NULL
isolated	NULL
monocytes	NULL
,	NULL
IL-4	NULL
increases	NULL
both	NULL
viral	NULL
replication	NULL
and	NULL
cell	NULL
proliferation	NULL
(	NULL
160	NULL
,	NULL
349	NULL
)	NULL
.	NULL

In	NULL
differentiated	NULL
macrophages	NULL
,	NULL
IL-4	NULL
has	NULL
a	NULL
suppressive	NULL
effect	NULL
on	NULL
HIV-1	NULL
gene	NULL
expression	NULL
(	NULL
267	NULL
,	NULL
349	NULL
)	NULL
.	NULL

IL-4	NULL
seems	NULL
to	NULL
have	NULL
no	NULL
effect	NULL
on	NULL
HIV-1	NULL
replication	NULL
or	NULL
HIV-1	NULL
LTR-directed	NULL
chloramphenicol	NULL
acetyltransferase	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
96	NULL
,	NULL
274	NULL
)	NULL
.	NULL

Differences	NULL
in	NULL
culture	NULL
conditions	NULL
,	NULL
strain	NULL
of	NULL
virus	NULL
,	NULL
differentiation	NULL
state	NULL
of	NULL
cells	NULL
,	NULL
and	NULL
time	NULL
of	NULL
cytokine	NULL
addition	NULL
relative	NULL
to	NULL
HIV-1	NULL
exposure	NULL
may	NULL
account	NULL
for	NULL
differences	NULL
in	NULL
modulatory	NULL
effects	NULL
seen	NULL
in	NULL
various	NULL
studies	NULL
.	NULL

Inhibitory	NULL
Cytokines	NULL
The	NULL
type	NULL
1	NULL
IFNs	NULL
possess	NULL
a	NULL
broad	NULL
spectrum	NULL
of	NULL
antiviral	NULL
,	NULL
im-munoregulatory	NULL
,	NULL
and	NULL
antiproliferative	NULL
activities	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
340	NULL
)	NULL
.	NULL

Type	NULL
1	NULL
IFNs	NULL
are	NULL
produced	NULL
mainly	NULL
in	NULL
leukocytes	NULL
(	NULL
IFN-	NULL
«	NULL
)	NULL
and	NULL
fibroblasts	NULL
(	NULL
IFN-	NULL
)	NULL
in	NULL
response	NULL
to	NULL
viral	NULL
infection	NULL
.	NULL

A	NULL
single	NULL
gene	NULL
encodes	NULL
IFN-B	NULL
,	NULL
whereas	NULL
over	NULL
20	NULL
subtypes	NULL
of	NULL
IFN-a	NULL
«	NULL
exist	NULL
,	NULL
each	NULL
encoded	NULL
by	NULL
a	NULL
distinct	NULL
gene	NULL
.	NULL

IFN-a	NULL
«	NULL
and	NULL
IFN-B	NULL
bind	NULL
to	NULL
a	NULL
common	NULL
ubiquitously	NULL
expressed	NULL
cell	NULL
surface	NULL
receptor	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
specific	NULL
genes	NULL
,	NULL
the	NULL
interferon-stimulated	NULL
genes	NULL
,	NULL
which	NULL
are	NULL
responsible	NULL
for	NULL
cellular	NULL
antiviral	NULL
and	NULL
immunoregulatory	NULL
activities	NULL
(	NULL
340	NULL
)	NULL
.	NULL

Two	NULL
of	NULL
the	NULL
best-character-ized	NULL
interferon-stimulated	NULL
genes	NULL
encode	NULL
2',5	NULL
``	NULL
-oligoadenylate	NULL
synthetase	NULL
and	NULL
PKR	NULL
(	NULL
340	NULL
)	NULL
.	NULL

2',5'-Oligoadenylate	NULL
synthetase	NULL
exerts	NULL
antiviral	NULL
activity	NULL
by	NULL
activating	NULL
an	NULL
RNase	NULL
that	NULL
degrades	NULL
viral	NULL
RNA	NULL
,	NULL
whereas	NULL
PKR	NULL
phosphorylates	NULL
the	NULL
initiation	NULL
factor	NULL
eukaryotic	NULL
initiation	NULL
factor	NULL
2	NULL
«	NULL
thus	NULL
preventing	NULL
efficient	NULL
translation	NULL
of	NULL
viral	NULL
proteins	NULL
(	NULL
340	NULL
)	NULL
.	NULL

Both	NULL
IFN-	NULL
«	NULL
and	NULL
IFN-B	NULL
exert	NULL
similar	NULL
anti-HIV-1	NULL
effects	NULL
on	NULL
replication	NULL
in	NULL
monocytes	NULL
and	NULL
macrophages	NULL
and	NULL
appear	NULL
to	NULL
act	NULL
at	NULL
Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
multiple	NULL
stages	NULL
of	NULL
the	NULL
viral	NULL
life	NULL
cycle	NULL
(	NULL
299	NULL
)	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Virus	NULL
strain	NULL
,	NULL
multiplicity	NULL
of	NULL
infection	NULL
,	NULL
time	NULL
of	NULL
IFN	NULL
addition	NULL
,	NULL
and	NULL
differentiation	NULL
state	NULL
of	NULL
the	NULL
cell	NULL
all	NULL
modulate	NULL
the	NULL
degree	NULL
of	NULL
HIV-1	NULL
inhibition	NULL
by	NULL
IFN	NULL
.	NULL

When	NULL
viral	NULL
infection	NULL
and	NULL
IFN	NULL
treatment	NULL
occur	NULL
simultaneously	NULL
,	NULL
replication	NULL
is	NULL
blocked	NULL
early	NULL
in	NULL
monocyte	NULL
infection	NULL
,	NULL
prior	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
proviral	NULL
DNA	NULL
(	NULL
131	NULL
,	NULL
177	NULL
,	NULL
238	NULL
,	NULL
309	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
IFN	NULL
may	NULL
affect	NULL
HIV-1	NULL
receptor	NULL
binding	NULL
,	NULL
fusion	NULL
,	NULL
uncoating	NULL
,	NULL
or	NULL
reverse	NULL
transcription	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
treatment	NULL
of	NULL
HIV-1-infected	NULL
monocytes	NULL
with	NULL
IFN	NULL
after	NULL
infection	NULL
does	NULL
not	NULL
affect	NULL
synthesis	NULL
of	NULL
proviral	NULL
DNA	NULL
but	NULL
causes	NULL
diminished	NULL
levels	NULL
of	NULL
viral	NULL
mRNA	NULL
(	NULL
113	NULL
,	NULL
114	NULL
)	NULL
.	NULL

Both	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
LTR-directed	NULL
transcription	NULL
and	NULL
increased	NULL
mRNA	NULL
degradation	NULL
are	NULL
responsible	NULL
for	NULL
the	NULL
IFN-mediated	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
(	NULL
113	NULL
)	NULL
.	NULL

Studies	NULL
of	NULL
acute	NULL
HIV-1	NULL
infection	NULL
of	NULL
PBMCs	NULL
demonstrate	NULL
that	NULL
IFN	NULL
inhibits	NULL
replication	NULL
at	NULL
a	NULL
posttranslational	NULL
level	NULL
(	NULL
141	NULL
,	NULL
366	NULL
,	NULL
410	NULL
)	NULL
,	NULL
since	NULL
the	NULL
synthesis	NULL
of	NULL
viral	NULL
proteins	NULL
is	NULL
unaffected	NULL
.	NULL

IFN	NULL
inhibits	NULL
terminal	NULL
events	NULL
in	NULL
the	NULL
replication	NULL
cycle	NULL
,	NULL
including	NULL
viral	NULL
assembly	NULL
and	NULL
budding	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
defective	NULL
viral	NULL
particles	NULL
attached	NULL
to	NULL
the	NULL
host	NULL
cell	NULL
membrane	NULL
(	NULL
366	NULL
)	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
,	NULL
IFN	NULL
interrupts	NULL
the	NULL
HIV-1	NULL
life	NULL
cycle	NULL
through	NULL
transient	NULL
reductions	NULL
in	NULL
viral	NULL
mRNA	NULL
synthesis	NULL
and	NULL
through	NULL
inhibition	NULL
of	NULL
virus	NULL
assembly	NULL
and	NULL
release	NULL
(	NULL
113	NULL
,	NULL
412	NULL
)	NULL
.	NULL

IFN-	NULL
«	NULL
also	NULL
blocks	NULL
an	NULL
early	NULL
event	NULL
following	NULL
viral	NULL
entry	NULL
,	NULL
preventing	NULL
the	NULL
reverse	NULL
transcription	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
in	NULL
acutely	NULL
infected	NULL
CEM	NULL
T	NULL
cells	NULL
(	NULL
362	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
both	NULL
IFN-	NULL
«	NULL
and	NULL
zidovu-dine	NULL
(	NULL
AZT	NULL
)	NULL
are	NULL
synergistic	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
slow	NULL
the	NULL
spread	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
promonocytic	NULL
cells	NULL
(	NULL
76	NULL
)	NULL
.	NULL

Clinically	NULL
,	NULL
IFN-	NULL
«	NULL
is	NULL
used	NULL
to	NULL
treat	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
(	NULL
KS	NULL
)	NULL
(	NULL
190	NULL
)	NULL
,	NULL
and	NULL
current	NULL
clinical	NULL
trials	NULL
are	NULL
exploring	NULL
the	NULL
potential	NULL
benefit	NULL
of	NULL
the	NULL
combined	NULL
use	NULL
of	NULL
IFN-	NULL
«	NULL
and	NULL
AZT	NULL
or	NULL
other	NULL
nucleoside	NULL
analogs	NULL
(	NULL
303	NULL
)	NULL
.	NULL

Two	NULL
additional	NULL
cytokines	NULL
,	NULL
IL-10	NULL
and	NULL
IL-13	NULL
,	NULL
also	NULL
specifically	NULL
inhibit	NULL
HIV-1	NULL
replication	NULL
in	NULL
MDMs	NULL
.	NULL

Both	NULL
cytokines	NULL
are	NULL
members	NULL
of	NULL
the	NULL
IL-4	NULL
superfamily	NULL
,	NULL
released	NULL
by	NULL
activated	NULL
Th2	NULL
lymphocytes	NULL
,	NULL
and	NULL
negatively	NULL
regulate	NULL
the	NULL
activities	NULL
of	NULL
antigen-stim-ulated	NULL
Th1	NULL
cells	NULL
(	NULL
IL-10	NULL
)	NULL
and	NULL
monocytes	NULL
(	NULL
IL-13	NULL
)	NULL
(	NULL
1	NULL
,	NULL
241	NULL
)	NULL
.	NULL

IL-10	NULL
is	NULL
thought	NULL
to	NULL
inhibit	NULL
at	NULL
the	NULL
level	NULL
of	NULL
virus	NULL
assembly	NULL
(	NULL
175	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
IL-13	NULL
inhibits	NULL
HIV-1	NULL
is	NULL
still	NULL
not	NULL
clear	NULL
,	NULL
although	NULL
no	NULL
effect	NULL
on	NULL
viral	NULL
entry	NULL
,	NULL
reverse	NULL
transcriptase	NULL
,	NULL
or	NULL
viral	NULL
release	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
246	NULL
)	NULL
.	NULL

CYTOKINES	NULL
AND	NULL
HIV-1-ASSOCIATED	NULL
DISORDERS	NULL
Enhanced	NULL
levels	NULL
of	NULL
TNF-	NULL
«	NULL
(	NULL
172	NULL
,	NULL
188	NULL
,	NULL
194	NULL
)	NULL
,	NULL
IL-1	NULL
(	NULL
224	NULL
)	NULL
,	NULL
IL-6	NULL
(	NULL
32	NULL
,	NULL
40	NULL
)	NULL
,	NULL
TGF-B	NULL
(	NULL
8	NULL
)	NULL
,	NULL
and	NULL
IFN-y	NULL
(	NULL
104	NULL
)	NULL
are	NULL
detected	NULL
in	NULL
the	NULL
circulation	NULL
of	NULL
patients	NULL
with	NULL
advanced	NULL
infection	NULL
and	NULL
may	NULL
contribute	NULL
to	NULL
symptoms	NULL
associated	NULL
with	NULL
AIDS	NULL
,	NULL
including	NULL
fever	NULL
,	NULL
cachexia	NULL
,	NULL
neurological	NULL
and	NULL
hematological	NULL
disorders	NULL
,	NULL
and	NULL
AIDS-associated	NULL
malignancies	NULL
.	NULL

Neurological	NULL
Disorders	NULL
As	NULL
many	NULL
as	NULL
80	NULL
%	NULL
of	NULL
all	NULL
AIDS	NULL
patients	NULL
with	NULL
advanced	NULL
disease	NULL
have	NULL
neurological	NULL
abnormalities	NULL
,	NULL
and	NULL
approximately	NULL
half	NULL
of	NULL
these	NULL
suffer	NULL
symptoms	NULL
associated	NULL
with	NULL
CNS	NULL
disorders	NULL
(	NULL
234	NULL
)	NULL
.	NULL

The	NULL
most	NULL
common	NULL
disorder	NULL
in	NULL
HIV-1-infected	NULL
individuals	NULL
is	NULL
encephalopathy	NULL
,	NULL
a	NULL
fatal	NULL
illness	NULL
causing	NULL
severe	NULL
dementia	NULL
.	NULL

Events	NULL
leading	NULL
to	NULL
encephalopathy	NULL
are	NULL
unclear	NULL
,	NULL
but	NULL
infiltration	NULL
by	NULL
monocytes	NULL
and	NULL
macrophages	NULL
is	NULL
a	NULL
consistent	NULL
finding	NULL
in	NULL
the	NULL
brains	NULL
and	NULL
CNS	NULL
of	NULL
AIDS	NULL
patients	NULL
(	NULL
173	NULL
)	NULL
.	NULL

In	NULL
AIDS	NULL
dementia	NULL
,	NULL
macrophages	NULL
and	NULL
microglial	NULL
cells	NULL
of	NULL
the	NULL
CNS	NULL
are	NULL
the	NULL
predominant	NULL
cell	NULL
types	NULL
that	NULL
are	NULL
infected	NULL
and	NULL
produce	NULL
HIV-1	NULL
.	NULL

These	NULL
cells	NULL
also	NULL
produce	NULL
cytokines	NULL
such	NULL
as	NULL
IL-1	NULL
,	NULL
TNF-	NULL
«	NULL
,	NULL
TGF-B	NULL
,	NULL
G-CSF	NULL
,	NULL
GM-CSF	NULL
,	NULL
prostaglandin	NULL
E	NULL
;	NULL
,	NULL
and	NULL
IL-6	NULL
.	NULL

Many	NULL
of	NULL
these	NULL
cytokines	NULL
are	NULL
chemotactic	NULL
for	NULL
other	NULL
monocytes	NULL
and	NULL
cause	NULL
death	NULL
of	NULL
oligodendrocytes	NULL
and/or	NULL
destruction	NULL
of	NULL
myelin	NULL
in	NULL
vitro	NULL
REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
495	NULL
(	NULL
322	NULL
,	NULL
400	NULL
)	NULL
.	NULL

In	NULL
a	NULL
study	NULL
of	NULL
38	NULL
patients	NULL
,	NULL
elevated	NULL
levels	NULL
of	NULL
cytokines	NULL
such	NULL
as	NULL
IL-1B8	NULL
and	NULL
IL-6	NULL
were	NULL
present	NULL
in	NULL
the	NULL
cerebrospinal	NULL
fluid	NULL
of	NULL
about	NULL
half	NULL
of	NULL
the	NULL
HIV-1-infected	NULL
individuals	NULL
studied	NULL
(	NULL
105	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
many	NULL
of	NULL
the	NULL
clinical	NULL
and	NULL
histological	NULL
effects	NULL
of	NULL
HIV-1	NULL
infection	NULL
in	NULL
the	NULL
CNS	NULL
may	NULL
be	NULL
an	NULL
indirect	NULL
effect	NULL
of	NULL
cytokines	NULL
and	NULL
other	NULL
soluble	NULL
mediators	NULL
secreted	NULL
by	NULL
resident	NULL
macrophages	NULL
and	NULL
microglial	NULL
cells	NULL
.	NULL

Hematopoietic	NULL
Disorders	NULL
Viral	NULL
infection	NULL
of	NULL
CD34*	NULL
myeloid	NULL
precursor	NULL
cells	NULL
may	NULL
be	NULL
related	NULL
to	NULL
a	NULL
variety	NULL
of	NULL
hematological	NULL
abnormalities	NULL
(	NULL
cytope-nias	NULL
)	NULL
seen	NULL
in	NULL
adults	NULL
and	NULL
children	NULL
with	NULL
AIDS	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
73	NULL
)	NULL
.	NULL

Hematopoietic	NULL
stem	NULL
cells	NULL
can	NULL
also	NULL
act	NULL
as	NULL
reservoirs	NULL
of	NULL
HIV-1	NULL
within	NULL
the	NULL
bone	NULL
marrow	NULL
,	NULL
which	NULL
may	NULL
enable	NULL
the	NULL
virus	NULL
to	NULL
spread	NULL
to	NULL
other	NULL
cells	NULL
,	NULL
thus	NULL
accelerating	NULL
hematopoietic	NULL
failure	NULL
(	NULL
73	NULL
,	NULL
225	NULL
)	NULL
.	NULL

Anemia	NULL
is	NULL
the	NULL
most	NULL
common	NULL
cytopenia	NULL
associated	NULL
with	NULL
HIV-1	NULL
infection	NULL
,	NULL
and	NULL
the	NULL
condition	NULL
increases	NULL
in	NULL
severity	NULL
with	NULL
disease	NULL
progression	NULL
(	NULL
418	NULL
)	NULL
.	NULL

Approximately	NULL
,	NULL
10	NULL
to	NULL
20	NULL
%	NULL
of	NULL
patients	NULL
with	NULL
AIDS-related	NULL
complex	NULL
and	NULL
35	NULL
to	NULL
75	NULL
%	NULL
of	NULL
those	NULL
with	NULL
full-blown	NULL
AIDS	NULL
have	NULL
neutropenia	NULL
,	NULL
granulocytopenia	NULL
,	NULL
or	NULL
monocytopenia	NULL
and	NULL
also	NULL
exhibit	NULL
abnormalities	NULL
of	NULL
the	NULL
bone	NULL
marrow	NULL
(	NULL
73	NULL
,	NULL
342	NULL
)	NULL
.	NULL

Hematological	NULL
abnormalities	NULL
during	NULL
the	NULL
course	NULL
of	NULL
HIV-1	NULL
disease	NULL
are	NULL
largely	NULL
due	NULL
to	NULL
ineffective	NULL
hema-topoiesis	NULL
,	NULL
which	NULL
may	NULL
be	NULL
the	NULL
result	NULL
of	NULL
HIV-1	NULL
infection	NULL
of	NULL
bone	NULL
marrow	NULL
stromal	NULL
cells	NULL
.	NULL

HIV-1	NULL
infection	NULL
of	NULL
bone	NULL
marrow	NULL
stromal	NULL
cells	NULL
,	NULL
particularly	NULL
cells	NULL
of	NULL
the	NULL
monocyte	NULL
lineage	NULL
,	NULL
induces	NULL
alterations	NULL
in	NULL
the	NULL
production	NULL
of	NULL
growth	NULL
factors	NULL
and	NULL
cytokines	NULL
that	NULL
adversely	NULL
affect	NULL
hematopoiesis	NULL
(	NULL
240	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
levels	NULL
of	NULL
IFN	NULL
secretion	NULL
early	NULL
in	NULL
HIV-1	NULL
infection	NULL
are	NULL
lower	NULL
than	NULL
those	NULL
seen	NULL
in	NULL
other	NULL
viral	NULL
infections	NULL
.	NULL

Later	NULL
in	NULL
the	NULL
disease	NULL
,	NULL
IFN	NULL
levels	NULL
in	NULL
serum	NULL
may	NULL
be	NULL
elevated	NULL
to	NULL
myelosuppressive	NULL
levels	NULL
,	NULL
not	NULL
inhibitory	NULL
to	NULL
HIV-1	NULL
replication	NULL
(	NULL
57	NULL
,	NULL
99	NULL
,	NULL
325	NULL
)	NULL
.	NULL

IFN-	NULL
«	NULL
,	NULL
in	NULL
particular	NULL
,	NULL
can	NULL
inhibit	NULL
bone	NULL
marrow	NULL
progenitor	NULL
cell	NULL
development	NULL
(	NULL
107	NULL
)	NULL
.	NULL

Concentrations	NULL
of	NULL
IL-1	NULL
,	NULL
TNF-	NULL
«	NULL
,	NULL
IFN-	NULL
«	NULL
,	NULL
and	NULL
TGF-	NULL
in	NULL
blood	NULL
serum	NULL
increase	NULL
with	NULL
progression	NULL
of	NULL
HIV-1	NULL
infection	NULL
,	NULL
and	NULL
each	NULL
of	NULL
these	NULL
cytokines	NULL
can	NULL
have	NULL
detrimental	NULL
effects	NULL
on	NULL
hematopoiesis	NULL
(	NULL
15	NULL
,	NULL
161	NULL
,	NULL
244	NULL
,	NULL
320	NULL
)	NULL
.	NULL

Both	NULL
IL-1	NULL
and	NULL
TNF-	NULL
«	NULL
induce	NULL
the	NULL
secretion	NULL
of	NULL
growth	NULL
factors	NULL
such	NULL
as	NULL
CSFs	NULL
from	NULL
stromal	NULL
cells	NULL
,	NULL
which	NULL
can	NULL
stimulate	NULL
HIV-1	NULL
replication	NULL
.	NULL

These	NULL
cytokines	NULL
are	NULL
also	NULL
responsible	NULL
for	NULL
T-cell	NULL
activation	NULL
and	NULL
subsequent	NULL
production	NULL
of	NULL
IFN-y	NULL
that	NULL
can	NULL
in	NULL
turn	NULL
suppress	NULL
hematopoiesis	NULL
(	NULL
38	NULL
,	NULL
90	NULL
,	NULL
316	NULL
)	NULL
.	NULL

AIDS-Associated	NULL
Malignancies	NULL
KS	NULL
is	NULL
the	NULL
most	NULL
common	NULL
malignancy	NULL
in	NULL
AIDS	NULL
patients	NULL
,	NULL
followed	NULL
by	NULL
B-cell	NULL
lymphoma	NULL
(	NULL
122	NULL
)	NULL
.	NULL

Although	NULL
HIV-1	NULL
does	NULL
not	NULL
infect	NULL
either	NULL
KS-derived	NULL
spindle	NULL
cells	NULL
or	NULL
B	NULL
lymphocytes	NULL
in	NULL
vivo	NULL
,	NULL
several	NULL
cytokines	NULL
directly	NULL
influence	NULL
the	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
these	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

These	NULL
cytokines	NULL
include	NULL
basic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
,	NULL
IL-1B	NULL
,	NULL
IL-6	NULL
,	NULL
GM-CSF	NULL
,	NULL
and	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
for	NULL
KS-derived	NULL
cells	NULL
(	NULL
81	NULL
)	NULL
and	NULL
IL-6	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-10	NULL
for	NULL
B	NULL
lymphocytes	NULL
(	NULL
122	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
DNA	NULL
encoding	NULL
a	NULL
new	NULL
herpesvirus	NULL
was	NULL
isolated	NULL
from	NULL
over	NULL
90	NULL
%	NULL
of	NULL
KS	NULL
tissues	NULL
from	NULL
AIDS	NULL
patients	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Elevated	NULL
levels	NULL
of	NULL
cytokines	NULL
may	NULL
arise	NULL
in	NULL
KS-derived	NULL
cells	NULL
as	NULL
a	NULL
result	NULL
of	NULL
infection	NULL
with	NULL
a	NULL
virus	NULL
such	NULL
as	NULL
a	NULL
herpesvirus	NULL
.	NULL

As	NULL
mentioned	NULL
previously	NULL
,	NULL
elevated	NULL
levels	NULL
of	NULL
IL-1	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
TNF	NULL
are	NULL
present	NULL
in	NULL
the	NULL
sera	NULL
of	NULL
AIDS	NULL
patients	NULL
,	NULL
particularly	NULL
in	NULL
the	NULL
advanced	NULL
stages	NULL
of	NULL
disease	NULL
(	NULL
40	NULL
,	NULL
188	NULL
,	NULL
194	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
that	NULL
increased	NULL
circulating	NULL
cytokine	NULL
levels	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
development	NULL
of	NULL
AIDS-associated	NULL
malignancies	NULL
.	NULL

496	NULL
ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

POTENTIAL	NULL
ANTI-HIV-1	NULL
THERAPIES	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
an	NULL
important	NULL
transcription	NULL
factor	NULL
in	NULL
all	NULL
hematopoietic	NULL
cells	NULL
and	NULL
plays	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
host	NULL
immune	NULL
response	NULL
to	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
pathogens	NULL
.	NULL

A	NULL
cysteine	NULL
deficiency	NULL
is	NULL
reported	NULL
in	NULL
AIDS	NULL
patients	NULL
(	NULL
74	NULL
)	NULL
,	NULL
and	NULL
since	NULL
cysteine	NULL
has	NULL
an	NULL
anti-oxidant	NULL
effect	NULL
,	NULL
its	NULL
decrease	NULL
in	NULL
immune	NULL
cells	NULL
of	NULL
HIV-1-infected	NULL
individuals	NULL
might	NULL
create	NULL
a	NULL
prooxidant	NULL
state	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
(	NULL
74	NULL
,	NULL
344	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
antioxidants	NULL
bu-tylated	NULL
hydroxyanisole	NULL
and	NULL
N-acetyl-L-cysteine	NULL
inhibit	NULL
TNF-	NULL
or	NULL
PMA-induced	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
in	NULL
HIV-1-infected	NULL
cells	NULL
,	NULL
limited	NULL
effects	NULL
on	NULL
HIV-1	NULL
replication	NULL
are	NULL
observed	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
antioxidants	NULL
have	NULL
a	NULL
suppressive	NULL
effect	NULL
on	NULL
PBMC	NULL
immune	NULL
function	NULL
in	NULL
vitro	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Although	NULL
a	NULL
rationale	NULL
may	NULL
exist	NULL
for	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
during	NULL
the	NULL
early	NULL
latent	NULL
phase	NULL
of	NULL
infection	NULL
,	NULL
impeding	NULL
hematopoietic	NULL
cell	NULL
function	NULL
at	NULL
later	NULL
stages	NULL
of	NULL
disease	NULL
may	NULL
enhance	NULL
immunodeficiency	NULL
and	NULL
increase	NULL
the	NULL
risk	NULL
of	NULL
secondary	NULL
pathogenic	NULL
infections	NULL
.	NULL

In	NULL
the	NULL
face	NULL
of	NULL
profound	NULL
immunosuppression	NULL
,	NULL
such	NULL
as	NULL
that	NULL
induced	NULL
by	NULL
HIV-1	NULL
,	NULL
it	NULL
is	NULL
logical	NULL
to	NULL
propose	NULL
the	NULL
administration	NULL
of	NULL
immunostimulants	NULL
.	NULL

These	NULL
agents	NULL
,	NULL
however	NULL
,	NULL
may	NULL
induce	NULL
proliferation	NULL
of	NULL
resting	NULL
CD4	NULL
*	NULL
cells	NULL
and	NULL
enhance	NULL
viral	NULL
spread	NULL
,	NULL
thus	NULL
provoking	NULL
an	NULL
effect	NULL
opposite	NULL
to	NULL
the	NULL
one	NULL
they	NULL
were	NULL
designed	NULL
to	NULL
avoid	NULL
(	NULL
225	NULL
)	NULL
.	NULL

A	NULL
more	NULL
beneficial	NULL
approach	NULL
may	NULL
be	NULL
the	NULL
use	NULL
of	NULL
immunosuppressants	NULL
such	NULL
as	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
,	NULL
particularly	NULL
in	NULL
early	NULL
stages	NULL
of	NULL
disease	NULL
before	NULL
the	NULL
onset	NULL
of	NULL
HIV-1-induced	NULL
immunodeficiency	NULL
(	NULL
86	NULL
)	NULL
.	NULL

CsA	NULL
is	NULL
commonly	NULL
used	NULL
to	NULL
prevent	NULL
tissue	NULL
rejection	NULL
in	NULL
patients	NULL
undergoing	NULL
organ	NULL
transplantation	NULL
(	NULL
365	NULL
)	NULL
.	NULL

The	NULL
drug	NULL
suppresses	NULL
T-cell	NULL
activation	NULL
by	NULL
blocking	NULL
the	NULL
activation	NULL
of	NULL
NF-AT	NULL
(	NULL
67	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
CsA	NULL
inhibits	NULL
HIV-1	NULL
expression	NULL
and	NULL
cell	NULL
growth	NULL
in	NULL
chronically	NULL
infected	NULL
cells	NULL
(	NULL
157	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
vivo	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
CsA	NULL
treatment	NULL
in	NULL
HIV-l-infected	NULL
individuals	NULL
leads	NULL
to	NULL
either	NULL
clinical	NULL
improvement	NULL
(	NULL
11	NULL
)	NULL
or	NULL
deterioration	NULL
(	NULL
296	NULL
)	NULL
,	NULL
possibly	NULL
as	NULL
a	NULL
function	NULL
of	NULL
the	NULL
stage	NULL
at	NULL
which	NULL
CsA	NULL
treatment	NULL
is	NULL
commenced	NULL
.	NULL

A	NULL
marked	NULL
delay	NULL
in	NULL
HIV-1	NULL
disease	NULL
progression	NULL
and	NULL
AIDS	NULL
development	NULL
is	NULL
reported	NULL
to	NULL
occur	NULL
in	NULL
transplant	NULL
patients	NULL
receiving	NULL
CsA	NULL
treatment	NULL
from	NULL
the	NULL
onset	NULL
of	NULL
infection	NULL
(	NULL
351	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
blocking	NULL
cellular	NULL
activation	NULL
,	NULL
CsA	NULL
may	NULL
affect	NULL
other	NULL
stages	NULL
of	NULL
the	NULL
viral	NULL
life	NULL
cycle	NULL
.	NULL

CsA	NULL
blocks	NULL
HIV-1	NULL
virion	NULL
binding	NULL
to	NULL
CD4	NULL
(	NULL
170	NULL
)	NULL
and	NULL
is	NULL
thought	NULL
to	NULL
interfere	NULL
with	NULL
replication	NULL
by	NULL
preventing	NULL
interactions	NULL
between	NULL
cyclophilins	NULL
and	NULL
the	NULL
HIV-1	NULL
Gag	NULL
protein	NULL
(	NULL
213	NULL
)	NULL
.	NULL

Immunosuppressants	NULL
and	NULL
anti-inflammatory	NULL
drugs	NULL
may	NULL
also	NULL
interfere	NULL
with	NULL
the	NULL
NF-kB	NULL
pathway	NULL
.	NULL

For	NULL
example	NULL
,	NULL
aspirin	NULL
(	NULL
sodium	NULL
salicylate	NULL
)	NULL
(	NULL
176	NULL
)	NULL
and	NULL
rapa-mycin	NULL
(	NULL
189	NULL
)	NULL
inhibit	NULL
NF-kB	NULL
activation	NULL
by	NULL
interfering	NULL
with	NULL
the	NULL
degradation	NULL
of	NULL
IxBa	NULL
«	NULL
.	NULL

Furthermore	NULL
,	NULL
dexamethasone	NULL
,	NULL
when	NULL
bound	NULL
to	NULL
endogenous	NULL
glucocorticoid	NULL
receptor	NULL
,	NULL
can	NULL
inhibit	NULL
the	NULL
ability	NULL
of	NULL
p50	NULL
,	NULL
RelA	NULL
,	NULL
and	NULL
c-Rel	NULL
subunits	NULL
to	NULL
bind	NULL
DNA	NULL
(	NULL
313	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
immunosuppressants	NULL
and	NULL
anti-inflammatory	NULL
drugs	NULL
may	NULL
provide	NULL
therapeutic	NULL
intervention	NULL
at	NULL
multiple	NULL
levels	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

CONCLUDING	NULL
REMARKS	NULL
This	NULL
review	NULL
summarizes	NULL
studies	NULL
characterizing	NULL
the	NULL
mechanisms	NULL
in	NULL
which	NULL
chronic	NULL
HIV-1	NULL
infection	NULL
of	NULL
myeloid	NULL
cells	NULL
can	NULL
lead	NULL
to	NULL
physiological	NULL
changes	NULL
that	NULL
perpetuate	NULL
HIV-1	NULL
replication	NULL
and	NULL
contribute	NULL
indirectly	NULL
to	NULL
AIDS-associated	NULL
disorders	NULL
and	NULL
symptoms	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

HIV-1-infected	NULL
myeloid	NULL
cells	NULL
are	NULL
often	NULL
diminished	NULL
in	NULL
the	NULL
ability	NULL
to	NULL
participate	NULL
in	NULL
chemotaxis	NULL
,	NULL
phagocytosis	NULL
,	NULL
and	NULL
intracellular	NULL
killing	NULL
.	NULL

Chronic	NULL
HIV-1	NULL
infection	NULL
of	NULL
promonocytic	NULL
cells	NULL
leads	NULL
to	NULL
constitutive	NULL
NF-kB	NULL
DNA-binding	NULL
activity	NULL
and	NULL
increased	NULL
intracellular	NULL
stores	NULL
of	NULL
latent	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
the	NULL
cytoplasmic	NULL
inhibitor	NULL
IxBa	NULL
are	NULL
crucial	NULL
regulatory	NULL
events	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Both	NULL
N-	NULL
and	NULL
C-terminal	NULL
residues	NULL
of	NULL
MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

[	NULL
Chronic	NULL
viral	NULL
infection	NULL
of	NULL
myeloid	NULL
cells	NULL
|	NULL
Impaired	NULL
immunological	NULL
functions	NULL
Differentiation	NULL
Constitutive	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
Increased	NULL
intracellular	NULL
pools	NULL
of	NULL
NF-xB	NULL
Secondary	NULL
bacterial	NULL
or	NULL
viral	NULL
infection	NULL
Potentiated	NULL
immune	NULL
response	NULL
Increased	NULL
cytokine	NULL
mRNA	NULL
levels	NULL
More	NULL
rapid	NULL
cytokine	NULL
expression	NULL
kinetics	NULL
Increased	NULL
cytokine	NULL
secretion	NULL
Elevated	NULL
cytokine	NULL
levels	NULL
in	NULL
sera	NULL
puts	NULL
'	NULL
H|	NULL
Pathogenesis	NULL
mem	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Role	NULL
of	NULL
HIV-1-infected	NULL
myeloid	NULL
cells	NULL
in	NULL
AIDS-associated	NULL
pathogenesis	NULL
.	NULL

IxBa	NULL
are	NULL
required	NULL
for	NULL
inducer-mediated	NULL
degradation	NULL
.	NULL

Changes	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
provide	NULL
an	NULL
intranuclear	NULL
environment	NULL
capable	NULL
of	NULL
maintaining	NULL
a	NULL
high	NULL
level	NULL
of	NULL
HIV-1	NULL
LTR	NULL
activity	NULL
and	NULL
NF-	NULL
«	NULL
B-dependent	NULL
cytokine	NULL
gene	NULL
expression	NULL
.	NULL

HIV-1	NULL
infection	NULL
of	NULL
myeloid	NULL
cells	NULL
can	NULL
also	NULL
lead	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
surface	NULL
receptors	NULL
associated	NULL
with	NULL
cellular	NULL
activation	NULL
and/or	NULL
differentiation	NULL
and	NULL
increase	NULL
the	NULL
responsiveness	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
cytokines	NULL
secreted	NULL
by	NULL
neighboring	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
bacteria	NULL
or	NULL
other	NULL
pathogens	NULL
.	NULL

In	NULL
response	NULL
to	NULL
secondary	NULL
pathogenic	NULL
infections	NULL
,	NULL
cytokine	NULL
gene	NULL
expression	NULL
is	NULL
rapidly	NULL
induced	NULL
and	NULL
levels	NULL
may	NULL
be	NULL
sustained	NULL
over	NULL
prolonged	NULL
periods	NULL
in	NULL
HIV-1-infected	NULL
myeloid	NULL
cells	NULL
compared	NULL
with	NULL
uninfected	NULL
cells	NULL
.	NULL

Altered	NULL
cytokine	NULL
responsiveness	NULL
of	NULL
HIV-1-infected	NULL
myeloid	NULL
cells	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
elevated	NULL
levels	NULL
of	NULL
several	NULL
inflammatory	NULL
cytokines	NULL
present	NULL
in	NULL
the	NULL
sera	NULL
of	NULL
HIV-1-infected	NULL
individuals	NULL
.	NULL

Secondary	NULL
bacterial	NULL
or	NULL
viral	NULL
infections	NULL
in	NULL
HIV-1-infected	NULL
individuals	NULL
may	NULL
result	NULL
in	NULL
unscheduled	NULL
cytokine	NULL
production	NULL
by	NULL
infected	NULL
monocytic	NULL
cells	NULL
and	NULL
may	NULL
generate	NULL
a	NULL
potentiated	NULL
inflammatory	NULL
response	NULL
.	NULL

Secretion	NULL
of	NULL
myeloid	NULL
cell-derived	NULL
cytokines	NULL
in	NULL
lymph	NULL
nodes	NULL
or	NULL
in	NULL
the	NULL
circulation	NULL
of	NULL
infected	NULL
individuals	NULL
may	NULL
increase	NULL
viral	NULL
production	NULL
and	NULL
spread	NULL
and	NULL
may	NULL
contribute	NULL
to	NULL
AIDS-associated	NULL
pathogenesis	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Future	NULL
directives	NULL
for	NULL
therapeutic	NULL
intervention	NULL
may	NULL
therefore	NULL
be	NULL
designed	NULL
to	NULL
immu-nocompromise	NULL
asymptomatic	NULL
individuals	NULL
as	NULL
a	NULL
means	NULL
of	NULL
controlling	NULL
HIV-1	NULL
replication	NULL
.	NULL

Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
ACKNOWLEDGMENTS	NULL
Research	NULL
from	NULL
our	NULL
laboratory	NULL
is	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
of	NULL
Canada	NULL
(	NULL
MRC	NULL
)	NULL
and	NULL
the	NULL
National	NULL
Health	NULL
Research	NULL
Development	NULL
Program	NULL
(	NULL
NHRDP	NULL
)	NULL
,	NULL
Health	NULL
and	NULL
Welfare	NULL
Canada	NULL
(	NULL
to	NULL
J.H	NULL
.	NULL

and	NULL
M.A.W	NULL
.	NULL
)	NULL

.	NULL

A.R	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
a	NULL
studentship	NULL
from	NULL
the	NULL
Fonds	NULL
pour	NULL
la	NULL
formation	NULL
de	NULL
chercheurs	NULL
et	NULL
Faide	NULL
a	NULL
la	NULL
recherche	NULL
(	NULL
FCAR	NULL
)	NULL
,	NULL
R.L	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
an	NULL
MRC	NULL
postdoctoral	NULL
fellowship	NULL
,	NULL
P.B	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
an	NULL
MRC	NULL
studentship	NULL
,	NULL
and	NULL
J.H	NULL
.	NULL

is	NULL
the	NULL
recipient	NULL
of	NULL
an	NULL
MRC	NULL
Scientist	NULL
Award	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

REFERENCES	NULL
.	NULL

Abbas	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
A.	NULL
H.	NULL
Lichtman	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pober	NULL
.	NULL

1991	NULL
.	NULL

Cellular	NULL
and	NULL
molecular	NULL
immunology	NULL
.	NULL

The	NULL
W.	NULL
B.	NULL
Saunders	NULL
Co.	NULL
,	NULL
Philadelphia	NULL
.	NULL

.	NULL

Adams	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Romeo	NULL
,	NULL
J.	NULL
Kimpton	NULL
,	NULL
J.	NULL
Garcia	NULL
,	NULL
B.	NULL
Peterlin	NULL
,	NULL
and	NULL
M.	NULL
Emerman	NULL
.	NULL

1994	NULL
.	NULL

Cellular	NULL
latency	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus-infected	NULL
individuals	NULL
with	NULL
high	NULL
CD4	NULL
levels	NULL
can	NULL
be	NULL
detected	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
promoter-proximal	NULL
transcripts	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:3862-3866.	NULL
.	NULL

Aderka	NULL
,	NULL
D.	NULL
,	NULL
L.	NULL
Holtmann	NULL
,	NULL
L.	NULL
Toker	NULL
,	NULL
T.	NULL
Hahn	NULL
,	NULL
and	NULL
D.	NULL
Wallach	NULL
.	NULL

1986	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
induction	NULL
by	NULL
Sendai	NULL
virus	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

136:2938-2942.	NULL
.	NULL

Aillet	NULL
,	NULL
F.	NULL
,	NULL
M.	NULL
A.	NULL
Gourgerot-Pocidalo	NULL
,	NULL
J.	NULL
L.	NULL
Virelizier	NULL
,	NULL
and	NULL
N.	NULL
Israél	NULL
.	NULL

1994	NULL
.	NULL

Appraisal	NULL
of	NULL
potential	NULL
therapeutic	NULL
index	NULL
of	NULL
antioxidants	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
their	NULL
in	NULL
vitro	NULL
effects	NULL
on	NULL
HIV	NULL
replication	NULL
in	NULL
monocytes	NULL
and	NULL
interleukin	NULL
2-induced	NULL
lymphocyte	NULL
proliferation	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
10:405-411.	NULL
.	NULL

Akira	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Hirano	NULL
,	NULL
T.	NULL
Taga	NULL
,	NULL
and	NULL
T.	NULL
Kishimoto	NULL
.	NULL

1990	NULL
.	NULL

Biology	NULL
of	NULL
multi-	NULL
functional	NULL
cytokines	NULL
:	NULL
IL-6	NULL
and	NULL
related	NULL
molecules	NULL
(	NULL
IL-1	NULL
and	NULL
TNF	NULL
)	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

4:2860-2867.	NULL
.	NULL

Alkalay	NULL
,	NULL
I.	NULL
,	NULL
A.	NULL
Yaron	NULL
,	NULL
A.	NULL
Hatzubai	NULL
,	NULL
S.	NULL
Jung	NULL
,	NULL
A.	NULL
Avraham	NULL
,	NULL
O.	NULL
Gerlitz	NULL
,	NULL
I.	NULL
Pashut-Lavon	NULL
,	NULL
and	NULL
Y.	NULL
Ben-Neriah	NULL
.	NULL

1995	NULL
.	NULL

In	NULL
vivo	NULL
stimulation	NULL
of	NULL
IxB	NULL
phosphorylation	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:1294-1301.	NULL
.	NULL

Allen	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
N.	NULL
McCartney-Francis	NULL
,	NULL
P.	NULL
D.	NULL
Smith	NULL
,	NULL
G.	NULL
Simon	NULL
,	NULL
S.	NULL
Gartner	NULL
,	NULL
L.	NULL
M.	NULL
Wahl	NULL
,	NULL
M.	NULL
Popovic	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Wahl	NULL
.	NULL

1990	NULL
.	NULL

Expression	NULL
of	NULL
interleukin	NULL
2	NULL
receptors	NULL
by	NULL
monocytes	NULL
from	NULL
patients	NULL
with	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
and	NULL
induction	NULL
of	NULL
monocyte	NULL
interleukin	NULL
2	NULL
receptors	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

85:192-199.	NULL
.	NULL

Allen	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
H.	NULL
L.	NULL
Wong	NULL
,	NULL
P.	NULL
M.	NULL
Guyre	NULL
,	NULL
G.	NULL
L.	NULL
Simon	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Wahl	NULL
.	NULL

1991	NULL
.	NULL

Association	NULL
of	NULL
circulating	NULL
receptor	NULL
FeyRIII-positive	NULL
monocytes	NULL
in	NULL
AIDS	NULL
patients	NULL
with	NULL
elevated	NULL
levels	NULL
of	NULL
transforming	NULL
growth	NULL
factor-8B	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

87:1773-1778.	NULL
.	NULL

Amirhessami-Aghili	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
S.	NULL
A.	NULL
Spector	NULL
.	NULL

1991	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
of	NULL
human	NULL
placenta	NULL
:	NULL
potential	NULL
route	NULL
for	NULL
fetal	NULL
infection	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:2231-2236	NULL
.	NULL

Andreesen	NULL
,	NULL
R.	NULL
,	NULL
W.	NULL
Brugger	NULL
,	NULL
R.	NULL
Kunze	NULL
,	NULL
W.	NULL
Stille	NULL
,	NULL
and	NULL
H.	NULL
yon	NULL
Briesen	NULL
.	NULL

1990	NULL
.	NULL

Defective	NULL
monocyte	NULL
to	NULL
macrophage	NULL
differentiation	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Res	NULL
.	NULL

Virol	NULL
.	NULL

141:217-224	NULL
.	NULL

Andrieu	NULL
,	NULL
J.-M.	NULL
,	NULL
P.	NULL
Even	NULL
,	NULL
A.	NULL
Venet	NULL
,	NULL
J.	NULL
M.	NULL
Tourani	NULL
,	NULL
M.	NULL
Stern	NULL
,	NULL
W.	NULL
Lowenstein	NULL
,	NULL
C.	NULL
Audroin	NULL
,	NULL
D.	NULL
Eme	NULL
,	NULL
D.	NULL
Masson	NULL
,	NULL
and	NULL
H.	NULL
Sors	NULL
.	NULL

1988	NULL
.	NULL

Effects	NULL
of	NULL
cyclosporin	NULL
on	NULL
T-cell	NULL
subsets	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
disease	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Immunopathol	NULL
.	NULL

46:181-198	NULL
.	NULL

Antoni	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
S.	NULL
B.	NULL
Stein	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
.	NULL

1994	NULL
.	NULL

Regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
:	NULL
implications	NULL
for	NULL
pathogenesis	NULL
.	NULL

Adv	NULL
.	NULL

Virus	NULL
Res	NULL
.	NULL

43:53-145	NULL
.	NULL

Arai	NULL
,	NULL
K.-L.	NULL
,	NULL
F.	NULL
Lee	NULL
,	NULL
A.	NULL
Miyajima	NULL
,	NULL
S.	NULL
Miyatake	NULL
,	NULL
N.	NULL
Arai	NULL
,	NULL
and	NULL
T.	NULL
Yokota	NULL
.	NULL

1990	NULL
.	NULL

Cytokines	NULL
:	NULL
coordinators	NULL
of	NULL
immune	NULL
and	NULL
inflammatory	NULL
responses	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

59:783-836	NULL
.	NULL

Arenzana-Seisdedos	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
Thompson	NULL
,	NULL
M.	NULL
S.	NULL
Rodriguez	NULL
,	NULL
F.	NULL
Bachelerie	NULL
,	NULL
D.	NULL
Thomas	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Hay	NULL
.	NULL

1995	NULL
.	NULL

Inducible	NULL
nuclear	NULL
expression	NULL
of	NULL
newly	NULL
synthesized	NULL
IxBo	NULL
negatively	NULL
regulates	NULL
DNA-binding	NULL
and	NULL
the	NULL
transcriptional	NULL
activities	NULL
of	NULL
NF-kB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2689-2696	NULL
.	NULL

Axelrod	NULL
,	NULL
A	NULL
.	NULL

A	NULL
.	NULL

1990	NULL
.	NULL

Some	NULL
hematopoictic	NULL
negative	NULL
regulators	NULL
.	NULL

Exp	NULL
.	NULL

Hema-tol	NULL
.	NULL

18:143-150	NULL
.	NULL

Bachelerie	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
F.	NULL
Arenzana-Seisdedos	NULL
,	NULL
and	NULL
J.-L.	NULL
Virelizier	NULL
.	NULL

1991	NULL
.	NULL

HIV	NULL
enhancer	NULL
activity	NULL
perpetuated	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
on	NULL
infection	NULL
of	NULL
monocytes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
350:709-712	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
T.	NULL
Henkel	NULL
.	NULL

1994	NULL
.	NULL

Function	NULL
and	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12:141-179	NULL
.	NULL

Bagasra	NULL
,	NULL
O.	NULL
,	NULL
K.	NULL
Khalili	NULL
,	NULL
T.	NULL
Seshamma	NULL
,	NULL
J.	NULL
Taylor	NULL
,	NULL
and	NULL
R.	NULL
Pomerantz	NULL
.	NULL

1992	NULL
.	NULL

TAR-independent	NULL
replication	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
in	NULL
glial	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:7522-7528	NULL
.	NULL

Bagasra	NULL
,	NULL
O.	NULL
,	NULL
S.	NULL
D.	NULL
Wright	NULL
,	NULL
T.	NULL
Seshamma	NULL
,	NULL
J.	NULL
W.	NULL
Oakes	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Pomerantz	NULL
.	NULL

1992	NULL
.	NULL

CD14	NULL
is	NULL
involved	NULL
in	NULL
control	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
expression	NULL
in	NULL
latently	NULL
infected	NULL
cells	NULL
by	NULL
lipopolysaccharide	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:6285-6289	NULL
.	NULL

Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
E.	NULL
P.	NULL
Dixon	NULL
,	NULL
N.	NULL
J.	NULL
Peffer	NULL
,	NULL
H.	NULL
Bogerd	NULL
,	NULL
S.	NULL
Doerre	NULL
,	NULL
B.	NULL
Stein	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
65-kDa	NULL
subunit	NULL
of	NULL
human	NULL
NF-	NULL
«	NULL
B	NULL
functions	NULL
as	NULL
a	NULL
potent	NULL
transcriptional	NULL
activator	NULL
and	NULL
a	NULL
target	NULL
for	NULL
v-rel-mediated	NULL
repression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:1875-1879	NULL
.	NULL

Barre-Sinoussi	NULL
,	NULL
F.	NULL
,	NULL
J.-C.	NULL
Chermann	NULL
,	NULL
F.	NULL
Rey	NULL
,	NULL
M.	NULL
T.	NULL
Nugeyre	NULL
,	NULL
S.	NULL
Chamaret	NULL
,	NULL
J.	NULL
Gruest	NULL
,	NULL
C.	NULL
Dauguet	NULL
,	NULL
C.	NULL
Axler-Blin	NULL
,	NULL
F.	NULL
Vezinet-Brun	NULL
,	NULL
C.	NULL
Rouzioux	NULL
,	NULL
W.	NULL
Ro-zenbaum	NULL
,	NULL
and	NULL
L.	NULL
Montagnier	NULL
.	NULL

1983	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
T-lymphotropic	NULL
retrovi-	NULL
REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
22	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

497	NULL
rus	NULL
from	NULL
a	NULL
patient	NULL
at	NULL
risk	NULL
for	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
(	NULL
AIDS	NULL
)	NULL
.	NULL

Science	NULL
220:868-871	NULL
.	NULL

Beauparlant	NULL
,	NULL
P.	NULL
,	NULL
I.	NULL
Kwan	NULL
,	NULL
R.	NULL
Bitar	NULL
,	NULL
P.	NULL
Chou	NULL
,	NULL
A.	NULL
E.	NULL
Koromilas	NULL
,	NULL
N.	NULL
Sonen-berg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1994	NULL
.	NULL

Disruption	NULL
of	NULL
IxBa	NULL
«	NULL
regulation	NULL
by	NULL
antisense	NULL
RNA	NULL
expression	NULL
leads	NULL
to	NULL
malignant	NULL
transformation	NULL
.	NULL

Oncogene	NULL
9:3189-3197.	NULL
.	NULL

Beauparlant	NULL
,	NULL
P.	NULL
,	NULL
R.	NULL
Lin	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

Inducer	NULL
mediated	NULL
degradation	NULL
of	NULL
IxBa	NULL
requires	NULL
a	NULL
cluster	NULL
of	NULL
casein	NULL
kinase	NULL
II	NULL
sites	NULL
in	NULL
the	NULL
C-terminal	NULL
PEST	NULL
domain	NULL
.	NULL

Submitted	NULL
for	NULL
publication	NULL
.	NULL

.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1993	NULL
.	NULL

The	NULL
IxB	NULL
proteins	NULL
multifunctional	NULL
regulators	NULL
of	NULL
Rel/NF-	NULL
«	NULL
B	NULL
transcription	NULL
factors	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:2064-2070.	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
T.	NULL
S.	NULL
Finco	NULL
,	NULL
P.	NULL
V.	NULL
Nantermet	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1993	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
and	NULL
interleukin-1	NULL
lead	NULL
to	NULL
phosphorylation	NULL
and	NULL
loss	NULL
of	NULL
IxBa	NULL
:	NULL
a	NULL
mechanism	NULL
for	NULL
NF-xB	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:3301-3310	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
S.	NULL
M.	NULL
Ruben	NULL
,	NULL
R.	NULL
I.	NULL
Scheinman	NULL
,	NULL
S.	NULL
Haskill	NULL
,	NULL
C.	NULL
A.	NULL
Rosen	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1992	NULL
.	NULL

IxB	NULL
interacts	NULL
with	NULL
the	NULL
nuclear	NULL
localization	NULL
sequences	NULL
of	NULL
the	NULL
subunits	NULL
of	NULL
NF-kB	NULL
:	NULL
a	NULL
mechanism	NULL
for	NULL
cytoplasmic	NULL
retention	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

6:1899-1913	NULL
.	NULL

Bender	NULL
,	NULL
B.	NULL
S.	NULL
,	NULL
B.	NULL
L.	NULL
Davidson	NULL
,	NULL
R.	NULL
Kline	NULL
,	NULL
C.	NULL
Brown	NULL
,	NULL
and	NULL
T.	NULL
C.	NULL
Quinn	NULL
.	NULL

1988	NULL
.	NULL

Role	NULL
of	NULL
mononuclear	NULL
phagocyte	NULL
system	NULL
in	NULL
the	NULL
immunopathogenesis	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
and	NULL
the	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
.	NULL

Rev	NULL
.	NULL

Infect	NULL
.	NULL

Dis	NULL
.	NULL

10:1142-1154	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
A.	NULL
Gatignol	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
and	NULL
K.-T.	NULL
Jeang	NULL
.	NULL

1990	NULL
.	NULL

TAR-independent	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
:	NULL
evidence	NULL
that	NULL
Tat	NULL
requires	NULL
specific	NULL
regions	NULL
of	NULL
the	NULL
promoter	NULL
.	NULL

Cell	NULL
62:757-767	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
K.	NULL
T.	NULL
Jeang	NULL
.	NULL

1992	NULL
.	NULL

Functional	NULL
roles	NULL
for	NULL
the	NULL
TATA	NULL
promoter	NULL
and	NULL
enhancers	NULL
in	NULL
basal	NULL
and	NULL
Tat-induced	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:139-149	NULL
.	NULL

Bernstein	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
S.	NULL
E.	NULL
Tong-Starksen	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Locksley	NULL
.	NULL

1991	NULL
.	NULL

Activation	NULL
of	NULL
monocyte-derived	NULL
macrophages	NULL
with	NULL
lipopolysaccharide	NULL
decreases	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
replication	NULL
in	NULL
vitro	NULL
at	NULL
the	NULL
level	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

88:540-546	NULL
.	NULL

Beutler	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
A.	NULL
Cerami	NULL
.	NULL

1988	NULL
.	NULL

Tumor	NULL
necrosis	NULL
,	NULL
cachexia	NULL
,	NULL
shock	NULL
,	NULL
and	NULL
inflammation	NULL
:	NULL
a	NULL
common	NULL
mediator	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

57:505-518	NULL
.	NULL

Birx	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
R.	NULL
R.	NULL
Redfield	NULL
,	NULL
K.	NULL
Tencer	NULL
,	NULL
A.	NULL
Fowler	NULL
,	NULL
D.	NULL
S.	NULL
Burke	NULL
,	NULL
and	NULL
G.	NULL
Tosato	NULL
.	NULL

1990	NULL
.	NULL

Induction	NULL
of	NULL
interleukin-6	NULL
during	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Blood	NULL
11:2303-2310	NULL
.	NULL

Biswas	NULL
,	NULL
P.	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
A.	NULL
L.	NULL
Kinter	NULL
,	NULL
J.	NULL
S.	NULL
Justement	NULL
,	NULL
S.	NULL
K.	NULL
Stanley	NULL
,	NULL
M.	NULL
J.	NULL
Maury	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1992	NULL
.	NULL

Interferon-y	NULL
modulates	NULL
the	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
persistently	NULL
infected	NULL
promonocytic	NULL
cells	NULL
by	NULL
redirecting	NULL
the	NULL
production	NULL
of	NULL
virions	NULL
to	NULL
intracytoplasmic	NULL
vacuoles	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:739-750	NULL
.	NULL

Blank	NULL
,	NULL
V.	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
and	NULL
A.	NULL
Israél	NULL
.	NULL

1991	NULL
.	NULL

Cytoplasmic	NULL
retention	NULL
,	NULL
DNA	NULL
binding	NULL
and	NULL
processing	NULL
of	NULL
the	NULL
NF-kB	NULL
p50	NULL
precursor	NULL
are	NULL
controlled	NULL
by	NULL
a	NULL
small	NULL
region	NULL
in	NULL
its	NULL
C-terminus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:4159-4167	NULL
.	NULL

Blank	NULL
,	NULL
V.	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1992	NULL
.	NULL

NF-kB	NULL
and	NULL
related	NULL
proteins	NULL
:	NULL
Rel/dorsal	NULL
homologies	NULL
meet	NULL
ankyrin-like	NULL
repeats	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

17:135-140	NULL
.	NULL

Bours	NULL
,	NULL
V.	NULL
,	NULL
J.	NULL
Villalobos	NULL
,	NULL
P.	NULL
R.	NULL
Burd	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1990	NULL
.	NULL

Cloning	NULL
of	NULL
a	NULL
mitogen-inducible	NULL
gene	NULL
encoding	NULL
a	NULL
xB	NULL
DNA-binding	NULL
protein	NULL
with	NULL
homology	NULL
to	NULL
the	NULL
ref	NULL
oncogene	NULL
and	NULL
to	NULL
cell-cycle	NULL
motifs	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
348:76-80	NULL
.	NULL

Brach	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
H.-J	NULL
.	NULL

Gruss	NULL
,	NULL
D.	NULL
Riedel	NULL
,	NULL
R.	NULL
Mertelsmann	NULL
,	NULL
and	NULL
F.	NULL
Herrmann	NULL
.	NULL

1992	NULL
.	NULL

Activation	NULL
of	NULL
NF-kB	NULL
by	NULL
interleukin	NULL
2	NULL
in	NULL
human	NULL
blood	NULL
monocytes	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

3:421-427	NULL
.	NULL

Brach	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
F.	NULL
Herrmann	NULL
.	NULL

1991	NULL
.	NULL

Hematopoictic	NULL
growth	NULL
factors	NULL
:	NULL
interactions	NULL
and	NULL
regulation	NULL
of	NULL
production	NULL
.	NULL

Acta	NULL
Haematol	NULL
.	NULL

86:128-137	NULL
.	NULL

Bravo-Cuellar	NULL
,	NULL
A.	NULL
,	NULL
W.	NULL
Nowacki	NULL
,	NULL
F.	NULL
Vuillier	NULL
,	NULL
J.	NULL
de	NULL
Saint-Martin	NULL
,	NULL
and	NULL
S.	NULL
Orbach-Arbouys	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
bacterial	NULL
capacity	NULL
of	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
from	NULL
HIV	NULL
positive	NULL
patients	NULL
may	NULL
collapse	NULL
very	NULL
soon	NULL
after	NULL
infection	NULL
.	NULL

Immunol	NULL
.	NULL

Lett	NULL
.	NULL

31:297-300	NULL
.	NULL

Breen	NULL
,	NULL
E.	NULL
,	NULL
A.	NULL
Rezai	NULL
,	NULL
K.	NULL
Nakajima	NULL
,	NULL
G.	NULL
Beall	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
T.	NULL
Hirano	NULL
,	NULL
T.	NULL
Kishimoto	NULL
,	NULL
and	NULL
O.	NULL
Martinez-Maza	NULL
.	NULL

1990	NULL
.	NULL

Infection	NULL
with	NULL
HIV	NULL
is	NULL
associated	NULL
with	NULL
elevated	NULL
IL-6	NULL
levels	NULL
and	NULL
production	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

144:480-484	NULL
.	NULL

Brockman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
D.	NULL
C.	NULL
Scherer	NULL
,	NULL
T.	NULL
A.	NULL
McKinsey	NULL
,	NULL
S.	NULL
M.	NULL
Hall	NULL
,	NULL
X.	NULL
Qi	NULL
,	NULL
W.	NULL
Y.	NULL
Lee	NULL
,	NULL
and	NULL
D.	NULL
W.	NULL
Ballard	NULL
.	NULL

1995	NULL
.	NULL

Coupling	NULL
of	NULL
a	NULL
signal	NULL
response	NULL
domain	NULL
in	NULL
IxBa	NULL
.	NULL

to	NULL
multiple	NULL
pathway	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2809-2818	NULL
.	NULL

Brown	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Gertsberger	NULL
,	NULL
L.	NULL
Carlson	NULL
,	NULL
G.	NULL
Franzoso	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1995	NULL
.	NULL

Control	NULL
of	NULL
IxB-	NULL
«	NULL
proteolysis	NULL
by	NULL
site-specific	NULL
,	NULL
signal-induced	NULL
phosphorylation	NULL
.	NULL

Science	NULL
267:1485-1488	NULL
.	NULL

Brown	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Park	NULL
,	NULL
T.	NULL
Kanno	NULL
,	NULL
G.	NULL
Franzoso	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1993	NULL
.	NULL

Mutual	NULL
regulation	NULL
of	NULL
the	NULL
transcriptional	NULL
activator	NULL
NF-kB	NULL
and	NULL
its	NULL
inhibitor	NULL
,	NULL
IxB-e.	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:2532-2536	NULL
.	NULL

Bukrinsky	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Haggerty	NULL
,	NULL
M.	NULL
P.	NULL
Dempsey	NULL
,	NULL
N.	NULL
Sharova	NULL
,	NULL
A.	NULL
Adzhubei	NULL
,	NULL
L.	NULL
Spitz	NULL
,	NULL
P.	NULL
Lewis	NULL
,	NULL
D.	NULL
Goldfarb	NULL
,	NULL
M.	NULL
Emerman	NULL
,	NULL
and	NULL
M.	NULL
Stevenson	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
nuclear	NULL
localization	NULL
signal	NULL
within	NULL
HIV-1	NULL
matrix	NULL
protein	NULL
that	NULL
governs	NULL
infection	NULL
of	NULL
non-dividing	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
365:666-669	NULL
.	NULL

Bull	NULL
,	NULL
P.	NULL
,	NULL
T.	NULL
Hunter	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1989	NULL
.	NULL

Transcriptional	NULL
induction	NULL
of	NULL
the	NULL
murine	NULL
c-re/	NULL
gene	NULL
with	NULL
serum	NULL
and	NULL
phorbol-12-myristate-13-acetate	NULL
in	NULL
fibro-blasts	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

95239-5243	NULL
.	NULL

Bull	NULL
,	NULL
P.	NULL
,	NULL
K.	NULL
L.	NULL
Morley	NULL
,	NULL
M.	NULL
F.	NULL
Hoekstra	NULL
,	NULL
T.	NULL
Hunter	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
mouse	NULL
c-Rel	NULL
protein	NULL
has	NULL
an	NULL
N-terminal	NULL
regulatory	NULL
domain	NULL
and	NULL
a	NULL
C-terminal	NULL
transcriptional	NULL
transactivation	NULL
domain	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:5473-5485	NULL
.	NULL

498	NULL
47	NULL
48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

58	NULL
:	NULL
59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

72	NULL
.	NULL

ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

.	NULL

Butera	NULL
,	NULL
S.	NULL
1993	NULL
.	NULL

Cytokine	NULL
involvement	NULL
in	NULL
viral	NULL
permissiveness	NULL
and	NULL
the	NULL
progression	NULL
of	NULL
HIV	NULL
disease	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biochem	NULL
.	NULL

53:336-342	NULL
.	NULL

Butera	NULL
,	NULL
S.	NULL
,	NULL
B.	NULL
D.	NULL
Roberts	NULL
,	NULL
K.	NULL
Leung	NULL
,	NULL
G.	NULL
J.	NULL
Nabel	NULL
,	NULL
and	NULL
T.	NULL
M.	NULL
Folks	NULL
.	NULL

1993	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
expression	NULL
and	NULL
signal	NULL
transduction	NULL
in	NULL
HIV-1-infected	NULL
cells	NULL
.	NULL

AIDS	NULL
7:911-918	NULL
.	NULL

Cannon	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
D.	NULL
G.	NULL
Tenen	NULL
,	NULL
M.	NULL
B.	NULL
Feinberg	NULL
,	NULL
H.	NULL
S.	NULL
Shin	NULL
,	NULL
and	NULL
K.	NULL
Kim	NULL
.	NULL

1993	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus-1	NULL
infection	NULL
of	NULL
the	NULL
human	NULL
promyelocytic	NULL
cell	NULL
line	NULL
HL-60	NULL
:	NULL
high	NULL
frequency	NULL
of	NULL
low-level	NULL
infection	NULL
and	NULL
effect	NULL
of	NULL
subsequent	NULL
cell	NULL
differentiation	NULL
.	NULL

Blood	NULL
2:437-445	NULL
.	NULL

Cao	NULL
,	NULL
Y	NULL
.	NULL

Z.	NULL
,	NULL
D.	NULL
Dietrich	NULL
,	NULL
P.	NULL
A.	NULL
Thomas	NULL
,	NULL
Y.	NULL
X.	NULL
Huang	NULL
,	NULL
M.	NULL
Mirabile	NULL
,	NULL
and	NULL
D.	NULL
D.	NULL
Ho	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
and	NULL
quantitation	NULL
of	NULL
HIV-1	NULL
in	NULL
the	NULL
liver	NULL
of	NULL
patients	NULL
with	NULL
AIDS	NULL
.	NULL

AIDS	NULL
6:65-70	NULL
.	NULL

Chandra	NULL
,	NULL
R.	NULL
K.	NULL
1983	NULL
.	NULL

Nutrition	NULL
,	NULL
immunity	NULL
,	NULL
and	NULL
infection	NULL
:	NULL
present	NULL
knowledge	NULL
and	NULL
future	NULL
directions	NULL
.	NULL

Lancet	NULL
i:688-691	NULL
.	NULL

Chang	NULL
,	NULL
Y.	NULL
,	NULL
E.	NULL
Cesarman	NULL
,	NULL
M.	NULL
S.	NULL
Pessin	NULL
,	NULL
F.	NULL
Lee	NULL
,	NULL
J.	NULL
Culpepper	NULL
,	NULL
D.	NULL
M.	NULL
Knowles	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Moore	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
of	NULL
herpesvirus-like	NULL
DNA	NULL
sequences	NULL
in	NULL
AIDS-associated	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
.	NULL

Science	NULL
266:1865-1869	NULL
.	NULL

Chehimi	NULL
,	NULL
J.	NULL
,	NULL
S.	NULL
E.	NULL
Starr	NULL
,	NULL
I.	NULL
Frank	NULL
,	NULL
A	NULL
.	NULL

D'Andrea	NULL
,	NULL
X.	NULL
Ma	NULL
,	NULL
R.	NULL
R.	NULL
MacGregor	NULL
,	NULL
and	NULL
G.	NULL
Trinchieri	NULL
.	NULL

1994	NULL
.	NULL

Impaired	NULL
interleukin	NULL
12	NULL
production	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus-infected	NULL
patients	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:1361-1366	NULL
.	NULL

Cheung	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Hamilton	NULL
.	NULL

1992	NULL
.	NULL

Regulation	NULL
of	NULL
human	NULL
monocyte	NULL
DNA	NULL
synthesis	NULL
by	NULL
colony-stimulating	NULL
factors	NULL
,	NULL
cytokines	NULL
,	NULL
and	NULL
cyclic	NULL
adeno-sine	NULL
monophosphate	NULL
.	NULL

Blood	NULL
79:1972-1981	NULL
.	NULL

Clouse	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
D.	NULL
Powell	NULL
,	NULL
I.	NULL
Washington	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
K.	NULL
Strebel	NULL
,	NULL
W.	NULL
Farrar	NULL
,	NULL
P.	NULL
Barstad	NULL
,	NULL
J.	NULL
Kovacs	NULL
,	NULL
A.	NULL
S.	NULL
Fauci	NULL
,	NULL
and	NULL
T.	NULL
M.	NULL
Folks	NULL
.	NULL

1989	NULL
.	NULL

Monokine	NULL
regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
expression	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
human	NULL
T	NULL
cell	NULL
clone	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:431-438	NULL
.	NULL

Coffin	NULL
,	NULL
J.	NULL
M.	NULL
1995	NULL
.	NULL

HIV	NULL
population	NULL
dynamics	NULL
in	NULL
vivo	NULL
:	NULL
implications	NULL
for	NULL
genetic	NULL
variation	NULL
,	NULL
pathogenesis	NULL
,	NULL
and	NULL
therapy	NULL
.	NULL

Science	NULL
267:483-489	NULL
.	NULL

Collart	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
D.	NULL
Belin	NULL
,	NULL
J.-D.	NULL
Vassalli	NULL
,	NULL
S.	NULL
De	NULL
Kossodo	NULL
,	NULL
and	NULL
P.	NULL
Vassalli	NULL
.	NULL

1986	NULL
.	NULL

Gamma	NULL
interferon	NULL
enhances	NULL
macrophage	NULL
transcription	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor/cachetin	NULL
,	NULL
interleukin	NULL
1	NULL
,	NULL
and	NULL
urokinase	NULL
genes	NULL
,	NULL
which	NULL
are	NULL
controlled	NULL
by	NULL
short-lived	NULL
repressors	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

164:2113-2118	NULL
.	NULL

Collman	NULL
,	NULL
R.	NULL
,	NULL
N.	NULL
F.	NULL
Hassan	NULL
,	NULL
R.	NULL
Walker	NULL
,	NULL
B.	NULL
Godfrey	NULL
,	NULL
J.	NULL
Cutilli	NULL
,	NULL
J.	NULL
C.	NULL
Hastings	NULL
,	NULL
H.	NULL
Fried	NULL
S.	NULL
D.	NULL
Douglas	NULL
,	NULL
and	NULL
N.	NULL
Nath	NULL
1989	NULL
.	NULL

Infection	NULL
of	NULL
monocyte-derived	NULL
macrophages	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

170:1149-1163.	NULL
a.Conti	NULL
,	NULL
L.	NULL
,	NULL
J.	NULL
Hiscott	NULL
,	NULL
M.	NULL
Papachini	NULL
,	NULL
A.	NULL
Roulston	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
F.	NULL
Bel-lardelli	NULL
,	NULL
and	NULL
S.	NULL
Gessani	NULL
.	NULL

Induction	NULL
of	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
and	NULL
IxBa	NULL
subunit	NULL
expression	NULL
during	NULL
differentiation	NULL
of	NULL
human	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
to	NULL
macrophages	NULL
.	NULL

Submitted	NULL
for	NULL
publication	NULL
.	NULL

Cooney	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
S.	NULL
Y.	NULL
Tsai	NULL
,	NULL
B.	NULL
W.	NULL
O'Malley	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Tsai	NULL
.	NULL

1991	NULL
.	NULL

Chicken	NULL
ovalbumin	NULL
upstream	NULL
promoter	NULL
transcription	NULL
factor	NULL
binds	NULL
to	NULL
a	NULL
negative	NULL
regulatory	NULL
region	NULL
in	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:2853-2860	NULL
.	NULL

Cressman	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
and	NULL
R.	NULL
Taub	NULL
.	NULL

1993	NULL
.	NULL

IxBa	NULL
can	NULL
localize	NULL
in	NULL
the	NULL
nucleus	NULL
but	NULL
shows	NULL
no	NULL
direct	NULL
transactivation	NULL
potential	NULL
.	NULL

Oncogene	NULL
8:2567-2573	NULL
.	NULL

Crowe	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
R.	NULL
S.	NULL
Kornbluth	NULL
.	NULL

1994	NULL
.	NULL

HIV	NULL
and	NULL
cells	NULL
of	NULL
macrophage	NULL
lineage	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

56:215-422	NULL
.	NULL

Cullen	NULL
,	NULL
B.	NULL
R.	NULL
1992	NULL
.	NULL

Mechanism	NULL
of	NULL
action	NULL
of	NULL
regulatory	NULL
proteins	NULL
encoded	NULL
by	NULL
complex	NULL
retroviruses	NULL
.	NULL

Microbiol	NULL
.	NULL

Rev	NULL
.	NULL

56:375-394	NULL
.	NULL

D'Addario	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Roulston	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1990	NULL
.	NULL

Coordinate	NULL
enhancement	NULL
of	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1-infected	NULL
promonocytic	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:6080-6089	NULL
.	NULL

D'Addario	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1992	NULL
.	NULL

Activation	NULL
of	NULL
cytokine	NULL
genes	NULL
in	NULL
HIV-1	NULL
infected	NULL
myelomonoblastic	NULL
cells	NULL
by	NULL
phorbol	NULL
ester	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:1222-1229	NULL
.	NULL

Davis	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
S.	NULL
C.	NULL
Kenney	NULL
,	NULL
J.	NULL
Kamine	NULL
,	NULL
J.	NULL
S.	NULL
Pagano	NULL
,	NULL
and	NULL
E.	NULL
S.	NULL
Huang	NULL
.	NULL

1987	NULL
.	NULL

Immediate-early	NULL
gene	NULL
region	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
trans-activates	NULL
the	NULL
promoter	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:8642-8646	NULL
.	NULL

Davis	NULL
,	NULL
N.	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
D.	NULL
L.	NULL
Simmons	NULL
,	NULL
P.	NULL
Tempst	NULL
,	NULL
H.-C.	NULL
Liou	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
H.	NULL
R.	NULL
Bose	NULL
,	NULL
Jr.	NULL
1991	NULL
.	NULL

Rel-associated	NULL
pp40	NULL
:	NULL
an	NULL
inhibitor	NULL
of	NULL
the	NULL
rel	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Science	NULL
253:1268-1271	NULL
.	NULL

DeFranco	NULL
,	NULL
A.	NULL
L.	NULL
1991	NULL
.	NULL

Immunosuppressants	NULL
at	NULL
work	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
352:754-755	NULL
.	NULL

Dembic	NULL
,	NULL
Z.	NULL
,	NULL
H.	NULL
Loetscher	NULL
,	NULL
U.	NULL
Gubler	NULL
,	NULL
Y.	NULL
C.	NULL
Pan	NULL
,	NULL
H.	NULL
W.	NULL
Lahm	NULL
,	NULL
R.	NULL
Gentz	NULL
,	NULL
M.	NULL
Brockhaus	NULL
,	NULL
and	NULL
W.	NULL
Lesslauer	NULL
.	NULL

1990	NULL
.	NULL

Two	NULL
human	NULL
TNF	NULL
receptors	NULL
have	NULL
similar	NULL
extracellular	NULL
but	NULL
distinct	NULL
intracellular	NULL
domain	NULL
sequences	NULL
.	NULL

Cytokine	NULL
2:231-237	NULL
.	NULL

Diaz-Meco	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
E.	NULL
Berra	NULL
,	NULL
M.	NULL
M.	NULL
Municio	NULL
,	NULL
L.	NULL
Sanz	NULL
,	NULL
I.	NULL
Dominguez	NULL
,	NULL
V.	NULL
Diaz-Golpe	NULL
,	NULL
M.	NULL
T.	NULL
Lain	NULL
de	NULL
Lera	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
C.	NULL
V.	NULL
Paya	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
dominant	NULL
negative	NULL
protein	NULL
kinase	NULL
C	NULL
{	NULL
subspecies	NULL
blocks	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:4770-4775	NULL
.	NULL

Diaz-Meco	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
I.	NULL
Dominguez	NULL
,	NULL
L.	NULL
Sanz	NULL
,	NULL
P.	NULL
Dent	NULL
,	NULL
J.	NULL
Lozano	NULL
,	NULL
M.	NULL
M.	NULL
Municio	NULL
,	NULL
E.	NULL
Berra	NULL
,	NULL
R.	NULL
T.	NULL
Hay	NULL
,	NULL
T.	NULL
W.	NULL
Sturgill	NULL
,	NULL
and	NULL
J.	NULL
Moscat	NULL
.	NULL

1994	NULL
.	NULL

{	NULL
PKC	NULL
induces	NULL
phosphorylation	NULL
and	NULL
inactivation	NULL
of	NULL
IxBa	NULL
in	NULL
vifro	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13	NULL
:	NULL
2842-2848	NULL
.	NULL

DiDonato	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
F.	NULL
Mercurio	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1995	NULL
.	NULL

Phosphorylation	NULL
of	NULL
IxBo	NULL
.	NULL

precedes	NULL
but	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
its	NULL
dissociation	NULL
from	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:1302-1311	NULL
.	NULL

Dinarello	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

1989	NULL
.	NULL

Interleukin-1	NULL
and	NULL
its	NULL
biologically	NULL
related	NULL
cytokines	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

75	NULL
.	NULL

76	NULL
.	NULL

77	NULL
.	NULL

78	NULL
.	NULL

79	NULL
.	NULL

80	NULL
.	NULL

81	NULL
.	NULL

82	NULL
.	NULL

83	NULL
.	NULL

84	NULL
.	NULL

85	NULL
.	NULL

86	NULL
.	NULL

87	NULL
.	NULL

88	NULL
.	NULL

89	NULL
.	NULL

90	NULL
.	NULL

91	NULL
.	NULL

92	NULL
.	NULL

93	NULL
.	NULL

94	NULL
.	NULL

95	NULL
.	NULL

96	NULL
.	NULL

97	NULL
.	NULL

98	NULL
.	NULL

MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

Adv	NULL
.	NULL

Immunol	NULL
.	NULL

44:153-204	NULL
.	NULL

Doweiko	NULL
,	NULL
J.	NULL
P.	NULL
1993	NULL
.	NULL

Hematologic	NULL
aspects	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

AIDS	NULL
7:753-757	NULL
.	NULL

Drigue	NULL
,	NULL
W.	NULL
,	NULL
H.-P.	NULL
Eck	NULL
,	NULL
and	NULL
S.	NULL
Mihm	NULL
.	NULL

1992	NULL
.	NULL

HIV-induced	NULL
cysteine	NULL
deficiency	NULL
and	NULL
T	NULL
cell	NULL
dysfunction-a	NULL
rationale	NULL
for	NULL
treatment	NULL
with	NULL
N-acetylcys-teine	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
13:211-214	NULL
.	NULL

Du	NULL
,	NULL
W.	NULL
,	NULL
D.	NULL
Thanos	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1993	NULL
.	NULL

Mechanisms	NULL
of	NULL
transcriptional	NULL
synergism	NULL
between	NULL
distinct	NULL
virus-inducible	NULL
enhancer	NULL
elements	NULL
.	NULL

Cell	NULL
74:887-898	NULL
.	NULL

Dubreuil	NULL
,	NULL
M.	NULL
,	NULL
L.	NULL
Sportza	NULL
,	NULL
M.	NULL
D'Addario	NULL
,	NULL
J.	NULL
Lacoste	NULL
,	NULL
R.	NULL
Rooke	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1990	NULL
.	NULL

Inhibition	NULL
of	NULL
HIV-1	NULL
transmission	NULL
by	NULL
interferon	NULL
and	NULL
3-azido-3'-deoxythymidine	NULL
during	NULL
de	NULL
novo	NULL
infection	NULL
of	NULL
promonocytic	NULL
cells	NULL
.	NULL

Virology	NULL
179:388-394	NULL
.	NULL

Duckett	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
N.	NULL
D.	NULL
Perkins	NULL
,	NULL
T.	NULL
F.	NULL
Kowalik	NULL
,	NULL
R.	NULL
M.	NULL
Schmid	NULL
,	NULL
E.-S.	NULL
Huang	NULL
,	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1993	NULL
.	NULL

Dimerization	NULL
of	NULL
NF-	NULL
«	NULL
B2	NULL
with	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
regulates	NULL
DNA	NULL
binding	NULL
,	NULL
transcriptional	NULL
activation	NULL
,	NULL
and	NULL
inhibition	NULL
by	NULL
an	NULL
IxB-	NULL
«	NULL
(	NULL
MAD3	NULL
)	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:1315-1322	NULL
.	NULL

Dudding	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Haskill	NULL
,	NULL
B.	NULL
D.	NULL
Clark	NULL
,	NULL
P.	NULL
E.	NULL
Auron	NULL
,	NULL
S.	NULL
Sporn	NULL
,	NULL
and	NULL
E.-S.	NULL
Huang	NULL
.	NULL

1989	NULL
.	NULL

Cytomegalovirus	NULL
infection	NULL
stimulates	NULL
expression	NULL
of	NULL
mono-cyte-associated	NULL
mediator	NULL
genes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143:3343-3352	NULL
.	NULL

Dub	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
W.	NULL
J.	NULL
Maury	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
A.	NULL
S.	NULL
Fauci	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
activates	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
through	NULL
induction	NULL
of	NULL
a	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
NF-B	NULL
sites	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:5974-5978	NULL
.	NULL

Emilie	NULL
,	NULL
D.	NULL
,	NULL
M.	NULL
Peuchmaur	NULL
,	NULL
M.	NULL
C.	NULL
Maillot	NULL
,	NULL
M.	NULL
C.	NULL
Crevon	NULL
,	NULL
N.	NULL
Brousse	NULL
,	NULL
J.	NULL
F.	NULL
Delfraissy	NULL
,	NULL
J.	NULL
Dormont	NULL
,	NULL
and	NULL
P.	NULL
Galanaud	NULL
.	NULL

1991	NULL
.	NULL

Production	NULL
of	NULL
interleukins	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus-1-replicating	NULL
lymph	NULL
nodes	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

86:148-159	NULL
.	NULL

Ensoli	NULL
,	NULL
B.	NULL
,	NULL
G.	NULL
Barillari	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1992	NULL
.	NULL

Cytokines	NULL
and	NULL
growth	NULL
factors	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
AIDS-associated	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

127:147-155	NULL
.	NULL

Ernst	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
L.	NULL
L.	NULL
Dunn	NULL
,	NULL
and	NULL
N.	NULL
R.	NULL
Rice	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
PEST-like	NULL
sequence	NULL
of	NULL
IxBa	NULL
is	NULL
responsible	NULL
for	NULL
inhibition	NULL
of	NULL
DNA	NULL
binding	NULL
but	NULL
not	NULL
for	NULL
cytoplasmic	NULL
retention	NULL
of	NULL
c-Rel	NULL
or	NULL
RelA	NULL
homodimers	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:872-882	NULL
.	NULL

Estevez	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
I.	NULL
J.	NULL
Ballart	NULL
,	NULL
R.	NULL
A.	NULL
Diez	NULL
,	NULL
N.	NULL
Planes	NULL
,	NULL
C.	NULL
Scaglione	NULL
,	NULL
and	NULL
L.	NULL
Sen.	NULL
1986	NULL
.	NULL

Early	NULL
defect	NULL
of	NULL
phagocytic	NULL
cell	NULL
function	NULL
in	NULL
subjects	NULL
at	NULL
risk	NULL
for	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:215-221	NULL
.	NULL

Fan	NULL
,	NULL
C.-M.	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1991	NULL
.	NULL

Generation	NULL
of	NULL
p50	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
processing	NULL
of	NULL
p105	NULL
through	NULL
an	NULL
ATP-dependent	NULL
pathway	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
354:395-398	NULL
.	NULL

Farrar	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
M.	NULL
Korner	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Clouse	NULL
.	NULL

1991	NULL
.	NULL

Cytokine	NULL
regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
expression	NULL
.	NULL

Cytokine	NULL
3:531-542	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
1993	NULL
.	NULL

Multifactorial	NULL
nature	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
disease	NULL
:	NULL
implications	NULL
for	NULL
therapy	NULL
.	NULL

Science	NULL
262:1011-1018	NULL
.	NULL

Fauci	NULL
,	NULL
A.	NULL
S.	NULL
1993	NULL
.	NULL

Immunopathogenesis	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

Ann	NULL
.	NULL

N.	NULL
Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

685:409-419	NULL
.	NULL

Felber	NULL
,	NULL
B.	NULL
K.	NULL
,	NULL
and	NULL
G.	NULL
N.	NULL
Pavlakis	NULL
,	NULL
1993	NULL
.	NULL

Molecular	NULL
biology	NULL
of	NULL
HIV-1	NULL
:	NULL
positive	NULL
and	NULL
negative	NULL
regulatory	NULL
elements	NULL
important	NULL
for	NULL
virus	NULL
expression	NULL
.	NULL

AIDS	NULL
7	NULL
:	NULL
s51-s62	NULL
.	NULL

Feng	NULL
,	NULL
C.-P.	NULL
,	NULL
M.	NULL
Kulka	NULL
,	NULL
and	NULL
L.	NULL
Aurelian	NULL
.	NULL

1993	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
binding	NULL
proteins	NULL
induced	NULL
by	NULL
HSV-1	NULL
infection	NULL
of	NULL
U937	NULL
cells	NULL
are	NULL
not	NULL
involved	NULL
in	NULL
activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Virology	NULL
192:491-500	NULL
.	NULL

Fibbe	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
and	NULL
R.	NULL
Willems	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
interleukin-1	NULL
in	NULL
hemato-poiesis	NULL
.	NULL

Acta	NULL
Haematol	NULL
.	NULL

86:148-154	NULL
.	NULL

Filhol	NULL
,	NULL
O.	NULL
,	NULL
J.	NULL
Baudier	NULL
,	NULL
C.	NULL
Delphin	NULL
,	NULL
P.	NULL
Loue-Mackenbach	NULL
,	NULL
E.	NULL
M.	NULL
Chamt	NULL
and	NULL
C.	NULL
Cochet	NULL
.	NULL

1992	NULL
.	NULL

Casein	NULL
kinase	NULL
II	NULL
and	NULL
tumor	NULL
suppressor	NULL
protein	NULL
pS3	NULL
associate	NULL
in	NULL
a	NULL
molecular	NULL
complex	NULL
that	NULL
is	NULL
negatively	NULL
regulated	NULL
upon	NULL
pS3	NULL
phosphorylation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:20577-20583	NULL
.	NULL

Finco	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1993	NULL
.	NULL

«	NULL
B	NULL
site-dependent	NULL
induction	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
diverse	NULL
inducers	NULL
of	NULL
nuclear	NULL
factor	NULL
xB	NULL
requires	NULL
Raf-1	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:17676-17679	NULL
.	NULL

Finco	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Beg	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1994	NULL
.	NULL

Inducible	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
its	NULL
dissociation	NULL
from	NULL
NF-kB	NULL
and	NULL
is	NULL
inhibited	NULL
by	NULL
protease	NULL
inhibitors	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:11884-11888	NULL
.	NULL

Fisher	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
B.	NULL
Ensoli	NULL
,	NULL
D.	NULL
Looney	NULL
,	NULL
A	NULL
.	NULL

Rose	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
M.	NULL
S.	NULL
Saag	NULL
,	NULL
G.	NULL
M.	NULL
Shaw	NULL
,	NULL
B.	NULL
H.	NULL
Hahn	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1988	NULL
.	NULL

Biologically	NULL
diverse	NULL
molecular	NULL
variants	NULL
within	NULL
a	NULL
single	NULL
HIV-1	NULL
isolate	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
334:444-447	NULL
.	NULL

Foley	NULL
,	NULL
P.	NULL
,	NULL
F.	NULL
Kazazi	NULL
,	NULL
R.	NULL
Biti	NULL
,	NULL
T.	NULL
C.	NULL
Sorrell	NULL
,	NULL
and	NULL
A.	NULL
L.	NULL
Cunningham	NULL
.	NULL

1992	NULL
.	NULL

HIV	NULL
infection	NULL
of	NULL
monocytes	NULL
inhibits	NULL
the	NULL
T-lymphocyte	NULL
proliferative	NULL
response	NULL
to	NULL
recall	NULL
antigens	NULL
,	NULL
via	NULL
production	NULL
of	NULL
eicosanoids	NULL
.	NULL

Immunology	NULL
75	NULL
:	NULL
391-397	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
K.	NULL
A.	NULL
Clouse	NULL
,	NULL
J.	NULL
Justement	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
E.	NULL
Dub	NULL
,	NULL
J.	NULL
H.	NULL
Kerhl	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
induces	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
T-cell	NULL
clone	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2365-2368	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
J.	NULL
S.	NULL
Justement	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
C.	NULL
A.	NULL
Dinarello	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1987	NULL
.	NULL

Cytokine	NULL
induced	NULL
expression	NULL
of	NULL
HIV-1	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
promonocytic	NULL
cell	NULL
line	NULL
.	NULL

Science	NULL
238:800-802	NULL
.	NULL

Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
S.	NULL
W.	NULL
Kessler	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
J.	NULL
S.	NULL
Justement	NULL
,	NULL
E.	NULL
S.	NULL
Jaffe	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1988	NULL
.	NULL

Infection	NULL
and	NULL
replication	NULL
of	NULL
HIV-1	NULL
in	NULL
purified	NULL
progenitor	NULL
cells	NULL
of	NULL
normal	NULL
human	NULL
bone	NULL
marrow	NULL
.	NULL

Science	NULL
242:919-922	NULL
.	NULL

Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
99	NULL
.	NULL

100	NULL
.	NULL

101	NULL
.	NULL

102	NULL
.	NULL

103	NULL
.	NULL

104	NULL
.	NULL

105	NULL
.	NULL

106	NULL
.	NULL

107	NULL
.	NULL

108	NULL
.	NULL

109	NULL
.	NULL

110	NULL
.	NULL

111	NULL
.	NULL

112	NULL
.	NULL

113	NULL
.	NULL

114	NULL
.	NULL

115	NULL
.	NULL

116	NULL
.	NULL

117	NULL
.	NULL

118	NULL
.	NULL

119	NULL
.	NULL

120	NULL
.	NULL

Francis	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
M.	NULL
S.	NULL
Meltzer	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Gendelman	NULL
.	NULL

1992	NULL
.	NULL

Interferons	NULL
in	NULL
the	NULL
persistence	NULL
,	NULL
pathogenesis	NULL
,	NULL
and	NULL
treatment	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
8:199-207	NULL
.	NULL

Frankenberger	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Pforte	NULL
,	NULL
T.	NULL
Sternsdorf	NULL
,	NULL
B.	NULL
Passlick	NULL
,	NULL
P.	NULL
A.	NULL
Baeverle	NULL
,	NULL
and	NULL
H.	NULL
W.	NULL
L.	NULL
Ziegler-Heitbrock	NULL
.	NULL

1994	NULL
.	NULL

Constitutive	NULL
nuclear	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
monocyte	NULL
lineage	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

304:87-94	NULL
.	NULL

Franza	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
F.	NULL
J.	NULL
Raucher	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
and	NULL
T.	NULL
Curran	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
fos	NULL
complex	NULL
and	NULL
fos-related	NULL
antigens	NULL
recognize	NULL
sequence	NULL
elements	NULL
that	NULL
contain	NULL
AP-1	NULL
binding	NULL
sites	NULL
.	NULL

Science	NULL
239:1150-1153	NULL
.	NULL

Franzoso	NULL
,	NULL
G.	NULL
,	NULL
P.	NULL
Biswas	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
L.	NULL
M.	NULL
Carlson	NULL
,	NULL
K.	NULL
D.	NULL
Brown	NULL
,	NULL
M.	NULL
Tomita-Yamaguchi	NULL
,	NULL
A.	NULL
S.	NULL
Fauci	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
family	NULL
of	NULL
serine	NULL
proteases	NULL
expressed	NULL
exclusively	NULL
in	NULL
myelo-monocytic	NULL
cells	NULL
specifically	NULL
processes	NULL
the	NULL
nuclear	NULL
factor-kB	NULL
subunit	NULL
p65	NULL
in	NULL
vitro	NULL
and	NULL
may	NULL
impair	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
replication	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:1445-1456	NULL
.	NULL

Franzoso	NULL
,	NULL
G.	NULL
,	NULL
V.	NULL
Bours	NULL
,	NULL
S.	NULL
Park	NULL
,	NULL
M.	NULL
Tomita-Yamaguchi	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
candidate	NULL
oncoprotein	NULL
Bcl-3	NULL
is	NULL
an	NULL
antagonist	NULL
of	NULL
p50/	NULL
NF-	NULL
«	NULL
B-mediated	NULL
inhibition	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
359:339-342	NULL
.	NULL

Fuchs	NULL
,	NULL
D.	NULL
,	NULL
A.	NULL
Hausen	NULL
,	NULL
G.	NULL
Reibnegger	NULL
,	NULL
E.	NULL
R.	NULL
Werner	NULL
,	NULL
G.	NULL
Werner-Felmayer	NULL
,	NULL
M.	NULL
P.	NULL
Dierich	NULL
,	NULL
and	NULL
H.	NULL
Wachter	NULL
.	NULL

1989	NULL
.	NULL

Interferon-y	NULL
concentrations	NULL
are	NULL
increased	NULL
in	NULL
sera	NULL
from	NULL
individuals	NULL
infected	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

2:158-162	NULL
.	NULL

Gallo	NULL
,	NULL
P.	NULL
,	NULL
K.	NULL
Frei	NULL
,	NULL
C.	NULL
Rordorf	NULL
,	NULL
J.	NULL
Lazdins	NULL
,	NULL
B.	NULL
Tavolato	NULL
,	NULL
and	NULL
A.	NULL
Fontana	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
infection	NULL
of	NULL
the	NULL
central	NULL
nervous	NULL
system	NULL
:	NULL
an	NULL
evaluation	NULL
of	NULL
cytokines	NULL
in	NULL
cerebrospinal	NULL
fluid	NULL
.	NULL

J.	NULL
Neuroimmunol	NULL
.	NULL

23:109-116	NULL
.	NULL

Gallo	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
M.	NULL
Popovic	NULL
,	NULL
G.	NULL
M.	NULL
Shearer	NULL
,	NULL
M.	NULL
Kaplan	NULL
,	NULL
B.	NULL
F.	NULL
Haynes	NULL
,	NULL
T.	NULL
J.	NULL
Palker	NULL
,	NULL
R.	NULL
Redfield	NULL
,	NULL
J.	NULL
Oleske	NULL
,	NULL
B.	NULL
Safai	NULL
,	NULL
F.	NULL
White	NULL
,	NULL
R.	NULL
Foster	NULL
,	NULL
and	NULL
P.	NULL
D.	NULL
Markham	NULL
.	NULL

1984	NULL
.	NULL

Frequent	NULL
detection	NULL
and	NULL
isolation	NULL
of	NULL
cytopathic	NULL
retroviruses	NULL
(	NULL
HTLV-II	NULL
)	NULL
from	NULL
patients	NULL
with	NULL
AIDS	NULL
and	NULL
at	NULL
risk	NULL
for	NULL
AIDS	NULL
.	NULL

Science	NULL
224:500-503	NULL
.	NULL

Ganser	NULL
,	NULL
A.	NULL
,	NULL
C.	NULL
Carlo-Stella	NULL
,	NULL
J.	NULL
Greher	NULL
,	NULL
B.	NULL
Volkers	NULL
,	NULL
and	NULL
D.	NULL
Hoelzer	NULL
.	NULL

1987	NULL
.	NULL

Effect	NULL
of	NULL
recombinant	NULL
interferons	NULL
alpha	NULL
and	NULL
gamma	NULL
on	NULL
human	NULL
bone	NULL
mar-row-derived	NULL
megakaryocytic	NULL
progenitor	NULL
cells	NULL
.	NULL

Blood	NULL
70:1173-1179	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
D.	NULL
Harrich	NULL
,	NULL
L.	NULL
Pearson	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
Gaynor	NULL
.	NULL

1988	NULL
.	NULL

Functional	NULL
domains	NULL
required	NULL
for	NULL
Tat-induced	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7:3143-3147	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
D.	NULL
Harrich	NULL
,	NULL
E.	NULL
Soultanakis	NULL
,	NULL
F.	NULL
Wu	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
Gaynor	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
LTR	NULL
TATA	NULL
and	NULL
TAR	NULL
region	NULL
sequences	NULL
required	NULL
for	NULL
transcriptional	NULL
regulation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:765-778	NULL
.	NULL

Gartner	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
M.	NULL
Markovitz	NULL
,	NULL
R.	NULL
F.	NULL
Markovitz	NULL
,	NULL
M.	NULL
H.	NULL
Kaplan	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
M.	NULL
Popovic	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
role	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
in	NULL
HTLV-IIl/	NULL
LAV	NULL
infection	NULL
.	NULL

Science	NULL
233:215-219	NULL
.	NULL

Gaynor	NULL
,	NULL
R.	NULL
1992	NULL
.	NULL

Cellular	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
.	NULL

AIDS	NULL
6:347-363	NULL
.	NULL

Gazzolo	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
K.	NULL
Mace	NULL
.	NULL

1990	NULL
.	NULL

Regulation	NULL
of	NULL
HIV1	NULL
replication	NULL
in	NULL
promonocytic	NULL
U937	NULL
cells	NULL
.	NULL

Res	NULL
.	NULL

Virol	NULL
.	NULL

141:259-265	NULL
.	NULL

Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
L.	NULL
Baca	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Turpin	NULL
,	NULL
D.	NULL
C.	NULL
Kalter	NULL
,	NULL
B.	NULL
D.	NULL
Hansen	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
R.	NULL
M.	NULL
Friedman	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Meltzer	NULL
.	NULL

1990	NULL
.	NULL

Restriction	NULL
of	NULL
HIV	NULL
replication	NULL
in	NULL
infected	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
by	NULL
interferon-alpha	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
6:1045-1049	NULL
.	NULL

Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
L.	NULL
M.	NULL
Baca	NULL
,	NULL
J.	NULL
Turpin	NULL
,	NULL
D.	NULL
C.	NULL
Kalter	NULL
,	NULL
B.	NULL
Hansen	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
C.	NULL
W.	NULL
Diefenbach	NULL
,	NULL
R.	NULL
M.	NULL
Friedman	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Meltzer	NULL
.	NULL

1990	NULL
.	NULL

Regulation	NULL
of	NULL
HIV	NULL
replication	NULL
in	NULL
infected	NULL
monocytes	NULL
by	NULL
IFN-	NULL
«	NULL
:	NULL
mechanisms	NULL
for	NULL
viral	NULL
restriction	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

145:2669-2676	NULL
.	NULL

Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
R.	NULL
M.	NULL
Friedman	NULL
,	NULL
S.	NULL
Joe	NULL
,	NULL
L.	NULL
M.	NULL
Baca	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Turpin	NULL
,	NULL
G.	NULL
Dveksler	NULL
,	NULL
M.	NULL
S.	NULL
Meltzer	NULL
,	NULL
and	NULL
C.	NULL
Diefenbach	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
selective	NULL
defect	NULL
of	NULL
interferon	NULL
a	NULL
production	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus-infected	NULL
monocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:1433-1442	NULL
.	NULL

Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
M.	NULL
A.	NULL
Martin	NULL
,	NULL
C.	NULL
Ferrua	NULL
,	NULL
R.	NULL
Mitra	NULL
,	NULL
T.	NULL
Phipps	NULL
,	NULL
L.	NULL
A.	NULL
Wahl	NULL
,	NULL
C.	NULL
H.	NULL
Lane	NULL
,	NULL
A.	NULL
S.	NULL
Fauci	NULL
,	NULL
D.	NULL
S.	NULL
Burke	NULL
,	NULL
D.	NULL
Skillman	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Meltzer	NULL
.	NULL

1988	NULL
.	NULL

Efficient	NULL
isolation	NULL
and	NULL
propagation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
on	NULL
recombinant	NULL
colony-stimulating	NULL
factor	NULL
1-treated	NULL
monocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

167:1428-1441	NULL
.	NULL

Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
W.	NULL
Phelps	NULL
,	NULL
L.	NULL
Feigenbaum	NULL
,	NULL
J.	NULL
M.	NULL
Ostrove	NULL
,	NULL
A.	NULL
Adachi	NULL
,	NULL
P.	NULL
M.	NULL
Howley	NULL
,	NULL
G.	NULL
Khoury	NULL
,	NULL
H.	NULL
S.	NULL
Ginsberg	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1986	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
sequence	NULL
by	NULL
DNA	NULL
viruses	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:9759-9763	NULL
.	NULL

Gersoft	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
Malchow-Moller	NULL
,	NULL
I.	NULL
Bygbjyrb	NULL
,	NULL
E.	NULL
Dickmeiss	NULL
,	NULL
C.	NULL
Enk	NULL
,	NULL
J.	NULL
O.	NULL
Nielsen	NULL
,	NULL
H.	NULL
K.	NULL
Thomsen	NULL
,	NULL
J.	NULL
Sindergaard	NULL
,	NULL
and	NULL
I.	NULL
Lorenzen	NULL
.	NULL

1982	NULL
.	NULL

Severe	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
in	NULL
European	NULL
homosexual	NULL
men	NULL
.	NULL

Br	NULL
.	NULL

Med	NULL
.	NULL

J	NULL
.	NULL

285:17-19	NULL
.	NULL

Gessani	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
Puddu	NULL
,	NULL
B.	NULL
Varano	NULL
,	NULL
P.	NULL
Borghi	NULL
,	NULL
L.	NULL
Conti	NULL
,	NULL
L.	NULL
Fantuzzi	NULL
,	NULL
and	NULL
F.	NULL
Belardelli	NULL
.	NULL

1994	NULL
.	NULL

Induction	NULL
of	NULL
beta	NULL
interferon	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
and	NULL
its	NULL
gp120	NULL
protein	NULL
in	NULL
human	NULL
monocytes-macrophages	NULL
:	NULL
role	NULL
of	NULL
beta	NULL
interferon	NULL
in	NULL
restriction	NULL
of	NULL
virus	NULL
replication	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:1983-1986	NULL
.	NULL

Ghosh	NULL
,	NULL
G.	NULL
,	NULL
G.	NULL
Van	NULL
Duyne	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
and	NULL
P.	NULL
Sigler	NULL
.	NULL

1995	NULL
.	NULL

Structure	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
homodimer	NULL
bound	NULL
to	NULL
a	NULL
xB	NULL
site	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
373:303-310	NULL
.	NULL

120a.Giese	NULL
,	NULL
K.	NULL
Personal	NULL
communication	NULL
.	NULL

121	NULL
.	NULL

Giese	NULL
,	NULL
K.	NULL
,	NULL
C.	NULL
Kingsley	NULL
,	NULL
J.	NULL
R.	NULL
Kirshner	NULL
,	NULL
and	NULL
R.	NULL
GrosschedI	NULL
.	NULL

1995	NULL
.	NULL

Assembly	NULL
and	NULL
function	NULL
of	NULL
a	NULL
TCRa	NULL
«	NULL
enhancer	NULL
complex	NULL
is	NULL
dependent	NULL
on	NULL
LEF-1-induced	NULL
DNA	NULL
bending	NULL
and	NULL
multiple	NULL
protein-protein	NULL
interactions	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

9:995-1008	NULL
.	NULL

REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
122	NULL
.	NULL

123	NULL
.	NULL

124	NULL
.	NULL

125	NULL
.	NULL

126	NULL
.	NULL

127	NULL
.	NULL

128	NULL
.	NULL

129	NULL
.	NULL

130	NULL
.	NULL

131	NULL
.	NULL

132	NULL
.	NULL

133	NULL
.	NULL

134	NULL
.	NULL

135	NULL
.	NULL

136	NULL
.	NULL

137	NULL
.	NULL

138	NULL
.	NULL

139	NULL
.	NULL

140	NULL
.	NULL

141	NULL
.	NULL

142	NULL
.	NULL

143	NULL
.	NULL

144	NULL
.	NULL

145	NULL
.	NULL

146	NULL
.	NULL

499	NULL
Gill	NULL
,	NULL
P.	NULL
S.	NULL
1991	NULL
.	NULL

Pathogenesis	NULL
of	NULL
HIV-related	NULL
malignancies	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Oncol	NULL
.	NULL

3:867-871	NULL
.	NULL

Glienke	NULL
,	NULL
W.	NULL
,	NULL
H.	NULL
von	NULL
Briesen	NULL
,	NULL
R.	NULL
Esser	NULL
,	NULL
S.	NULL
Miller	NULL
,	NULL
R.	NULL
Andreesen	NULL
,	NULL
and	NULL
H.	NULL
Riibsamen-Waigmann	NULL
.	NULL

1993	NULL
.	NULL

Expression	NULL
of	NULL
macrophage	NULL
products	NULL
after	NULL
in	NULL
vitro	NULL
infection	NULL
of	NULL
human	NULL
monocytes/macrophages	NULL
with	NULL
HIV	NULL
.	NULL

Res	NULL
.	NULL

Virol	NULL
.	NULL

144:35-40	NULL
.	NULL

Gong	NULL
,	NULL
J.-H.	NULL
,	NULL
H.	NULL
Sprenger	NULL
,	NULL
F.	NULL
Hinder	NULL
,	NULL
A.	NULL
Bender	NULL
,	NULL
A.	NULL
Schmidt	NULL
,	NULL
S.	NULL
Horch	NULL
,	NULL
M.	NULL
Nain	NULL
,	NULL
and	NULL
D.	NULL
Gemsa	NULL
.	NULL

1991	NULL
.	NULL

Influenza	NULL
A	NULL
virus	NULL
infection	NULL
of	NULL
macrophages	NULL
:	NULL
enhanced	NULL
TNFa	NULL
gene	NULL
expression	NULL
and	NULL
LPS-triggered	NULL
TNFa	NULL
release	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

147:3507-3513	NULL
.	NULL

Gorman	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
R.	NULL
Kertzner	NULL
.	NULL

1990	NULL
.	NULL

Psychoncuroimmunology	NULL
and	NULL
HIV	NULL
infection	NULL
.	NULL

J.	NULL
Neuropsychiatry	NULL
2241-251	NULL
.	NULL

Graeble	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
M.	NULL
J.	NULL
Churcher	NULL
,	NULL
A.	NULL
D.	NULL
Lowe	NULL
,	NULL
M.	NULL
J.	NULL
Gait	NULL
,	NULL
and	NULL
J.	NULL
Karn	NULL
.	NULL

1993	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
transactivator	NULL
protein	NULL
,	NULL
tat	NULL
,	NULL
stimulates	NULL
transcriptional	NULL
read-through	NULL
of	NULL
distal	NULL
terminator	NULL
sequences	NULL
in	NULL
vitro	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:6184-6188	NULL
.	NULL

Griffin	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
K.	NULL
Leung	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Activation	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
during	NULL
monocyte	NULL
differentiation	NULL
by	NULL
induction	NULL
of	NULL
NF-xB	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
339:70-73	NULL
.	NULL

Grilli	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
J.-S.	NULL
Chiu	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Lenardo	NULL
.	NULL

1993	NULL
.	NULL

NF-kB	NULL
and	NULL
Rel	NULL
:	NULL
participants	NULL
in	NULL
a	NULL
multiform	NULL
transcriptional	NULL
regulatory	NULL
system	NULL
.	NULL

Int	NULL
.	NULL

Rev	NULL
.	NULL

Cytol	NULL
.	NULL

143:1-62	NULL
.	NULL

Grimm	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
P.	NULL
Baeuerle	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
inducible	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
structure-function	NULL
relationship	NULL
of	NULL
its	NULL
protein	NULL
subunits	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

290:297-308	NULL
.	NULL

Haas	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
G.	NULL
Riethmuller	NULL
,	NULL
and	NULL
H.	NULL
W.	NULL
L.	NULL
Ziegler-Heitbrock	NULL
.	NULL

1987	NULL
.	NULL

Monocyte	NULL
phenotype	NULL
and	NULL
function	NULL
in	NULL
patients	NULL
with	NULL
the	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
and	NULL
AIDS-related	NULL
disorders	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

26:371-379	NULL
.	NULL

Haseltine	NULL
,	NULL
W.	NULL
A	NULL
.	NULL

1991	NULL
.	NULL

Molecular	NULL
biology	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

5:2349-2360	NULL
.	NULL

Haskill	NULL
,	NULL
S.	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Beg	NULL
,	NULL
S.	NULL
M.	NULL
Tompkins	NULL
,	NULL
J.	NULL
S.	NULL
Morris	NULL
,	NULL
A.	NULL
D.	NULL
Yurochko	NULL
,	NULL
A.	NULL
Sampson-Johannes	NULL
,	NULL
K.	NULL
Mondal	NULL
,	NULL
P.	NULL
Ralph	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
1991	NULL
.	NULL

Characterization	NULL
of	NULL
an	NULL
immediate-early	NULL
gene	NULL
induced	NULL
in	NULL
adherent	NULL
monocytes	NULL
that	NULL
encodes	NULL
IxB-like	NULL
activity	NULL
.	NULL

Cell	NULL
65:1281-1289	NULL
.	NULL

Hassan	NULL
,	NULL
N.	NULL
F.	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Douglas	NULL
.	NULL

1990	NULL
.	NULL

Stress-related	NULL
neuroimmunomodu-lation	NULL
of	NULL
monocyte-macrophage	NULL
functions	NULL
in	NULL
HIV-1	NULL
infection	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Immunopathol	NULL
.	NULL

54:220-227	NULL
.	NULL

Hatada	NULL
,	NULL
E.	NULL
N.	NULL
,	NULL
A.	NULL
Nieters	NULL
,	NULL
F.	NULL
G.	NULL
Wulczyn	NULL
,	NULL
M.	NULL
Naumann	NULL
,	NULL
R.	NULL
Meyer	NULL
,	NULL
G.	NULL
Nucifora	NULL
,	NULL
T.	NULL
W.	NULL
McKeithan	NULL
,	NULL
and	NULL
C.	NULL
Scheidereit	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
ankyrin	NULL
repeat	NULL
domains	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
precursor	NULL
p105	NULL
and	NULL
the	NULL
proto-oncogene	NULL
bel-3	NULL
act	NULL
as	NULL
specific	NULL
inhibitors	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:2489-2493	NULL
.	NULL

Hazan	NULL
,	NULL
U.	NULL
,	NULL
D.	NULL
Thomas	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
F.	NULL
Bachelerie	NULL
,	NULL
N.	NULL
Israél	NULL
,	NULL
H.	NULL
Yssel	NULL
,	NULL
J.-L.	NULL
Virelizier	NULL
,	NULL
and	NULL
F.	NULL
Arenzana-Seisdedos	NULL
.	NULL

1990	NULL
.	NULL

Stimulation	NULL
of	NULL
a	NULL
human	NULL
T-cell	NULL
clone	NULL
with	NULL
anti-CD3	NULL
or	NULL
tumor	NULL
necrosis	NULL
factor	NULL
induces	NULL
NF-kappa	NULL
B	NULL
translocation	NULL
but	NULL
not	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
enhancer-dependent	NULL
transcription	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:7861-7865	NULL
.	NULL

Heagy	NULL
,	NULL
W.	NULL
,	NULL
V.	NULL
E.	NULL
Kelley	NULL
,	NULL
T.	NULL
B.	NULL
Strom	NULL
,	NULL
K.	NULL
Mayer	NULL
,	NULL
H.	NULL
M.	NULL
Shapiro	NULL
,	NULL
R.	NULL
Mandel	NULL
,	NULL
and	NULL
R.	NULL
Finberg	NULL
.	NULL

1984	NULL
.	NULL

Decreased	NULL
expression	NULL
of	NULL
human	NULL
class	NULL
II	NULL
antigens	NULL
on	NULL
monocytes	NULL
from	NULL
patients	NULL
with	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
:	NULL
increased	NULL
expression	NULL
with	NULL
interferon-y	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

74:2089-2096	NULL
.	NULL

Heinzinger	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
M.	NULL
I	NULL
Bukrinsky	NULL
,	NULL
S.	NULL
A.	NULL
Haggerty	NULL
,	NULL
A.	NULL
M.	NULL
Ragland	NULL
,	NULL
V.	NULL
Kevalramani	NULL
,	NULL
M.-A	NULL
.	NULL

Lee	NULL
,	NULL
H.	NULL
E.	NULL
Gendelman	NULL
,	NULL
L.	NULL
Ratner	NULL
,	NULL
M.	NULL
Stevenson	NULL
,	NULL
and	NULL
M.	NULL
Emerman	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
Vpr	NULL
protein	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
influences	NULL
nuclear	NULL
localization	NULL
of	NULL
viral	NULL
nucleic	NULL
acids	NULL
in	NULL
nondividing	NULL
host	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:7311-7315	NULL
.	NULL

Henkel	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Machleidt	NULL
,	NULL
I.	NULL
Alkalay	NULL
,	NULL
M.	NULL
Kronke	NULL
,	NULL
Y.	NULL
Ben-Neriah	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1993	NULL
.	NULL

Rapid	NULL
proteolysis	NULL
of	NULL
IxB-	NULL
«	NULL
is	NULL
necessary	NULL
for	NULL
activation	NULL
of	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
365:182-185	NULL
.	NULL

Henkel	NULL
,	NULL
T.	NULL
,	NULL
U.	NULL
Zabel	NULL
,	NULL
K.	NULL
van	NULL
Zee	NULL
,	NULL
J.	NULL
M.	NULL
Miller	NULL
,	NULL
E.	NULL
Fanning	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1992	NULL
.	NULL

Intramolecular	NULL
masking	NULL
of	NULL
the	NULL
nuclear	NULL
location	NULL
signal	NULL
and	NULL
dimerization	NULL
domain	NULL
in	NULL
the	NULL
precursor	NULL
for	NULL
the	NULL
p50	NULL
NF-kB	NULL
subunit	NULL
.	NULL

Cell	NULL
68:1121-1133	NULL
.	NULL

Herrmann	NULL
,	NULL
C.	NULL
P.	NULL
,	NULL
S.	NULL
Kraiss	NULL
,	NULL
and	NULL
M.	NULL
Montenarh	NULL
.	NULL

1991	NULL
.	NULL

Association	NULL
of	NULL
casein	NULL
kinase	NULL
II	NULL
with	NULL
immunopurified	NULL
p53	NULL
.	NULL

Oncogene	NULL
6:877-884	NULL
.	NULL

Ho	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
K.	NULL
L.	NULL
Hartshorn	NULL
,	NULL
T.	NULL
R.	NULL
Rota	NULL
,	NULL
C.	NULL
A.	NULL
Andrews	NULL
,	NULL
J.	NULL
C.	NULL
Kaplan	NULL
,	NULL
R.	NULL
T.	NULL
Schooley	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Hirsch	NULL
.	NULL

1985	NULL
.	NULL

Recombinant	NULL
human	NULL
interferon	NULL
alpha-A	NULL
suppresses	NULL
HTLV-III	NULL
replication	NULL
in	NULL
vitro	NULL
.	NULL

Lancet	NULL
i:602-604	NULL
.	NULL

Ho	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
A.	NULL
U.	NULL
Neumann	NULL
,	NULL
A.	NULL
S.	NULL
Perelson	NULL
,	NULL
W.	NULL
Chen	NULL
,	NULL
J.	NULL
M.	NULL
Leonard	NULL
,	NULL
and	NULL
M.	NULL
Markowitz	NULL
.	NULL

1995	NULL
.	NULL

Rapid	NULL
turnover	NULL
of	NULL
plasma	NULL
virions	NULL
and	NULL
CD4	NULL
lymphocytes	NULL
in	NULL
HIV-1	NULL
infection	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
373:123-126	NULL
.	NULL

Ho	NULL
,	NULL
W.-Z	NULL
.	NULL

,	NULL
R.	NULL
Cherukuri	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Douglas	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
macrophage	NULL
and	NULL
HIV-1	NULL
.	NULL

Immunol	NULL
.	NULL

Ser	NULL
.	NULL

60:569-587	NULL
.	NULL

Hufert	NULL
,	NULL
F.	NULL
T.	NULL
,	NULL
D.	NULL
yon	NULL
Laer	NULL
,	NULL
C.	NULL
Schramm	NULL
,	NULL
A.	NULL
Tarnok	NULL
,	NULL
and	NULL
H.	NULL
Schmitz	NULL
.	NULL

1989	NULL
.	NULL

Detection	NULL
of	NULL
HIV-1	NULL
DNA	NULL
in	NULL
different	NULL
subsets	NULL
of	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
using	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

Arch	NULL
.	NULL

Virol	NULL
.	NULL

106	NULL
:	NULL
341-345	NULL
.	NULL

Hwang	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
T.	NULL
J.	NULL
Boyle	NULL
,	NULL
H.	NULL
K.	NULL
Lyerly	NULL
,	NULL
and	NULL
B.	NULL
R.	NULL
Cullen	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
envelope	NULL
V3	NULL
loop	NULL
as	NULL
the	NULL
primary	NULL
determinant	NULL
of	NULL
cell	NULL
tropism	NULL
in	NULL
HIV-1	NULL
.	NULL

Science	NULL
253:71-74	NULL
.	NULL

Innocenti	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
Ottmann	NULL
,	NULL
P.	NULL
Morand	NULL
,	NULL
P.	NULL
Leclercq	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Seigneurin	NULL
.	NULL

500	NULL
147	NULL
.	NULL

148	NULL
.	NULL

149	NULL
.	NULL

150	NULL
.	NULL

151	NULL
.	NULL

152	NULL
.	NULL

153	NULL
.	NULL

154	NULL
.	NULL

155	NULL
.	NULL

156	NULL
.	NULL

157	NULL
.	NULL

158	NULL
.	NULL

159	NULL
.	NULL

160	NULL
.	NULL

161	NULL
.	NULL

162	NULL
.	NULL

163	NULL
.	NULL

164	NULL
.	NULL

165	NULL
.	NULL

166	NULL
.	NULL

167	NULL
.	NULL

168	NULL
.	NULL

169	NULL
.	NULL

170	NULL
.	NULL

171	NULL
.	NULL

ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

1992	NULL
.	NULL

HIV-1	NULL
in	NULL
blood	NULL
monocytes	NULL
:	NULL
frequency	NULL
of	NULL
detection	NULL
of	NULL
proviral	NULL
DNA	NULL
using	NULL
PCR	NULL
and	NULL
comparison	NULL
with	NULL
the	NULL
total	NULL
CD4	NULL
count	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
8:261-268	NULL
.	NULL

Inoue	NULL
,	NULL
J.	NULL
L	NULL
,	NULL
L.	NULL
D.	NULL
Kerr	NULL
,	NULL
A.	NULL
Kakizuka	NULL
,	NULL
and	NULL
I.	NULL
Verma	NULL
.	NULL

1992	NULL
.	NULL

IxBy	NULL
,	NULL
a	NULL
70	NULL
kd	NULL
protein	NULL
identical	NULL
to	NULL
the	NULL
c-terminal	NULL
half	NULL
of	NULL
p110	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
IxB	NULL
family	NULL
.	NULL

Cell	NULL
68:1109-1120	NULL
.	NULL

Inoue	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
L.	NULL
D.	NULL
Kerr	NULL
,	NULL
L.	NULL
J.	NULL
Ransone	NULL
,	NULL
E.	NULL
Bengal	NULL
,	NULL
T.	NULL
Hunter	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1991.	NULL
c-rel	NULL
activates	NULL
but	NULL
v-rel	NULL
suppresses	NULL
transcription	NULL
from	NULL
B	NULL
sites	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:3715-3719	NULL
.	NULL

Ioachim	NULL
,	NULL
H.	NULL
L.	NULL
1990	NULL
.	NULL

Biopsy	NULL
diagnosis	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
and	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
.	NULL

Arch	NULL
.	NULL

Pathol	NULL
.	NULL

Lab	NULL
.	NULL

Med	NULL
.	NULL

114:284-294	NULL
.	NULL

Ishikawa	NULL
,	NULL
Y.	NULL
,	NULL
N.	NULL
Mukaida	NULL
,	NULL
K.	NULL
Kuno	NULL
,	NULL
N.	NULL
Rice	NULL
,	NULL
S.	NULL
Okamoto	NULL
,	NULL
and	NULL
K.	NULL
Matsu-shima	NULL
.	NULL

1995	NULL
.	NULL

Establishment	NULL
of	NULL
lipopolysaccharide-dependent	NULL
nuclear	NULL
factor	NULL
kappa-B	NULL
activation	NULL
in	NULL
a	NULL
cell-free	NULL
system	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:4158-4164	NULL
.	NULL

Jaffray	NULL
,	NULL
E.	NULL
,	NULL
K.	NULL
M.	NULL
Wood	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Hay	NULL
.	NULL

1995	NULL
.	NULL

Domain	NULL
organization	NULL
of	NULL
IxBa	NULL
«	NULL
and	NULL
the	NULL
sites	NULL
of	NULL
interaction	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2166-2172	NULL
.	NULL

Jin	NULL
,	NULL
Y.	NULL
J.	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Burakoff	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
25-kDa	NULL
FK506-binding	NULL
protein	NULL
is	NULL
localized	NULL
in	NULL
the	NULL
nucleus	NULL
and	NULL
associates	NULL
with	NULL
casein	NULL
kinase	NULL
II	NULL
and	NULL
nucleolin	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:7769-7773	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
J.	NULL
T.	NULL
Kadonaga	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1986	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
AIDS	NULL
retrovirus	NULL
promoter	NULL
by	NULL
the	NULL
cellular	NULL
transcription	NULL
factor	NULL
Spl	NULL
.	NULL

Science	NULL
232:755-759	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
N.	NULL
Duchange	NULL
.	NULL

1988	NULL
.	NULL

Structural	NULL
arrangements	NULL
of	NULL
transcription	NULL
control	NULL
domains	NULL
within	NULL
the	NULL
5	NULL
'	NULL
untranslated	NULL
leader	NULL
regions	NULL
of	NULL
the	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
promoters	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

21101-1114	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1994	NULL
.	NULL

Control	NULL
of	NULL
RNA	NULL
initiation	NULL
and	NULL
elongation	NULL
at	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63:717-743	NULL
.	NULL

Kandil	NULL
,	NULL
O.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Fishman	NULL
,	NULL
H.	NULL
Koziel	NULL
,	NULL
P.	NULL
Pinkston	NULL
,	NULL
R.	NULL
M.	NULL
Rose	NULL
,	NULL
and	NULL
H.	NULL
G.	NULL
Remold	NULL
.	NULL

1994	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
of	NULL
human	NULL
macrophages	NULL
modulates	NULL
the	NULL
cytokine	NULL
response	NULL
to	NULL
Prewmocystis	NULL
carinii	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

62:644-650	NULL
.	NULL

Karpas	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Lowdell	NULL
,	NULL
S.	NULL
K.	NULL
Jacobson	NULL
,	NULL
and	NULL
F.	NULL
Hill	NULL
.	NULL

1992	NULL
.	NULL

Inhibition	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
and	NULL
growth	NULL
of	NULL
infected	NULL
T	NULL
cells	NULL
by	NULL
the	NULL
im-munosuppressive	NULL
drugs	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:8351-8355	NULL
.	NULL

Kasid	NULL
,	NULL
A.	NULL
,	NULL
E.	NULL
P.	NULL
Director	NULL
,	NULL
and	NULL
S.	NULL
A.	NULL
Rosenberg	NULL
.	NULL

1989	NULL
.	NULL

Induction	NULL
of	NULL
endogenous	NULL
cytokine-mRNA	NULL
in	NULL
circulating	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
by	NULL
IL-2	NULL
administration	NULL
to	NULL
cancer	NULL
patients	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143:736-739	NULL
.	NULL

Kato	NULL
,	NULL
H.	NULL
,	NULL
M.	NULL
Horikoshi	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1991	NULL
.	NULL

Repression	NULL
of	NULL
HIV-1	NULL
transcription	NULL
by	NULL
a	NULL
cellular	NULL
protein	NULL
.	NULL

Science	NULL
251:1476-1479	NULL
.	NULL

Kazazi	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
M.	NULL
Mathijs	NULL
,	NULL
J.	NULL
Chang	NULL
,	NULL
P.	NULL
Malafiej	NULL
,	NULL
A.	NULL
Lopez	NULL
,	NULL
D.	NULL
Dowton	NULL
,	NULL
T.	NULL
C.	NULL
Sorrel	NULL
,	NULL
M.	NULL
A.	NULL
Vadas	NULL
,	NULL
and	NULL
A.	NULL
L.	NULL
Cunningham	NULL
.	NULL

1992	NULL
.	NULL

Recombinant	NULL
interleukin	NULL
4	NULL
stimulates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
production	NULL
by	NULL
infected	NULL
monocytes	NULL
and	NULL
macrophages	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

73:941-949	NULL
.	NULL

Kekow	NULL
,	NULL
J.	NULL
,	NULL
W.	NULL
Wachsman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
McCutchan	NULL
,	NULL
M.	NULL
Cronin	NULL
,	NULL
D.	NULL
A.	NULL
Carson	NULL
,	NULL
and	NULL
M.	NULL
Lotz	NULL
.	NULL

1990	NULL
.	NULL

Transforming	NULL
growth	NULL
factor	NULL
beta	NULL
and	NULL
non	NULL
cytopathic	NULL
mechanisms	NULL
of	NULL
immunodeficiency	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:8321-8325	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Kamine	NULL
,	NULL
D.	NULL
Markovitz	NULL
,	NULL
R.	NULL
Fenrrack	NULL
,	NULL
and	NULL
F.	NULL
Pagano	NULL
.	NULL

1988	NULL
.	NULL

An	NULL
Epstein-Barr	NULL
virus	NULL
immediate-early	NULL
gene	NULL
product	NULL
trans-activates	NULL
gene	NULL
expression	NULL
from	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:1652-1656	NULL
.	NULL

Kerr	NULL
,	NULL
L.	NULL
D.	NULL
,	NULL
C.	NULL
S.	NULL
Duckett	NULL
,	NULL
P.	NULL
Wamsley	NULL
,	NULL
Q.	NULL
Zhang	NULL
,	NULL
P.	NULL
Chiao	NULL
,	NULL
G.	NULL
J.	NULL
Nabel	NULL
,	NULL
T.	NULL
W.	NULL
McKeithan	NULL
,	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
proto-oncogene	NULL
BCL-3	NULL
encodes	NULL
an	NULL
IxB	NULL
protein	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

6:2352-2363	NULL
.	NULL

Kerr	NULL
,	NULL
L.	NULL
D.	NULL
,	NULL
J.	NULL
I.	NULL
Inoue	NULL
,	NULL
N.	NULL
Davis	NULL
,	NULL
E.	NULL
Link	NULL
,	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
,	NULL
H.	NULL
R.	NULL
Bose	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
rel-associated	NULL
pp40	NULL
protein	NULL
prevents	NULL
DNA	NULL
binding	NULL
of	NULL
Rel	NULL
and	NULL
NF-xB	NULL
:	NULL
relationship	NULL
with	NULL
IxBB	NULL
and	NULL
regulation	NULL
by	NULL
phosphorylation	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

5:1464-1476	NULL
.	NULL

Kessler	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Mathews	NULL
.	NULL

1992	NULL
.	NULL

Premature	NULL
termination	NULL
and	NULL
processing	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1-promoted	NULL
transcripts	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:4488-4496	NULL
.	NULL

Kieran	NULL
,	NULL
M.	NULL
,	NULL
V.	NULL
Blank	NULL
,	NULL
F.	NULL
Logeat	NULL
,	NULL
J.	NULL
Vandekerckhove	NULL
,	NULL
F.	NULL
Lottspeich	NULL
,	NULL
O	NULL
.	NULL

Le	NULL
Bail	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

Urban	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
,	NULL
and	NULL
A.	NULL
Israél	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
DNA-binding	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
identical	NULL
to	NULL
factor	NULL
KBF1	NULL
and	NULL
homolo-gous	NULL
to	NULL
the	NULL
ref	NULL
oncogene	NULL
product	NULL
.	NULL

Cell	NULL
62:1007-1018	NULL
.	NULL

Kimura	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Kameoka	NULL
,	NULL
and	NULL
K.	NULL
Ikuta	NULL
.	NULL

1993	NULL
.	NULL

Amplification	NULL
of	NULL
superoxide	NULL
anion	NULL
generation	NULL
in	NULL
phagocytic	NULL
cells	NULL
by	NULL
HIV-1	NULL
infection	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

326	NULL
:	NULL
232-236	NULL
.	NULL

Kirkpatrick	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
K.	NULL
C.	NULL
Davis	NULL
,	NULL
and	NULL
C.	NULL
R.	NULL
Horsburgh	NULL
,	NULL
Jr.	NULL
1984	NULL
.	NULL

Reduced	NULL
Ta-positive	NULL
Langerhans	NULL
'	NULL
cells	NULL
in	NULL
AIDS	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

311:857-858	NULL
.	NULL

(	NULL
Let-ter	NULL
.	NULL
)	NULL

Kizaki	NULL
,	NULL
M.	NULL
,	NULL
Y.	NULL
Ikeda	NULL
,	NULL
K.	NULL
J.	NULL
Simon	NULL
,	NULL
M.	NULL
Nanjo	NULL
,	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
.	NULL

1993	NULL
.	NULL

Effect	NULL
of	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
and	NULL
its	NULL
analogs	NULL
on	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
in	NULL
monocytes/macrophages	NULL
.	NULL

Leukemia	NULL
7:1525-1530	NULL
.	NULL

Klatzmann	NULL
,	NULL
D.	NULL
,	NULL
J.	NULL
P.	NULL
Laporte	NULL
,	NULL
A.	NULL
Achour	NULL
,	NULL
E.	NULL
Brisson	NULL
,	NULL
J.	NULL
Gruest	NULL
,	NULL
L.	NULL
Mon-tagnier	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Gluckman	NULL
.	NULL

1986	NULL
.	NULL

Functional	NULL
inhibition	NULL
by	NULL
cyclosporin	NULL
A	NULL
of	NULL
the	NULL
lymphocyte	NULL
receptor	NULL
for	NULL
the	NULL
AIDS	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
.	NULL

C.	NULL
R.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

(	NULL
Paris	NULL
)	NULL
9:343-348	NULL
.	NULL

Kliewer	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Garcia	NULL
,	NULL
I.	NULL
Pearson	NULL
,	NULL
E.	NULL
Soultanakis	NULL
,	NULL
A.	NULL
Dasgupta	NULL
,	NULL
and	NULL
R.	NULL
Gaynor	NULL
.	NULL

1989	NULL
.	NULL

Multiple	NULL
transcriptional	NULL
regulatory	NULL
domains	NULL
in	NULL
the	NULL
human	NULL
172	NULL
.	NULL

173	NULL
.	NULL

174	NULL
.	NULL

175	NULL
.	NULL

176	NULL
.	NULL

177	NULL
.	NULL

178	NULL
.	NULL

179	NULL
.	NULL

180	NULL
.	NULL

181	NULL
.	NULL

182	NULL
.	NULL

183	NULL
.	NULL

184	NULL
.	NULL

185	NULL
.	NULL

186	NULL
.	NULL

187	NULL
.	NULL

188	NULL
.	NULL

189	NULL
.	NULL

190	NULL
.	NULL

191	NULL
.	NULL

192	NULL
.	NULL

193	NULL
.	NULL

194	NULL
.	NULL

195	NULL
.	NULL

196	NULL
.	NULL

MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
are	NULL
involved	NULL
in	NULL
basal	NULL
and	NULL
E1A/E1B-induced	NULL
promoter	NULL
activity	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4616-4625	NULL
.	NULL

Kobayashi	NULL
,	NULL
S.	NULL
,	NULL
Y.	NULL
Hamamoto	NULL
,	NULL
N.	NULL
Kobayashi	NULL
,	NULL
and	NULL
N.	NULL
Yamamoto	NULL
.	NULL

1990	NULL
.	NULL

Serum	NULL
level	NULL
of	NULL
TNFa	NULL
in	NULL
HIV-infected	NULL
individuals	NULL
.	NULL

AIDS	NULL
4:169-170	NULL
.	NULL

Koenig	NULL
,	NULL
S.	NULL
,	NULL
H.	NULL
E.	NULL
Gendelman	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
M.	NULL
C.	NULL
Dal	NULL
Canto	NULL
,	NULL
G.	NULL
H.	NULL
Pezeshkpour	NULL
,	NULL
M.	NULL
Yungbluth	NULL
,	NULL
F.	NULL
Janotta	NULL
,	NULL
A.	NULL
Aksamit	NULL
,	NULL
M.	NULL
A.	NULL
Martin	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1986	NULL
.	NULL

Detection	NULL
of	NULL
AIDS	NULL
virus	NULL
in	NULL
macrophages	NULL
in	NULL
brain	NULL
tissue	NULL
from	NULL
patients	NULL
with	NULL
encephalopathy	NULL
.	NULL

Science	NULL
233:1089-1092	NULL
.	NULL

Koong	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
E.	NULL
Y.	NULL
Chen	NULL
,	NULL
N.	NULL
F.	NULL
Mivechi	NULL
,	NULL
N.	NULL
C.	NULL
Denko	NULL
,	NULL
P.	NULL
Stambrook	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Giaccia	NULL
.	NULL

1994	NULL
.	NULL

Hypoxic	NULL
activation	NULL
of	NULL
nuclear	NULL
factor-	NULL
«	NULL
B	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
Ras	NULL
and	NULL
Raf	NULL
signaling	NULL
pathway	NULL
and	NULL
does	NULL
not	NULL
involve	NULL
MAP	NULL
kinase	NULL
(	NULL
ERK1	NULL
or	NULL
ERK2	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

54:5273-5279	NULL
.	NULL

Kootstra	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
va	NULL
n't	NULL
Wout	NULL
,	NULL
H.	NULL
G.	NULL
Huisman	NULL
,	NULL
F.	NULL
Miedema	NULL
,	NULL
and	NULL
H.	NULL
Schuitemaker	NULL
.	NULL

1994	NULL
.	NULL

Interference	NULL
of	NULL
interleukin-10	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
in	NULL
primary	NULL
monocyte-derived	NULL
macrophages	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:6967-6975	NULL
.	NULL

Kopp	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
S.	NULL
Ghosh	NULL
.	NULL

1994	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-xB	NULL
by	NULL
sodium	NULL
salicylate	NULL
and	NULL
aspirin	NULL
.	NULL

Science	NULL
265:956-959	NULL
.	NULL

Kornbluth	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
P.	NULL
S.	NULL
Oh	NULL
,	NULL
J.	NULL
R.	NULL
Munis	NULL
,	NULL
P.	NULL
H.	NULL
Cleveland	NULL
,	NULL
and	NULL
D.	NULL
D.	NULL
Richman	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
role	NULL
of	NULL
interferons	NULL
in	NULL
the	NULL
control	NULL
of	NULL
HIV	NULL
replication	NULL
in	NULL
macrophages	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Immunopathol	NULL
.	NULL

54:200-219	NULL
.	NULL

Koyanagi	NULL
,	NULL
Y.	NULL
,	NULL
S.	NULL
Miles	NULL
,	NULL
R.	NULL
T.	NULL
Mitsuyasu	NULL
,	NULL
J.	NULL
E.	NULL
Merrill	NULL
,	NULL
H.	NULL
V.	NULL
Vinters	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1987	NULL
.	NULL

Dual	NULL
infection	NULL
of	NULL
the	NULL
central	NULL
nervous	NULL
system	NULL
by	NULL
AIDS	NULL
viruses	NULL
with	NULL
distinct	NULL
cellular	NULL
tropisms	NULL
.	NULL

Science	NULL
236:819-822	NULL
.	NULL

Koyanagi	NULL
,	NULL
Y.	NULL
,	NULL
W.	NULL
A.	NULL
O'Brien	NULL
,	NULL
J.	NULL
Q.	NULL
Zhao	NULL
,	NULL
D.	NULL
W.	NULL
Golde	NULL
,	NULL
J.	NULL
C.	NULL
Gasson	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1988	NULL
.	NULL

Cytokines	NULL
alter	NULL
production	NULL
of	NULL
HIV-1	NULL
from	NULL
primary	NULL
mononuclear	NULL
phagocytes	NULL
.	NULL

Science	NULL
241:1673-1675	NULL
.	NULL

Krasnow	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
L.	NULL
Q.	NULL
Zhang	NULL
,	NULL
K.	NULL
Y.	NULL
Leung	NULL
,	NULL
L.	NULL
Osborn	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1991	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor-alpha	NULL
,	NULL
interleukin	NULL
1	NULL
,	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
are	NULL
independent	NULL
activators	NULL
of	NULL
NF-kappa	NULL
B	NULL
which	NULL
differentially	NULL
activates	NULL
T	NULL
cells	NULL
.	NULL

Cytokine	NULL
3:372-379	NULL
.	NULL

Krek	NULL
,	NULL
W.	NULL
,	NULL
G.	NULL
Maridor	NULL
,	NULL
and	NULL
E.	NULL
A.	NULL
Nigg	NULL
.	NULL

1992	NULL
.	NULL

Casein	NULL
kinase	NULL
II	NULL
is	NULL
a	NULL
predominantly	NULL
nuclear	NULL
enzyme	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

116:43-55	NULL
.	NULL

Krowka	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
D.	NULL
J.	NULL
Moody	NULL
,	NULL
and	NULL
D.	NULL
P.	NULL
Stites	NULL
.	NULL

1989	NULL
.	NULL

Immunological	NULL
effects	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

Immunol	NULL
.	NULL

Ser	NULL
.	NULL

44:257-303	NULL
.	NULL

Kumar	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Hague	NULL
,	NULL
J.	NULL
Lacoste	NULL
,	NULL
J.	NULL
Hiscott	NULL
,	NULL
and	NULL
B.	NULL
R.	NULL
G.	NULL
Williams	NULL
.	NULL

1994	NULL
.	NULL

Double-stranded	NULL
RNA-dependent	NULL
protein	NULL
kinase	NULL
activates	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
phosphorylating	NULL
IxB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:6288-6292	NULL
.	NULL

Kumar	NULL
,	NULL
S.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
and	NULL
C.	NULL
Gélinas	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
RXXRXRXXC	NULL
motif	NULL
conserved	NULL
in	NULL
all	NULL
rel/	NULL
«	NULL
B	NULL
proteins	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
DNA-binding	NULL
activity	NULL
and	NULL
redox	NULL
regulation	NULL
of	NULL
the	NULL
v-re/	NULL
oncoprotein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:3094-3106	NULL
.	NULL

Kunsch	NULL
,	NULL
C.	NULL
,	NULL
S.	NULL
M.	NULL
Ruben	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Rosen	NULL
.	NULL

1992	NULL
.	NULL

Selection	NULL
of	NULL
optimal	NULL
«	NULL
B/Rel	NULL
DNA-binding	NULL
motifs	NULL
:	NULL
interaction	NULL
of	NULL
both	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
with	NULL
DNA	NULL
is	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:4412-4421	NULL
.	NULL

Kuppuswamy	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Subramanian	NULL
,	NULL
A.	NULL
Srinivasan	NULL
,	NULL
and	NULL
G.	NULL
Chinnadurai	NULL
.	NULL

1989	NULL
.	NULL

Multiple	NULL
functional	NULL
domains	NULL
of	NULL
Tat	NULL
,	NULL
the	NULL
trans-activator	NULL
of	NULL
HIV-1	NULL
defined	NULL
by	NULL
mutational	NULL
analysis	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:3551-3561	NULL
.	NULL

Lacoste	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
D'Addario	NULL
,	NULL
A.	NULL
Roulston	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1990	NULL
.	NULL

Cell-specific	NULL
differences	NULL
in	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
regulatory	NULL
elements	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
and	NULL
beta	NULL
interferon	NULL
promoters	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:4726-4734	NULL
.	NULL

Lahdevirta	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
P.	NULL
Maury	NULL
,	NULL
A.	NULL
M.	NULL
Teppo	NULL
,	NULL
and	NULL
H.	NULL
Repo	NULL
.	NULL

1988	NULL
.	NULL

Elevated	NULL
levels	NULL
of	NULL
circulating	NULL
cachetin/tumor	NULL
necrosis	NULL
factor	NULL
in	NULL
patients	NULL
with	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

85:289-295	NULL
.	NULL

Lai	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
T.	NULL
H.	NULL
Tan	NULL
.	NULL

1994	NULL
.	NULL

CD28	NULL
signaling	NULL
causes	NULL
a	NULL
sustained	NULL
downregulation	NULL
of	NULL
IxBa	NULL
which	NULL
can	NULL
be	NULL
prevented	NULL
by	NULL
the	NULL
immunosuppressant	NULL
rapamycin	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:30077-30080	NULL
.	NULL

Lane	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kovacs	NULL
,	NULL
J.	NULL
Feinberg	NULL
,	NULL
B.	NULL
Herpin	NULL
,	NULL
V.	NULL
Davey	NULL
,	NULL
R.	NULL
Walker	NULL
,	NULL
L.	NULL
Deyton	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Metcalf	NULL
,	NULL
M.	NULL
Baseler	NULL
,	NULL
N.	NULL
Sal	NULL
:	NULL
J.	NULL
Manischewitz	NULL
,	NULL
G.	NULL
Quin-nan	NULL
,	NULL
H.	NULL
Masur	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1988	NULL
.	NULL

Antiretroviral	NULL
effects	NULL
of	NULL
interferon-in	NULL
AIDS-associated	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
.	NULL

Lancet	NULL
ii:1218-1222	NULL
.	NULL

Laspia	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
A.	NULL
P.	NULL
Rice	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Mathew	NULL
.	NULL

1989	NULL
.	NULL

HIV-1	NULL
Tat	NULL
protein	NULL
increases	NULL
transcriptional	NULL
initiation	NULL
and	NULL
stabilizes	NULL
elongation	NULL
.	NULL

Cell	NULL
59:283-292	NULL
.	NULL

Lazdins	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
T.	NULL
Klimkait	NULL
,	NULL
K.	NULL
Woods-Cook	NULL
,	NULL
M.	NULL
Walker	NULL
,	NULL
E.	NULL
Alteri	NULL
,	NULL
D.	NULL
Cox	NULL
,	NULL
N.	NULL
Cerletti	NULL
,	NULL
R.	NULL
Shipman	NULL
,	NULL
G.	NULL
Bilbe	NULL
,	NULL
and	NULL
G.	NULL
McMaster	NULL
.	NULL

1991	NULL
.	NULL

In	NULL
vitro	NULL
effect	NULL
of	NULL
transforming	NULL
growth	NULL
factor-B	NULL
on	NULL
progression	NULL
of	NULL
HIV-1	NULL
infection	NULL
in	NULL
primary	NULL
mononuclear	NULL
phagocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

147:1201-1207	NULL
.	NULL

Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
R.	NULL
Schmidt-Ullrich	NULL
,	NULL
and	NULL
A.	NULL
Israél	NULL
.	NULL

1993	NULL
.	NULL

Promoter	NULL
analysis	NULL
of	NULL
the	NULL
gene	NULL
encoding	NULL
the	NULL
I	NULL
«	NULL
Ba/MAD-3	NULL
inhibitor	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
positive	NULL
regulation	NULL
by	NULL
members	NULL
of	NULL
the	NULL
rel/NF-	NULL
«	NULL
B	NULL
family	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:5043-5049	NULL
.	NULL

Lepe-Zuniga	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
P.	NULL
W.	NULL
A.	NULL
Mansell	NULL
,	NULL
and	NULL
E.	NULL
M.	NULL
Hersh	NULL
.	NULL

1987	NULL
.	NULL

Idiopathic	NULL
production	NULL
of	NULL
interleukin-1	NULL
in	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Microbiol	NULL
.	NULL

25:1695-1699	NULL
.	NULL

Levy	NULL
,	NULL
D.	NULL
N.	NULL
,	NULL
L.	NULL
S.	NULL
Fernandes	NULL
,	NULL
W.	NULL
V.	NULL
Williams	NULL
,	NULL
and	NULL
D.	NULL
B.	NULL
Weiner	NULL
.	NULL

1993	NULL
.	NULL

Induction	NULL
of	NULL
cell	NULL
differentiation	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
vpr	NULL
.	NULL

Cell	NULL
72:541-550	NULL
.	NULL

Levy	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

1993	NULL
.	NULL

Pathogenesis	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Microbiol	NULL
.	NULL

Rev	NULL
.	NULL

57:183-289	NULL
.	NULL

Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
197	NULL
.	NULL

198	NULL
.	NULL

199	NULL
.	NULL

200	NULL
.	NULL

201	NULL
.	NULL

202	NULL
.	NULL

203	NULL
.	NULL

204	NULL
.	NULL

205	NULL
.	NULL

206	NULL
.	NULL

207	NULL
.	NULL

208	NULL
.	NULL

209	NULL
.	NULL

210	NULL
.	NULL

211	NULL
.	NULL

212	NULL
.	NULL

213	NULL
.	NULL

214	NULL
.	NULL

215	NULL
.	NULL

216	NULL
.	NULL

217	NULL
.	NULL

218	NULL
.	NULL

219	NULL
.	NULL

220	NULL
.	NULL

221	NULL
.	NULL

222	NULL
.	NULL

Levy	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
A.	NULL
D.	NULL
Hoffman	NULL
,	NULL
S.	NULL
M.	NULL
Kramer	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Landis	NULL
,	NULL
J.	NULL
M.	NULL
Shimabukuro	NULL
,	NULL
and	NULL
L.	NULL
S.	NULL
Oshiro	NULL
.	NULL

1984	NULL
.	NULL

Isolation	NULL
of	NULL
lymphocytopathic	NULL
retroviruses	NULL
from	NULL
San	NULL
Francisco	NULL
patients	NULL
with	NULL
AIDS	NULL
.	NULL

Science	NULL
225:840-842	NULL
.	NULL

Lewis	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
J.	NULL
S.	NULL
Slater	NULL
,	NULL
L.	NULL
I	NULL
Leverone	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Campbell	NULL
.	NULL

1990	NULL
.	NULL

Enhancement	NULL
of	NULL
interleukin-1	NULL
activity	NULL
by	NULL
murine	NULL
cytomegalovirus	NULL
infection	NULL
of	NULL
a	NULL
macrophage	NULL
cell	NULL
line	NULL
.	NULL

Virology	NULL
178:452-460	NULL
.	NULL

Lewis	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
C.	NULL
Reynolds-Kobler	NULL
,	NULL
H.	NULL
E.	NULL
Fox	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Nelson	NULL
.	NULL

1990	NULL
.	NULL

HIV-1	NULL
in	NULL
trophoblastic	NULL
and	NULL
villous	NULL
Hofbauer	NULL
cells	NULL
,	NULL
and	NULL
haematological	NULL
precursors	NULL
in	NULL
cight-week	NULL
fetuses	NULL
.	NULL

Lancet	NULL
335:565-568	NULL
.	NULL

Li	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Sedivy	NULL
.	NULL

1993	NULL
.	NULL

Raf-1	NULL
protein	NULL
kinase	NULL
activates	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factor	NULL
by	NULL
dissociating	NULL
the	NULL
cytoplasmic	NULL
NF-	NULL
«	NULL
B-IxB	NULL
complex	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:9247-9251	NULL
.	NULL

Lin	NULL
,	NULL
A.	NULL
,	NULL
J	NULL
.	NULL

Frost	NULL
,	NULL
T.	NULL
Deng	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
N.	NULL
al-Alawi	NULL
,	NULL
U.	NULL
Kikkawa	NULL
,	NULL
T.	NULL
Hunter	NULL
,	NULL
D.	NULL
Brenner	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1992	NULL
.	NULL

Casein	NULL
kinase	NULL
II	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
c-Jun	NULL
DNA	NULL
binding	NULL
and	NULL
AP-1	NULL
activity	NULL
.	NULL

Cell	NULL
70:777-789	NULL
.	NULL

Lin	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Beauparlant	NULL
,	NULL
C.	NULL
Makris	NULL
,	NULL
S.	NULL
Meloche	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

Phosphorylation	NULL
of	NULL
IxBa	NULL
«	NULL
in	NULL
the	NULL
C-terminal	NULL
PEST	NULL
domain	NULL
by	NULL
casein	NULL
kinase	NULL
II	NULL
Submitted	NULL
for	NULL
publication	NULL
.	NULL

Lin	NULL
,	NULL
R.	NULL
,	NULL
D.	NULL
Gewert	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1995	NULL
.	NULL

Differential	NULL
transcriptional	NULL
activation	NULL
in	NULL
vitro	NULL
by	NULL
NF-	NULL
«	NULL
B/Re	NULL
!	NULL

proteins	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:3123-3131	NULL
.	NULL

Lin	NULL
,	NULL
Y.-C.	NULL
,	NULL
K.	NULL
Brown	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
requires	NULL
proteolysis	NULL
of	NULL
the	NULL
inhibitor	NULL
IxB-	NULL
«	NULL
:	NULL
signal-induced	NULL
phosphorylation	NULL
of	NULL
IxB-a	NULL
alone	NULL
does	NULL
not	NULL
release	NULL
active	NULL
NF-kB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:552-556	NULL
.	NULL

Liou	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1993	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B/rel	NULL
transcription	NULL
factor	NULL
and	NULL
IxB	NULL
inhibitor	NULL
system	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

5:477-487	NULL
.	NULL

Liou	NULL
,	NULL
H.-C.	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
T.	NULL
Fujita	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
precursor	NULL
,	NULL
p105	NULL
,	NULL
contains	NULL
an	NULL
internal	NULL
IxB-like	NULL
inhibitor	NULL
that	NULL
preferentially	NULL
inhibits	NULL
p50	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:3003-3009	NULL
.	NULL

Locardi	NULL
,	NULL
C.	NULL
,	NULL
C.	NULL
Petrini	NULL
,	NULL
G.	NULL
Boccoli	NULL
,	NULL
U.	NULL
Testa	NULL
,	NULL
C.	NULL
Dieffenbach	NULL
,	NULL
S.	NULL
Butto	NULL
,	NULL
and	NULL
F.	NULL
Belardelli	NULL
.	NULL

1990	NULL
.	NULL

Increased	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
expression	NULL
in	NULL
chronically	NULL
infected	NULL
U937	NULL
cells	NULL
upon	NULL
in	NULL
vitro	NULL
differentiation	NULL
by	NULL
hydroxyvitamin	NULL
D	NULL
;	NULL
:	NULL
roles	NULL
of	NULL
interferon	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
in	NULL
regulation	NULL
of	NULL
HIV	NULL
production	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:5874-5882	NULL
.	NULL

Loetscher	NULL
,	NULL
H.	NULL
,	NULL
Y.-C.	NULL
E.	NULL
Pan	NULL
,	NULL
H.-W.	NULL
Lahm	NULL
,	NULL
R.	NULL
Gentz	NULL
,	NULL
M.	NULL
Brockhaus	NULL
,	NULL
H.	NULL
Tabuchi	NULL
,	NULL
and	NULL
W.	NULL
Lesslauer	NULL
.	NULL

1990	NULL
.	NULL

Molecular	NULL
cloning	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
55	NULL
kd	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
.	NULL

Cell	NULL
61:351-359	NULL
.	NULL

Lofquist	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
K.	NULL
Mondal	NULL
,	NULL
J.	NULL
S.	NULL
Morris	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Haskill	NULL
.	NULL

1995	NULL
.	NULL

Tran-scription-independent	NULL
turnover	NULL
of	NULL
IxBa	NULL
during	NULL
monocyte	NULL
adherence	NULL
:	NULL
implications	NULL
for	NULL
a	NULL
translational	NULL
component	NULL
regulating	NULL
IxBo/MAD-3	NULL
mRNA	NULL
levels	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:1737-1746	NULL
.	NULL

Logeat	NULL
,	NULL
F.	NULL
,	NULL
N.	NULL
Israél	NULL
,	NULL
R.	NULL
Ten	NULL
,	NULL
V.	NULL
Blank	NULL
,	NULL
O	NULL
.	NULL

Le	NULL
Bail	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
and	NULL
A.	NULL
Israél	NULL
.	NULL

1991	NULL
.	NULL

Inhibition	NULL
of	NULL
transcription	NULL
factors	NULL
belonging	NULL
to	NULL
the	NULL
rel/NF-	NULL
«	NULL
B	NULL
family	NULL
by	NULL
a	NULL
transdominant	NULL
negative	NULL
mutant	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:1827-1832	NULL
.	NULL

Lu	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Stenzel	NULL
,	NULL
J.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
Haseltine	NULL
.	NULL

1989	NULL
.	NULL

Effects	NULL
of	NULL
long	NULL
terminal	NULL
repeat	NULL
mutations	NULL
on	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:4115-4119	NULL
.	NULL

Lu	NULL
,	NULL
Y.	NULL
C.	NULL
,	NULL
N.	NULL
Touzjian	NULL
,	NULL
M.	NULL
Stenzel	NULL
,	NULL
T.	NULL
Dorfman	NULL
,	NULL
J.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
cis-acting	NULL
repressive	NULL
sequences	NULL
within	NULL
the	NULL
negative	NULL
regulatory	NULL
element	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:5226-5229	NULL
.	NULL

Luban	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
Bossolt	NULL
,	NULL
E.	NULL
K.	NULL
Franke	NULL
,	NULL
S.	NULL
P.	NULL
Kalpana	NULL
,	NULL
and	NULL
S.	NULL
P.	NULL
Goff	NULL
.	NULL

1993	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Gag	NULL
protein	NULL
binds	NULL
to	NULL
cyclophilins	NULL
A	NULL
and	NULL
B	NULL
.	NULL

Cell	NULL
73:1067-1078	NULL
.	NULL

Lusso	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
DeMaria	NULL
,	NULL
M.	NULL
Malnati	NULL
,	NULL
and	NULL
F.	NULL
Lori	NULL
.	NULL

1991	NULL
.	NULL

Induction	NULL
of	NULL
CD4	NULL
and	NULL
susceptibility	NULL
to	NULL
HIV-1	NULL
infection	NULL
in	NULL
human	NULL
CD8+	NULL
T	NULL
lymphocytes	NULL
by	NULL
human	NULL
herpesvirus-6	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
349:533-535	NULL
.	NULL

Lusso	NULL
,	NULL
P.	NULL
,	NULL
B.	NULL
Ensoli	NULL
,	NULL
P.	NULL
D.	NULL
Markham	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
E.	NULL
Tschalchler	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1989	NULL
.	NULL

Productive	NULL
dual	NULL
infection	NULL
of	NULL
human	NULL
CD4+	NULL
T	NULL
lymphocytes	NULL
by	NULL
HIV-1	NULL
and	NULL
HHV-6	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
337:370-373	NULL
.	NULL

Maran	NULL
,	NULL
A.	NULL
,	NULL
R.	NULL
K.	NULL
Maitra	NULL
,	NULL
A.	NULL
Kumar	NULL
,	NULL
B.	NULL
Dong	NULL
,	NULL
W.	NULL
Xiao	NULL
,	NULL
G.	NULL
Li	NULL
,	NULL
B.	NULL
R.	NULL
G.	NULL
Williams	NULL
,	NULL
P.	NULL
Torrence	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Silverman	NULL
.	NULL

1994	NULL
.	NULL

Blockage	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
signalling	NULL
by	NULL
selective	NULL
ablation	NULL
of	NULL
an	NULL
mRNA	NULL
target	NULL
by	NULL
2-5A	NULL
antisense	NULL
chi-meras	NULL
.	NULL

Science	NULL
265:789-792	NULL
.	NULL

Marciniak	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
B.	NULL
J.	NULL
Calnan	NULL
,	NULL
A.	NULL
D.	NULL
Frankel	NULL
,	NULL
and	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
.	NULL

1990	NULL
.	NULL

HIV-1	NULL
Tat	NULL
protein	NULL
trans-activates	NULL
transcription	NULL
in	NULL
vitro	NULL
.	NULL

Cell	NULL
63:791-802	NULL
.	NULL

Marciniak	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
M.	NULL
A.	NULL
Garcia-Blanco	NULL
,	NULL
and	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
HeLa	NULL
nuclear	NULL
protein	NULL
that	NULL
specifically	NULL
binds	NULL
to	NULL
the	NULL
trans-activation-responsive	NULL
TAR	NULL
element	NULL
RNA	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:3624-3628	NULL
.	NULL

Marciniak	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
.	NULL

1991	NULL
.	NULL

HIV-1	NULL
Tat	NULL
protein	NULL
promotes	NULL
formation	NULL
of	NULL
more	NULL
processive	NULL
elongation	NULL
complexes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:4189-4196	NULL
.	NULL

Margolick	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
D.	NULL
J.	NULL
Volkman	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1987	NULL
.	NULL

Amplification	NULL
of	NULL
HTLV-II/LAV	NULL
infection	NULL
by	NULL
antigen-induced	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
direct	NULL
suppression	NULL
by	NULL
virus	NULL
by	NULL
lymphocyte	NULL
blastogenic	NULL
responses	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

138:1719-1724	NULL
.	NULL

Marrich	NULL
,	NULL
D.	NULL
,	NULL
J.	NULL
Garcia	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
Gaynor	NULL
.	NULL

1990	NULL
.	NULL

TAR	NULL
independent	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
phorbol	NULL
ester	NULL
stimulated	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

94417-4423	NULL
.	NULL

Massague	NULL
,	NULL
J	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
transforming	NULL
growth	NULL
factor-beta	NULL
family	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
223	NULL
.	NULL

224	NULL
.	NULL

225	NULL
.	NULL

226	NULL
.	NULL

227	NULL
.	NULL

228	NULL
.	NULL

229	NULL
.	NULL

230	NULL
.	NULL

231	NULL
.	NULL

232	NULL
.	NULL

233	NULL
.	NULL

234	NULL
.	NULL

235	NULL
.	NULL

236	NULL
.	NULL

237	NULL
.	NULL

238	NULL
.	NULL

239	NULL
.	NULL

240	NULL
.	NULL

241	NULL
.	NULL

242	NULL
.	NULL

243	NULL
.	NULL

244	NULL
.	NULL

245	NULL
.	NULL

246	NULL
.	NULL

501	NULL
Cell	NULL
Biol	NULL
.	NULL

6597-641	NULL
.	NULL

Matthews	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
N.	NULL
Wakasugi	NULL
,	NULL
J.-L.	NULL
Virelizier	NULL
,	NULL
J.	NULL
Yodoi	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Hay	NULL
.	NULL

1992	NULL
.	NULL

Thioredoxin	NULL
regulates	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
reduction	NULL
of	NULL
a	NULL
disulphide	NULL
bond	NULL
involving	NULL
cysteine	NULL
62	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

30:3821-3830	NULL
.	NULL

Maury	NULL
,	NULL
C.	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Lahdevirta	NULL
.	NULL

1990	NULL
.	NULL

Correlation	NULL
of	NULL
serum	NULL
cytokine	NULL
levels	NULL
with	NULL
haematological	NULL
abnormalities	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

J.	NULL
Intern	NULL
.	NULL

Med	NULL
.	NULL

227:253-257	NULL
.	NULL

McCune	NULL
,	NULL
J.	NULL
M.	NULL
1991	NULL
.	NULL

HIV-1	NULL
:	NULL
the	NULL
infective	NULL
process	NULL
in	NULL
vivo	NULL
.	NULL

Cell	NULL
64:351-363	NULL
.	NULL

McKeating	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
P.	NULL
D.	NULL
Griffiths	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Weiss	NULL
.	NULL

1990	NULL
.	NULL

HIV	NULL
susceptibility	NULL
conferred	NULL
to	NULL
human	NULL
fibroblasts	NULL
by	NULL
cytomegalovirus-induced	NULL
Fc	NULL
receptor	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
343:659-661	NULL
.	NULL

Meisner	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
M.	NULL
P.	NULL
Czech	NULL
.	NULL

1991	NULL
.	NULL

Phosphorylation	NULL
of	NULL
transcriptional	NULL
factors	NULL
and	NULL
cell-cycle-dependent	NULL
proteins	NULL
by	NULL
casein	NULL
kinase	NULL
IL	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

3:474-483	NULL
.	NULL

Melendez-Guerro	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
J.	NULL
K.	NULL
A.	NULL
Nicholson	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
McDougal	NULL
.	NULL

1990.	NULL
in	NULL
vitro	NULL
infection	NULL
of	NULL
monocytes	NULL
with	NULL
HIVbal	NULL
.	NULL

Effect	NULL
on	NULL
cell	NULL
surface	NULL
expression	NULL
of	NULL
CD4	NULL
,	NULL
CD14	NULL
,	NULL
HLA-DR	NULL
and	NULL
HLA-DQ	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
6:731-741	NULL
.	NULL

Meltzer	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Gendelman	NULL
.	NULL

1992	NULL
.	NULL

Mononuclear	NULL
phagocytes	NULL
as	NULL
targets	NULL
,	NULL
tissue	NULL
reservoirs	NULL
,	NULL
and	NULL
immunoregulatory	NULL
cells	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
disease	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

181:239-263	NULL
.	NULL

Meltzer	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
D.	NULL
R.	NULL
Skillman	NULL
,	NULL
P.	NULL
J.	NULL
Gomatos	NULL
,	NULL
D.	NULL
C.	NULL
Kalter	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Gendelman	NULL
.	NULL

1990	NULL
.	NULL

Role	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8:169-194	NULL
.	NULL

Meltzer	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
D.	NULL
R.	NULL
Skillman	NULL
,	NULL
D.	NULL
L.	NULL
Hoover	NULL
,	NULL
B.	NULL
D.	NULL
Hanson	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Turpin	NULL
,	NULL
D.	NULL
C.	NULL
Kalter	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Gendelman	NULL
.	NULL

1990	NULL
.	NULL

HIV	NULL
and	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
11:217-223	NULL
.	NULL

Mercurio	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
DiDonato	NULL
,	NULL
C.	NULL
Rosette	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1992	NULL
.	NULL

Molecular	NULL
cloning	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
novel	NULL
Rel/NF-	NULL
«	NULL
B	NULL
family	NULL
member	NULL
displaying	NULL
structural	NULL
and	NULL
functional	NULL
homology	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
p50/p105	NULL
.	NULL

DNA	NULL
Cell	NULL
Biol	NULL
.	NULL

11:523-537	NULL
.	NULL

Mercurio	NULL
,	NULL
F.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
DiDonato	NULL
,	NULL
C.	NULL
Rosette	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1993.	NULL
p105	NULL
and	NULL
p98	NULL
precursor	NULL
proteins	NULL
play	NULL
an	NULL
active	NULL
role	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
mediated	NULL
signal	NULL
transduction	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:705-718	NULL
.	NULL

Merrill	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1991	NULL
.	NULL

HIV-1	NULL
,	NULL
macrophages	NULL
,	NULL
glial	NULL
cells	NULL
,	NULL
and	NULL
cytokines	NULL
in	NULL
AIDS	NULL
nervous	NULL
system	NULL
disease	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

5:2391-2397	NULL
.	NULL

Merrill	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Y.	NULL
Koyanagi	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1989	NULL
.	NULL

Interleukin-1	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
can	NULL
be	NULL
induced	NULL
from	NULL
mononuclear	NULL
phagocytes	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
binding	NULL
to	NULL
the	NULL
CD4	NULL
receptor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63	NULL
:	NULL
4404-4408	NULL
.	NULL

Metcalf	NULL
,	NULL
D.	NULL
1989	NULL
.	NULL

The	NULL
molecular	NULL
control	NULL
of	NULL
cell	NULL
division	NULL
,	NULL
differentiation	NULL
,	NULL
commitment	NULL
and	NULL
maturation	NULL
in	NULL
hemopoietic	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
339	NULL
:	NULL
27-30	NULL
.	NULL

Meyer	NULL
,	NULL
R.	NULL
,	NULL
E.	NULL
H.	NULL
Hatada	NULL
,	NULL
H.	NULL
P.	NULL
Hohmann	NULL
,	NULL
M.	NULL
Haiker	NULL
,	NULL
C.	NULL
Bartsch	NULL
,	NULL
U.	NULL
Rothlisberger	NULL
,	NULL
H.	NULL
W.	NULL
Lahm	NULL
,	NULL
E.	NULL
J.	NULL
Schlaeger	NULL
,	NULL
A.	NULL
P.	NULL
G.	NULL
M.	NULL
Van	NULL
Loon	NULL
,	NULL
and	NULL
C.	NULL
Scheidereit	NULL
.	NULL

1991	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
DNA-binding	NULL
subunit	NULL
of	NULL
human	NULL
nuclear	NULL
factor	NULL
xB	NULL
:	NULL
the	NULL
level	NULL
of	NULL
its	NULL
mRNA	NULL
is	NULL
strongly	NULL
regulated	NULL
phorbol	NULL
ester	NULL
or	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:966-970	NULL
.	NULL

Meylan	NULL
,	NULL
P.	NULL
R.	NULL
A.	NULL
,	NULL
J.	NULL
C.	NULL
Guatelli	NULL
,	NULL
J.	NULL
R.	NULL
Munis	NULL
,	NULL
D.	NULL
D.	NULL
Richman	NULL
,	NULL
and	NULL
R.	NULL
S.	NULL
Kornbluth	NULL
.	NULL

1993	NULL
.	NULL

Mechanisms	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
HIV	NULL
replication	NULL
by	NULL
interferons-	NULL
«	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-y	NULL
in	NULL
primary	NULL
human	NULL
macrophages	NULL
.	NULL

Virology	NULL
193	NULL
:	NULL
138-148	NULL
.	NULL

Miedema	NULL
,	NULL
F.	NULL
,	NULL
L.	NULL
Meyaard	NULL
,	NULL
M.	NULL
Koot	NULL
,	NULL
M.	NULL
R.	NULL
Klein	NULL
,	NULL
M.	NULL
T.	NULL
L.	NULL
Roos	NULL
,	NULL
M.	NULL
Groenink	NULL
,	NULL
R.	NULL
A.	NULL
M.	NULL
Fouchier	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
va	NULL
n't	NULL
Wout	NULL
,	NULL
M.	NULL
Tersmette	NULL
,	NULL
P.	NULL
T.	NULL
A.	NULL
Schellekens	NULL
,	NULL
and	NULL
H.	NULL
Schuitemaker	NULL
.	NULL

1994	NULL
.	NULL

Changing	NULL
virus-host	NULL
interactions	NULL
in	NULL
the	NULL
course	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

140:35-72	NULL
.	NULL

Miles	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
Lee	NULL
,	NULL
L.	NULL
Hutlin	NULL
,	NULL
M.	NULL
Zsebo	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Mitsuyasu	NULL
.	NULL

1991	NULL
.	NULL

Potential	NULL
use	NULL
of	NULL
human	NULL
stem	NULL
cell	NULL
factor	NULL
as	NULL
adjunctive	NULL
therapy	NULL
for	NULL
human	NULL
immunodeficiency	NULL
virus-related	NULL
cytopenias	NULL
.	NULL

Blood	NULL
78:3200-3208	NULL
.	NULL

Minty	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Chalon	NULL
,	NULL
J.M	NULL
.	NULL

Derocq	NULL
,	NULL
X.	NULL
Dumont	NULL
,	NULL
J.-C.	NULL
Guillemot	NULL
,	NULL
M.	NULL
Kaghad	NULL
,	NULL
C.	NULL
Labit	NULL
,	NULL
P.	NULL
Leplatois	NULL
,	NULL
P.	NULL
Liauzun	NULL
,	NULL
B.	NULL
Miloux	NULL
,	NULL
C.	NULL
Minty	NULL
,	NULL
P.	NULL
Casel-las	NULL
,	NULL
G.	NULL
Loison	NULL
,	NULL
J.	NULL
Lupker	NULL
,	NULL
D.	NULL
Shire	NULL
,	NULL
P.	NULL
Ferrara	NULL
,	NULL
and	NULL
D.	NULL
Caput	NULL
.	NULL

1993	NULL
.	NULL

Inter-leukin-13	NULL
is	NULL
a	NULL
new	NULL
human	NULL
lymphokine	NULL
regulating	NULL
inflammatory	NULL
and	NULL
immune	NULL
responses	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
362:248-251	NULL
.	NULL

Mitsuyama	NULL
,	NULL
T.	NULL
,	NULL
N.	NULL
Kobayashi	NULL
,	NULL
and	NULL
N.	NULL
Yamamoto	NULL
.	NULL

1991	NULL
.	NULL

Cytokines	NULL
and	NULL
HIV	NULL
infection	NULL
:	NULL
is	NULL
AIDS	NULL
a	NULL
tumor	NULL
necrosis	NULL
factor	NULL
disease	NULL
?	NULL

AIDS	NULL
5:1405-1417	NULL
.	NULL

Molina	NULL
,	NULL
J.-M.	NULL
,	NULL
D.	NULL
T.	NULL
Scadden	NULL
,	NULL
C.	NULL
Amirault	NULL
,	NULL
A.	NULL
Woon	NULL
,	NULL
E.	NULL
Vannier	NULL
,	NULL
A.	NULL
Dinarello	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Groopman	NULL
.	NULL

1990	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
does	NULL
not	NULL
induce	NULL
interleukin-1	NULL
,	NULL
interleukin-6	NULL
,	NULL
or	NULL
tumor	NULL
necrosis	NULL
factor	NULL
in	NULL
mononuclear	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2901-2906	NULL
.	NULL

Molina	NULL
,	NULL
J.-M.	NULL
,	NULL
D.	NULL
T.	NULL
Scadden	NULL
,	NULL
R.	NULL
Burn	NULL
,	NULL
C.	NULL
A.	NULL
Dinarello	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Groopman	NULL
.	NULL

1989	NULL
.	NULL

Production	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
and	NULL
interleukin	NULL
1	NULL
beta	NULL
by	NULL
monocytic	NULL
cells	NULL
infected	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

84:733-737	NULL
.	NULL

Molina	NULL
,	NULL
J.-M.	NULL
,	NULL
R.	NULL
Schindler	NULL
,	NULL
R.	NULL
Ferriani	NULL
,	NULL
M.	NULL
Sakaguchi	NULL
,	NULL
E.	NULL
Vannier	NULL
,	NULL
C.	NULL
A.	NULL
Dinarello	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Groopman	NULL
.	NULL

1990	NULL
.	NULL

Production	NULL
of	NULL
cytokines	NULL
by	NULL
peripheral	NULL
blood	NULL
monocytes/macrophages	NULL
infected	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
.	NULL

J	NULL
.	NULL

Invest	NULL
.	NULL

Dermatol	NULL
.	NULL

161:888-893	NULL
.	NULL

Montaner	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
A.	NULL
G.	NULL
Doyle	NULL
,	NULL
M.	NULL
Collin	NULL
,	NULL
G.	NULL
Herbein	NULL
,	NULL
P.	NULL
Illei	NULL
,	NULL
W.	NULL
James	NULL
,	NULL
A.	NULL
Minty	NULL
,	NULL
D.	NULL
Caput	NULL
,	NULL
P.	NULL
Ferrara	NULL
,	NULL
and	NULL
S.	NULL
Gordon	NULL
.	NULL

1993	NULL
.	NULL

Interleukin	NULL
13	NULL
inhibits	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
production	NULL
in	NULL
primary	NULL
blood-derived	NULL
502	NULL
247	NULL
.	NULL

248	NULL
.	NULL

249	NULL
.	NULL

250	NULL
.	NULL

251	NULL
.	NULL

252	NULL
.	NULL

253	NULL
.	NULL

254	NULL
.	NULL

255	NULL
.	NULL

256	NULL
.	NULL

257	NULL
.	NULL

258	NULL
.	NULL

259	NULL
.	NULL

260	NULL
.	NULL

261	NULL
.	NULL

262	NULL
.	NULL

263	NULL
.	NULL

264	NULL
.	NULL

265	NULL
.	NULL

266	NULL
.	NULL

267	NULL
.	NULL

268	NULL
.	NULL

269	NULL
.	NULL

ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

human	NULL
macrophages	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:743-747	NULL
.	NULL

Mosborg-Petersen	NULL
,	NULL
P.	NULL
,	NULL
F.	NULL
D.	NULL
Toth	NULL
,	NULL
V.	NULL
Zachar	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Villadsen	NULL
,	NULL
N.	NULL
Norskov-Lauritsen	NULL
,	NULL
G.	NULL
Aboagye-Mathiesen	NULL
,	NULL
J.-C.	NULL
Chermann	NULL
,	NULL
and	NULL
P.	NULL
Ebbesen	NULL
.	NULL

1991	NULL
.	NULL

Differential	NULL
HIV	NULL
replication	NULL
and	NULL
HIV-induced	NULL
interferon	NULL
production	NULL
in	NULL
mononuclear	NULL
phagocytes	NULL
:	NULL
relationship	NULL
to	NULL
cell	NULL
maturation	NULL
.	NULL

Res	NULL
.	NULL

Virol	NULL
.	NULL

142	NULL
:	NULL
353-361	NULL
.	NULL

Mosca	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
D.	NULL
P.	NULL
Bednarik	NULL
,	NULL
N.	NULL
B.	NULL
K.	NULL
Raj	NULL
,	NULL
C.	NULL
A.	NULL
Rosen	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
W.	NULL
A.	NULL
Haseltine	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1987	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
can	NULL
reactivate	NULL
transcription	NULL
of	NULL
latent	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
325:67-70	NULL
.	NULL

Moses	NULL
,	NULL
A.	NULL
V.	NULL
,	NULL
C.	NULL
Ibanez	NULL
,	NULL
R.	NULL
Gaynor	NULL
,	NULL
P.	NULL
Ghazal	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Nelson	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
role	NULL
of	NULL
long	NULL
terminal	NULL
repeat	NULL
control	NULL
elements	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
basal	NULL
and	NULL
Tat-mediated	NULL
transcription	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
primary	NULL
human	NULL
macrophages	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:298-307	NULL
.	NULL

Miller	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
F.	NULL
A.	NULL
Rey	NULL
,	NULL
M.	NULL
Sodeoka	NULL
,	NULL
G.	NULL
L.	NULL
Verdine	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Harrison	NULL
.	NULL

1995	NULL
.	NULL

Structure	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
homodimer	NULL
bound	NULL
to	NULL
DNA	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
373:311-317	NULL
.	NULL

Muller	NULL
,	NULL
E.	NULL
,	NULL
B.	NULL
Boldyreff	NULL
,	NULL
and	NULL
K.	NULL
H.	NULL
Scheidtmann	NULL
.	NULL

1993	NULL
.	NULL

Characterization	NULL
of	NULL
protein	NULL
kinase	NULL
activities	NULL
associated	NULL
with	NULL
p53-large-T	NULL
immune	NULL
complexes	NULL
from	NULL
SV40-transformed	NULL
rat	NULL
cells	NULL
.	NULL

Oncogene	NULL
8:2193-2205	NULL
.	NULL

Miiller	NULL
,	NULL
F.	NULL
,	NULL
H.	NULL
Réllag	NULL
,	NULL
and	NULL
S.	NULL
S.	NULL
Froland	NULL
.	NULL

1990	NULL
.	NULL

Reduced	NULL
oxidative	NULL
burst	NULL
responses	NULL
in	NULL
monocytes	NULL
and	NULL
monocyte-derived	NULL
macrophages	NULL
from	NULL
HIV-infected	NULL
subjects	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

82:10-15	NULL
.	NULL

Miller	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
H.	NULL
W.	NULL
L.	NULL
Ziegler-Heitbrock	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1993	NULL
.	NULL

Nuclear	NULL
factor	NULL
kappa	NULL
B	NULL
,	NULL
a	NULL
mediator	NULL
of	NULL
lipopolysaccharide	NULL
effects	NULL
.	NULL

Immunobi-ology	NULL
187:233-256	NULL
.	NULL

Munis	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
D.	NULL
D.	NULL
Richman	NULL
,	NULL
and	NULL
R.	NULL
S.	NULL
Korobluth	NULL
.	NULL

1990	NULL
.	NULL

Human	NULL
immu-nodefficiency	NULL
virus-1	NULL
infection	NULL
of	NULL
macrophages	NULL
in	NULL
vitro	NULL
neither	NULL
induces	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
/cachetin	NULL
gene	NULL
expression	NULL
nor	NULL
alters	NULL
TNF/cachetin	NULL
induction	NULL
by	NULL
lipopolysaccharide	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

85:591-596	NULL
.	NULL

Murray	NULL
,	NULL
H.	NULL
,	NULL
R.	NULL
A.	NULL
Gellene	NULL
,	NULL
D.	NULL
M.	NULL
Libby	NULL
,	NULL
C.	NULL
D.	NULL
Rothermel	NULL
,	NULL
and	NULL
B.	NULL
Y.	NULL
Rubin	NULL
.	NULL

1985	NULL
.	NULL

Activation	NULL
of	NULL
tissue	NULL
macrophages	NULL
from	NULL
AIDS	NULL
patients	NULL
:	NULL
in	NULL
vitro	NULL
response	NULL
of	NULL
AIDS	NULL
alveolar	NULL
macrophages	NULL
to	NULL
lymphokines	NULL
and	NULL
interferon-y	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

135:2374-2377	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

Nain	NULL
,	NULL
M.	NULL
,	NULL
F.	NULL
Hinder	NULL
,	NULL
J.-H.	NULL
Gong	NULL
,	NULL
A.	NULL
Schmidt	NULL
,	NULL
A.	NULL
Bender	NULL
,	NULL
H.	NULL
Sprenger	NULL
,	NULL
and	NULL
D.	NULL
Gemsa	NULL
.	NULL

1990	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
production	NULL
of	NULL
influenza	NULL
A	NULL
virus-infected	NULL
macrophages	NULL
and	NULL
potentiating	NULL
effect	NULL
of	NULL
lipopolysaccharides	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

145:1921-1928	NULL
.	NULL

Nakajima	NULL
,	NULL
K.	NULL
,	NULL
O.	NULL
Martinez-Maza	NULL
,	NULL
T.	NULL
Hirano	NULL
,	NULL
E.	NULL
C.	NULL
Breen	NULL
,	NULL
P.	NULL
G.	NULL
Nishanian	NULL
,	NULL
J.	NULL
F.	NULL
Salazar-Gonzalez	NULL
,	NULL
J.	NULL
L.	NULL
Fahey	NULL
,	NULL
and	NULL
T.	NULL
Kishimoto	NULL
.	NULL

1989	NULL
.	NULL

Induction	NULL
of	NULL
IL-6	NULL
(	NULL
B	NULL
cell	NULL
stimulatory	NULL
factor	NULL
)	NULL
production	NULL
by	NULL
HIV	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:531-536	NULL
.	NULL

Naumann	NULL
,	NULL
M.	NULL
,	NULL
F.	NULL
G.	NULL
Wulczyn	NULL
,	NULL
and	NULL
C.	NULL
Scheidereit	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
NF-kB	NULL
precursor	NULL
p105	NULL
and	NULL
the	NULL
proto-oncogene	NULL
product	NULL
Bel-3	NULL
are	NULL
IxB	NULL
molecules	NULL
and	NULL
control	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:213-222	NULL
.	NULL

Nelson	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
P.	NULL
Ghazal	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Wiley	NULL
.	NULL

1990	NULL
.	NULL

Role	NULL
of	NULL
opportunistic	NULL
infections	NULL
in	NULL
AIDS	NULL
.	NULL

AIDS	NULL
4:1-10	NULL
.	NULL

Nelson	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
J.	NULL
W.	NULL
Gnann	NULL
,	NULL
and	NULL
P.	NULL
Ghazal	NULL
.	NULL

1990	NULL
.	NULL

Regulation	NULL
and	NULL
tissue	NULL
specific	NULL
regulation	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
.	NULL

Curr	NULL
.	NULL

Top	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

154:77-103	NULL
.	NULL

Neri	NULL
,	NULL
A.	NULL
,	NULL
C.-C.	NULL
Chang	NULL
,	NULL
L.	NULL
Lombardi	NULL
,	NULL
M.	NULL
Salina	NULL
,	NULL
P.	NULL
Corradini	NULL
,	NULL
A.	NULL
T.	NULL
Maiolo	NULL
,	NULL
R.	NULL
S.	NULL
K.	NULL
Chaganti	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1991	NULL
.	NULL

B	NULL
cell	NULL
lymphoma-associated	NULL
chromosomal	NULL
translocation	NULL
involves	NULL
candidate	NULL
oncogene	NULL
yt-10	NULL
,	NULL
homolo-gous	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
.	NULL

Cell	NULL
67:1075-1087	NULL
.	NULL

Newman	NULL
,	NULL
G.	NULL
W.	NULL
,	NULL
T.	NULL
G.	NULL
Kelley	NULL
,	NULL
H.	NULL
Gan	NULL
,	NULL
O.	NULL
Kandil	NULL
,	NULL
M.	NULL
J.	NULL
Newman	NULL
,	NULL
P.	NULL
Pinkston	NULL
,	NULL
R.	NULL
M.	NULL
Rose	NULL
,	NULL
and	NULL
H.	NULL
G.	NULL
Remold	NULL
.	NULL

1993	NULL
.	NULL

Concurrent	NULL
infection	NULL
of	NULL
human	NULL
macrophages	NULL
with	NULL
HIV-1	NULL
and	NULL
Mycobacterium	NULL
avium	NULL
results	NULL
in	NULL
decreased	NULL
cell	NULL
viability	NULL
,	NULL
increased	NULL
M.	NULL
evium	NULL
multiplication	NULL
and	NULL
altered	NULL
cytokine	NULL
production	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:2261-2272	NULL
.	NULL

Nielsen	NULL
,	NULL
H.	NULL
,	NULL
A.	NULL
Kharazmi	NULL
,	NULL
and	NULL
V.	NULL
Faber	NULL
.	NULL

1986	NULL
.	NULL

Blood	NULL
monocyte	NULL
and	NULL
neu-trophil	NULL
functions	NULL
in	NULL
the	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:291-296	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
P.	NULL
1994	NULL
.	NULL

NF-AT-AP-1	NULL
and	NULL
Rel-bzip	NULL
:	NULL
hybrid	NULL
vigor	NULL
and	NULL
binding	NULL
under	NULL
the	NULL
influence	NULL
.	NULL

Cell	NULL
77:795-798	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
T.	NULL
Fujita	NULL
,	NULL
K.	NULL
Bhatia	NULL
,	NULL
C.	NULL
Huppi	NULL
,	NULL
H.-C.	NULL
Liou	NULL
,	NULL
M.	NULL
L.	NULL
Scott	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
be/-3	NULL
proto-oncogene	NULL
encodes	NULL
a	NULL
nuclear	NULL
IxB-like	NULL
molecule	NULL
that	NULL
preferentially	NULL
interacts	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
and	NULL
p52	NULL
in	NULL
a	NULL
phos-phorylation-dependent	NULL
manner	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:3557-3566	NULL
.	NULL

Novak	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
T.	NULL
J.	NULL
Holzer	NULL
,	NULL
M.	NULL
M.	NULL
Kennedy	NULL
,	NULL
C.	NULL
A.	NULL
Heynen	NULL
,	NULL
and	NULL
G.	NULL
Dawson	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
interleukin	NULL
4	NULL
(	NULL
BSF-1	NULL
)	NULL
on	NULL
infection	NULL
of	NULL
peripheral	NULL
blood	NULL
monocyte-derived	NULL
macrophages	NULL
with	NULL
HIV-1	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
6:973-976	NULL
.	NULL

O'Brien	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Y.	NULL
Koyanagi	NULL
,	NULL
A.	NULL
Namazie	NULL
,	NULL
J.-Q	NULL
.	NULL

Zhao	NULL
,	NULL
A.	NULL
Diagne	NULL
,	NULL
K.	NULL
Idler	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Zack	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
C.	NULL
Chen	NULL
.	NULL

1990	NULL
.	NULL

HIV-1	NULL
tropism	NULL
for	NULL
mononuclear	NULL
phagocytes	NULL
can	NULL
be	NULL
determined	NULL
by	NULL
regions	NULL
of	NULL
gp120	NULL
outside	NULL
the	NULL
CD4-binding	NULL
domain	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
348:69-73	NULL
.	NULL

O'Brien	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
A.	NULL
Namazi	NULL
,	NULL
H.	NULL
Kalhor	NULL
,	NULL
S.-H.	NULL
Mae	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Zack	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1994	NULL
.	NULL

Kinetics	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
reverse	NULL
270	NULL
.	NULL

271	NULL
.	NULL

272	NULL
.	NULL

273	NULL
.	NULL

274	NULL
.	NULL

275	NULL
.	NULL

276	NULL
.	NULL

277	NULL
.	NULL

278	NULL
.	NULL

279	NULL
.	NULL

280	NULL
.	NULL

281	NULL
.	NULL

282	NULL
.	NULL

283	NULL
.	NULL

284	NULL
.	NULL

285	NULL
.	NULL

286	NULL
.	NULL

287	NULL
.	NULL

288	NULL
.	NULL

289	NULL
.	NULL

290	NULL
.	NULL

291	NULL
.	NULL

292	NULL
.	NULL

293	NULL
.	NULL

MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

transcription	NULL
in	NULL
blood	NULL
mononuclear	NULL
phagocytes	NULL
are	NULL
slowed	NULL
by	NULL
limitations	NULL
of	NULL
nucleotide	NULL
precursors	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:1258-1263	NULL
.	NULL

Ohno	NULL
,	NULL
H.	NULL
,	NULL
G.	NULL
Takimoto	NULL
,	NULL
and	NULL
T.	NULL
W.	NULL
McKeithan	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
candidate	NULL
proto-oncogene	NULL
bel-3	NULL
is	NULL
related	NULL
to	NULL
genes	NULL
implicated	NULL
in	NULL
cell	NULL
lineage	NULL
determination	NULL
and	NULL
cell-cycle	NULL
control	NULL
.	NULL

Cell	NULL
60:991-997	NULL
.	NULL

Okamoto	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Benter	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
M.	NULL
R.	NULL
Sadaie	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1990	NULL
.	NULL

Transcriptional	NULL
activation	NULL
from	NULL
the	NULL
long-terminal	NULL
repeat	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
vitro	NULL
.	NULL

Virology	NULL
177:606-614	NULL
.	NULL

Olafsson	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
S.	NULL
Smith	NULL
,	NULL
P.	NULL
Marshburn	NULL
,	NULL
S.	NULL
G.	NULL
Carter	NULL
,	NULL
and	NULL
S.	NULL
Haskill	NULL
.	NULL

1991	NULL
.	NULL

Variation	NULL
of	NULL
HIV	NULL
infectibility	NULL
of	NULL
macrophages	NULL
as	NULL
a	NULL
function	NULL
of	NULL
donor	NULL
,	NULL
stage	NULL
of	NULL
differentiation	NULL
,	NULL
and	NULL
site	NULL
of	NULL
origin	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

4:154-164	NULL
.	NULL

Oliff	NULL
,	NULL
A	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
role	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
cachetin	NULL
)	NULL
in	NULL
cachexia	NULL
.	NULL

Cell	NULL
54:141-142	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
xB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2336-2340	NULL
.	NULL

Ostrove	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
J.	NULL
Leonard	NULL
,	NULL
K.	NULL
E.	NULL
Weck	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
and	NULL
H.	NULL
E.	NULL
Gendelman	NULL
.	NULL

1987	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
by	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:3726-3732	NULL
.	NULL

Padmanabha	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
L.	NULL
Chen-Wu	NULL
,	NULL
D.	NULL
E.	NULL
Hanna	NULL
,	NULL
and	NULL
C.	NULL
V.	NULL
Glover	NULL
.	NULL

1990	NULL
.	NULL

Isolation	NULL
,	NULL
sequencing	NULL
and	NULL
disruption	NULL
of	NULL
the	NULL
yeast	NULL
CKAZ	NULL
gene	NULL
:	NULL
casein	NULL
kinase	NULL
II	NULL
is	NULL
essential	NULL
for	NULL
viability	NULL
in	NULL
Saccharomyces	NULL
cerevisiae	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:4089-4099	NULL
.	NULL

Palombella	NULL
,	NULL
V.	NULL
J.	NULL
,	NULL
O.	NULL
J.	NULL
Rando	NULL
,	NULL
A.	NULL
L.	NULL
Goldberg	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
ubiquitin-proteosome	NULL
pathway	NULL
is	NULL
required	NULL
for	NULL
processing	NULL
the	NULL
NF-	NULL
«	NULL
B1	NULL
precursor	NULL
protein	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
NF-xB	NULL
.	NULL

Cell	NULL
78:773-785	NULL
.	NULL

Pantaleo	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
Graziosi	NULL
,	NULL
L.	NULL
Butini	NULL
,	NULL
P.	NULL
A.	NULL
Pizzo	NULL
,	NULL
S.	NULL
M.	NULL
Schnittman	NULL
,	NULL
D.	NULL
P.	NULL
Kotler	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1991	NULL
.	NULL

Lymphoid	NULL
organs	NULL
function	NULL
as	NULL
major	NULL
reservoirs	NULL
for	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:9838-9842	NULL
.	NULL

Pantaleo	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
Graziosi	NULL
,	NULL
J.	NULL
F.	NULL
Demarest	NULL
,	NULL
L.	NULL
Butini	NULL
,	NULL
M.	NULL
Montroni	NULL
,	NULL
C.	NULL
H.	NULL
Fox	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
D.	NULL
P.	NULL
Kotler	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1993	NULL
.	NULL

HIV	NULL
infection	NULL
is	NULL
active	NULL
and	NULL
progressive	NULL
in	NULL
lymphoid	NULL
tissue	NULL
during	NULL
clinically	NULL
latent	NULL
stage	NULL
of	NULL
disease	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
362:355-359	NULL
.	NULL

Pantaleo	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
Graziosi	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
role	NULL
of	NULL
lymphoid	NULL
organs	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

Semin	NULL
.	NULL

Immunol	NULL
.	NULL

5:157-163	NULL
.	NULL

Pantaleo	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
Graziosi	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
immunopathogenesis	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

328:327-335	NULL
.	NULL

Parrott	NULL
,	NULL
C.	NULL
,	NULL
T.	NULL
Seidner	NULL
,	NULL
E.	NULL
Dub	NULL
,	NULL
J.	NULL
Leonard	NULL
,	NULL
T.	NULL
S.	NULL
Theodore	NULL
,	NULL
A.	NULL
Buckler-White	NULL
,	NULL
M.	NULL
A.	NULL
Martin	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
.	NULL

1991	NULL
.	NULL

Variable	NULL
role	NULL
of	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
:	NULL
Sp1-binding	NULL
sites	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
replication	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:1414-1419	NULL
.	NULL

Paul	NULL
,	NULL
W.	NULL
E.	NULL
1991	NULL
.	NULL

Interleukin	NULL
4	NULL
:	NULL
a	NULL
prototypic	NULL
immunoregulatory	NULL
lympho-kine	NULL
.	NULL

Blood	NULL
77:1859-1870	NULL
.	NULL

Pautrat	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Suzan	NULL
,	NULL
D.	NULL
Salaun	NULL
,	NULL
P.	NULL
Corbeau	NULL
,	NULL
C.	NULL
Allasia	NULL
,	NULL
G.	NULL
Morel	NULL
,	NULL
and	NULL
P.	NULL
Filippi	NULL
.	NULL

1990	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
of	NULL
U937	NULL
cells	NULL
promotes	NULL
cell	NULL
differentiation	NULL
and	NULL
a	NULL
new	NULL
pathway	NULL
of	NULL
viral	NULL
assembly	NULL
.	NULL

Virology	NULL
179:749-758	NULL
.	NULL

Pauza	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
J.	NULL
Galindo	NULL
,	NULL
and	NULL
D.	NULL
D.	NULL
Richman	NULL
.	NULL

1988	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
of	NULL
monoblastoid	NULL
cells	NULL
:	NULL
cellular	NULL
differentiation	NULL
determines	NULL
the	NULL
pattern	NULL
of	NULL
virus	NULL
replication	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:3558-3564	NULL
.	NULL

Paya	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
R.	NULL
M.	NULL
Ten	NULL
,	NULL
C.	NULL
Bessia	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
R.	NULL
T.	NULL
Hay	NULL
,	NULL
and	NULL
J.-L.	NULL
Virelizier	NULL
.	NULL

1992	NULL
.	NULL

NF-	NULL
«	NULL
kB-dependent	NULL
induction	NULL
of	NULL
the	NULL
NF-kB	NULL
p50	NULL
subunit	NULL
gene	NULL
promoter	NULL
underlies	NULL
self-perpetuation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
transcription	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:7826-7830	NULL
.	NULL

Paya	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
J.-L.	NULL
Virelizier	NULL
,	NULL
and	NULL
S.	NULL
Michelson	NULL
.	NULL

1991	NULL
.	NULL

Modulation	NULL
of	NULL
T-cell	NULL
activation	NULL
through	NULL
protein	NULL
kinase	NULL
C-	NULL
or	NULL
A-dependent	NULL
signalling	NULL
pathways	NULL
synergistically	NULL
increases	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
induction	NULL
by	NULL
cytomegalovirus	NULL
immediate-early	NULL
proteins	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65	NULL
:	NULL
5477-5484	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Agranoff	NULL
,	NULL
C.	NULL
S.	NULL
Duckett	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1994	NULL
.	NULL

Transcription	NULL
factor	NULL
AP-2	NULL
regulates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
gene	NULL
expression	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:6820-6823	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Schmid	NULL
,	NULL
C.	NULL
S.	NULL
Duckett	NULL
,	NULL
K.	NULL
Leung	NULL
,	NULL
N.	NULL
R.	NULL
Rice	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1992	NULL
.	NULL

Distinct	NULL
combinations	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
determine	NULL
the	NULL
specificity	NULL
of	NULL
transcriptional	NULL
activation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:1529-1533	NULL
.	NULL

Perry	NULL
,	NULL
S.	NULL
,	NULL
B.	NULL
Fishman	NULL
,	NULL
L.	NULL
Jacobsberg	NULL
,	NULL
and	NULL
A.	NULL
Frances	NULL
.	NULL

1992	NULL
.	NULL

Relationships	NULL
over	NULL
1	NULL
year	NULL
between	NULL
lymphocyte	NULL
subsets	NULL
and	NULL
psychosocial	NULL
variables	NULL
among	NULL
adults	NULL
with	NULL
infection	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Arch	NULL
.	NULL

Gen.	NULL
Psychiatry	NULL
49:396-401	NULL
.	NULL

Peters	NULL
,	NULL
A.	NULL
,	NULL
F.-S.	NULL
Jager	NULL
,	NULL
A.	NULL
Warneke	NULL
,	NULL
K.	NULL
Muller	NULL
,	NULL
U.	NULL
Brunkborst	NULL
,	NULL
I.	NULL
Schedel	NULL
,	NULL
and	NULL
M.	NULL
Gahr	NULL
.	NULL

1991	NULL
.	NULL

Cytokine	NULL
secretion	NULL
by	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
from	NULL
human	NULL
immunodeficiency	NULL
virus-infected	NULL
patients	NULL
is	NULL
normal	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Immunopathol	NULL
.	NULL

61:343-352	NULL
.	NULL

Peters	NULL
,	NULL
J.-M.	NULL
1994	NULL
.	NULL

Proteasomes	NULL
:	NULL
protein	NULL
degradation	NULL
machines	NULL
of	NULL
the	NULL
cell	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

19:377-382	NULL
.	NULL

Peterson	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
G.	NULL
Gekker	NULL
,	NULL
C.	NULL
C.	NULL
Chao	NULL
,	NULL
S.	NULL
Hu	NULL
,	NULL
C.	NULL
Edelman	NULL
,	NULL
H.	NULL
H.	NULL
Balfour	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
J.	NULL
Verhoef	NULL
.	NULL

1992	NULL
.	NULL

Human	NULL
cytomegalovirus-stimulated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
induce	NULL
HIV-1	NULL
replication	NULL
via	NULL
a	NULL
tumor	NULL
necrosis	NULL
Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
294	NULL
.	NULL

295	NULL
.	NULL

296	NULL
.	NULL

297	NULL
.	NULL

298	NULL
.	NULL

299	NULL
.	NULL

300	NULL
.	NULL

301	NULL
.	NULL

302	NULL
.	NULL

303	NULL
.	NULL

304	NULL
.	NULL

305	NULL
.	NULL

306	NULL
.	NULL

307	NULL
.	NULL

308	NULL
.	NULL

309	NULL
.	NULL

310	NULL
.	NULL

311	NULL
.	NULL

312	NULL
.	NULL

313	NULL
.	NULL

314	NULL
.	NULL

315	NULL
.	NULL

316	NULL
.	NULL

317	NULL
.	NULL

318	NULL
.	NULL

319.	NULL
factor-alpha-mediated	NULL
mechanism	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

89:574-580	NULL
.	NULL

Peterson	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
G.	NULL
Gekker	NULL
,	NULL
C.	NULL
C.	NULL
Chao	NULL
,	NULL
T.	NULL
W.	NULL
Molitor	NULL
,	NULL
and	NULL
H.	NULL
H.	NULL
Balfour	NULL
.	NULL

1991	NULL
.	NULL

Cocaine	NULL
potentiates	NULL
HIV-1	NULL
replication	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
cocultures	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:81-84	NULL
.	NULL

Petit	NULL
,	NULL
A.	NULL
J.	NULL
C.	NULL
,	NULL
F.	NULL
Terpstra	NULL
,	NULL
and	NULL
F.	NULL
Miedema	NULL
.	NULL

1987	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
down-regulates	NULL
HLA	NULL
class	NULL
II	NULL
expression	NULL
and	NULL
induces	NULL
differentiation	NULL
in	NULL
promonocytic	NULL
U937	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

79:1883-1889	NULL
.	NULL

Phillips	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
R.	NULL
Coates	NULL
,	NULL
M.	NULL
Klein	NULL
,	NULL
A.	NULL
Rachlis	NULL
,	NULL
S.	NULL
Read	NULL
,	NULL
F.	NULL
Shepherd	NULL
,	NULL
H.	NULL
Vellend	NULL
,	NULL
S.	NULL
Walmsley	NULL
,	NULL
and	NULL
P.	NULL
Halloran	NULL
.	NULL

1989	NULL
.	NULL

Cyclosporine-induced	NULL
deterioration	NULL
in	NULL
patients	NULL
with	NULL
AIDS	NULL
.	NULL

Can	NULL
.	NULL

Med	NULL
.	NULL

Assoc	NULL
.	NULL

J	NULL
.	NULL

140:1456-1460	NULL
.	NULL

Pinna	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

1990	NULL
.	NULL

Casein	NULL
kinase	NULL
II	NULL
:	NULL
an	NULL
'eminence	NULL
grise	NULL
'	NULL
in	NULL
cellular	NULL
regula-tion	NULL
?	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1054:267-284	NULL
.	NULL

Pise	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
P.	NULL
E.	NULL
Newburger	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Holland	NULL
.	NULL

1992	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1-infected	NULL
HL-60	NULL
cells	NULL
are	NULL
capable	NULL
of	NULL
both	NULL
monocytic	NULL
and	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

73:3257-3261	NULL
.	NULL

Pitha	NULL
,	NULL
P.	NULL
M.	NULL
1991	NULL
.	NULL

Multiple	NULL
effects	NULL
of	NULL
interferon	NULL
on	NULL
HIV-1	NULL
replication	NULL
.	NULL

J.	NULL
Interferon	NULL
Res	NULL
.	NULL

11:313-318	NULL
.	NULL

Plata	NULL
,	NULL
F.	NULL
,	NULL
B.	NULL
Autran	NULL
,	NULL
L.	NULL
P.	NULL
Martins	NULL
,	NULL
S.	NULL
Wain-Hobson	NULL
,	NULL
M.	NULL
Raphael	NULL
,	NULL
C.	NULL
Mayaud	NULL
,	NULL
M.	NULL
Denis	NULL
,	NULL
J.-M.	NULL
Guillon	NULL
,	NULL
and	NULL
P.	NULL
Debre	NULL
.	NULL

1987	NULL
.	NULL

AIDS	NULL
virus	NULL
specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
in	NULL
lung	NULL
disorders	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
328:348-350	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
B.	NULL
Botazzi	NULL
,	NULL
R.	NULL
Acero	NULL
,	NULL
L.	NULL
Bersani	NULL
,	NULL
V.	NULL
Rossi	NULL
,	NULL
M.	NULL
Introna	NULL
,	NULL
A.	NULL
Lazzarin	NULL
,	NULL
M.	NULL
Galli	NULL
,	NULL
and	NULL
A.	NULL
Mantovani	NULL
.	NULL

1985	NULL
.	NULL

Monocyte	NULL
function	NULL
in	NULL
intravenous	NULL
drug	NULL
abusers	NULL
with	NULL
lymphadenopathy	NULL
syndrome	NULL
and	NULL
in	NULL
patients	NULL
with	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
:	NULL
selective	NULL
impairment	NULL
of	NULL
chemotaxis	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

62:136-142	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
E.	NULL
Duh	NULL
,	NULL
W.	NULL
C.	NULL
Timmer	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
J.	NULL
S.	NULL
Justement	NULL
,	NULL
S.	NULL
Stanley	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1990	NULL
.	NULL

Interleukin	NULL
6	NULL
induces	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
expression	NULL
in	NULL
infected	NULL
monocytic	NULL
cells	NULL
alone	NULL
and	NULL
in	NULL
synergy	NULL
with	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
by	NULL
transcriptional	NULL
and	NULL
post-transcrip-tional	NULL
mechanisms	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:151-158	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
cytokines	NULL
and	NULL
pharmacologic	NULL
agents	NULL
on	NULL
chronic	NULL
HIV	NULL
infection	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
8:191-207	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
role	NULL
of	NULL
monocyte/macrophages	NULL
and	NULL
cytokines	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

Pathobiology	NULL
60:246-251	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1993	NULL
.	NULL

Cytokine	NULL
modulation	NULL
of	NULL
HIV	NULL
expression	NULL
.	NULL

Semin	NULL
.	NULL

Immunol	NULL
.	NULL

5:165-173	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
J.	NULL
S.	NULL
Justement	NULL
,	NULL
J.	NULL
H.	NULL
Kebrl	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
S.	NULL
Stanley	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1990	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
functions	NULL
in	NULL
an	NULL
autocrine	NULL
manner	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
expression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:782-785	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
L.	NULL
Kinter	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1994	NULL
.	NULL

Interleukin	NULL
1	NULL
induces	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
alone	NULL
and	NULL
in	NULL
synergy	NULL
with	NULL
interleukin	NULL
6	NULL
in	NULL
chronically	NULL
infected	NULL
U1	NULL
cells	NULL
:	NULL
inhibition	NULL
of	NULL
inductive	NULL
effects	NULL
by	NULL
the	NULL
interleukin	NULL
1	NULL
receptor	NULL
antagonist	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:108-112	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
L.	NULL
Kinter	NULL
,	NULL
J.	NULL
S.	NULL
Justement	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
J.	NULL
H.	NULL
Kehrl	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1991	NULL
.	NULL

Transforming	NULL
growth	NULL
factor	NULL
B	NULL
suppresses	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
expression	NULL
and	NULL
replication	NULL
in	NULL
infected	NULL
cells	NULL
of	NULL
the	NULL
monocyte/	NULL
macrophage	NULL
lincage	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

173:589-597	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1989	NULL
.	NULL

Interferon-	NULL
«	NULL
but	NULL
not	NULL
AZT	NULL
suppresses	NULL
HIV	NULL
expression	NULL
in	NULL
chronically	NULL
infected	NULL
cell	NULL
lines	NULL
.	NULL

Science	NULL
244:575-577	NULL
.	NULL

Pomerantz	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
M.	NULL
B.	NULL
Feinberg	NULL
,	NULL
D.	NULL
Trono	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

Lipopolysaccharide	NULL
is	NULL
a	NULL
potent	NULL
monocyte/macrophage-specific	NULL
stimulator	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
expression	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:253-262	NULL
.	NULL

Pugh	NULL
,	NULL
B.	NULL
F.	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1992	NULL
.	NULL

Diverse	NULL
transcriptional	NULL
functions	NULL
of	NULL
the	NULL
multisubunit	NULL
eukaryotic	NULL
TFIID	NULL
complexes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:679-682	NULL
.	NULL

Ratnasabapathy	NULL
,	NULL
R.	NULL
,	NULL
M.	NULL
Sheldon	NULL
,	NULL
L.	NULL
Johal	NULL
,	NULL
and	NULL
N.	NULL
Hernandez	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
contains	NULL
an	NULL
unusual	NULL
element	NULL
that	NULL
induces	NULL
the	NULL
synthesis	NULL
of	NULL
short	NULL
RNAs	NULL
from	NULL
various	NULL
mRNA	NULL
and	NULL
snRNA	NULL
promoters	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

42061-2074	NULL
.	NULL

Ray	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
K.	NULL
E.	NULL
Prefontaine	NULL
.	NULL

1994	NULL
.	NULL

Physical	NULL
association	NULL
and	NULL
functional	NULL
antagonism	NULL
between	NULL
the	NULL
p65	NULL
subunit	NULL
of	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:752-756	NULL
.	NULL

Raziuddin	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Mikovits	NULL
,	NULL
L	NULL
Calvert	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
H.-F.	NULL
Kung	NULL
,	NULL
and	NULL
F.	NULL
W.	NULL
Ruscetti	NULL
.	NULL

1991	NULL
.	NULL

Negative	NULL
regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
expression	NULL
in	NULL
monocytes	NULL
:	NULL
role	NULL
of	NULL
the	NULL
65-kDa	NULL
plus	NULL
50-kDa	NULL
NF-kB	NULL
dimer	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:9426-9430	NULL
.	NULL

Reddy	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
and	NULL
P.	NULL
Dasgupta	NULL
.	NULL

1992	NULL
.	NULL

Regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
by	NULL
cellular	NULL
transcription	NULL
factors	NULL
.	NULL

Pathobiology	NULL
60:219-224	NULL
.	NULL

Reuben	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
B.	NULL
Goni	NULL
,	NULL
S.	NULL
Li	NULL
,	NULL
L.	NULL
Loo	NULL
,	NULL
and	NULL
J.	NULL
Turbin	NULL
.	NULL

1991	NULL
.	NULL

Induction	NULL
of	NULL
cytokines	NULL
in	NULL
normal	NULL
placental	NULL
cells	NULL
by	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Lymphokine	NULL
Cytokine	NULL
Res	NULL
.	NULL

10:195-199	NULL
.	NULL

Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
and	NULL
M.	NULL
K.	NULL
Ernst	NULL
.	NULL

1993	NULL
.	NULL

/n	NULL
vivo	NULL
control	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
IxBa	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:4685-4695	NULL
.	NULL

Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
M.	NULL
L.	NULL
MacKichan	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
precursor	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
has	NULL
IxB-like	NULL
functions	NULL
.	NULL

Cell	NULL
71:243-253	NULL
.	NULL

Rich	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
I	NULL
S.	NULL
Y.	NULL
Chen	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Zack	NULL
,	NULL
M.	NULL
L.	NULL
Leonard	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
O'Brien	NULL
.	NULL

1992	NULL
.	NULL

Increased	NULL
susceptibility	NULL
of	NULL
differentiated	NULL
mononuclear	NULL
phagocytes	NULL
to	NULL
productive	NULL
infection	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
(	NULL
HIV-1	NULL
)	NULL
.	NULL

J	NULL
.	NULL

REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
320	NULL
.	NULL

321	NULL
.	NULL

322	NULL
.	NULL

323	NULL
.	NULL

324	NULL
.	NULL

325	NULL
.	NULL

326	NULL
.	NULL

327	NULL
.	NULL

328	NULL
.	NULL

329	NULL
.	NULL

330	NULL
.	NULL

331	NULL
.	NULL

332	NULL
.	NULL

333	NULL
.	NULL

334	NULL
.	NULL

335	NULL
.	NULL

336	NULL
.	NULL

337	NULL
.	NULL

338	NULL
.	NULL

339	NULL
.	NULL

340	NULL
.	NULL

341	NULL
.	NULL

342	NULL
.	NULL

343	NULL
.	NULL

344	NULL
.	NULL

503	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

89:176-183	NULL
.	NULL

Rieckmann	NULL
,	NULL
P.	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
J.	NULL
H.	NULL
Kehrl	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1991	NULL
.	NULL

Activated	NULL
B	NULL
lymphocytes	NULL
from	NULL
human	NULL
immunodeficiency	NULL
virus-infected	NULL
individuals	NULL
induce	NULL
virus	NULL
expression	NULL
in	NULL
infected	NULL
T	NULL
cells	NULL
and	NULL
a	NULL
promonocytic	NULL
cell	NULL
line	NULL
,	NULL
U1	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

173:1-5	NULL
.	NULL

Riviere	NULL
,	NULL
Y.	NULL
,	NULL
V.	NULL
Blank	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1991	NULL
.	NULL

Processing	NULL
of	NULL
the	NULL
precursor	NULL
of	NULL
NF-kB	NULL
by	NULL
the	NULL
HIV-1	NULL
protease	NULL
during	NULL
acute	NULL
infection	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
350:625-626	NULL
.	NULL

Robbins	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
Y.	NULL
Shirazi	NULL
,	NULL
B.	NULL
E.	NULL
Drysdale	NULL
,	NULL
A.	NULL
Lieberman	NULL
,	NULL
H.	NULL
S.	NULL
Shin	NULL
,	NULL
and	NULL
M.	NULL
L.	NULL
Shin	NULL
.	NULL

1987	NULL
.	NULL

Production	NULL
of	NULL
cytotoxic	NULL
factors	NULL
for	NULL
oligodendrocytes	NULL
by	NULL
stimulated	NULL
astrocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

139:2593-2597	NULL
.	NULL

Rodrigues	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
I.	NULL
Michalopoulos	NULL
,	NULL
F.	NULL
Arenzana-Seisdedos	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Hay	NULL
.	NULL

1995	NULL
.	NULL

Inducible	NULL
degradation	NULL
of	NULL
IxBa	NULL
:	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
requires	NULL
the	NULL
acidic	NULL
C-terminal	NULL
domain	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2413-2419	NULL
.	NULL

Rogers	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
Wells	NULL
,	NULL
and	NULL
M.	NULL
Rechsteiner	NULL
.	NULL

1986	NULL
.	NULL

Amino	NULL
acid	NULL
sequences	NULL
common	NULL
to	NULL
rapidly	NULL
degraded	NULL
proteins	NULL
:	NULL
the	NULL
PEST	NULL
hypothesis	NULL
.	NULL

Science	NULL
234	NULL
:	NULL
364-368	NULL
.	NULL

Rosenberg	NULL
,	NULL
Z.	NULL
F.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1990	NULL
.	NULL

Immunopathogenic	NULL
mechanisms	NULL
of	NULL
HIV	NULL
infection	NULL
:	NULL
cytokine	NULL
induction	NULL
of	NULL
HIV	NULL
expression	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
11:176-180	NULL
.	NULL

Rosenberg	NULL
,	NULL
Z.	NULL
F.	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1991	NULL
.	NULL

Immunopathogenesis	NULL
of	NULL
HIV	NULL
infection	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

5:2382-2390	NULL
.	NULL

Rossol	NULL
,	NULL
S.	NULL
,	NULL
G.	NULL
Gianni	NULL
,	NULL
R.	NULL
Rossol-Voth	NULL
,	NULL
H.	NULL
Gallati	NULL
,	NULL
W.	NULL
E.	NULL
G.	NULL
Miller	NULL
,	NULL
and	NULL
K.-H.	NULL
Meyer	NULL
zum	NULL
Biischenfelde	NULL
.	NULL

1992	NULL
.	NULL

Cytokine-mediated	NULL
regulation	NULL
of	NULL
monocyte/macrophage	NULL
cytotoxicity	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
infection	NULL
.	NULL

Med	NULL
.	NULL

Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

181:267-281	NULL
.	NULL

Roulston	NULL
,	NULL
A	NULL
.	NULL

Unpublished	NULL
results	NULL
.	NULL

Roulston	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Beauparlant	NULL
,	NULL
N.	NULL
R.	NULL
Rice	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1993	NULL
.	NULL

Chronic	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
stimulates	NULL
distinct	NULL
NF-	NULL
«	NULL
B/	NULL
rel	NULL
DNA-binding	NULL
activities	NULL
in	NULL
myelomonoblastic	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:5235-5246	NULL
.	NULL

Roulston	NULL
,	NULL
A.	NULL
,	NULL
L.	NULL
Conti	NULL
,	NULL
V.	NULL
McKiel	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1994	NULL
.	NULL

Virus	NULL
induction	NULL
of	NULL
NF-xB/rel	NULL
proteins	NULL
and	NULL
type	NULL
1	NULL
interferon	NULL
gene	NULL
expression	NULL
in	NULL
myelomonoblastic	NULL
cells	NULL
.	NULL

Leukemia	NULL
8:8170-	NULL
$	NULL
174	NULL
.	NULL

Roulston	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
D'Addario	NULL
,	NULL
F.	NULL
Boulerice	NULL
,	NULL
S.	NULL
Caplan	NULL
,	NULL
M.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1992	NULL
.	NULL

Induction	NULL
of	NULL
monocytic	NULL
differentiation	NULL
and	NULL
NF-	NULL
«	NULL
B-like	NULL
activities	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus-1	NULL
infection	NULL
of	NULL
human	NULL
myelomonoblastic	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:751-763	NULL
.	NULL

Roux-Lombard	NULL
,	NULL
P.	NULL
,	NULL
D.	NULL
Aladjem	NULL
,	NULL
J.-F.	NULL
Balavoine	NULL
,	NULL
M.	NULL
Chofflon	NULL
,	NULL
J.-P.	NULL
Despont	NULL
,	NULL
B.	NULL
Hirschel	NULL
,	NULL
M.	NULL
Jeannet	NULL
,	NULL
Y.	NULL
Kapanci	NULL
,	NULL
R.	NULL
Lang	NULL
,	NULL
M.-F.	NULL
Toccanier	NULL
,	NULL
B.	NULL
Voinier	NULL
,	NULL
A.	NULL
Wilhelm	NULL
,	NULL
J.-M.	NULL
Dayer	NULL
,	NULL
and	NULL
A.	NULL
Cruchaud	NULL
.	NULL

1986	NULL
.	NULL

Altered	NULL
functions	NULL
of	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
in	NULL
homosexual	NULL
males	NULL
and	NULL
intravenous	NULL
drug	NULL
users	NULL
with	NULL
persistent	NULL
generalized	NULL
lymphadenopathy	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

16:262-270	NULL
.	NULL

Roy	NULL
,	NULL
G.	NULL
,	NULL
N.	NULL
Rojo	NULL
,	NULL
and	NULL
F.	NULL
Leyya-Cobian	NULL
.	NULL

1987	NULL
.	NULL

Phenotypic	NULL
changes	NULL
in	NULL
monocytes	NULL
and	NULL
alveolar	NULL
macrophages	NULL
in	NULL
patients	NULL
with	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
(	NULL
AIDS	NULL
)	NULL
and	NULL
AIDS-related	NULL
complex	NULL
(	NULL
ARC	NULL
)	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Lab	NULL
.	NULL

Immunol	NULL
.	NULL

23:135-141	NULL
.	NULL

Roy	NULL
,	NULL
S.	NULL
,	NULL
U.	NULL
Delling	NULL
,	NULL
C.-H.	NULL
Chen	NULL
,	NULL
C.	NULL
A.	NULL
Rosen	NULL
,	NULL
and	NULL
N.	NULL
Sonenberg	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
bulge	NULL
structure	NULL
in	NULL
HIV-1	NULL
TAR	NULL
RNA	NULL
is	NULL
required	NULL
for	NULL
Tat	NULL
binding	NULL
and	NULL
Tat-mediated	NULL
frans-activation	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:1365-1373	NULL
.	NULL

Roy	NULL
,	NULL
S.	NULL
,	NULL
N.	NULL
T.	NULL
Parkin	NULL
,	NULL
C.	NULL
Rosen	NULL
,	NULL
J.	NULL
Itovitch	NULL
,	NULL
and	NULL
N.	NULL
Sonenberg	NULL
.	NULL

1990	NULL
.	NULL

Structural	NULL
requirement	NULL
for	NULL
trans-activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat-directed	NULL
gene	NULL
expression	NULL
by	NULL
Tat	NULL
:	NULL
importance	NULL
of	NULL
base	NULL
pairing	NULL
,	NULL
loop	NULL
sequence	NULL
,	NULL
and	NULL
bulge	NULL
in	NULL
the	NULL
Tat-responsive	NULL
sequence	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1402-1406	NULL
.	NULL

Roy	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Wainberg	NULL
.	NULL

1988	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
mononuclear	NULL
phagocyte	NULL
system	NULL
in	NULL
the	NULL
development	NULL
of	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
(	NULL
AIDS	NULL
)	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

43:91-97	NULL
.	NULL

Ruben	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
Perkins	NULL
,	NULL
K.	NULL
Purcell	NULL
,	NULL
K.	NULL
Joung	NULL
,	NULL
R.	NULL
Sia	NULL
,	NULL
R.	NULL
Burghoff	NULL
,	NULL
W.	NULL
A.	NULL
Haseltine	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Rosen	NULL
.	NULL

1989	NULL
.	NULL

Structural	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
tat	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:1-8	NULL
.	NULL

Ruben	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
J.	NULL
F.	NULL
Klement	NULL
,	NULL
T.	NULL
A.	NULL
Coleman	NULL
,	NULL
M.	NULL
Maber	NULL
,	NULL
C.-H.	NULL
Chen	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Rosen	NULL
.	NULL

1992	NULL
.	NULL

I-Rel	NULL
:	NULL
a	NULL
novel	NULL
re/-related	NULL
protein	NULL
that	NULL
inhibits	NULL
NF-	NULL
«	NULL
B	NULL
transcriptional	NULL
activity	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

6:745-760	NULL
.	NULL

Salahuddin	NULL
,	NULL
S.	NULL
Z.	NULL
,	NULL
R.	NULL
M.	NULL
Rose	NULL
,	NULL
J.	NULL
E.	NULL
Groopman	NULL
,	NULL
P.	NULL
D.	NULL
Markham	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1986	NULL
.	NULL

Human	NULL
T-lymphotrophic	NULL
virus	NULL
type	NULL
III	NULL
infection	NULL
of	NULL
human	NULL
alveolar	NULL
macrophages	NULL
.	NULL

Blood	NULL
68:281-284	NULL
.	NULL

Samuel	NULL
,	NULL
C.	NULL
E.	NULL
1991	NULL
.	NULL

Antiviral	NULL
actions	NULL
of	NULL
interferon	NULL
:	NULL
interferon-regulated	NULL
cellular	NULL
proteins	NULL
and	NULL
their	NULL
surprisingly	NULL
selective	NULL
antiviral	NULL
activities	NULL
.	NULL

Virology	NULL
183:1-11	NULL
.	NULL

Samuel	NULL
,	NULL
C.	NULL
E.	NULL
1993	NULL
.	NULL

The	NULL
eIF-2	NULL
«	NULL
protein	NULL
kinases	NULL
,	NULL
regulators	NULL
of	NULL
translation	NULL
in	NULL
cukaryotes	NULL
from	NULL
yeasts	NULL
to	NULL
humans	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:7603-7606	NULL
.	NULL

Scadden	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
L.	NULL
I.	NULL
Zon	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Groopman	NULL
.	NULL

1989	NULL
.	NULL

Pathophysiology	NULL
and	NULL
management	NULL
of	NULL
HIV-associated	NULL
hematologic	NULL
disorders	NULL
.	NULL

Blood	NULL
74:1455-1463	NULL
.	NULL

Schmitz	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
p65	NULL
subunit	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
strong	NULL
transcription	NULL
activating	NULL
potential	NULL
of	NULL
NF-kB	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:3805-3817	NULL
.	NULL

Schreck	NULL
,	NULL
R.	NULL
,	NULL
K.	NULL
Albermann	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1992	NULL
.	NULL

Nuclear	NULL
factor	NULL
kappa	NULL
B	NULL
:	NULL
an	NULL
oxidative	NULL
stress-responsive	NULL
transcription	NULL
factor	NULL
of	NULL
eukaryotic	NULL
cells	NULL
(	NULL
a	NULL
review	NULL
)	NULL
.	NULL

Free	NULL
Radical	NULL
Res	NULL
.	NULL

Commun	NULL
.	NULL

17:221-237	NULL
.	NULL

504	NULL
345	NULL
.	NULL

346	NULL
.	NULL

347	NULL
.	NULL

348	NULL
.	NULL

349	NULL
.	NULL

350	NULL
.	NULL

351	NULL
.	NULL

352	NULL
.	NULL

353	NULL
.	NULL

354	NULL
.	NULL

355	NULL
.	NULL

356	NULL
.	NULL

357	NULL
.	NULL

358	NULL
.	NULL

359	NULL
.	NULL

360	NULL
.	NULL

361	NULL
.	NULL

362	NULL
.	NULL

363	NULL
.	NULL

364	NULL
.	NULL

365	NULL
.	NULL

366	NULL
.	NULL

367	NULL
.	NULL

368	NULL
.	NULL

369	NULL
.	NULL

ROULSTON	NULL
ET	NULL
AL	NULL
.	NULL

Schrier	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
A.	NULL
McCutchan	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Wiley	NULL
.	NULL

1993	NULL
.	NULL

Mechanisms	NULL
of	NULL
immune	NULL
activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
monocytes/macrophages	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:5713-5720	NULL
.	NULL

Schrier	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
McCutchan	NULL
,	NULL
J.	NULL
C.	NULL
Venable	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Nelson	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Wiley	NULL
.	NULL

1990	NULL
.	NULL

T-cell-induced	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
macrophages	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:3280-3288	NULL
.	NULL

Schuitemaker	NULL
,	NULL
H.	NULL
1994	NULL
.	NULL

Macrophage	NULL
tropic	NULL
HIV-1	NULL
variants	NULL
:	NULL
initiators	NULL
of	NULL
infection	NULL
and	NULL
AIDS	NULL
pathogenesis	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

56:218-224	NULL
.	NULL

Schuitemaker	NULL
,	NULL
H.	NULL
,	NULL
N.	NULL
A.	NULL
Kootstra	NULL
,	NULL
R.	NULL
A.	NULL
M.	NULL
Fouchier	NULL
,	NULL
B.	NULL
Hooibrink	NULL
,	NULL
and	NULL
F.	NULL
Miedema	NULL
.	NULL

1994	NULL
.	NULL

Productive	NULL
HIV-1	NULL
infection	NULL
of	NULL
macrophages	NULL
restricted	NULL
to	NULL
the	NULL
cell	NULL
fraction	NULL
with	NULL
proliferative	NULL
capacity	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:5929-5936	NULL
.	NULL

Schuitemaker	NULL
,	NULL
H.	NULL
,	NULL
N.	NULL
A.	NULL
Kootstra	NULL
,	NULL
M.	NULL
H.	NULL
Koppelman	NULL
,	NULL
S.	NULL
M.	NULL
Bruisten	NULL
,	NULL
H.	NULL
G.	NULL
Hui	NULL
M.	NULL
Tersmette	NULL
,	NULL
and	NULL
F.	NULL
Mied	NULL
1992	NULL
.	NULL

Proliferation-dependent	NULL
HIV-1	NULL
infection	NULL
of	NULL
monocytes	NULL
occurs	NULL
during	NULL
differentiation	NULL
into	NULL
macrophages	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

89:1154-1160	NULL
.	NULL

Schutze	NULL
,	NULL
S.	NULL
,	NULL
K.	NULL
Potthoff	NULL
,	NULL
T.	NULL
Machleidt	NULL
,	NULL
D.	NULL
Berkovic	NULL
,	NULL
K.	NULL
Wiegmann	NULL
,	NULL
and	NULL
M.	NULL
Kronke	NULL
.	NULL

1992	NULL
.	NULL

TNF	NULL
activates	NULL
NF-kB	NULL
by	NULL
phophatidylcholine-specific	NULL
phos-pholiase	NULL
C-induced	NULL
``	NULL
acidic	NULL
``	NULL
sphingomyelin	NULL
breakdown	NULL
.	NULL

Cell	NULL
71:765-776	NULL
.	NULL

Schwarz	NULL
,	NULL
A.	NULL
,	NULL
G.	NULL
Offerman	NULL
,	NULL
F.	NULL
Keller	NULL
,	NULL
I.	NULL
Bennhold	NULL
,	NULL
J.	NULL
Lage-Stebr	NULL
,	NULL
P.	NULL
H.	NULL
Krause	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Minatsch	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
cyclosporine	NULL
on	NULL
the	NULL
progression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
transmitted	NULL
by	NULL
transplantation-data	NULL
on	NULL
four	NULL
cases	NULL
and	NULL
review	NULL
of	NULL
the	NULL
literature	NULL
.	NULL

Transplantation	NULL
55:95-103	NULL
.	NULL

Scott	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
T.	NULL
Fujita	NULL
,	NULL
H.-C.	NULL
Liou	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
p65	NULL
subunit	NULL
of	NULL
NF-kB	NULL
regulates	NULL
IxB	NULL
by	NULL
two	NULL
distinct	NULL
mechanisms	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:1266-1276	NULL
.	NULL

Selby	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
E.	NULL
S.	NULL
Bain	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1989	NULL
.	NULL

Structure	NULL
,	NULL
sequence	NULL
,	NULL
and	NULL
position	NULL
of	NULL
the	NULL
stem-loop	NULL
in	NULL
TAR	NULL
determine	NULL
transcriptional	NULL
elongation	NULL
by	NULL
Tat	NULL
through	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:547-558	NULL
.	NULL

Seldin	NULL
,	NULL
D.	NULL
C	NULL
,	NULL
,	NULL
and	NULL
P.	NULL
Leder	NULL
.	NULL

1995	NULL
.	NULL

Casein	NULL
kinase	NULL
Io	NULL
:	NULL
transgence-induced	NULL
murine	NULL
lymphoma	NULL
:	NULL
relation	NULL
to	NULL
theileriosis	NULL
in	NULL
cattle	NULL
.	NULL

Science	NULL
267:894-897	NULL
.	NULL

Serwadda	NULL
,	NULL
D.	NULL
,	NULL
N.	NULL
K.	NULL
Sewankambo	NULL
,	NULL
J.	NULL
W.	NULL
Carswell	NULL
,	NULL
A.	NULL
C.	NULL
Bayley	NULL
,	NULL
R.	NULL
S.	NULL
Tedder	NULL
,	NULL
R.	NULL
A.	NULL
S.	NULL
Weiss	NULL
,	NULL
R.	NULL
D.	NULL
Mugerwa	NULL
,	NULL
A.	NULL
Lwegaba	NULL
,	NULL
G.	NULL
B.	NULL
Kirya	NULL
,	NULL
R.	NULL
G.	NULL
Downing	NULL
,	NULL
S.	NULL
A.	NULL
Clayden	NULL
,	NULL
and	NULL
A.	NULL
G.	NULL
Dalgleish	NULL
.	NULL

1985	NULL
.	NULL

Slim	NULL
disease	NULL
:	NULL
a	NULL
new	NULL
disease	NULL
in	NULL
Uganda	NULL
and	NULL
its	NULL
association	NULL
with	NULL
HTLV-II	NULL
infection	NULL
.	NULL

Lancet	NULL
ii:849-852	NULL
.	NULL

Sha	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
H.-C.	NULL
Liou	NULL
,	NULL
E.	NULL
I.	NULL
Tuomanen	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1995	NULL
.	NULL

Targeted	NULL
disruption	NULL
of	NULL
the	NULL
p50	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
leads	NULL
to	NULL
multifocal	NULL
defects	NULL
in	NULL
immune	NULL
responses	NULL
.	NULL

Cell	NULL
80:321-330	NULL
.	NULL

Shannon	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
J.	NULL
Cowan	NULL
,	NULL
E.	NULL
Ball	NULL
,	NULL
D.	NULL
Abrams	NULL
,	NULL
P.	NULL
Volberding	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Ammann	NULL
.	NULL

1985	NULL
.	NULL

Impaired	NULL
mononuclear-cell	NULL
proliferation	NULL
in	NULL
patients	NULL
with	NULL
the	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
results	NULL
from	NULL
abnormalities	NULL
of	NULL
both	NULL
T	NULL
lymphocyte	NULL
and	NULL
adherent	NULL
mononuclear	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

5:239-245	NULL
.	NULL

Sheldon	NULL
,	NULL
M.	NULL
,	NULL
R.	NULL
Ratnasbapathy	NULL
,	NULL
and	NULL
N.	NULL
Hernandez	NULL
.	NULL

1993	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
inducer	NULL
of	NULL
short	NULL
transcripts	NULL
,	NULL
a	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
transcriptional	NULL
element	NULL
that	NULL
activates	NULL
the	NULL
synthesis	NULL
of	NULL
short	NULL
RNAs	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:1251-1263	NULL
.	NULL

Sheline	NULL
,	NULL
C.	NULL
,	NULL
L.	NULL
Milocco	NULL
,	NULL
and	NULL
K.	NULL
Jones	NULL
.	NULL

1991	NULL
.	NULL

Two	NULL
distinct	NULL
nuclear	NULL
transcription	NULL
factors	NULL
recognize	NULL
loop	NULL
and	NULL
bulge	NULL
residues	NULL
of	NULL
the	NULL
HIV-1	NULL
TAR	NULL
RNA	NULL
hairpin	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

5:2508-2520	NULL
.	NULL

Sheline	NULL
,	NULL
C.	NULL
T.	NULL
,	NULL
L.	NULL
H.	NULL
Milocco	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Jones	NULL
.	NULL

1991	NULL
.	NULL

Two	NULL
distinct	NULL
nuclear	NULL
transcription	NULL
factors	NULL
recognize	NULL
loop	NULL
and	NULL
bulge	NULL
residues	NULL
of	NULL
the	NULL
HIV-1	NULL
TAR	NULL
RNA	NULL
hairpin	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

52508-2520	NULL
.	NULL

Shi	NULL
,	NULL
Y.	NULL
,	NULL
E.	NULL
D.	NULL
Brown	NULL
,	NULL
and	NULL
C.	NULL
T.	NULL
Walsh	NULL
.	NULL

1994	NULL
.	NULL

Expression	NULL
of	NULL
recombinant	NULL
casein	NULL
kinase	NULL
II	NULL
and	NULL
recombinant	NULL
heat	NULL
shock	NULL
protein	NULL
90	NULL
in	NULL
Escherichia	NULL
coli	NULL
and	NULL
characterization	NULL
of	NULL
their	NULL
interactions	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
:	NULL
2767-2771	NULL
.	NULL

Shirazi	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1992	NULL
.	NULL

Alpha	NULL
interferon	NULL
inhibits	NULL
early	NULL
stages	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
cycle	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66	NULL
:	NULL
1321-1328	NULL
.	NULL

Siekevitz	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
M.	NULL
Dukovich	NULL
,	NULL
N.	NULL
Peffer	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1987	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
HIV-LTR	NULL
by	NULL
T-cell	NULL
mitogens	NULL
and	NULL
the	NULL
trans-activator	NULL
protein	NULL
of	NULL
HTLV-1	NULL
.	NULL

Science	NULL
238:1575-1578	NULL
.	NULL

Sierra-Madero	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Z.	NULL
Toossi	NULL
,	NULL
D.	NULL
L.	NULL
Hom	NULL
,	NULL
C.	NULL
K.	NULL
Finegan	NULL
,	NULL
E.	NULL
Hoenig	NULL
,	NULL
and	NULL
E.	NULL
A	NULL
.	NULL

Rich	NULL
.	NULL

1994	NULL
.	NULL

Relationship	NULL
between	NULL
load	NULL
of	NULL
virus	NULL
in	NULL
alveolar	NULL
macrophages	NULL
from	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1-infected	NULL
persons	NULL
,	NULL
production	NULL
of	NULL
cytokines	NULL
,	NULL
and	NULL
clinical	NULL
status	NULL
.	NULL

J	NULL
.	NULL

Invest	NULL
.	NULL

Dermatol	NULL
.	NULL

169:18-27	NULL
.	NULL

Sigal	NULL
,	NULL
N.	NULL
H.	NULL
,	NULL
and	NULL
F.	NULL
J.	NULL
Dumont	NULL
.	NULL

1992	NULL
.	NULL

Cyclosporin	NULL
A	NULL
,	NULL
FK506	NULL
,	NULL
and	NULL
rapamy-cin	NULL
:	NULL
pharmacologic	NULL
probes	NULL
of	NULL
lymphocyte	NULL
signal	NULL
transduction	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

10:519-560	NULL
.	NULL

Smith	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
R.	NULL
J.	NULL
Thresher	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pagano	NULL
.	NULL

1991	NULL
.	NULL

Inhibition	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
morphogenesis	NULL
in	NULL
T	NULL
cells	NULL
by	NULL
alpha	NULL
interferon	NULL
.	NULL

Antimicrob	NULL
.	NULL

Agents	NULL
Chemother	NULL
.	NULL

35:62-67	NULL
.	NULL

Smith	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
K.	NULL
Obura	NULL
,	NULL
H.	NULL
Masur	NULL
,	NULL
H.	NULL
C.	NULL
Lane	NULL
,	NULL
A.	NULL
S.	NULL
Fauci	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Wahl	NULL
.	NULL

1984	NULL
.	NULL

Monocyte	NULL
function	NULL
in	NULL
the	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
.	NULL

Defective	NULL
chemotaxis	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

74:2121-2128	NULL
.	NULL

Spear	NULL
,	NULL
G.	NULL
T.	NULL
,	NULL
C.	NULL
Y.	NULL
Ou	NULL
,	NULL
H.	NULL
A.	NULL
Kessler	NULL
,	NULL
J.	NULL
L.	NULL
Moore	NULL
,	NULL
G.	NULL
Schocheteman	NULL
,	NULL
and	NULL
A.	NULL
L.	NULL
Landay	NULL
,	NULL
.	NULL

1990	NULL
.	NULL

Analysis	NULL
of	NULL
lymphocytes	NULL
,	NULL
monocytes	NULL
,	NULL
and	NULL
neutrophils	NULL
from	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
-infected	NULL
persons	NULL
for	NULL
HIV	NULL
DNA	NULL
.	NULL

J	NULL
.	NULL

Invest	NULL
.	NULL

Dermatol	NULL
.	NULL

162:1239-1244	NULL
.	NULL

Stanley	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
P.	NULL
B.	NULL
Bressler	NULL
,	NULL
G.	NULL
Poli	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1990	NULL
.	NULL

Heat	NULL
shock	NULL
370	NULL
.	NULL

371	NULL
.	NULL

372	NULL
.	NULL

373	NULL
.	NULL

374	NULL
.	NULL

375	NULL
.	NULL

376	NULL
.	NULL

377	NULL
.	NULL

378	NULL
.	NULL

379	NULL
.	NULL

380	NULL
.	NULL

381	NULL
.	NULL

382	NULL
.	NULL

383	NULL
.	NULL

384	NULL
.	NULL

385	NULL
.	NULL

386	NULL
.	NULL

387	NULL
.	NULL

388	NULL
.	NULL

389	NULL
.	NULL

390	NULL
.	NULL

391	NULL
.	NULL

392	NULL
.	NULL

393	NULL
.	NULL

394	NULL
.	NULL

MicroBtoL	NULL
.	NULL

Rev	NULL
.	NULL

induction	NULL
of	NULL
HIV	NULL
production	NULL
from	NULL
chronically	NULL
infected	NULL
promonocytic	NULL
and	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

145:1120-1126	NULL
.	NULL

Stanley	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1989	NULL
.	NULL

Induction	NULL
of	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
a	NULL
chronically	NULL
infected	NULL
promonocytic	NULL
line	NULL
by	NULL
ultraviolet	NULL
radiation	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
5:375-384	NULL
.	NULL

S	NULL
M.	NULL
,	NULL
T.	NULL
L.	NULL
S	NULL
ick	NULL
,	NULL
M.	NULL
P.	NULL
Dempsey	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Lamonica	NULL
.	NULL

1990	NULL
.	NULL

HIV-1	NULL
replication	NULL
is	NULL
controlled	NULL
at	NULL
the	NULL
level	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
proviral	NULL
integration	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:1551-1560	NULL
.	NULL

Sun	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
A.	NULL
Ganchi	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1993	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
controls	NULL
expression	NULL
of	NULL
inhibitor	NULL
IxBa	NULL
:	NULL
evidence	NULL
for	NULL
an	NULL
inducible	NULL
autoregulatory	NULL
pathway	NULL
.	NULL

Science	NULL
259:1912-1915	NULL
.	NULL

Sun	NULL
,	NULL
S.-C.	NULL
,	NULL
P.	NULL
A.	NULL
Ganchi	NULL
,	NULL
C.	NULL
Béraud	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1994	NULL
.	NULL

Autoregulation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
transactivator	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
by	NULL
multiple	NULL
cytoplasmic	NULL
inhibitors	NULL
containing	NULL
ankyrin	NULL
motifs	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:1346-1350	NULL
.	NULL

Suttmann	NULL
,	NULL
U.	NULL
,	NULL
J.	NULL
Ockenga	NULL
,	NULL
O.	NULL
Selberg	NULL
,	NULL
L.	NULL
Hoogestraat	NULL
,	NULL
H.	NULL
Deicher	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Miiller	NULL
.	NULL

1995	NULL
.	NULL

Incidence	NULL
and	NULL
prognostic	NULL
value	NULL
of	NULL
malnutrition	NULL
and	NULL
wasting	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus-infected	NULL
outpatients	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

8:239-246	NULL
.	NULL

Suzan	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
Salaun	NULL
,	NULL
C.	NULL
Neuveut	NULL
,	NULL
B.	NULL
Spire	NULL
,	NULL
I.	NULL
Hirsch	NULL
,	NULL
P.	NULL
Le	NULL
Bouteiller	NULL
,	NULL
G.	NULL
Querat	NULL
,	NULL
and	NULL
J.	NULL
Sire	NULL
.	NULL

1991	NULL
.	NULL

Induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
during	NULL
monocyte	NULL
differentiation	NULL
by	NULL
HIV	NULL
type	NULL
1	NULL
infection	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:377-383	NULL
.	NULL

Taylor	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
R.	NULL
Pomerantz	NULL
,	NULL
O.	NULL
Bagasra	NULL
,	NULL
M.	NULL
Chowdhury	NULL
,	NULL
J.	NULL
Rappaport	NULL
,	NULL
K.	NULL
Khalili	NULL
,	NULL
and	NULL
S.	NULL
Amini	NULL
.	NULL

1992	NULL
.	NULL

TAR-independent	NULL
transactivation	NULL
by	NULL
Tat	NULL
in	NULL
cells	NULL
derived	NULL
from	NULL
the	NULL
CNS	NULL
:	NULL
a	NULL
novel	NULL
mechanism	NULL
of	NULL
HIV-1	NULL
gene	NULL
regulation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:3395-3403	NULL
.	NULL

Tesmer	NULL
,	NULL
V.	NULL
M.	NULL
,	NULL
A.	NULL
Rajadhyaksha	NULL
,	NULL
J.	NULL
Babin	NULL
,	NULL
and	NULL
M.	NULL
Bina	NULL
.	NULL

1993	NULL
.	NULL

NF-IL6-mediated	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:7298-7302	NULL
.	NULL

Tevethia	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
D.	NULL
J.	NULL
Spector	NULL
,	NULL
K.	NULL
M.	NULL
Leisure	NULL
,	NULL
and	NULL
M.	NULL
F.	NULL
Stinski	NULL
.	NULL

1987	NULL
.	NULL

Participation	NULL
of	NULL
two	NULL
human	NULL
cytomegalovirus	NULL
immediate-carly	NULL
gene	NULL
regions	NULL
in	NULL
transcriptional	NULL
activation	NULL
of	NULL
adenovirus	NULL
promoters	NULL
.	NULL

Virology	NULL
161:276-285	NULL
.	NULL

Thompson	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
R.	NULL
J.	NULL
Phillips	NULL
,	NULL
H.	NULL
Erdjument-Bromage	NULL
,	NULL
P.	NULL
Tempst	NULL
,	NULL
and	NULL
S.	NULL
Ghosh	NULL
.	NULL

1995	NULL
.	NULL

IxB-B	NULL
regulates	NULL
the	NULL
persistent	NULL
response	NULL
in	NULL
a	NULL
biphasic	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Cell	NULL
80:573-582	NULL
.	NULL

Tindall	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Cooper	NULL
.	NULL

1991	NULL
.	NULL

Primary	NULL
HIV	NULL
infection	NULL
:	NULL
host	NULL
responses	NULL
and	NULL
intervention	NULL
strategies	NULL
.	NULL

AIDS	NULL
5:1-14	NULL
.	NULL

Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1989	NULL
.	NULL

Signalling	NULL
through	NULL
T	NULL
lymphocyte	NULL
surface	NULL
proteins	NULL
,	NULL
TCR/CD3	NULL
and	NULL
CD28	NULL
,	NULL
activates	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:702-707	NULL
.	NULL

Tracey	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Y.	NULL
Fong	NULL
,	NULL
D.	NULL
G.	NULL
Hesse	NULL
,	NULL
K.	NULL
R.	NULL
Manogue	NULL
,	NULL
A.	NULL
T.	NULL
Lee	NULL
,	NULL
G.	NULL
C.	NULL
Kuo	NULL
,	NULL
S.	NULL
F.	NULL
Lowry	NULL
,	NULL
and	NULL
A.	NULL
Cerami	NULL
.	NULL

1987	NULL
.	NULL

Anti-cachetin/TNF	NULL
monoclonal	NULL
antibodies	NULL
prevent	NULL
septic	NULL
shock	NULL
during	NULL
lethal	NULL
bacteraemia	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
330	NULL
:	NULL
662-664	NULL
.	NULL

Traenckner	NULL
,	NULL
E.	NULL
B.-M.	NULL
,	NULL
S.	NULL
Wilk	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
proteasome	NULL
inhibitor	NULL
prevents	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
stabilizes	NULL
a	NULL
newly	NULL
phosphorylated	NULL
form	NULL
of	NULL
IxB-	NULL
«	NULL
that	NULL
is	NULL
still	NULL
bound	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:5433-5441	NULL
.	NULL

Travis	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Amsterdam	NULL
,	NULL
C.	NULL
Belanger	NULL
,	NULL
and	NULL
R.	NULL
Grossched	NULL
]	NULL
.	NULL

1991	NULL
.	NULL

LEF-1	NULL
,	NULL
a	NULL
gene	NULL
encoding	NULL
a	NULL
lymphoid-specific	NULL
protein	NULL
with	NULL
an	NULL
HMG	NULL
domain	NULL
,	NULL
regulates	NULL
T-cell	NULL
receptor	NULL
«	NULL
enhancer	NULL
function	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

5:880-894	NULL
.	NULL

Trinchieri	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Wysocka	NULL
,	NULL
A	NULL
.	NULL

D'Andrea	NULL
,	NULL
M.	NULL
Rengaraju	NULL
,	NULL
M.	NULL
Aste-Amezaga	NULL
,	NULL
M.	NULL
Kubin	NULL
,	NULL
N.	NULL
M.	NULL
Valiante	NULL
,	NULL
and	NULL
J.	NULL
Chehimi	NULL
.	NULL

1992	NULL
.	NULL

Natural	NULL
killer	NULL
cell	NULL
stimulatory	NULL
factor	NULL
(	NULL
NKSF	NULL
)	NULL
or	NULL
interleukin-12	NULL
is	NULL
a	NULL
key	NULL
regulator	NULL
of	NULL
immune	NULL
response	NULL
and	NULL
inflammation	NULL
.	NULL

Prog	NULL
.	NULL

Growth	NULL
Factor	NULL
Res	NULL
.	NULL

4:355-368	NULL
.	NULL

Tschachler	NULL
,	NULL
E.	NULL
,	NULL
V.	NULL
Groh	NULL
,	NULL
M.	NULL
Popovic	NULL
,	NULL
D.	NULL
L.	NULL
Mann	NULL
,	NULL
K.	NULL
Konrad	NULL
,	NULL
B.	NULL
Safai	NULL
,	NULL
L.	NULL
Eron	NULL
,	NULL
F.	NULL
Veronese	NULL
,	NULL
K.	NULL
Wolff	NULL
,	NULL
and	NULL
G.	NULL
Stingl	NULL
.	NULL

1987	NULL
.	NULL

Epidermal	NULL
Langerhans	NULL
cells	NULL
:	NULL
a	NULL
target	NULL
for	NULL
HTLV/LAV	NULL
infection	NULL
.	NULL

J	NULL
.	NULL

Invest	NULL
.	NULL

Dermatol	NULL
.	NULL

88:233-240	NULL
.	NULL

Twu	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
C.	NULL
A.	NULL
Rosen	NULL
,	NULL
W.	NULL
A.	NULL
Haseltine	NULL
,	NULL
and	NULL
W.	NULL
S.	NULL
Robinson	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
region	NULL
within	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
that	NULL
is	NULL
essential	NULL
for	NULL
transactivation	NULL
by	NULL
the	NULL
hepatitis	NULL
B	NULL
virus	NULL
gene	NULL
X.	NULL
J.	NULL
Virol	NULL
.	NULL

63:2857-2860	NULL
.	NULL

Urban	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
p50	NULL
and	NULL
p6S	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
recognition	NULL
of	NULL
cognate	NULL
sequences	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

3:279-288	NULL
.	NULL

Vaishnay	NULL
,	NULL
Y.	NULL
N.	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
biochemistry	NULL
of	NULL
AIDS	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

60:577-630	NULL
.	NULL

Valentin	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Matsuda	NULL
,	NULL
and	NULL
B.	NULL
Asjo	NULL
.	NULL

1990	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
in	NULL
vitro	NULL
maturation	NULL
of	NULL
monocytes	NULL
and	NULL
the	NULL
susceptibility	NULL
to	NULL
HIV	NULL
infection	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
6:977-978	NULL
.	NULL

Valentin	NULL
,	NULL
A.	NULL
,	NULL
A	NULL
.	NULL

Von	NULL
Gegerfelt	NULL
,	NULL
S.	NULL
Matsuda	NULL
,	NULL
K.	NULL
Nilsson	NULL
,	NULL
and	NULL
B.	NULL
Asjo	NULL
.	NULL

1991	NULL
.	NULL

In	NULL
vitro	NULL
maturation	NULL
of	NULL
mononuclear	NULL
phagocytes	NULL
and	NULL
susceptibility	NULL
to	NULL
HIV-1	NULL
infection	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

4751-759	NULL
.	NULL

Valerie	NULL
,	NULL
K.	NULL
,	NULL
A.	NULL
Delers	NULL
,	NULL
C.	NULL
Bruck	NULL
,	NULL
C.	NULL
Thiriart	NULL
,	NULL
H.	NULL
Rosenberg	NULL
,	NULL
C.	NULL
Debouck	NULL
,	NULL
and	NULL
M.	NULL
Rosenberg	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
by	NULL
DNA	NULL
damage	NULL
in	NULL
human	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
333:78-81	NULL
.	NULL

Veillette	NULL
,	NULL
A.	NULL
,	NULL
N.	NULL
Abraham	NULL
,	NULL
L.	NULL
Caron	NULL
,	NULL
and	NULL
D.	NULL
Davidson	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
lympho-cyte-specific	NULL
tyrosine	NULL
kinase	NULL
p56*	NULL
.	NULL

Semin	NULL
.	NULL

Immunol	NULL
.	NULL

3:143-152	NULL
.	NULL

Vilcek	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
T.	NULL
H.	NULL
Lee	NULL
.	NULL

1991	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

New	NULL
insights	NULL
into	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
its	NULL
multiple	NULL
actions	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:7313-7316	NULL
.	NULL

Vou	NULL
.	NULL

59	NULL
,	NULL
1995	NULL
395	NULL
.	NULL

396	NULL
.	NULL

397	NULL
.	NULL

398	NULL
.	NULL

399	NULL
.	NULL

400	NULL
.	NULL

401	NULL
.	NULL

402	NULL
.	NULL

403	NULL
.	NULL

404	NULL
.	NULL

405	NULL
.	NULL

Virelizier	NULL
,	NULL
J.	NULL
L.	NULL
1990	NULL
.	NULL

Cellular	NULL
activation	NULL
and	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

2409-413	NULL
.	NULL

Voth	NULL
,	NULL
R.	NULL
,	NULL
S.	NULL
Rossol	NULL
,	NULL
K.	NULL
Klein	NULL
,	NULL
G.	NULL
Hess	NULL
,	NULL
K.	NULL
H.	NULL
Schiitt	NULL
,	NULL
H.	NULL
C.	NULL
Schroder	NULL
,	NULL
K.-H.	NULL
Meyer	NULL
zum	NULL
Biischenfelde	NULL
,	NULL
and	NULL
W.	NULL
E.	NULL
G.	NULL
Miller	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
gene	NULL
expression	NULL
of	NULL
IFN	NULL
«	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
AIDS	NULL
related	NULL
complex	NULL
and	NULL
AIDS	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

144:970-975	NULL
.	NULL

Vyakarnam	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
McKeating	NULL
,	NULL
A	NULL
.	NULL

Meager	NULL
,	NULL
and	NULL
P.	NULL
C.	NULL
Beverley	NULL
.	NULL

1990	NULL
.	NULL

Tu-mour	NULL
necrosis	NULL
factors	NULL
(	NULL
«	NULL
,	NULL
B	NULL
)	NULL
induced	NULL
by	NULL
HIV-1	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
potentiate	NULL
virus	NULL
replication	NULL
.	NULL

AIDS	NULL
4:21-27	NULL
.	NULL

Wabl	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
M.	NULL
L.	NULL
Corcoran	NULL
,	NULL
S.	NULL
W.	NULL
Pyle	NULL
,	NULL
L.	NULL
O.	NULL
Arthur	NULL
,	NULL
A.	NULL
Harel-Bellan	NULL
,	NULL
and	NULL
W.	NULL
L.	NULL
Farrar	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
glycoprotein	NULL
(	NULL
gp120	NULL
)	NULL
induction	NULL
of	NULL
monocyte	NULL
arachidonic	NULL
acid	NULL
metabolites	NULL
and	NULL
interleukin	NULL
1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:621-625	NULL
.	NULL

Wabl	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Allen	NULL
,	NULL
S.	NULL
Gartner	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
M.	NULL
Popovic	NULL
,	NULL
D.	NULL
E.	NULL
Chenoweth	NULL
,	NULL
L.	NULL
O.	NULL
Arthur	NULL
,	NULL
W.	NULL
L.	NULL
Farrar	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Wahl	NULL
.	NULL

1989	NULL
.	NULL

HIV-1	NULL
and	NULL
its	NULL
envelope	NULL
glycoprotein	NULL
down-regulate	NULL
chemotactic	NULL
ligand	NULL
receptors	NULL
and	NULL
chemotactic	NULL
function	NULL
of	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142	NULL
:	NULL
2097-2105	NULL
.	NULL

Wabl	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Allen	NULL
,	NULL
N.	NULL
McCartney-Francis	NULL
,	NULL
M.	NULL
C.	NULL
Morganti-Koss-mann	NULL
,	NULL
L.	NULL
Ellingsworth	NULL
,	NULL
U.	NULL
E.	NULL
H.	NULL
Mai	NULL
,	NULL
S.	NULL
E.	NULL
Mergenbagen	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Orenstein	NULL
.	NULL

1991	NULL
.	NULL

Macrophage-	NULL
and	NULL
astrocyte-derived	NULL
transforming	NULL
growth	NULL
factor	NULL
B	NULL
as	NULL
a	NULL
mediator	NULL
of	NULL
central	NULL
nervous	NULL
system	NULL
dysfunction	NULL
in	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

173:981-991	NULL
.	NULL

Waterman	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
K.	NULL
A.	NULL
Jones	NULL
.	NULL

1990	NULL
.	NULL

Purification	NULL
of	NULL
TCF-1a	NULL
,	NULL
a	NULL
T-cell	NULL
specific	NULL
transcription	NULL
factor	NULL
that	NULL
activates	NULL
the	NULL
T-cell	NULL
receptor	NULL
Ca	NULL
gene	NULL
enhancer	NULL
in	NULL
a	NULL
context-dependent	NULL
manner	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

2:621-636	NULL
.	NULL

Wei	NULL
,	NULL
X.	NULL
,	NULL
S.	NULL
K.	NULL
Ghosh	NULL
,	NULL
M.	NULL
E.	NULL
Taylor	NULL
,	NULL
V.	NULL
A.	NULL
Johnson	NULL
,	NULL
E.	NULL
Emini	NULL
,	NULL
P.	NULL
Deutsch	NULL
,	NULL
J.	NULL
D.	NULL
Lifson	NULL
,	NULL
S.	NULL
Bonhoeffer	NULL
,	NULL
M.	NULL
A.	NULL
Nowak	NULL
,	NULL
B.	NULL
H.	NULL
Hahn	NULL
,	NULL
M.	NULL
S.	NULL
Saag	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Shaw	NULL
.	NULL

1995	NULL
.	NULL

Viral	NULL
dynamics	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
373:117-122	NULL
.	NULL

Weih	NULL
,	NULL
F.	NULL
,	NULL
D.	NULL
Carrasco	NULL
,	NULL
S.	NULL
K.	NULL
Durham	NULL
,	NULL
D.	NULL
S.	NULL
Barton	NULL
,	NULL
C.	NULL
A.	NULL
Rizzo	NULL
,	NULL
RP	NULL
.	NULL

Ryseck	NULL
,	NULL
S.	NULL
A.	NULL
Lira	NULL
,	NULL
and	NULL
R.	NULL
Bravo	NULL
.	NULL

1995	NULL
.	NULL

Multiorgan	NULL
inflammation	NULL
and	NULL
hematopoietic	NULL
abnormalities	NULL
in	NULL
mice	NULL
with	NULL
a	NULL
targeted	NULL
disruption	NULL
of	NULL
RelB	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
NF-kB/Rel	NULL
family	NULL
.	NULL

Cell	NULL
80:331-340	NULL
.	NULL

Weinberg	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
T.	NULL
J.	NULL
Mathews	NULL
,	NULL
B.	NULL
R.	NULL
Cullen	NULL
,	NULL
and	NULL
M.	NULL
H.	NULL
Malim	NULL
.	NULL

1991	NULL
.	NULL

Productive	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
infection	NULL
of	NULL
nonproliferating	NULL
human	NULL
monocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

174:1477-1482	NULL
.	NULL

Westwick	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
C.	NULL
Weitzel	NULL
,	NULL
A.	NULL
Minden	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Brenner	NULL
.	NULL

1995	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
stimulates	NULL
AP-1	NULL
activity	NULL
through	NULL
prolonged	NULL
REGULATION	NULL
OF	NULL
HIV-1	NULL
AND	NULL
CYTOKINE	NULL
EXPRESSION	NULL
BY	NULL
NF-	NULL
«	NULL
B	NULL
406	NULL
.	NULL

407	NULL
.	NULL

408	NULL
.	NULL

409	NULL
.	NULL

410	NULL
.	NULL

411	NULL
.	NULL

412	NULL
.	NULL

413	NULL
.	NULL

414	NULL
.	NULL

415	NULL
.	NULL

416	NULL
.	NULL

417	NULL
.	NULL

418	NULL
.	NULL

505	NULL
activation	NULL
of	NULL
the	NULL
c-jun	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:26396-26401	NULL
.	NULL

Williams	NULL
,	NULL
T.	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
B.	NULL
Luscher	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1988	NULL
.	NULL

Cloning	NULL
and	NULL
expression	NULL
of	NULL
AP-2	NULL
,	NULL
a	NULL
cell-type-specific	NULL
transcription	NULL
factor	NULL
that	NULL
activates	NULL
inducible	NULL
enhancer	NULL
elements	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2:1557-1569	NULL
.	NULL

Wong-Staal	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1992	NULL
.	NULL

Regulatory	NULL
genes	NULL
of	NULL
human	NULL
immunodeficiency	NULL
viruses	NULL
.	NULL

Mol	NULL
.	NULL

Gen.	NULL
Med	NULL
.	NULL

2:189-219	NULL
.	NULL

Wright	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
A.	NULL
Jewett	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
B.	NULL
Bonavida	NULL
.	NULL

1988	NULL
.	NULL

Spontancous	NULL
cytotoxicity	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
production	NULL
by	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
from	NULL
AIDS	NULL
patients	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

141:99-104	NULL
.	NULL

Wulezyn	NULL
,	NULL
F.	NULL
G.	NULL
,	NULL
M.	NULL
Naumann	NULL
,	NULL
and	NULL
C.	NULL
Scheidereit	NULL
.	NULL

1992	NULL
.	NULL

Candidate	NULL
proto-oncogene	NULL
bel-3	NULL
encodes	NULL
a	NULL
subunit-specific	NULL
inhibitor	NULL
of	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
358:597-599	NULL
.	NULL

Yamamoto	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
F.	NULL
Barre-Sinoussi	NULL
,	NULL
V.	NULL
Bolton	NULL
,	NULL
N.	NULL
C.	NULL
Pedersen	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Gardner	NULL
.	NULL

1986	NULL
.	NULL

Human	NULL
alpha-	NULL
and	NULL
beta-interferon	NULL
but	NULL
not	NULL
gamma	NULL
suppresses	NULL
the	NULL
in	NULL
vitro	NULL
replication	NULL
of	NULL
LAV	NULL
,	NULL
HTLV-II	NULL
,	NULL
and	NULL
ARV-2	NULL
.	NULL

J.	NULL
Interferon	NULL
Res	NULL
.	NULL

6:143-152	NULL
.	NULL

Yamato	NULL
,	NULL
K.	NULL
,	NULL
Z.	NULL
El-Hajjaoui	NULL
,	NULL
K.	NULL
Simon	NULL
,	NULL
and	NULL
H.	NULL
P.	NULL
Koeffler	NULL
.	NULL

1990	NULL
.	NULL

Modulation	NULL
of	NULL
interleukin	NULL
18	NULL
RNA	NULL
in	NULL
monocytoid	NULL
cells	NULL
infected	NULL
with	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

86:1109-1116	NULL
.	NULL

Yasuda	NULL
,	NULL
Y.	NULL
,	NULL
S.	NULL
Miyake	NULL
,	NULL
S.	NULL
Kato	NULL
,	NULL
M.	NULL
Kita	NULL
,	NULL
T.	NULL
Kishida	NULL
,	NULL
T.	NULL
Kimura	NULL
,	NULL
and	NULL
K.	NULL
Ikuta	NULL
.	NULL

1991	NULL
.	NULL

Interferon	NULL
alpha	NULL
treatment	NULL
leads	NULL
to	NULL
accumulation	NULL
of	NULL
virus	NULL
particles	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
cells	NULL
persistently	NULL
infected	NULL
.	NULL

AIDS	NULL
3:1046-1051	NULL
.	NULL

Yu	NULL
,	NULL
I.	NULL
J.	NULL
,	NULL
D.	NULL
L.	NULL
Spector	NULL
,	NULL
Y.-S.	NULL
Bae	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Marshak	NULL
,	NULL
1991	NULL
.	NULL

Immunocytochemical	NULL
localization	NULL
of	NULL
casein	NULL
kinase	NULL
II	NULL
during	NULL
interphase	NULL
and	NULL
mitosis	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

114:1217-1232	NULL
.	NULL

Zabel	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1990	NULL
.	NULL

Purified	NULL
human	NULL
IxB	NULL
can	NULL
rapidly	NULL
dissociate	NULL
the	NULL
complex	NULL
of	NULL
the	NULL
NF-xB	NULL
transcription	NULL
factor	NULL
with	NULL
its	NULL
cognate	NULL
DNA	NULL
.	NULL

Cell	NULL
61:255-265	NULL
.	NULL

Zack	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
S.	NULL
J.	NULL
Arrigo	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1990	NULL
.	NULL

Control	NULL
of	NULL
expression	NULL
and	NULL
cell	NULL
tropism	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Adv	NULL
.	NULL

Virus	NULL
Res	NULL
.	NULL

38:125-146	NULL
.	NULL

Zack	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
S.	NULL
J.	NULL
Arrigo	NULL
,	NULL
S.	NULL
R.	NULL
Weitzmann	NULL
,	NULL
A.	NULL
S.	NULL
Goo	NULL
,	NULL
A.	NULL
Haislip	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1990	NULL
.	NULL

HIV-1	NULL
entry	NULL
into	NULL
quiescent	NULL
primary	NULL
lymphocytes	NULL
:	NULL
molecular	NULL
analysis	NULL
reveals	NULL
a	NULL
labile	NULL
latent	NULL
viral	NULL
structure	NULL
.	NULL

Cell	NULL
61:213-222	NULL
.	NULL

Zack	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
A.	NULL
J.	NULL
Cann	NULL
,	NULL
J.	NULL
P.	NULL
Lugo	NULL
,	NULL
and	NULL
I.	NULL
S.	NULL
Y.	NULL
Chen	NULL
.	NULL

1988	NULL
.	NULL

HIV-1	NULL
production	NULL
from	NULL
infected	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
after	NULL
HTLV-1	NULL
induced	NULL
mitogenic	NULL
stimulation	NULL
.	NULL

Science	NULL
240:1026-1028	NULL
.	NULL

Zon	NULL
,	NULL
L.	NULL
L	NULL
,	NULL
C.	NULL
Arin	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Groopman	NULL
.	NULL

1987	NULL
.	NULL

Hematologic	NULL
manifestations	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
.	NULL

Br	NULL
.	NULL

J.	NULL
Haematol	NULL
.	NULL

66:251-256	NULL
.	NULL

Activators	NULL
of	NULL
NF-xB	NULL
Cytokines	NULL
(	NULL
IL-1	NULL
,	NULL
TNFa	NULL
)	NULL
Lipapolysaccharide	NULL
Mitogens	NULL
(	NULL
PMA	NULL
,	NULL
PHA	NULL
)	NULL
Viruses	NULL
,	NULL
ds	NULL
RNA	NULL
Ub	NULL
1	NULL
)	NULL
Phosphorylation	NULL
I	NULL
2	NULL
)	NULL
Poly-ubiquitination	NULL
Ub	NULL
p105	NULL
Signaling	NULL
molecules	NULL
/	NULL
'	NULL
and	NULL
protein	NULL
kinases	NULL
g	NULL
in	NULL
“	NULL
Proteasome	NULL
mediated	NULL
Degradation	NULL
1	NULL
)	NULL
Phosphorylation	NULL
2	NULL
)	NULL
Poly-ubiquitination	NULL
Feedback	NULL
inhibition	NULL
IkBa	NULL
mRNA	NULL
|	NULL
newly	NULL
synthesized	NULL
IxBo	NULL

